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Abstract 
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Objective: To provide six-year cumulative incidence of visual impairment and 
blindness, diabetic retinopathy (DR), age related macular degeneration (AMD), 
visually impairing cataract and features of glaucoma in an older age Kenyan 
population and the risk factors for each. 
Design: Population based cohort study with six-year follow-up (n=2,171; 50% 
participation) 
Main outcome measures: Six-year cumulative incidence of visual impairment and 
blindness, DM, DR, AMD, visually impairing cataract and features of glaucoma, risk 
factors for incidence and population estimates. 
Results: The six-year cumulative incidence of visual impairment and blindness was 
119.4 (103.1 - 137.9) and 15.1 (10.4 – 21.7) per 1000 of population respectively.  
The six-year cumulative incidence of DM and DR (in those with diabetes mellitus) 
was 61.0 (50.3 - 73.7) and 224.7 (116.9 - 388.2) per 1000 of population respectively. 
The six-year cumulative incidence of AMD was 164.2 (136.7 - 195.9) per 1000 of 
population and the six-year cumulative incidence of visually impairing cataract was 
235.6 (213.5 – 259.3) per 1000 of population. Associations with incident cases were 
demonstrated for each with age and diabetes being the leading associations across 
the primary outcome measures.  
Conclusions: This six-year follow-up of a population-based cohort indicates a high 
incidence of visual impairment and blindness and provides data, for the first time, on 
the incidence of DR, AMD and cataract in Kenya. A large gap exists between 
provision and need for services and cataract control should remain the priority focus 
with work to strengthen health care systems as posterior segment eye diseases will 
become a greater issue as services improve and cataract comes under greater 
control.  
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Abbreviations: 
AMD  Age-Related Macular Degeneration 
AREDS Age Related Eye Diseases Study 
BDES  Beaver Dam Eye Study 
BMES  Blue Mountain Eye Study 
CBM  Christoffel Blinden Mission 
CI  Confidence Interval 
CO  Corneal Opacity 
CNVM  Choroidal Neovascular Membrane 
CSME  Clinically significant macula (o)edema 
D  Dioptres 
DALYs  Disability-adjusted life years 
DEFF  Design Effect 
DM  Diabetes Mellitus 
DR  Diabetic Retinopathy 
ET  Examination Team 
ETDRS Early Treatment of Diabetic Retinopathy Study 
FDT  Frequency Doubling Technology 
GA  Geographic Atrophy 
GAT  Goldmann Applanation Tonometry 
HIV  Human Immunodeficiency Virus 
IAPB  International Agency for the Prevention of Blindness 
ID  Identification 
IOP  Intraocular pressure 
IOVs  Inter observer variations 
IRMA  Intraretinal Microvascular Anomalies 
ISGEO International Society Geographical & Epidemiological Ophthalmology 
LALES  Los Angeles Latino Eye Study 
LMIC  Low and Middle Income Countries 
mmHg  Millimeters of mercury 
NCDs  Non-communicable Diseases 
NPDR  Non-Proliferative Diabetic Retinopathy 
OCO  Ophthalmic Clinical Officer 
PDR  Proliferative Diabetic Retinopathy 
POAG  Primary Open Angle Glaucoma 
PSED  Posterior Segment Eye Disease 
PY   Person-years 
RAAB  Rapid Assessment of Avoidable Blindness 
RVPGH Rift Valley Provincial General Hospital 
SSA  Sub-Saharan Africa 
TBC  To be confirmed 
USA  United States of America 
VA  Visual Acuity 
VCDR  Vertical Cup to Disc Ratio 
VF  Visual Fields 
VI   Visual Impairment 
WHO  World Health Organisation  
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Format of the Thesis !
The thesis for this PhD is in the “research papers” format and includes a number of 
published papers (7) as well as two being submitted for peer-review and publication. 
 
Chapters listed in italics in the Contents are in this research/review paper format, 
and includes publication details in a cover sheet, including acknowledgement of 
contributions.  
 
The other chapters of the thesis are composed of “linking material” which includes 
information/data not covered in the research papers and helps to make the thesis a 
coherent body. 
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Chapter 1. Introduction      
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This chapter will provide an overview of eye disease in sub-Saharan Africa (SSA), 
what we know, and gaps in knowledge that this thesis hopes to contribute to filling. 
Cataract and Posterior Segment Eye Disease (PSED) in SSA will be reviewed in more 
detail in chapters 2 and 3. 
 
In recent decades there has been a marked rise in life expectancy that has 
contributed to a major epidemiological shift in populations worldwide. (1) These 
changes have led to the emergence of new major public health issues in low and 
middle-income countries (LMIC). (2) Current projections suggest that non-
communicable diseases (NCDs), such as diabetes mellitus and hypertension will 
contribute to two-thirds of global mortality by the year 2030. (2) The emergence of 
NCDs in LMICs, including in SSA is happening at an alarming rate with the Global 
Burden of Disease study showing that the leading cause of death in people from 
Africa aged 60 years and over is already NCDs. (3) NCDs in LMIC have shown 
substantial variation in prevalence, incidence, natural history and risk factors to 
NCDs in populations in high-income countries and so a detailed local understanding 
is needed for us to effectively respond to this growing public health problem.  
 
The majority of existing data on NCDs from LMIC are from cross-sectional studies 
providing valuable data on prevalence and risk factors. Longitudinal studies provide 
the opportunity to investigate the natural history of diseases, which is necessary in 
developing health policies at local and national levels. Longitudinal cohort studies 
from LMIC are few due to barriers including: expense; complex logistical planning; 
and political challenges. Inferring data from high-income countries is inappropriate 
due to the unique combination of genetic and environmental factors in other 
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contexts, and moreover undermines efforts to establish studies in LMIC which will 
guide the effective use of minimal existing resources to deal with the growing burden 
of NCDs. 
As the disease profile is changing from infectious (communicable diseases) to NCDs 
in LMICs, this is also happening for the causes of blindness. 285 million people are 
visually impaired (VI) worldwide, of whom 39 million are blind. (4) Approximately 
90% of those worldwide with VI live in low-income countries. NCDs (e.g. cataract, 
refractive error) are the leading causes of VI, in part due to the successful control of 
infectious causes of VI such as trachoma and onchocerciasis.(5-7) VI is ranked sixth 
in the top ten causes of burden of disease in terms of disability-adjusted life-years 
(DALYs) worldwide in the Global Burden of Disease Study. (8)  
 
The number of people visually impaired in the World Health Organisation (WHO) 
African region is estimated to be 26 million of whom, almost 6 million are blind. (4) 
Despite Africa having a high prevalence of blindness, it is the most underserved 
continent in terms or human resources available to treat and manage eye disease, (9) 
with the greatest gap between existing need and provision. (10) 
 
The Global Burden of Disease Study conducted a major review of the prevalence of 
blindness in SSA and trends over two decades (1990-2010). Overall the prevalence 
of blindness and VI had reduced although the absolute number of people who are 
blind or VI had gone up in this period. In 2010 the estimated age-standardised 
prevalence of blindness was 1.3% (95% CI 1.1% to 1.5%) and visual impairment was 
4.0% (95% CI 0.2% to 0.3%). The major causes of blindness were; cataract 35%, 
other/unidentified causes 33.1%, refractive error 13.2%, macular degeneration 6.3%, 
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trachoma 5.2%, glaucoma 4.4% and diabetic retinopathy 2.8%. (11) PSED are defined 
as conditions primarily affecting the back of the eye include Diabetic Retinopathy, 
Age-Related Macula Degeneration, and Glaucoma.  
 
Cross-sectional population based studies from the last two decades performed in 
SSA support the main rends reported from the GBD. While cataract often 
dominates as the cause of blindness, these surveys have shown glaucoma and/or 
PSED to be either the primary or secondary cause of blindness in multiple countries. 
This includes studies from Kenya, (12, 13) Nigeria, (14) Tanzania (15), Rwanda (16), 
Cameroon (17), Ghana (18), Zanzibar (19) and Guinea (20).  
 
Posterior segment eye diseases (PSED) differ from the leading anterior segment eye 
diseases (cataract and refractive error) in prevention/treatment, as no cures 
currently exist (with the exception of angle closure glaucoma). Surgical intervention 
can restore vision in those visually impaired from cataract and provision of glasses 
can restore or improve vision in people with refractive error. However, those who 
have established visual loss from PSED cannot be cured (See Figure 1). Medical 
and/or surgical intervention for glaucoma can slow disease progression and thereby 
prevent sight loss. (21) Systematic control of diabetes mellitus (DM) and laser 
treatment to the retina in sight-threatening DR can stabilise and, to a small degree, 
improve DR status and thereby also prevent sight loss. (22) Currently no known 
cure for AMD exists, although intravitreal therapy is available for end-stage wet 
AMD (approximately 10% of all AMD cases). It is currently prohibitively expensive 
for use in most LMIC, but is widely used in high-income countries. (23) Vitamin 
supplementation has shown some evidence of risk reduction of progression of 
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subtypes of AMD (24) but not prevention of AMD (25), but again may be 
prohibitively expensive. It is therefore imperative that PSED are diagnosed early in 
their course so that early treatment and prevention of vision loss can be a realistic 
target. This remains true in SSA, as well as in other world regions. 
 
 
 
 
 
Figure 1. Blue curve showing progressive sight loss with age. Green dotted line shows effect of 
intervention in anterior segment disease (cataract, refractive error), i.e. sight restoration. The red 
dotted line shows the effect of intervention with PSED, i.e. Reduction in rate of visual loss. 
 
 
Although PSED  are frequently collated and presented as a single condition or group 
of conditions, they are clinically and pathophysiological distinct. The most common 
types of PSED are Diabetic Retinopathy, Age-Related Macula Degeneration, 
Glaucoma. These conditions form the focus of this thesis, and are described here 
briefly. 
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Glaucoma is a group of eye diseases leading to progressive sight loss. The common 
feature of glaucoma is damage to the optic nerve, which results in progressive loss of 
visual field until eventually the central vision is affected. (26) Glaucoma can be sub-
divided anatomically based on the angle formed between the cornea and iris. Primary 
open-angle glaucoma (POAG) is more common in African and Caucasian populations 
and Narrow-angle glaucoma more common in Asian populations. The only known 
modifiable risk factor is intraocular pressure (IOP), which can be reduced through 
topical, oral or intravenous medication, laser procedures or surgery. 
 
Diabetic retinopathy (DR) is one of the micro-vascular complications of diabetes and 
is a severe ocular complication of diabetes. DR is defined as the presence of typical 
retinal microvascular signs in an individual with diabetes mellitus (DM). 
Hyperglycamia (elevated blood sugar) initiates several vascular events (see figure 2) 
 
 
 
Figure 2. Pathogenesis of Diabetic Retinopathy 
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Vision loss develops from the sequelae of these pathophysiological changes at the 
macula, known as maculopathy (macular oedema and ischaemia) and from the 
formation of fragile new blood vessels known as proliferative disease.  Proliferative 
DR can lead to vitreous haemorrhage and retinal detachment. (27)  
 
These processes lead a variety of the clinical manifestations. DR is graded on the 
basis of these features: 
• Microaneurysms  
o outpouchings in the vessel walls due to pericyte loss 
• Retinal haemorrhages  
o leakage of blood from blood vessels in to the retina 
• Infarcts of the retinal nerve fibre layer known as 'cotton wool spots'  
o due to local ischaemia from poor blood/oxygen supply 
•  Intra-retinal microvascular abnormalities (IRMA) 
• Venous vessel wall dilatation ('beading') 
• Neovascularisation (new-vessel formation), seen on the disc, retina or 
iris 
Good control of blood sugar and blood pressure by persons with diabetes reduces 
the risk of developing DR, however prevention of diabetes in the fist plae must 
remain the primary public health concern. 
 
 
AMD is a degenerative condition affecting the central retina leading to central vision 
loss. It is highly associated with age and multiple classification systems are in use. (28) 
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Common descriptive terms include “dry” and “wet” AMD and “early” and “late” or 
“advanced” AMD.  Most vision loss occurs in the late stage of the disease, which is 
defined as the presence of atrophy or neovascularisation. In the dry form of the 
disease, deposits known as drusen are deposited between the retina and choroid 
and subtypes of drusen (based on size and morphology) form part of the more 
detailed classifications. Wet AMD leads to destruction of the macula architecture 
due to abnormal vessel growth (neovascularisation). These new vessels break 
through Bruch’s membrane from the choriocapillaris. Leakage (blood and protein) 
from new vessels leads to photoreceptor damage and ultimately sight loss.  
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Posterior Segment Eye Disease in Africa 
 
Cross-sectional population based studies from the last two decades performed in 
SSA have shown glaucoma and/or PSED to be either the primary or secondary cause 
of blindness. This includes studies from Kenya, (12, 13) Nigeria, (14) Tanzania (15), 
Rwanda (16), Cameroon (17), Ghana (18), Zanzibar (19) and Guinea (20) (See table 
1).  No longitudinal data on PSED from population-based studies in Africa have been 
published. A single cohort in Uganda has three-year cumulative incidence data on 
visual impairment, (age standardised incidence rate of 13.2, per 1000 PY) with AMD 
and glaucoma amongst the leading causes of visual loss in new cases. (29) However, 
no baseline data of eye health status was available in the incident cases.  
  
The majority of available prevalence data in SSA comes from the Rapid Assessment 
of Avoidable Blindness (RAAB) methodology (31), which, although a validated survey 
method (13), like more comprehensive surveys such as the Nigeria study (32) only 
examine eye health status in those found to have existing visual impairment. Since 
glaucoma patients only lose central vision at the end stage of the disease they are 
frequently missed unless visual field assessment is performed.  
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Table.  Primary and secondary causes of blindness and visual impairment by country 
in which a population based study has been performed 
 
 
Country Main cause of 
blindness 
2nd Main cause of 
blindness 
Main cause of VI 2nd Main cause of VI 
Nigeria Cataract (43.0%) Glaucoma (16.7%) Refractive Error (57.1%) Cataract (25.8%) 
Tanzania Cataract (51.2%) PSED (35.7%) Cataract (54.8%) Refractive Error (32.7%) 
Kenya Cataract (42.0%) PSED (30.4%) Cataract (36.0%) Refractive Error (31.5%) 
Rwanda Cataract (65.0%) PSED (20.0%) Cataract (54.7%) Refractive Error (29.9%) 
Eritrea Cataract (55.1%) Glaucoma (15.2%) Cataract (55.4%) Refractive Error (30.9%) 
South Sudan Cataract (41.2%) Trachoma (35.3%) Trachoma (58.1%) Cataract (29.3%) 
Cameroon  Cataract (62.1%) PSED & Oncho (13.8%) Cataract (40.0%) PSED (27.8%) 
Cameroon  PSED (29%) Cataract (21%) Cataract (48%) Refractive Error (22%) 
Zanzibar Cataract (67%) PSED (25%) Cataract (47%) Refractive Error (39%) 
Ethiopia Cataract (49.9%) Trachoma (7.7%) Cataract (42.3%) Refractive Error (33.4%) 
Ethiopia Cataract (50.4%) Trachoma (19.5%) Cataract (33.7%) Refractive Error (25.5%) 
Guinea Cataract (61.3%) Macular affection (25.3%) Cataracts (86.6%) Macular affection (29.3%) 
Malawi Cataract (48.2%) Glaucoma (15.8%) Cataract (46.3) Refractive Error (41.1%) 
Uganda Glaucoma (38.5%) Cataract (23.1%) Cataract (57.4%) Refractive Error (18.5%) 
Nigeria Cataract (46%) Surgical complications 
(20%) 
Cataract (40.3%) Refractive Error (39.8%) 
 
 
The majority of these surveys have used the WHO coding instructions, which use 
the “principal” disorder responsible for visual loss in the individual after considering 
disorders in either eye which are most amenable to treatment or prevention”(30). In 
other words, if a patient has PSED co-existent with cataract it will be deemed that 
cataract is the primary cause of blindness/VI. Therefore most VI prevalence data 
available in which cataract or refractive error is the primary cause will underestimate 
the prevalence of PSED. 
 !
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Glaucoma in Africa 
 
Current estimates suggest that there are 6.5 million people with glaucoma in sub-
Saharan Africa (SSA) with a projected increase to 8.4 million in 2020 (33). Glaucoma 
is estimated to be the second leading cause of blindness in Africa (34). These 
estimates are based on only seven population-based studies, of which two examined 
individuals of Africans descent living outside of the African continent: in Baltimore, 
USA (35) and Barbados (36). Of the five based in Africa, three were undertaken in 
South Africa (37-39) one in Ghana (40) and one in Tanzania (41). The studies used 
varying sampling methods and criteria for diagnosis of glaucoma.  
 
No specific and sensitive test for glaucoma exists. Current gold-standard diagnosis 
requires expensive visual field-testing equipment with expert interpretation of optic 
disc changes and visual field findings; the diagnosis is relatively subjective with poor 
agreement between experts. (42) Standardised definitions and classifications of 
glaucoma in recent years have allowed for better prevalence estimates and 
comparisons between populations. (26)  
 
There are several unique characteristics of glaucoma in Africa. First, POAG 
disproportionately affects individuals of African descent (33). This condition is 
difficult to diagnose in early disease and when diagnosis is confirmed there is still 
debate on the best management in the context of limited resources and prospects 
for long-term follow up (43). Second, studies have shown that those of African 
descent (not living in Africa) have a higher prevalence of glaucoma, are more likely to 
develop glaucoma at an early age with more aggressive diseases and a higher risk of 
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glaucoma related blindness than Caucasians or Asians. (44, 45). It is therefore vital 
that the epidemiology of glaucoma is investigated in more detail in various 
populations in Africa. This includes investigation of the progression and incidence of 
glaucoma in Africa, as this data is currently lacking. 
 
 
Diabetic Retinopathy in Africa 
 
Diabetes is a major threat to global public health. The estimated prevalence of 
diabetes worldwide was 285 million in 2010, representing 6.4% of the world’s adult 
population, with a prediction that by 2030 there will be 438 million people with 
diabetes (46). The most substantial increases (7 to 15 million, 111%) between 2010 
and 2030 are expected to be in Africa and the Middle East as a result of population 
growth, ageing, and the increase in obesity and sedentary lifestyles in these regions 
(47). The predicted rise in proportion of adults suffering from diabetes will inevitably 
lead to an increase in the prevalence of DR (48). 
 
The detection of DR in Africa remains a challenge; a lack of necessary equipment and 
skilled human resources (49) has contributed to there being minimal evidence 
available of the contribution of DR to blindness in African countries. 
 
Studies investigating DR in Africa have been reported in Egypt, (50) Mauritius, (51) 
South Africa (52) and Nigeria. (14) These studies are not generalisable to other 
countries in Africa, since populations in Egypt and Mauritius are ethnically and 
demographically different to the majority of African populations, the study in South 
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Africa examined only Indian sub-population and the study in Nigeria only assessed 
DR in those with existing VI.  
 
Africa is on the cusp of a DR epidemic and data are urgently needed on the 
incidence and progression of DR in order to plan treatment and preventive services. 
More information is also needed on predictors of DR in Africa, as these may vary 
compared with other settings. For instance, retinopathy may occur early in the 
course of diabetes in Africa because of late diagnosis, inadequate control of diabetes, 
and co-occurring hypertension, (53) and possibly progression is more rapid in 
populations of African origin (54).  
 
 
Age-Related Macular Degeneration in Africa 
 
The majority of data globally on AMD are from Caucasians and Asian populations 
(55-63) with a paucity of data from people of African descent. Data that do exist are 
largely from studies undertaken in African populations living outside of the African 
continent.(64, 65). Comparative data between Caucasians and Africans living in the 
same geographical area have suggested differing predispositions towards AMD, with 
possible genetically protective factors for AMD progression in individuals of African 
descent compared to their Caucasian counterparts (Baltimore, USA).(66) 
Population-based evidence of African populations living in Africa on the prevalence, 
incidence and progression of the disease, and of the risk factors for AMD is 
currently absent, but important to collect in order to plan services and gain a better 
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understanding of the aetiology of the disease. Despite recent data it is still a widely 
held belief that the prevalence of AMD in Africa is low.  
 
Eye care services in Africa 
VISION2020 is the global initiative for the elimination of avoidable blindness, 
launched in 1999, jointly by the WHO and the International Agency for the 
Prevention of Blindness (IAPB) and provides technical support and advocacy to 
prevention of blindness activities worldwide. It aims over two decades to prevent 
100 million people from becoming blind. (67) The focus of IAPB has been on cataract 
and refractive error, as leading causes of VI, as well as on causes important to 
eliminate such as trachoma and onchocerciasis. As these conditions are being 
brought under control it will be important for IAPB to develop strategies for the 
control of PSED, which will require the generation of more robust data on these 
conditions from SSA where the prevalence of blindness is highest in the world. 
 
There is wide variability between eye health service availability in different countries 
and within countries in SSA. The WHO has established targets on the number of eye 
care providers needed per million of population based on the knowledge that 75% of 
vision loss is due to a combination of uncorrected refractive errors and cataract. 
(68) However, very few countries in SSA currently meet the VISION2020 human 
resource target (five in total) for number of ophthalmologists/cataract surgeons and 
no country has yet made the target number of optometrists/refractionists. (69) 
Kenya, the focus country of this study, has met the target for ophthalmologists, but 
it remains, however, well below the target cataract surgical rate of 2,000 surgeries 
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per million of population per year (only the Gambia and Sudan are on target).The 
chronic nature of PSED and complexities in their control, makes this a pressing issue 
in terms of supporting under resourced health systems and establishing evidence 
based estimates for both the magnitude and incidence of diseases that are growing in 
public health significance.  
The focus of this thesis is therefore to explore the incidence and progression of 
PSED, in order to gain a deeper understanding of the aetiology of these conditions, 
and to generate data for planning of eye care services in SSA. 
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Research and thesis overview 
 
The review chapters assess the current epidemiological understanding of both 
cataract (chapter 2) and posterior-segment eye diseases (chapter 3) in sub-Saharan 
Africa from population based cross sectional studies and the regional specific data 
which forms the baseline of this cohort. (chapter 4) is a summary of the baseline 
findings from the cohort and the rationale for follow-up. (chapter 5) looks at the 
relationship of ophthalmic human resources and the prevalence of blindness globally 
and the gap between need and provision in sub-Saharan Africa. 
 
The methods detailing how the study was undertaken are described in (chapter 6). 
 
The data chapters provide the incidence of blindness and visual impairment (chapter 
7), diabetes mellitus and diabetic retinopathy (chapter 8), age related macula 
degeneration (chapter 9), features of glaucoma in the population (chapter 10) and 
the incidence of cataract (chapter 11).  
 
The discussion section includes a summary of the results (chapter 12), and how the 
results fit in to the broader context, strengths and limitations of the study, ongoing 
and future research and new methods (Peek) for collecting population based survey 
data and delivering screening programmes. 
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ABSTRACT
Aim We aimed to evaluate age-related cataract as a
contributor to blindness and visual impairment (VI) in
sub-Saharan Africa (SSA).
Methods A systematic review of population-based
studies published between 2000 and October 2012.
Prevalence and proportions of blindness and VI due to
cataract, cataract surgical coverage (CSC), per cent
intraocular lens (IOL) implantation and visual outcomes
of surgery in accordance with WHO criteria were
ascertained.
Results Data from 17 surveys (subjects mostly aged
≥50-years-old) from 15 different countries in SSA were
included, comprising 96 402 people. Prevalence of
blindness (presenting visual acuity <3/60 in better eye)
ranged from 0.1% in Uganda to 9.0% in Eritrea, and
the proportion of total blindness due to cataract ranged
between 21% and 67%. Cataract was the principal
cause of blindness and VI in 15 and 14 studies,
respectively. There was a strong positive correlation
between good visual outcomes and IOL use (R=0.69,
p=0.027). Considerable inter-study heterogeneity was
evident in CSC and visual outcomes following surgery,
and between 40% and 100% of operations had used
IOL.
Conclusions Cataract represents the principal cause of
blindness and VI and should remain a priority objective
for eye care in SSA. However, the prevalence of
blindness and VI due to cataract was variable and may
reﬂect differences in the availability of cataract surgical
programmes and cataract incidence.
INTRODUCTION
Cataract can manifest across one’s lifespan but its
prevalence and incidence rise with increasing age.
Age-related (or senile) cataract is the most common
cause of cataract in adults. The burden of cataract
is expected to continue to pose a greater challenge
to healthcare systems worldwide in future years,
consistent with population ageing and increases in
life expectancy.1 Of 39 million people estimated to
be blind worldwide in 2010, 51% of cases were
attributed to cataract.2 Regional variations in the
prevalence and incidence of blindness and visual
impairment (VI) due to age-related cataract exist,
with a disproportionate prevalence in low- and
middle-income populations. Africa is home to
11.9% of the global population, but 15% of the
world’s blind, the majority of which is due to
cataract.2
As no effective prevention strategies exist, man-
agement of cataract is principally surgical removal
of the lens with simultaneous correction of
aphakia. In SSA, extra-capsular cataract extraction
is usually now performed, increasingly using a
small-incision approach, although the use of pha-
coemulsiﬁcation is rising. Cataract surgery constitu-
tes one of the most cost-effective of all health
interventions.3 Blindness and VI due to cataract are
associated with reduced quality of life4 and visual
function, which can be ameliorated following surgi-
cal management.5 Considerable social and eco-
nomic disadvantages can result from cataract,
especially in poor communities, and contribute to
the perpetual cycle of poverty.6 Indeed, provision
of cataract surgery may be an effective tool in
poverty alleviation.7 Management of cataract is
recognised as a priority of the VISION2020: The
Right for Sight global strategy that targets avoidable
blindness.
Knowledge of the epidemiology of cataract is
crucial for eye care programmes in sub-Saharan
Africa (SSA) to effectively plan public health eye
care. Since the implementation of VISION2020,
several population-based blindness surveys have
been conducted globally to guide the implementa-
tion, development and extension of services, which
include provision for cataract surgery. Moreover,
newer rapid assessment methodologies have been
developed and used including the rapid assessment
of avoidable blindness (RAAB), an extension of the
rapid assessment of cataract surgical services.8 We
aimed to determine the recent epidemiology of
blindness and VI due to cataract in SSA by investi-
gating its prevalence and public health impact via
assessment of relevant WHO targets and
indicators.3
METHODS
Our literature search was conducted for the years
2000–October 2012 using Medline, Embase and
Google Scholar. Key words used included but were
not limited to: cataract, lens opacity, visual impair-
ment, low vision, blindness, presenting visual
acuity, prevalence and population. All 48 SSA
African countries as well as ‘Africa’ and
‘sub-Saharan Africa’ were used in the search terms.
Studies were included if they were population-
based with a sample size >1000, reported present-
ing visual acuity (PVA) with its causes, had a high
participation rate (>75%) and provided the stand-
ard WHO categories of visual acuity. We also
searched reference lists of studies meeting inclusion
criteria. Published studies reported in English,
French and Portuguese languages were included.
Where a population-based study of blindness had
taken place more than once in a single country,
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data from the more recent survey (provided methodology was
equivalent or superior) are presented, unless two separate geo-
graphical areas within the same country were sampled within
5 years of one another. Estimates from national surveys were
used in preference to regional estimates from the same country.
Both detailed population-based surveys and rapid assessment
methods (rapid assessment of cataract surgical services and
RAAB) were included.
Blindness was deﬁned using WHO criteria as PVA in the better
eye of <3/60 (<20/400; <1.30 LogMAR) while VI was deﬁned
as PVA in the better eye of <6/18–3/60 (<20/60–20/400;
<0.48–1.30 LogMAR), representing the sum of moderate and
severe VI. Thus, we did not investigate mild VI. All-cause preva-
lence of blindness and VI were extracted from each study as well
as the proportion of blindness and VI due to cataract. Based on
this information, the sample population prevalence of cataract
blindness and cataract-related VI were computed using the
denominator (number of persons examined), while the numer-
ator was calculated using the proportion of blindness/VI due to
cataract. We also extracted cataract surgical coverage (CSC) (at
PVA<3/60 and PVA<6/18 levels for persons), visual outcomes
following cataract surgery and their causes (good (PVA>6/18),
borderline (6/18 to 6/60) and poor (PVA<6/60)), and per cent
intraocular lens (IOL) implantation. CSC was calculated as
CSC=a/(a+c) (where a=aphakic or pseudophakic, c=cataract
blindness or VI). Last, we collected data on barriers to cataract
surgery (unoperated subjects) and satisfaction with surgery (oper-
ated subjects).
RESULTS
Data from a total of 17 surveys from 15 different countries in
SSA were included, encompassing 96 402 subjects who were
examined (table 1). Most studies examined only adults aged
≥40 or ≥50 years; however, two studies included all ages,13 15
and one ≥5 years.14 There were two studies from Cameroon,
representing one rural and one urban district.10 11 The only
other country contributing two separate published studies was
Tanzania, including RAAB surveys from Kilimanjaro and
Zanzibar.20 21 Additional RAAB surveys were performed in
Botswana,9 Burundi,22 Malawi,17 Rwanda,19 Eritrea12 and
Kenya.16 Five studies were national surveys.9 12–14 18 All studies
employed cluster random sampling, with differences in the sam-
pling used within cluster.
Blindness prevalence ranged from 0.4% in Uganda to 9.0% in
Eritrea (table 2). Only two studies—Eritrea and Ethiopia—had
blindness prevalence estimates exceeding 5%. Cataract
accounted for between 21% of blindness in Cameroon and the
highest proportion, 67%, was in Zanzibar, Tanzania. Cataract
was the principal cause of blindness in 15 of 17 studies.
The prevalence of VI (sum of moderate and severe VI) ranged
from 1.6% in Gambia and Uganda to 17.1% in Ghana (table 3).
Table 1 Population-based studies from sub-Saharan Africa with data on blindness and age-related cataract
Country Level
Year
published
Sampling
method
Sampling within
cluster
Sample size (number
examined)
Response rate
(%)
Age
(years) References
Botswana National 2009 CRS Compact segment
sampling
2127 79.9 ≥50 9
Burundi Provincial 2012 CRS Compact segment
sampling
3684 97 ≥50 22
Cameroon Limbe 2007 CRS Compact segment
sampling
2215 92.3 ≥40 10
Cameroon Muyuku 2006 CRS Random walk 1787 89.3 ≥40 11
Eritrea National 2011 CRS Compact segment
sampling
3163 95.9 ≥50 12
Ethiopia National 2007 CRS Random walk 25 650 85.4 All 13
Gambia National 2000 CRS Compact segment
sampling
13 046 92 ≥5 14
Ghana City 2012 CRS House to house
census
5603 82.3 ≥40 38
Guinea District, Bioko 2002 CRS Household cluster
sampling
3218 NS All 15
Kenya District, Nakuru 2007 CRS Compact segment
sampling
3503 92.6 ≥50 16
Malawi District 2011 CRS Compact segment
sampling
3430 95.7 ≥50 17
Mali Subnational 2008 CRS Compact segment
sampling
2438 NS ≥50 39
Nigeria National 2009 CRS Random walk 13 599 89.9 ≥40 18
Rwanda Western province 2007 CRS Compact segment
sampling
2206 98 ≥50 19
South Sudan District 2006 CRS Random walk 2499 84.6 ≥5 40
Tanzania
(Kilimanjaro)
Regional 2010 CRS Random walk 3436 95.5 ≥50 20
Tanzania
(Zanzibar)
Island 2007 CRS Compact segment
sampling
3160 98.8 ≥50 21
Uganda 15 neighbouring
villages
2002 CRS NS 4076 98.9 ≥13 41
CRS, cluster random sampling; NS, not stated.
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Cataract was the major cause of VI in 14 of 17 studies. The
prevalence of VI due to cataract ranged from 18% to 87%.
CSC data were variable, and for blind persons ranged from
15% in Burundi to 80% in Limbe, Cameroon. This included
aphakia and pseudophakia; and for patients who had received
cataract surgery, between 62% and 100% had an IOL (table 4).
In terms of PVA, the proportion of good outcomes ranged from
23% to 70%. Poor outcomes (VA<6/60) accounted for more
than 20% in all studies and ranged from 23% to 64%.
There was a strong positive correlation between good visual
outcomes and IOL use (R=0.69, p=0.027). There was an
inverse correlation between IOL use and poor visual outcome
Table 2 Prevalence and leading causes of blindness (PVA<3/60 in worse eye) in sub-Saharan Africa
Country
Bilateral blindness
prevalence (95% CI)
Main cause of
blindness
Proportion of
blindness (%)
2nd Main cause of
blindness
Proportion of
blindness (%)
Prevalence of
cataract blindness References
Botswana 3.69 (2.4 to 5.0) Cataract 47 NS NS 1.7 9
Burundi 1.1 (0.8 to 1.4) Cataract 55 PSED 37 0.6 22
Cameroon
(Limbe)
1.1 (0.7 to 1.5) PSED 29 Cataract 21 0.2 10
Cameroon
(Muyuka)
1.6 (0.8 to 2.4) Cataract 62 PSED and
onchocerciasis
14 1.0 11
Eritrea 9.0 (8.0 to 10.0) Cataract 55 Glaucoma 15 5.0 12
Ethiopia 7.9 (6.9 to 8.9) Cataract 50 Trachoma 20 4.0 13
Gambia* 0.42 Cataract 45 Other corneal 16 0.2 14
Ghana† 1.2 Cataract 44 Glaucoma 22 0.5 38
Guinea 3.2 (2.6 to 3.9) Cataract 61 Macular affection 25 2.0 15
Kenya 2.0 (1.5 to 2.4) Cataract 42 PSED 30 0.8 16
Malawi 3.3 (2.5 to 4.1) Cataract 48 Glaucoma 16 1.6 17
Mali 11.07 (9.55 to 12.6) Cataract 61 Surgical
complications
10 6.8 39
Nigeria 4.2 (3.8 to 4.6) Cataract 43 Glaucoma 17 1.8 18
Rwanda 1.8 (1.2 to 2.4) Cataract 65 PSED 20 1.2 19
South Sudan 4.1 (3.4 to 4.8) Cataract 41 Trachoma 35 1.7 40
Tanzania
(Kilimanjaro)
2.4 (1.9 to 2.9) Cataract 51 PSED 36 1.2 20
Tanzania
(Zanzibar)
3.7 Cataract 67 PSED 25 2.5 21
Uganda 0.4 (0.3 to 0.7) Glaucoma 39 Cataract 23 0.1 41
*Estimates for ≥50 years.
†This study excludes refractive error from table of blindness/VI aetiology.
NS, not stated; PSED, posterior segment eye disease; PVA, presenting visual acuity; VI, visual impairment.
Table 3 Leading causes of visual impairment (VI) in sub-Saharan Africa
Country Main cause of VI Proportion of VI (%) 2nd Main cause of VI Proportion of VI (%) References
Botswana Cataract 59 NS NS 9
Burundi Refractive error 67 Cataract 18 22
Cameroon (Limbe) Cataract 48 Refractive error 22 10
Cameroon (Muyuka) Cataract 40 PSED 28 11
Eritrea Cataract 55 Refractive error 31 12
Ethiopia Cataract 34 Refractive error 26 13
Gambia Cataract 61 (≥50 years) Uncorrected aphakia 12 (≥50 years) 14
Ghana* Cataract 53* Glaucoma 14* 38
Guinea Cataract 87 Macular affection 29 15
Kenya Cataract 36 Refractive error 32 16
Malawi Cataract 46 Refractive error 41 17
Mali Cataract 61 Refractive error 22 39
Nigeria Refractive error 57 Cataract 26 18
Rwanda Cataract 55 Refractive error 30 19
South Sudan Trachoma 58 Cataract 29 40
Tanzania (Kilimanjaro) Cataract 55 Refractive error 33 20
Tanzania (Zanzibar) Cataract 47 Refractive error 39 21
Uganda Cataract 57 Refractive error 19 41
VI 6/18 to 3/60.
*This study excludes refractive error from table of blindness/VI aetiology.
NS, not stated; PSED, posterior segment eye disease.
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(R=−0.31, p=0.384). There was an inverse relationship
between the proportion of blindness due to cataract and CSC
(persons, blindness; R=−0.50, p=0.137). There was an
inverse relationship between CSC (blind) and good visual
outcome (R=−0.34, p=0.37).
The causes of a poor visual outcome, barriers to cataract surgery
and satisfaction rates with surgery were identiﬁed (table 5).
Insertion of an IOL is consistently associated with having a good
visual outcome. Lack of awareness and inability to pay were fre-
quently cited as major barriers to cataract surgery. The majority of
individuals surveyed reported being satisﬁed with their surgery.
DISCUSSION
We have provided an up-to-date review on blindness and VI due
to cataract in SSA obtained from 17 studies of nearly 100 000
individuals. Wide differences in estimates of blindness and VI
prevalence due to cataract were evident in this study, but cata-
ract remains the principal cause of blindness in SSA. Although
cataract prevalence is high in some Asian and South American
populations it is on average lower than Africa and much lower
in areas of higher HDI.23
Unsurprisingly, the population with the lowest blindness preva-
lence in this study, Uganda, has had a strong recent history of suc-
cessful eye care programme delivery. The differences between
countries are striking: a 74-fold difference in cataract blindness
prevalence between Uganda and Mali who have similar GDP (per
capita) of US$487 and US$669, respectively (World Bank 2011).
Successful blindness prevention programme delivery and available
cataract surgical services and human resources especially in rural
areas, shorter distances and easier transport for patients, affordable
fee structures or free services, and cultural barriers to service
access may account for these huge differences. Further studies are
required to quantify the resources required to make such differ-
ences and to examine how this has been achieved.
It has been suggested that a cataract surgical rate (CSR) of
≥2000 operations/million population/year should be achieved
annually to eliminate unnecessary blindness due to cataract in
Africa.24 This benchmark is in stark contrast to the current situ-
ation in many parts of Africa, with over 80% of WHO member
states in Africa having a CSR<1000.3 A substantial increase in
CSR is needed to reduce blindness and VI due to cataract in
SSA. Worse HDI ranks are associated with a higher prevalence
of cataract blindness, and in SSA a much higher proportion of
individuals undergoing surgery for cataract have preoperative
blindness or SVI compared with higher-income populations.25
The challenge remains reaching blind and visually impaired
people by providing accessible, affordable and sustainable cata-
ract surgical services.
Importantly, any increase in cataract surgical output is usually
accompanied by an increase in outcome. The proportion of
good outcomes ranged from 23% to 70%, all of which fail to
reach WHO target that ≥85% of eyes should achieve PVA<6/18
postoperatively. These proportion of good visual outcomes in
most studies were markedly lower than from recent hospital-
based studies on this continent.26 27 Prospective monitoring of
outcomes can improve quality,28 with a dynamic and learning
process for the surgeon of focusing on reducing surgical compli-
cations, greater emphasis on appropriate selection, need for
spectacle correction and sequelae of surgery. In many settings,
non-physician cataract surgeons provide the majority of cataract
surgery. There remains controversy as to whether this cadre of
surgeons is ideal to meeting the cataract surgical needs in SSA.
Greater regulation and long-term training of physician-surgeons
may provide a better long-term solution.
Population-based data on visual outcomes are highly valuable as
clinic/hospital-based outcome estimates are not often representa-
tive of the visual status in the community. However, as modern
techniques using extra-capsular cataract extraction with IOL
implantation are now ubiquitous in almost all areas of SSA,
population-based outcomes are likely to be worse as they may
capture outcomes for surgeries performed many years prior (eg,
intracapsular cataract extraction). Uncorrected aphakia remains an
important contributor to blindness and VI in many areas of SSA.29
More recently, performed cataract surgery is associated with more
frequent use of lOL,16 30 which in turn is positively correlated
with a good visual outcome. In some areas, cataract removal by
couching leading to aphakia is associated with extremely poor
visual outcomes, even with aphakic correction.31
Poor visual outcomes ranged from 23% to 64%, with the
causes of poor outcomes being variable, and representing differ-
ences in expertise, resources and monitoring/surveillance.
Understanding the causes of such poor outcomes is vital. Visual
outcomes can be ameliorated with improved case selection and
avoidance of surgery in patients who will not beneﬁt; improving
Table 4 CSC, visual outcomes following cataract surgery and per cent IOL use in sub-Saharan Africa
CSC (VA<6/18) persons CSC (blind persons (PVA<3/60)) Visual outcome (PVA)
Country Total persons Males Females Total persons Male Female Good (PVA>6/18) Poor (PVA<6/60)
IOL
(% of all operated eyes)
Botswana 53 62 48 62 73 55 NS NS NS
Burundi 12 9 13 22 17 24 70 30 100
Cameroon (Limbe) NS NS NS 80 NS NS 23 58 69
Cameroon (Muyuka) NS NS NS 55 NS NS 25 64 68
Eritrea 48 50 46 68 71 65 41 39 75
Kenya 51 51 51 78 78 78 50 31 58
Malawi 16 25 10 45 62 30 41 32 68
Mali 34 39 30 59 70 51 28 58 33
Nigeria NS NS NS NS NS NS 30 41 40
Rwanda 21 24 19 47 64 36 24 41 62
Tanzania (Kilimanjaro) 42 48 37 70 73 67 59 23 87
Tanzania (Zanzibar) 20 25 17 60 77 49 32 38 68
No data were available from Ethiopia, Ghana, Guinea, South Sudan and Uganda.
CSC, cataract surgical coverage; IOL, intraocular lens; NS, not stated; PVA, presenting visual acuity.
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Table 5 Causes of poor outcome and barriers to cataract surgery in studies with available data in sub-Saharan Africa
Causes of poor outcome
Country
Selection/
comorbidity
Surgical
complications
Uncorrected refractive
error, aphakia, late
sequelae Associations with poor outcome Barriers to surgery
Satisfaction with surgery
(postoperative subjects)
Cameroon
(Limbe)
NS Aphakia (compared with IOL use)
Older age
Inability to pay (40%), lack of awareness (17%), a feeling
they could cope with the cataract (10%) and that they
were waiting for cataract to mature (8%)
NS
Cameroon
(Muyuka)
NS Aphakia (compared with IOL use)
Older age
Lack of awareness of cataract (33.3%), inability to pay
(30.1%) and a feeling they could cope with the cataract
(9.6%)
NS
Eritrea 27% 24% 48% Having surgery performed at a voluntary or
charitable hospital compared with a
government hospital
30% reported ‘Cannot afford’, followed by ‘Waiting for
maturity’ (18%), ‘No company’ (17%), ‘Contra-indication’
(12%) and ‘Old age, no need’ (10%)
NS
Kenya 36% 30% 34% Not specified for poor outcome
However, good outcome was more likely if the
surgery was with an IOL, performed in last
5 years or undertaken in a volunteer/charity
hospital or private hospital rather than a
government hospital or eye camp
‘Not aware of surgery’ (34.1%), ‘cannot afford the
operation’ (24.4%) and ‘no one to take me’ (12.2%)
64% were very satisfied, 19% were
somewhat satisfied, 5% were
indifferent, and 12% were somewhat or
very dissatisfied
Malawi 40% 47% 13% NS Old age (‘no need felt’) was reported to be the
commonest barrier (23.5%) followed by ‘no one to
accompany’ (22.1%), ‘no services nearby’ (13.2) and
‘unaware that treatment was available’ (11.8%)
84.8% of all persons who had surgery
were either very satisfied or partially
satisfied. Only 3% of persons were very
unsatisfied with the results of surgery
Nigeria
NB: Barriers
refers to
Abubakar et al42
NS 19% 50% In multivariate analysis of data on
first-operated eyes, the only variable associated
with poor outcome (<6/60 at presentation) was
non-IOL surgery
Cost of surgery (over a third), other personal factors (a
quarter), and another quarter cited barriers such as being
too old, not knowing where to go and fear of surgery.
Provider-related factors, such as being told to attend later,
were reported by 9.8%
There were significant rural–urban differences in cost as a
barrier
NS
This refers to: Imam et al30
Rwanda 25% 50% 25% NS Lack of awareness of the availability of treatment (52%),
followed by a perceived lack of services (16%), inability to
afford the surgery (16%) and lack of a companion (8%)
41% were very satisfied, 28% were
partially satisfied, indifferent (7%),
partially dissatisfied (17%) or very
dissatisfied (7%)
Tanzania
(Kilimanjaro)
31% 38% 25% Eyes with an IOL had significantly better vision
than eyes without
NS NS
Tanzania
(Zanzibar)
The major cause of poor outcome for operations >3 years ago
was selection and presently it is due to sequelae
Surgery was a major cause for poor outcome for both time
periods
NS Unaware of treatment (30%), waiting for cataract to
mature (20%) and cost (10%)
56% very satisfied, 25.9% partially
satisfied, 7.9% very dissatisfied
IOL, intraocular lens; NS, not stated.
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the quality of surgery and avoiding surgical complications;
improving the operative (IOL) and/or postoperative correction
of refractive error and; and reducing late postoperative compli-
cations.32 Further cataract surgery outcomes data are needed
from studies in SSA, and globally, to assess not only the import-
ance and complexity of good outcomes and to revisit the para-
meters set by WHO, but most importantly to understand and
disseminate knowledge about how to improve outcomes.
It is intuitive that in order to reduce the blindness and VI due
to cataract the CSR needs to exceed the cataract incidence rate.
Lewallen et al have modelled the incidence of vision-reducing
cataract in Africa using data from RAAB surveys.33 Such derived
estimates may assist further with the planning of services in this
resource-poor region where incidence estimates are scarce and
have indicated disparities in cataract incidence in this continent.
WHO recommends the establishment of ≥1 cataract unit per
district of a million population in order to deal with cataract
blindness and VI.3 CSRs also reﬂect variations in genetic, envir-
onmental, or cultural factors and will vary with population
structure, which is not uniform across Africa.33
Two indicators can measure the impact of initiatives to target
cataract. First, performing serial cross-sectional population-based
surveys to demonstrate evidence of a reduction in prevalence of
cataract (and blindness and VI due to cataract) over time.14 34
Another indicator is to measure the CSC which represents a ratio
of the met and unmet need for cataract surgery and is a measure-
ment of the capability of a healthcare system to provide cataract
surgical services to the population.35 In these studies, the CSC
for persons for blinding cataract ranged from 22% to 70%, and
was usually higher in men reﬂecting probably gender inequity in
access to cataract surgical services.36 CSR is positively correlated
with CSC,25 but CSC does not take into account the quality of
surgery provided.
There are several limitations to this review. Inter-study differ-
ences exist with relation to the size, age/gender composition,
response rates and degree of urbanisation as well as degree of
government and non-government organisation involvement in
the surveyed areas. Such differences may account for some of
the heterogeneity between individual results. RAAB surveys have
several disadvantages including their lack of detailed cataract
phenotype information. Nonetheless, the validity of the RAAB
compared with a more detailed survey is high.37
In conclusion, cataract is by far the most common cause of
blindness and VI in SSA. Efforts to reduce the burden of blind-
ness and VI due to cataract should incorporate high-volume,
high-quality, affordable cataract surgery that greatly improves the
CSR and CSC in such populations. This can be achieved by the
implementation of well-run, cost-effective and sustainable cata-
ract units at the district level. Wide variation in the prevalence of
cataract blindness has been shown in this review, and although
this may be due to disparities in eye care programme delivery, it
may also reﬂect inter-population differences in cataract incidence.
The fundamental problems highlighted by this review are that
currently too few cataract surgeries are being performed and
there are too many poor outcomes. An open and urgent appraisal
of positive successes throughout SSA should be performed and
shared.
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Abstract objective To assess the burden of posterior segment eye diseases (PSEDs) in sub-Saharan Africa (SSA).
methods We reviewed published population-based data from SSA and other relevant populations
on the leading PSED, specifically glaucoma, diabetic retinopathy and age-related macular
degeneration, as causes of blindness and visual impairment in adults. Data were extracted from
population-based studies conducted in SSA and elsewhere where relevant.
results PSEDs, when grouped or as individual diseases, are a major contributor to blindness and
visual impairment in SSA. PSED, grouped together, was usually the second leading cause of blindness
after cataract, ranging as a proportion of blindness from 13 to 37%.
conclusions PSEDs are likely to grow in importance as causes of visual impairment and blindness
in SSA in the coming years as populations grow, age and become more urban in lifestyle. African-
based cohort studies are required to help estimate present and future needs and plan services to
prevent avoidable blindness.
keywords glaucoma, diabetic retinopathy, age-related macular degeneration, posterior segment eye
disease, prevalence, incidence, blindness, visual impairment, Africa
Introduction
Non-communicable diseases in low- and middle-income
countries
In recent decades, there has been a marked rise in life
expectancy that has contributed to a major epidemiologi-
cal shift in populations worldwide (Lopez et al. 2006).
These changes will increasingly lead to major public
health issues in low- and middle-income countries
(LMIC; Mathers & Loncar 2006). Current projections
suggest that non-communicable diseases (NCDs) will con-
tribute to two-thirds of global mortality by the year 2030
(Mathers & Loncar 2006). NCDs in LMIC have shown
substantial variation in prevalence, incidence, natural
history and risk factors compared with NCDs in popula-
tions in high-income countries (Boutayeb 2006).
Visual impairment and blindness
285 million people are visually impaired (VI) worldwide,
(severe visual impairment (SVI) defined as presenting
visual acuity (PVA) <6/60 but ≥3/60, moderate VI defined
as PVA <6/18 but ≥6/60) of whom 39 million are blind
(presenting visual acuity <3/60 in the better eye; Pascolini
& Mariotti 2012). Approximately 90% of those world-
wide with VI live in low-income countries. NCDs are the
leading causes of VI, in part due to the successful control
of infectious diseases. VI is ranked sixth in the top ten
causes of burden of disease in terms of disability-adjusted
life-years (DALYs) in low-income, middle-income and
high-income countries (Chiang et al. 2006). The sum of
DALYs from VI is 66 290 000 (4.3% of total), just
below HIV/AIDS at 71 460 000 (4.7%).
The number of people visually impaired in the World
Health Organization (WHO) African region is estimated
to be 26 million, of whom almost 6 million are blind.
This is based on estimates from population-based studies
in Botswana, Cameroon, Eritrea, Ethiopia, Gambia,
Ghana, Kenya, Mali, Nigeria, Rwanda, Uganda and Tan-
zania (Pascolini & Mariotti 2012). Despite Africa having
one of the highest prevalences of blindness, it is the most
underserved continent in terms of human resources
© 2014 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1
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available to treat and manage eye disease (Resnikoff
et al. 2012), with the greatest gap between existing need
and provision (Bastawrous & Hennig 2012).
In 2010, the WHO reported the leading causes of
visual impairment (VI) and blindness (Pascolini &
Mariotti 2012). Of these, three of the nine listed leading
causes are NCDs which are posterior segment in location,
(i.e. affecting the back of the eye). Posterior segment eye
disease (PSED) epidemiologically is commonly defined as
diseases of the retina, choroid and optic nerve and
primarily includes: glaucoma, age-related macular
degeneration (AMD) and diabetic retinopathy (DR).
These three conditions are the focus of this paper but do
not constitute all PSEDs. See Figure 1.
PSED and VISION2020
VISION2020 is the global initiative for the elimination of
avoidable blindness, launched in 1999, jointly by WHO
and the International Agency for the Prevention of Blind-
ness (IAPB) and provides technical support and advocacy
to prevention of blindness activities worldwide. It aims
over two decades to prevent 100 million people from
becoming blind.
VISION2020 has largely focused on the elimination of
anterior segment diseases, primarily cataract, as it alone
causes almost half of blindness and is amenable to cure
through surgery. VISION2020 has not focused on PSED
to date mostly due to a lack of data on the magnitude of
these conditions and lack of cost-effective treatment
options. This review aims to establish the magnitude of
visual impairment and blindness in SSA that can be
attributed to PSED.
Materials and methods
Our literature search was conducted for the years 1966
to September 2012 using PubMed. Keywords used
included the following: posterior segment eye disease,
glaucoma, age-related macular degeneration, diabetic
retinopathy, correctable visual impairment, preventable,
avoidable, Africa (MeSH), aphakia, blindness, visual
impairment, prevalence and population.
Studies were selected for inclusion if they were popula-
tion based, performed in sub-Saharan Africa with a sam-
ple size >1000, reported visual acuity impairment with its
causes, had a high participation rate (>80% of the tar-
geted sample) and presented results using the standard
WHO categories of VA. WHO definitions of visual
impairment are used (WHO/ICD-10 2007). We also
searched reference lists of studies meeting inclusion crite-
ria. Only published data were included.
All-cause prevalence (and 95% confidence interval
[CI]) of blindness, SVI and moderate VI was extracted
from each study, as well as the proportion of blindness,
SVI and moderate VI due to PSED (grouped or as single
diseases when available); then, the prevalence of blind-
ness, SVI and moderate VI due to PSED was calculated
from these estimates.
Results
Search results
In total, the initial search criteria identified 112 potential
manuscripts for inclusion. Review of the abstracts
reduced this to 39 potential studies, of which 17 sur-
veys, from 13 SSA countries, encompassing 88 067 indi-
viduals were included for analysis having fully met the
pre-specified search criteria. Data from the following
countries are presented: Burundi (Kandeke et al. 2012),
Cameroon (Oye et al. 2006; Oye & Kuper 2007), Eri-
trea (Muller et al. 2011), Ethiopia (Berhane et al. 2007),
Ghana (Budenz et al. 2012), Guinea (Moser et al.
2002), Kenya (Mathenge et al. 2007a, 2012), Malawi
(Kalua et al. 2011), Nigeria (Adegbehingbe et al. 2006;
Abdull et al. 2009), Rwanda (Mathenge et al. 2007b),
South Sudan (Ngondi et al. 2006), Tanzania (Kikira
Anterior segment Posterior segment
Cornea
Corneal opacity
Cataract
Refractive error Glaucoma
Diabetic retinopathy
Macula degeneration
Choroid
Retina
Optic nerve
Lens
Trachoma
Figure 1 Cross-sectional diagram of the
eye demonstrating the anterior and
posterior segments and their potential
diseases.
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2007; Habiyakire et al. 2010) and Uganda (Mbulaiteye
et al. 2002).
Posterior segment eye disease
Although PSEDs are frequently collated in SSA-based epi-
demiological studies and presented as a single entity or
group of conditions, they are clinically and pathophysio-
logical distinct. The most common methodological
approach deployed in SSA population-based studies, the
rapid assessment of avoidable blindness (RAAB; Dineen
et al. 2006), is not sufficiently sensitive to differentiate
posterior segment causes of low vision and hence
presented results are often collated.
Posterior segment eye disease in Africa
Cross-sectional population-based studies from the last
two decades performed in Africa have shown PSED to be
consistently the second (and occasionally the most com-
mon) leading cause of blindness. This includes studies
from Kenya (Mathenge et al. 2007a, 2012), Nigeria
(Rabiu & Muhammed 2008; Abdull et al. 2009), Tanza-
nia (Kikira 2007; Habiyakire et al. 2010), Rwanda
(Mathenge et al. 2007b), Cameroon (Oye et al. 2006;
Oye & Kuper 2007), Ghana (Guzek et al. 2005), Guinea
(Moser et al. 2002), Burundi (Kandeke et al. 2012) and
Ghana (Budenz et al. 2012; See Table 1). No longitudi-
nal data on PSED from population-based studies in
Africa have been published. A single cohort in Uganda
has 3-year cumulative incidence data on visual impair-
ment, (age-standardised incidence rate of 13.2, per 1000
PY) with AMD and glaucoma amongst the leading causes
of visual loss in new cases (Mbulaiteye et al. 2003).
However, no baseline clinical phenotyping data were col-
lected in eyes initially without visual impairment, so early
asymptomatic disease was not excluded.
The majority of available prevalence data in Africa
come from the rapid assessment of avoidable blindness
(RAAB) methodology (Dineen et al. 2006). Although
RAAB is a validated survey method (Mathenge et al.
2012), it has a limitation in common with more com-
prehensive surveys such as the Nigeria study (Dineen
et al. 2008) in that detailed eye examinations are only
performed in those found to have impairment of their
visual acuity. As glaucoma patients usually lose central
vision at the end stage of the disease, they are frequently
missed unless visual field assessment is performed. Fur-
thermore, ophthalmic assessment in RAAB relies on
direct ophthalmoscopy, constraining diagnostic accuracy,
so that the diseases are pragmatically grouped together
as one unit.
The majority of these surveys have used the WHO cod-
ing instructions, which use the ‘principal disorder respon-
sible for visual loss in the individual after considering
disorders in either eye which are most amenable to treat-
ment or prevention’ (World Health Organization 1988).
In other words, if a patient has PSED coexistent with cat-
aract, it will be deemed that cataract is the primary cause
of blindness/VI. Therefore, most VI prevalence data avail-
able in which cataract or refractive error is the primary
cause will underestimate the prevalence of PSED at all
levels of visual acuity.
Glaucoma in Africa
Prevalence. Current estimates suggest that there are 6.5
million people with glaucoma at all levels of vision in
sub-Saharan Africa (SSA) with a projected increase to 8.4
million in 2020 (Quigley & Broman 2006). Glaucoma is
estimated to be the second leading cause of blindness in
Africa (Cook 2009). These estimates undertaken by
Quigley and Broman (2006) are based on seven popula-
tion-based studies, of which two examined individuals of
African descent living outside of the African continent: in
Baltimore, USA (Leske et al. 1994) and Barbados (Tielsch
et al. 1991a) which has multiple limitations for inferring
data. Of the five based in Africa, three were undertaken
in South Africa (Salmon & Martell 1994; Rotchford &
Johnson 2002; Rotchford et al. 2003), one in Ghana
(Ntim-Amponsah et al. 2004) and one in Tanzania
(Buhrmann et al. 2000). The studies used varying sam-
pling methods and criteria for diagnosis of glaucoma.
No specific and sensitive test for glaucoma exists.
Current reference standard diagnosis requires expensive
visual field-testing equipment with expert interpretation
of the optic disc and visual field findings. Standardised
definitions and classifications of glaucoma in recent years
have allowed for better prevalence estimates and compar-
isons between populations (Foster et al. 2002).
Glaucoma may be congenital or acquired and further
subclassified into open-angle and closed-angle based on
the mechanism by which aqueous outflow from the eye is
compromised. The ‘angle’ refers to the junction between
cornea and iris, which forms an angle of varying degree
in each eye. Generally speaking, in glaucoma, when this
angle is large and the structures within it are visible on
clinical examination (gonioscopy), it is termed ‘open-
angle glaucoma’ and when these structures are limited or
not visible due to a narrow angle, it is termed ‘closed- or
narrow-angle glaucoma’ (Kanski 2007). Primary open-
angle glaucoma (POAG) disproportionately affects indi-
viduals of African descent (Quigley & Broman 2006)and
is difficult to diagnose in early disease, and when
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diagnosis is confirmed, there is still debate on the best
management in the context of limited resources and
prospects for long-term follow-up (Quigley et al. 2000).
Narrow-angle glaucoma prevalence is not well reported
in African populations, this is in large part due to gonios-
copy not being performed in the frequently used RAAB
methodology and also in other more comprehensive
surveys (Mathenge et al. 2012).
People of African descent (not living in Africa) have a
higher prevalence of glaucoma, are more likely to develop
glaucoma at an early age with more aggressive disease and
have a higher risk of glaucoma related blindness than Cau-
casians or Asians (Mason et al. 1989; Tielsch et al. 1991b).
It is therefore vital that the epidemiology of glaucoma is
investigated in more detail in various populations in Africa.
Comprehensive reviews on glaucoma in Africa were
published in 2009 (Cook 2009) and 2013 (Kyari et al.
2013), no new data from African population-based stud-
ies have since been published since 2009. The authors are
aware of awaited data to be published from study groups
in Nigeria (Dineen et al. 2008), Ghana and Kenya
(Mathenge et al. 2012).
Current data on glaucoma underestimate the true preva-
lence, as many cases of glaucoma have preservation of cen-
tral vision and do not include visual field assessment (Cook
2009). Furthermore, preferential coding of cataract due to
its reversible nature often means that glaucoma is not
assigned as the primary cause of blindness in a patient with
visual loss from coexistent glaucoma and lens opacity, as
per WHO criteria (World Health Organization 1988).
Incidence. It is assumed that incidence of glaucoma in
Africa will most closely reflect that of the Barbados Eye
Study, whose enrolled participants were of West African
descent (Leske et al. 2001, 2007). All other studies with
data on glaucoma incidence have been conducted in lar-
gely Caucasian populations: the Ponza Eye Study
(Cedrone et al. 2012), the Dalby Eye Study (Bengtsson
1991), the Blue Mountain Eye Study (Chandrasekaran
et al. 2006), the Melbourne Visual Impairment Study
(Dimitrov et al. 2003) and the Rotterdam Eye Study (de
Voogd et al. 2005). Annual incidence of new glaucoma
in these studies varied from 0.1 to 0.6%, the highest
being in the Barbados Eye Study which was largely made
up of people of African descent. To date, no data on
incident glaucoma or glaucoma progression from
population-based studies in Africa are available.
Diabetic retinopathy in Africa
Prevalence. Diabetes is a major threat to global public
health. The estimated prevalence of diabetes worldwide
was 285 million in 2010, representing 6.4% of the
world’s adult population, with a prediction that by 2030
there will be 438 million people with diabetes (DF 2009).
The most substantial increases (7 to 15 million, 111%)
are expected to be in Africa and the Middle East as a
result of various factors including population growth,
ageing, urbanisation, dietary changes and the increase in
obesity and sedentary lifestyles in these regions (King &
Herman 1998).
Although no data exist from population-based studies
(PBS) in Africa directly comparing ethnic variation as a risk
for DR, a hospital-based study in South Africa estimated
the prevalence of DR amongst patients with adult-onset
diabetes attending a large community hospital to be similar
in patients of African (37%), European (41%) or Indian
(37%) heritage. However, ‘severe DR’ (study specific clas-
sification) was significantly more frequent in Africans
(52%) and Indians (41%) than Europeans (26%; Kalk
et al. 1997). The predicted rise in proportion of adults
suffering from diabetes will inevitably lead to an increase
in the prevalence of DR (Williams et al. 2004).
The detection of DR in Africa remains a challenge in
part due to a lack of necessary equipment and skilled
manpower (Rotimi et al. 2003). The authors of this
review [also cited in reference: (Burgess et al. 2013)]
identified two high-quality, population-based, cross-sec-
tional studies reporting DR prevalence in Africa (but not
SSA). The Diabetes in Egypt project (1993; Herman et al.
1998) reported the proportion of DR and PDR in indi-
viduals with diabetes to be 31.6% and 0.9%, respec-
tively. The Mauritius diabetes complication study (Dowse
et al. 1998) reported 30.2% DR and 1.3% PDR; the
prevalence of PDR in subjects with known diabetes was
2.3%. These figures are comparable with prevalence esti-
mates reported in recent American and European studies.
Egypt and Mauritius are ethnically and demographi-
cally very different to most countries of sub-Saharan
Africa; the findings of these studies should be generalised
to other settings with caution.
There are also estimates of the prevalence of DR
amongst diabetics from high-quality clinic-based studies
in Africa. Very high prevalences of DR, PDR and macul-
opathy have been reported. A study from Malawi
reported 32.0% DR, 5.7% PDR, 15% sight-threatening
maculopathy (Glover et al. 2012). Two separate studies
from South Africa have found comparable results: Mash
et al. found 62.4% DR, 6.1% PDR and 15.2% with any
maculopathy (Mash et al. 2007); Rotchford et al. found
DR 40.3%, PDR 5.6%, 10.3% CSME (Rotchford 2002).
Evidence from unpublished data supports urbanisation
as a risk factor for DR. Slit-lamp assessment of the retina
assessing DR in a South-African PBS (Rotchford &
© 2014 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 5
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Johnson 2002; Rotchford et al. 2003) demonstrated a
0.7% prevalence of DR (NPDR 0.6%, PDR 0.1%) in
rural communities and a 2.1% prevalence of DR (NPDR
1.8%, PDR 0.3%) in urban communities (A. Rotchford,
unpublished data).
Estimates of the proportion of African patients with
diabetes who are visually impaired are high even com-
pared with older European and American studies. The
population-based Nigerian national blindness and visual
impairment survey was conducted between 2005 and
2007 (Abdull et al. 2009). DR was identified as the pri-
mary cause of visual impairment in 0.29% of 3129 sub-
jects with uncorrected VA worse than 6/12 and in 0.5%
of those with acuity less than 3/60. This study is likely to
underestimate the visual impact of DR as examiners were
instructed to preferentially record treatable, rather than
preventable, causes of visual impairment.
Incidence. No population-based cohort study was identi-
fied providing incidence data on DR in SSA. However,
two cohort studies of DR in Africa were identified by this
review, one of which was in SSA. A survey of diabetes
complications in Mauritius was followed up 6 years later
(Dowse et al. 1998). Of subjects with diabetes in the ini-
tial survey 40.5% were re-examined for DR (Tapp et al.
2006). Six-year incidence of DR was 23.8%. Duration of
diabetes and fasting blood glucose were independently
associated with incidence of retinopathy. Six-year pro-
gression to PDR was reported from no DR (0.4%), mild
NPDR (5.2%) and moderate NPDR (29.4%).
In South Africa, a cohort of patients with insulin-
dependent diabetes mellitus (IDDM) diagnosed before
age 30 years was followed up over time (Gill et al.
1984). In those subjects seen after 10 years of follow-up,
prevalence of DR had increased from 6% to 52% and
PDR from 0 to 3% (Gill et al. 1995). In subjects seen at
20 years, prevalence of DR had increased from 12% to
59%. No incidence data were collected (Gill et al. 2005).
No other prospective cohort studies were identified.
However, a study reflecting cumulative incidence of DR
from South Africa (Distiller et al. 2010) reported on 1520
type 1 and 8026 t ype 2 patients who had maintained
membership for ≥5 years in a community-based, privately
funded diabetes management programme. In type 1 partici-
pants, the prevalence of any retinopathy at baseline and at
5 years was 22.3% and 28.0%, respectively, and in type 2
participants 20.5% and 26.6%, respectively.
Age-related macular degeneration in Africa
Prevalence. The majority of data globally on AMD are
from Caucasians and Asian populations (Vingerling et al.
1996; Cruickshanks et al. 2001; Buch 2005; Buch et al.
2005; Munoz et al. 2005; Arnarsson et al. 2006; Chen
et al. 2008; Yasuda et al. 2009; Choudhury et al. 2011)
with a paucity of data from peoples of African descent.
Data on Africans are largely from studies undertaken in
African populations living outside of the African conti-
nent (Leske et al. 2004, 2007). Comparative data
between Caucasians and Africans living in the same geo-
graphical area have suggested differing predispositions
towards AMD (Sommer et al. 1991). A single popula-
tion-based study based in SSA (Kenya) determining the
prevalence of AMD was identified (Mathenge et al.
2013). Early and late AMD prevalence in adults aged
50 years and above was 11.2% and 1.2%, respectively,
amongst participants graded on digital retinal images
(n = 3,304). After controlling for age, women had a
higher prevalence of early AMD than men (odds ratio
1.5; 95% CI, 1.2–1.9), and the overall prevalence rose
significantly with each decade of age (Mathenge et al.
2013).
Incidence. The incidence of AMD has been reported in
population-based studies in the Americas, Australasia,
Europe, and Asia; however, no data exist from the Afri-
can continent to date. With the exceptions of the Latino
Eye Study (Varma et al. 2010) and the Barbados Eye
Study (Leske et al. 2004, 2006), all data are in Caucasian
populations, and inferred data from the Barbados study
suggest incident early AMD is similar to elsewhere in the
world, but late AMD is less common, possibly suggesting
a protective mechanism.
Discussion
We found through our review of the literature that
PSEDs are an important cause of vision loss in SSA coun-
tries. Selection bias may have led to information from
French- and Portuguese-speaking countries being omitted;
data from Egypt and Mauritius are unlikely to be repre-
sentative for the SSA, and data not in the peer-reviewed
literature were also omitted and may have been a source
of bias.
The detection of and treatment for PSED poses many
challenges to countries that currently lack the necessary
infrastructure and resources. VISION 2020 has placed
priority on conditions deemed more straightforward to
treat, and this strategy has proven largely successful.
PSEDs differ from the leading anterior segment eye dis-
eases (cataract and refractive error) in prevention/treat-
ment, as no cures currently exist (with the exception of
angle closure glaucoma). Surgical intervention can restore
vision in those visually impaired from cataract, and
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provision of glasses can restore or improve vision in peo-
ple with refractive error. However, established visual loss
from PSED is difficult to reverse, and for most condi-
tions, there is no ‘curative’ treatment.
Medical and/or surgical intervention for glaucoma can
slow disease progression and thereby reduce the risk of
further sight loss (Heijl et al. 2002). Systemic control of
diabetes mellitus, retinal laser treatment, intravitreal
injections and vitreoretinal surgery in sight-threatening
DR can stabilise and, to some degree, improve DR status
and thereby also prevent sight loss (1993). Currently no
cure for AMD exists, although intravitreal therapy is
available for end-stage wet AMD (approximately 10% of
all AMD cases). The infrastructure required to detect
AMD and deliver treatment as well as the cost of treat-
ment itself is currently prohibitively expensive for use in
most LMIC settings but is widely used in high-income
countries (Bowler et al. 2012). Vitamin supplementation
has shown some evidence of risk reduction in progression
of subtypes of AMD (Evans 2006), but not prevention of
AMD (Evans & Lawrenson 2012) and again may be
prohibitively expensive.
This review suggests that PSEDs account for a large
proportion of people with vision loss living in SSA. In
recent years, improved methodologies and understanding
may account for some increase in estimates of prevalence.
In particular, the affordable RAAB methodology (Dineen
et al. 2006) has led to increased numbers of researchers
undertaking population-based surveys in SSA.
The majority of existing data on NCDs, including
PSED, from LMIC are from cross-sectional studies pro-
viding valuable data on prevalence and risk factors. Lon-
gitudinal studies provide the opportunity to investigate
the natural history of diseases, which is necessary in
developing health policies at local and national levels.
Few longitudinal cohort studies from LMIC have been
conducted due to barriers including expense, complex
logistical planning and political challenges.
A change in the focus of programme managers and
policymakers over the coming decades is required if the
prevalence and incidence of PSED in SSA increases as
predicted. This increase is likely with extended life expec-
tancies and success of the VISION 2020 in the treatment
for anterior segment eye diseases and infectious diseases
of the eye. Urbanisation and westernised lifestyles may
also play a role in diseases such as diabetes and conse-
quently DR.
Many studies worldwide have collected cross -sectional
survey data on PSED prevalence; however, few studies
have data on incident PSED with no SSA-based eye dis-
ease cohort studies to date. The best estimates of inci-
dence for Africa are therefore extrapolated from studies
conducted elsewhere in the world. Furthermore, investi-
gating PSED in Africa offers a new perspective on
account of the different exposures and genetic make-up
of these populations compared with those studied thus
far, which may reveal new insights into the cause and
natural history of these diseases.
Inferring data from high-income countries undermines
efforts to establish studies in LMIC, which will guide the
effective use of minimal existing resources to deal with
the growing burden of NCDs.
Large, community-based cross-sectional and cohort
studies are needed to estimate prevalence of disease, risk
factors for disease, as well as incidence and progression
across Africa. Evidence for effectiveness and economics
of screening of and treatment for PSED in low resource
settings is vital for health service planners.
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Chapter 3.1. Cataract and Posterior segment eye disease in 
sub-Saharan Africa – update 
 !
Since the publication of the review papers (chapters 2 and 3), further population 
based cross sectional prevalence studies have been undertaken in SSA.  
 
In order to update the published reviews, the same search methodology (adapted for 
years of publication) was used as per the reviews in Chapters 2 and 3 which was: 
 
Our literature search was conducted for the years 2012 – April 2017 using Medline, 
Embase and Google Scholar. Key words used included but were not limited to: 
cataract, lens opacity, glaucoma, macula degeneration, diabetic retinopathy, visual 
impairment, low vision, blindness, presenting visual acuity, prevalence, and population.  All 
48 SSA African countries as well as “Africa” and “sub-Saharan Africa” were used in 
the search terms. Studies were included if they were population-based with a sample 
size > 1000, reported presenting visual acuity (PVA) with its causes, had a high 
participation rate (>75%) and provided the standard WHO categories of visual 
acuity. We also searched reference lists of studies meeting inclusion criteria. 
Published studies, reported in English, French and Portuguese languages were 
included.   
 
The majority of these studies have used a Rapid Assessment of Avoidable Blindness 
methodology. RAAB data from SSA was identified through the RAAB repository 
(2013-17, mostly unpublished). 
 
 
The existing data from the published reviews is presented below: 
 
Reproduced from chapter 2, Bastawrous et al, Blindness and visual impairment due 
to age-related cataract in sub-Saharan Africa: a systematic review of recent 
population-based studies. Br J Ophthalmol. 2013 Oct;97(10):1237-43. 
 
 
 
 
  
Reproduced from chapter 3, Bastawrous et al. Posterior segment eye disease in sub-
Saharan Africa: review of recent population-based studies. Trop Med Int Health. 2014 
May;19(5):600-9. 
 
!!!!!!!!!!!!!!!!!!!!!!
Table. Recent prevalence studies of blindness and visual impairment in sub-Saharan 
Africa taken from the RAAB Repository [http://raabdata.info/] 
 
 
 
*Unpublished data, +Studies completed but no data available yet 
 
This table shows the recent studies of blindness and VI from SSA from the RAAB 
repository. It identified 7 new RAAB studies, conducted in SSA. Cause of blindness 
and VI was presented for 5 out of the 7 studies. Among these, cataract was 
consistently the leading cause of blindness, and PSED was the second cause in four of 
the five studies (making up 19-38% of blindness). Only in the survey in Uganda was 
trachoma the second leading cause of blindness after cataract. 
 
Two further population based surveys of VI were identified, that did not use the 
RAAB methodology. These were a small survey conducted in Ghana and the national 
survey of blindness in Nigeria.  
 
The survey in Ghana assessing the prevalence and causes of visual impairment and 
blindness among cocoa farmers, the sample size was too small to report on causes of 
 Country Level 
Year 
undertak
en 
Sample 
size 
(number 
examined) 
Response 
Rate (%) 
Age 
(years) 
Primary 
cause of 
blindness 
Secondary 
cause of 
blindness 
Ref 
Madagascar National 2015+ n/a n/a ≥50 n/a n/a * 
Rwanda Regional 2015+ n/a n/a ≥50 n/a n/a * 
DR Congo District, Ituri 2015 3796 93.8 ≥50 
Cataract 
(72%) 
PSED 
(19%) * 
Botswana National 2015 3549 93.3 ≥50 Cataract (42%) 
PSED 
(29%) * 
Uganda State, 
Karamoja 
2015 3850 96.8 ≥50 Cataract 
(44%) 
Trachoma 
(26%) * 
Uganda District, Hoima 2013 3862 99.1 ≥50 
Cataract 
(49%) 
PSED 
(32%) * 
Burundi 
States, 
Ngozi and 
Kayanza 
2012 3879 95.0 All Cataract (55%) 
PSED 
(38%) * 
blindness, however the leading causes of visual impairment were cataract (38.8%), 
refractive errors (36.2%) and PSED (12.9%). (1) 
 
The Nigeria National Blindness Survey, a comprehensive prevalence study (n=13,591 
adults 40 years+) provides detailed information on the prevalence and causes of 
blindness and visual impairment. The leading causes of blindness were cataract 
(43.0%), glaucoma (16.7%) and uncorrected aphakia (8.4%). The leading causes of 
visual impairment were refractive error (61.6%) and cataract (22.1%) with PSED 
responsible for 25.7% and 7.1% of blindness and VI respectively.(2)  
 
The prevalence of cataract (including those that were not visually significant) was 
19.8% (95% CI: 7.9-21.7) increasing with age, and was higher in females and those 
not literate.(3) The age-adjusted prevalence of diabetes amongst the study 
population was 3.3% (95%CI 2.5-4.3); with 48% being unaware of their diabetes 
status at diagnosis. Digital retinal photography was conducted in participants with a 
presenting visual acuity of less than 6/12, of whom 52 were persons with diabetes. 
Lens opacity prevented gradable images in eights participants. 9/44 (20.5%) of the 
remaining participants had evidence of diabetic retinopathy. Persons with diabetes 
had three times greater odds of blindness and over 10% of people with diabetes aged 
≥40 years had sight-threatening DR.(4) 
 
The prevalence of glaucoma in the study sample was 5.02 % (95 % CI 4.60-5.47). 
with only 5.6 % (38/682) of participants with glaucoma being aware of their diagnosis 
at examination. 20% of participants with glaucoma were blind.(5) 
In addition, the results from the Nakuru Posterior Segment Eye Disease survey 
(which forms the baseline of the current study) were published in this time period. 
These are presented in chapter 4. 
 
Conclusion 
 
Although further RAABs studies have been complete since the reviews were 
undertaken, no data from these has yet been published in the peer-reviewed 
literature. The most significant body of new data comes from the Nigeria National 
Survey, a West African population representing nearly one quarter of all sub-Saharan 
African. This comprehensive survey is consistent with findings from other countries 
in the region.  
 
The primary conclusions of these two reviews still stand: 
 
Cataract is currently the most common cause of blindness and VI in SSA. Efforts 
to reduce the burden of blindness and VI due to cataract should incorporate high-
volume, high-quality, affordable cataract surgery that greatly improves the CSR 
and CSC in such populations. This can be achieved by the implementation of well-
run, cost-effective, and sustainable cataract units at the district level. Wide 
variation in the prevalence of cataract blindness has been shown in this review, 
and although this may be due to disparities in eye care programme delivery, it 
may also reflect inter-population differences in cataract incidence. The 
fundamental problems highlighted by this review are that currently too few 
cataract surgeries are being performed and there are too many poor outcomes.  
An open and urgent appraisal of positive successes throughout SSA should be 
performed and shared.(6) 
 
And, 
 
Many studies worldwide have collected cross sectional survey data on PSED 
prevalence; however few studies have data on incident PSED with no SSA based 
eye disease cohort studies to date. The best estimates of incidence for Africa are 
therefore extrapolated from studies conducted elsewhere in the world. 
Furthermore, investigating PSED in Africa offers a new perspective on account of 
the different exposures and genetic make-up of these populations compared to 
those studied thus far, which may reveal new insights into the cause and natural 
history of these diseases. 
 
Large, community-based cross-sectional and cohort studies are needed to 
estimate prevalence of disease, risk factors for disease, as well as incidence and 
progression across Africa. Inferring data from high-income countries undermines 
efforts to establish studies in LMIC, which will guide the effective use of minimal 
existing resources to deal with the growing burden of NCDs. Evidence for 
effectiveness and economics of screening and treatment of PSED in low resource 
settings is vital for health service planners.(7) 
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It is apparent that PSED is emerging as an important cause of blindness and VI in 
Africa. Consequently, a survey was planned in Nakuru in order to investigate the 
prevalence and causes of PSED in an elderly population. This was undertaken as 
the thesis for Dr Mathenge at LSHTM. (1-4) The methods and results are 
described here in brief. 
 
 
Methods [taken from Mathenge W, Bastawrous A, Foster A, Kuper H. The Nakuru Posterior 
Segment Eye Disease Study: Methods and Prevalence of Blindness and Visual Impairment in 
Nakuru, Kenya. Ophthalmology. 119(10); 2033-9. (2)] 
 
In 2007/8, 4,381 participants’ aged ≥50 years were recruited in a population-based 
survey in Nakuru, Kenya. (2) These participants form the baseline population of 
the 6-year follow-up. 
 
Sampling 
Recent census data for Kenya were not available (5), and therefore election role lists 
that were renewed in 2006 in preparation for the 2007 general elections were used 
as the sampling frame for this survey. The population size was updated for the year 
2007 using a population growth rate of 2.7% per year (6). 100 clusters were selected 
with a probability proportional to the size of the population. A cluster was defined as 
the area served by the polling station.  
 
Households were selected within clusters using a modified compact segment 
sampling method (7). Each cluster was divided into segments; so that each segment 
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included approximately 50 people aged ≥ 50 years. For instance, if a cluster included 
200 people aged ≥ 50 years then it was divided into four segments. One of the 
segments was chosen at random by drawing lots and all households in the segment 
were sequentially sampled, until 50 people aged ≥ 50 years were identified. An 
eligible individual was defined as someone aged ≥ 50 years living in the household for 
at least three months in the previous year. Age was determined using the subject’s 
testimony, national identity cards and a calendar of historic events. If the segment did 
not include 50 people aged ≥ 50 years then another segment was chosen at random 
and sampling continued. If after enumerating individual number 49 the next 
household had more than one person aged ≥50 all were enumerated and invited for 
examination.  
 
Examination: All participants underwent comprehensive ophthalmic and general 
examinations including retinal photographs detailed in the annex and repeated here: 
 
Suitable predetermined examination sites were selected on the recommendation of 
the village leader with close proximity for access to the cluster and electricity supply 
(mains or generator) for the equipment.  
 
The examination team was led by ophthalmologist (Wanjiku Mathenge), who 
examined every participant in the study and included two nurses delivering 
questionnaires, two fully trained ophthalmic nurses undertook visual acuity testing 
and autorefraction. A trained visual field technician performed field tests, an 
ophthalmic clinical officer took fundus photographs and a further nurse took weight, 
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height, blood pressure and blood tests. The team also included an office manager and 
two data entry clerks.  
 
Visual Acuity (VA): The presenting visual acuity was defined as the number of letters 
read correctly without glasses if the participant did not have glasses or with glasses if 
they had them. Testing was done by an ophthalmic nurse with an assistant. Each eye 
was tested separately at 4 meters using a reduced logarithm of the Minimal Angle of 
Resolution (LogMAR) tumbling ‘E’ chart (8) in a well illuminated area. If the subject's 
vision was too poor to read any letters on the chart at four meters, then the subject 
was tested at 1 meter, then as follows:  
• Counting Fingers (CF) - Ability to count fingers at 1m, 2m or 3m distance.  
• Hand Motion (HM) - Ability to distinguish if a hand is moving or not in front 
of the patient's face,  
• Light Perception (LP) - Ability to perceive any light and  
• No Light Perception (NLP) - Inability to see any light or Total blindness.  
Those who did not read 24 letters (VA<6/12) at 4m were scheduled for correction 
and to undergo a repeat VA measurement with the correction in place unless the 
vision was worse than CF in which case no correction was undertaken. 
 
Details on diagnosis of cause and disease definition are available in chapters 6-11 
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Summary of main results 
 
Table. Summary of Nakuru Cohort, baseline findings 
Condition Sub-Categories Definition 
Number of 
Participants Prevalence 
  LogMAR Letters Snellen Equivelant  (%, 95%CI) 
Visual 
Impairment 
Blindness 0.1 <3/60 71 1.6 (1.2 – 2.1) 
Severe VI 2 <6/60-3/60 18 0.4 (0.3 – 0.7)) 
Moderate VI 3-18 <6/18-6/60 356 8.1 (7.2 – 9.2) 
Mild VI 19-23 <6/12-6/18 224 5.1 (4.3 – 6.1) 
Cataract 
Any vision - - 1,944 44.5 (43.1-46.0) 
Blindness 0.1 <3/60 63/1,944 3.2 (2.5-4.1) 
Low Vision 2-23 <6/12-3/60 506/1,944 26.0 (24.1-28.0) 
Refractive 
Error - 
PVA <6/12 in the better eye improving 
to 6/12 or better after correction 346 7.4 (6.5-8.4) 
Glaucoma 
Definite 
Glaucoma ISGEO 
 
203 4.6 (3.9 – 5.5) 
Suspect 
Glaucoma 245 5.6 (4.9 – 6.4) 
Diabetic 
Retinopathy 
Any DR As below 70 35.9 (29.7-42.6) 
Mild NPDR 
Based on: Intraretinal haemorrhages, 
Microaneurysms venous beading 
Prominent IRMA and signs of PDR 
20 10.3 (6.9 -15.0) 
Moderate 
NPDR 24 
11.8 (7.6 -
17.9) 
Severe 
NPDR 9 5.1 (2.9 – 9.0) 
PDR Neovascularisation Vitreous/pre-retinal haemorrhage 17 
8.7 (5.7 – 
13.1) 
Age-Related 
Macular 
Degeneration 
Any AMD - 489 12.6 (11.5 – 13.8) 
Early Based on: Pigment, drusen 442 11.4 (10.3 – 12.7) 
Late GA, CNVM 47 1.3 (1.1 – 1.6) 
 
CI: Confidence Interval, VI: Visual Impairment, DR: Diabetic Retinopathy, NPDR: Non-Proliferative 
Diabetic Retinopathy, PDR: Proliferative Diabetic Retinopathy, IRMA: Intraretinal Microvascular 
Anomalies, AMD: Age-Related Macular Degeneration, GA: Geographic Atrophy, CNVM: Choroidal 
Neovascular Membrane, PVA: Presenting Visual Acuity 
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44.5% and 26.9% of the baseline population had evidence of cataract and PSED 
respectively. Of the 71 blind individuals, 32 (45.1%) were cataract blind and 23 
(32.3%) were blind from PSED. Among those with PSED and blindness the causes 
were: glaucoma 34.7%, DR 13.0%, AMD 30.4% and other PSED 21.7%. 
 
PSED were responsible for 11.1% of all VI in Nakuru (Glaucoma 18.9%, diabetic 
retinopathy 18.9%, AMD 37.8% and Other PSED 24.3%).   
 
The following manuscripts have been published on the baseline data and are included 
in the annex: 
 
The Nakuru posterior segment eye disease study: methods and prevalence of blindness and 
visual impairment in Nakuru, Kenya. 
Mathenge W, Bastawrous A, Foster A, Kuper H. 
Ophthalmology. 2012 Oct;119(10):2033-9. doi: 10.1016/j.ophtha.2012.04.019. Epub 2012 Jun 
19. 
 
Prevalence of age-related macular degeneration in Nakuru, Kenya: a cross-sectional 
population-based study. 
Mathenge W, Bastawrous A, Peto T, Leung I, Foster A, Kuper H. 
PLoS Med. 2013;10(2):e1001393. doi: 10.1371/journal.pmed.1001393. Epub 2013 Feb 19. 
 
Prevalence and predictors of refractive error and spectacle coverage in Nakuru, Kenya: a 
cross-sectional, population-based study. 
Bastawrous A, Mathenge W, Foster A, Kuper H. 
Int Ophthalmol. 2013 Oct;33(5):541-8. doi: 10.1007/s10792-013-9742-6. Epub 2013 Feb 26. 
 
Prevalence and correlates of diabetic retinopathy in a population-based survey of older 
people in Nakuru, Kenya. 
Mathenge W, Bastawrous A, Peto T, Leung I, Yorston D, Foster A, Kuper H. 
Ophthalmic Epidemiol. 2014 Jun;21(3):169-77. doi: 10.3109/09286586.2014.903982. Epub 
2014 Apr 23. 
 
 
The following diagrams summarise the findings in a per 1000 of population 
viewpoint. Note the estimated population of adults aged 50 years and older in Kenya 
in 2015 was 4.3 million and 150,000 in Nakuru County. 
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Figures of Baseline Data 
 
Blindness and Visual Impairment in Nakuru Kenya: There are an estimated 150,000 adults 
aged 50 years and older. For every 1,000 adults, 153 are visually impaired (16 blind and 137 
with low vision) 
 
 
 
Cataract Blindness and Visual Impairment in Nakuru Kenya: For every 1,000 adults, 445 have 
cataract, of whom 130 are visually impaired (116 have low vision and 14 are blind).  
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Diabetes Mellitus in Nakuru Kenya: For every 1,000 adults, 65 have diabetes mellitus 
 
 
 
Diabetic Retinopathy amongst adults aged 50 years and over in Nakuru Kenya: For every 
1,000 adults 65 have diabetes of which nine have sight-threatening diabetic retinopathy 
(proliferative and severe non-proliferative diabetic retinopathy) and 14 have non sight-
threatening diabetic retinopathy (mild and moderate non-proliferative diabetic retinopathy). 
42 adults with diabetes mellitus do not have diabetic retinopathy.   
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Diabetic Retinopathy amongst adults (aged 50 years and over) with diabetes in Nakuru 
Kenya: For every 1,000 adults with diabetes, 103 have proliferative diabetic retinopathy, 118 
have severe non-proliferative diabetic retinopathy, 51 have mild non-proliferative diabetic 
retinopathy and 87 have mild non-proliferative diabetic retinopathy.  
 
 
 
 
 
 
 
 
 
 
 
 
  
!! 10 
Glaucoma in Nakuru Kenya: For every 1,000 adults, 46 have definite glaucoma and 56 have 
suspect glaucoma based on ISGEO definitions.(9)  
 
 
 
Age related macular degeneration (AMD) in Nakuru Kenya: For every 1,000 adults, 126 have 
AMD, of whom 13 have late AMD and 113 have early AMD, 
 
 
Definition of AMD based on the modified version of the International Classification and grading system for age-related maculopathy and age-
related macular degeneration. Early = drusen and /or pigmentation, Late = geographic atrophy and / or neovascular membrane 
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Discussion 
 
Key findings (2-4, 10) 
 
Prevalence of Visual Impairment and Blindness (2) 
The results confirm that prevalence of blindness is relatively low as suggested by 
recent RAAB surveys (10, 11) and that it may be declining compared to earlier 
surveys.(12)  
 
Prevalence of age related macular degeneration (3) 
Despite the long held belief that AMD is not a public health concern in Africa, this 
study provides evidence that not only is AMD as prevalent as in some other world 
regions (12.6% in this population) but it is also an important problem contributing to 
both visual impairment and blindness in Africa. 9.9% of blindness in this survey was 
attributable to AMD. The Nigeria Survey used similar methodology including a 
population-based approach and fundus photographs, however, retinal imaging was 
only performed in individuals with a visual acuity of ≤6/12 (17); in the present study, 
75.1% of individuals identified as having AMD had an acuity of 6/12 or greater.  
 
Prevalence of Diabetes and Diabetic Retinopathy (4) 
The baseline survey found a 6.5% prevalence of diabetes. A The overall prevalence of 
any DR among the 195 definite patients with diabetes with retinal images in the 
study population was 35.9% (95% CI: 29.7-42.6). The most common grade of DR 
was mild/moderate NPDR (22.1%, 16.1-29.4), while severe NPDR or PDR were less 
frequent (13.9%, 10.0-18.8).  
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Prevalence of Cataract 
Cataract was widely prevalent in this study population with 1,944 participants having 
evidence of a lens opacity on dilated slit lamp examination, 44.5% (95% CI 43.1% - 
46.0%). Of those, 506, 11.6% (95% CI 10.7% - 12.6%) had vision between 6/18 and 
3/60 (low vision) and 63, 1.4% (95% CI 1.1% - 1.8%) were blind.  Of the 71 blind in 
the study, 63 were known to have cataract.  
 
Prevalence of Glaucoma 
It was not possible to accurately estimate glaucoma from the baseline data. The 
ISGEO classification (9) was used, however visual field data was unreliable and for 
logistical reasons, gonioscopy was not performed, meaning there was no direct 
visualisation of the angle and a true ISGEO classification of glaucoma was not 
possible. A description of the distribution of features associated with glaucoma (VA, 
intraocular pressure, vertical cup to disc ratio, angle OCT) are described in the data 
chapter.  
 
Strengths of the baseline survey 
 
The survey design for the baseline study was strong using a population-based sample 
with a high response rate (88%) and large sample size (comparable to other studies 
worldwide) enabling estimated with narrow confidence intervals. A single 
examination team throughout reduced measurement bias and comprehensive 
ophthalmic assessment methods and equipment were used providing high quality 
data on the eye health status of study participants, including digital retinal 
photography independently graded at a certified reading center enabled comparison 
with similar cross-sectional population-based studies from other parts of the world. 
Detailed risk factor analysis was undertaken, again using reference standard 
methods. 
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Limitations of the baseline survey 
 
The sampling frame ideally would have used the most recent census data, which was 
several years out of date, thus the electoral role was used. It was felt this was likely 
to be a fair reflection of the population. Despite a high response rate there was a 
slight gender bias with greater response from men than women (89 vs. 86%). The 
use of reference standard ophthalmic equipment was a barrier to data collection as 
the majority of equipment was designed for more developed infrastructure (reliable 
electricity, dust free, stationary) it was not suitable for use across multiple 
temporary examination clinics (n=100) resulting in retinal camera failure. Visual Field 
analysis was not reliable across all study participants for which it was undertaken 
making any assessment of glaucoma limited.  
 
 
Overall 
 
This study was undertaken in a challenging setting with the backdrop of a complex 
political situation. The quality of data despite all the challenges make this one of the 
most comprehensive prevalence studies of eye disease ever completed in Africa. An 
absence of incidence data from the region remains one of the main unexplored 
questions. This study therefore provides a solid foundation for a cohort study.   
 
 
Sample Size Implications 
 
4,381 participants were examined at baseline across 100 clusters. A pilot follow up 
retraced 408 participants from 10 of the 100 clusters at a mean of 1.5 years from 
completion of the baseline study.  
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Estimated follow-up at 6 years is based on an assumption of a constant rate of loss 
per year (constant proportion of those still in follow-up who are lost each year) 
 
Assuming that the pilot followed 438 individuals, and saw 408 at 1.5 years  
• We estimate that 2/3 of the 30 lost were lost in the first year (20/438= 4.6%) 
• If 4.6% are lost per year for each of the 6 years, then the number at follow-
up would be 4381*(1-0.046)^6 = 3,303. 
• This means follow-up of 3468/4381=75.4% 
• Which equates to a 4.2% loss per year. 
 
Due to anticipated displacement due to the post-election violence in the study 
region Follow up is estimated at a conservative 8% loss per year ([4381*(1-0.08)^6] 
equating to an approximate cumulative follow-up of 61%; n=2,656) examined at 6-
year follow up. All participants included in the baseline study were invited to attend 
for follow-up. 
 
The following table was a prediction of ranges of expected incidence for the key 
areas of interest in the cohort study based on studies of similar design.  
A Design Effect (DEFF) of 1.4, to account for clustering, has been used in all the 
following calculations: (http://www.sph.emory.edu/~cdckms/proportionDEFF.html. 
Version 7.02.15)  
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Table. Expected 5-year cumulative incidence (based on similar studies) (18-25). 
 
Outcome Number 
free of 
condition 
at baseline 
“At risk” 
Number free of 
condition at 
baseline 
examined at 
follow-up 
(assuming 65% 
follow-up) 
Expected 5 
year 
cumulative 
incidence  
Lower –  
Upper 
estimates 
 
95% CI 
Precision 
Actual 6 
(5.6) year 
cumulative 
incidence 
(95%CI) 
Blindness 
 
4310 2802 0.48- 
0.75* 
0.23-0.85% 
0.41-1.22% 
2.70% (1.8-
3.1) 
Visual 
Impairment 
3712 2413 3.0- 
4.5* 
2.26-3.89% 
3.57-5.55% 
11.9% (10.3-
13.8) 
AMD 3842 2497 4.75- 
11.25%* 
3.80-5.81% 
9.80-12.77% 
16.4% (13.7-
19.6) 
Glaucoma 4180 2717 3.7- 
5.2%** 
2.91-4.61% 
4.27-6.27% 
Unknown 
DR DM no DR 
190 
124  20- 
35%*** 
12.21-
28.88% 
25.54-
45.48% 
22.5% (11.7-
38.8) 
 
The five year cumulative incidence estimates for new cases of each disease are based on the 
following cohort studies: Beaver Dam Eye Study, Blue Mountain Eye Study, AREDS, 
Rotterdam Eye Study, PONZA study 
 
*Based on BDES, BMES, Copenhagen and LALES 
** Based on Barbados Eye Study 
*** Based on BDES, BMES, Japanese Eye Study and San Luis Valley Diabetes Study 
 
 
 
Lessons learnt from baseline for the cohort 
 
To maximize coverage and quality of data collection at follow up, with the same 
barriers to data collection as baseline, various modifications to the methodology 
were undertaken, with the majority of procedures remaining unchanged.  
 
Changes in methodology and rationale for this are discussed in detail in the 
methodology chapter. Key changes included use of a different retinal camera that 
would more likely survive the environment and the use of a different visual field 
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analyser. The lack of reliable visual field data at baseline limits the interpretation for 
longitudinal population changes (incidence and progression) for glaucoma.  
 
 
The importance of a cohort study 
 
The conclusion of the review of the baseline study is that this would make an 
appropriate foundation on which to establish a cohort study. There are several 
reasons why this may be a worthwhile endeavor.  
 
Many studies worldwide (26-29) have collected cross sectional survey data on 
cataract and PSED prevalence; however very few have data on incident cataract or 
PSED with no African based eye disease cohort studies to date (bar DR from studies 
of persons with DM). The best estimates of incidence for Africa are therefore 
extrapolated from studies conducted elsewhere in the world. 
 
Prevalence data is limited in terms of planning services for the sample population, as 
it does not provide information on the rate of change of conditions or the rate at 
which subjects might become cases that require an intervention. For example, 
knowing the prevalence of visually significant cataract at best defines that there is a 
need for more services; however defining the required services more specifically 
requires an estimate of the number of new cases over a period of time (usually one 
year).  
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The best estimates of incidence for Africa are therefore extrapolated from studies 
conducted elsewhere in the world. 
 
Planning healthcare provision requires a good estimate of new cases (incidence) not 
just prevalence.  An effective health service will provide treatment (curative or 
preventative) to its population at a rate that is equal to or greater than the number 
of new cases per population requiring those services. If the treatment rate is less 
than the incidence rate the backlog (waiting list or prevalence) will increase. The 
prevalence alone does not give accurate data for estimating the required level of 
service provision.  A high prevalence indicates insufficient services however as it is a 
snapshot of a single time frame it does not provide a complete picture.  
 
 
Figure. Prevalence, Incidence and the importance for planning services 
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Longitudinal data will also enable a greater understanding of the aetiology of 
diseases, their natural history and associated risk factors. This is particularly 
important in Africa where data is lacking and we cannot assume that the aetiology 
will be the same across the world, given the unique constellation of environmental 
and genetic conditions in Africa. As an example, there is a widespread belief that the 
aetiology of AMD is different in Africa to elsewhere, and that glaucoma may present 
more aggressively. 
 
Major population-based cohort studies of eye disease have predominantly taken 
place in high-income settings. 
 
 
 
 
It is assumed that incidence in Africa will most closely reflect that of the Barbados 
Eye Study in whom enrolled participants were of African descent. (30, 31) Other 
major cohort studies with comparable data to the Nakuru Cohort Study include the 
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Beaver Dam Eye Study, (18) Hisayama Eye Study, (19) Ponza Eye Study, (20) Beijing 
Eye Study, (21) the Dalby Eye Study (22), the Blue Mountain Eye Study, (23) the 
Melbourne Visual Impairment Study (24) and the Rotterdam Eye Study (25). These 
cohorts will be used for comparison with the findings from this cohort in the data 
chapters.  
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These major cohort studies are summarised in the table below: 
 
Study Location Year commenced 
Years of 
Follow up 
No of 
participants 
Age at 
Baseline 
Reference 
Beaver Dam Eye 
Study 
USA 1988 Baseline 
5 
10 
15 
4926 
3684 
2764 
2119 
43-86 (32-34) 
Blue Mountain 
Eye Study  
Australia 1992 Baseline 
5 
10 
3654 
2335 
1952 
49+ (35) 
Rotterdam Study  Netherlands 1990 Baseline 
2 
6.5 
11 
6418 
4953 
3406 
2387 
55+ (36, 37) 
Copenhagen City 
Eye Study  
Denmark 1986 Baseline 
14 
946 
359 
60-80 (38) 
Barbados Eye 
Study  
Barbados 1987 Baseline 
4 
9 
4631 
3427 
2793 
40+ (39, 40) 
Pathologies 
Oculaires Liees a 
L’Age  
France 1995 Baseline 
3 
2584 
1642 
60+ (41) 
Melbourne Visual 
Impairment 
Project  
Australia 1992 Baseline 
5 
5147 
3271 
40+ (42) 
Hisayama Study  Japan 1998 Baseline 
5 
9 
1482 
961 
(1401>40yrs) 
40+ (19, 43) 
Reykjavik Eye 
Study  
Iceland 1996 Baseline 
5 
1045 
846 
50+ (44) 
Los Angeles 
Latino Eye Study  
USA 2000 Baseline 
4 
6357 
4658 
40+ (45) 
 
It is therefore clear that the cohort studies on eye disease that exist focus on high 
income countries, and people of Caucasian ethnicity. A cohort study of eye disease 
conducted in SSA will therefore make an important contribution to the literature.  
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Aim of the study 
 
To investigate the epidemiology of cataract and posterior segment eye 
disease, including diabetic retinopathy and age related macular degeneration, 
in Nakuru county, Kenya. 
 
Objectives !
 
Incidence  
1. To estimate the age- and sex- specific incidence of visual impairment 
(VA<6/12) and blindness (VA<3/60)  
2. To estimate the age- and sex- specific incidence of diabetes mellitus and 
diabetic retinopathy 
3. To estimate the age- and sex- specific incidence of features of glaucoma 
4. To estimate the age- and sex- specific incidence of age related macular 
degeneration 
 
Causes & Risk Factors 
5. To identify the causes and risk factors for incident visual impairment 
and blindness, diabetes, diabetic retinopathy, age-related macula 
degeneration, cataract and features of glaucoma (specifically focusing on 
ophthalmic, demographic, anthropometric, behavioural, and vascular 
risk factors) 
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LETTER
The global inverse care law:
a distorted map of blindness
Statistical analysis can be used to interpret
and give meaning to data, however, the
ability to interpret large quantities of data
and it’s resulting statistical reporting is not
always straightforward. Graphical represen-
tations such as graphs and maps are a way of
translating or converting data into a visual
interpretation.
Commonly used world maps are imperfect
and contain distortions to allow a spherical
reality to be represented in 2-dimensions. This
distortion can be manipulated to produce
a world map that gives each deﬁned area
(country or region) a size proportional to its
population.1
Cartograms are used to effectively map
socioeconomic data and can be effective
means of mapping disease. In keeping with
the phrase ‘a picture equals a thousand words’
cartograms can be used to analyse spatial data
in an easily comprehensible style.
In 1971, Hart2 described the, ‘Inverse Care
Law’ as the availability of good medical care
varying inversely with the need for it in
the population served. Hart was describing
the situation in the National Health Service
in Great Britain at the time in which he
practiced as both a General Practitioner and
an epidemiologist.
Two recently published articles demon-
strate the ‘Inverse Care Law’ on a global
level. The prevalence of blindness worldwide
in 20103 was reported by the WHO and
veriﬁed that low- and middle-income coun-
tries, as expected, have the highest preva-
lence of blindness and visual impairment. In
stark contrast to this, a more recent report
describes the, “Number of ophthalmologists
in training and practice worldwide”4 pro-
viding global data for the number of
ophthalmologists per county and demon-
strates that despite a growing number in
practice the gap between need and supply is
widening.
The situation is also magniﬁed within
individual countries of high, middle and
low-income. For example, in France, an
inverse correlation was found between the
number of ophthalmologists and the preva-
lence of low vision for subjects of similar
age and socio-professional category5 and
another example is in Kenya where of the
86 practicing ophthalmologists, 43 are based
in Nairobi (personal correspondence). That
equates to 50% of the countries ophthalmol-
ogists serving 8% of an already underserved
population.
We have developed two cartograms to
depict the data from these two papers3 4
using ESRI’s ArcGIS 10 software with the
Cartogram Creator. These tools apply the
Gastner & Newman diffusion-based method.6
This allowed us to create density-equalised
maps based on the absolute values provided
in the papers. In the maps, each of the
reference areas (WHO regions and countries)
is resized according to these values. Larger
areas represent higher numbers and smaller
areas proportionally smaller data values (see
ﬁgures 1 and 2).
We believe these maps can be used to
share masses of data in a visual, intuitive and
comprehensible way, which will be under-
stood by policy makers and can be used by
advocates for global health.
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 In the “The global inverse care law: a distorted map of blindness” article I discuss the 
disproportionate provision of services to areas with least need and inversely, areas 
of greatest need having the least services. (1) 
 
The most recent population estimates in Kenya based on predicted growth by the 
World Bank indicate there are 48 million people  
(Source: http://www.worldometers.info/world-population/kenya-population/). 
 
 
 
This figures shows an approximate increase of ten million people since the baseline 
study was initiated in 2007. (2) 
The number of practicing ophthalmologists has also increased by approximately 10% 
in this time with current estimates being there are 100 practicing ophthalmologists in 
Kenya, although many of them do not work in the public sector and at least 50% are 
based in Nairobi or its suburbs (personal communication).   
 
Figure: Distribution of ophthalmologists throughout Kenya
 
 
In some areas of Kenya a single ophthalmologist is responsible for a population of up 
to three million people.  
 
Nakuru County in Kenya, the location in which this cohort study was undertaken 
has a population of 1.6 million people of which approximately 150,000 are adults 
aged 50 years and over.  
 
 
 
Figure: Nakuru County, Kenya (downloaded from:!
https://en.wikipedia.org/wiki/Nakuru_County)  
 
 
Nakuru County has one public sector eye unit in the Rift Valley Provincial General 
Hospital. The hospital has one ophthalmologist and two ophthalmic clinical officers, 
one of whom is also a cataract surgeon. The region also has a mission hospital, St 
Mary’s Hospital in Elementatita which has an active unit served by 1.2 ophthalmic 
clinical officers (both cataract surgeons) and one ophthalmologist in the private 
sector. In total, therefore, there are 2 ophthalmologists and 3.2 ophthalmic clinical 
officers for the population of 1.6 million. Patients who can afford eye services 
frequently travel to one of the numerous options in Nairobi and occasional outreach 
from service providers is arranged within Nakuru County.  
 
In conclusion, the current level of services available in Nakuru County are not able 
to meet the growing demand for services and those in the lowest economic groups 
and rural areas are the least likely to be able to access the services that are available. 
(3, 4) 
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The Nakuru eye disease cohort study:
methodology & rationale
Andrew Bastawrous1*, Wanjiku Mathenge3, Tunde Peto2, Helen A Weiss5, Hillary Rono6, Allen Foster1,
Matthew Burton1,2 and Hannah Kuper1,7
Abstract
Background: No longitudinal data from population-based studies of eye disease in sub-Saharan-Africa are available.
A population-based survey was undertaken in 2007/08 to estimate the prevalence and determinants of blindness
and low vision in Nakuru district, Kenya. This survey formed the baseline to a six-year prospective cohort study to
estimate the incidence and progression of eye disease in this population.
Methods/Design: A nationally representative sample of persons aged 50 years and above were selected between
January 2007 and November 2008 through probability proportionate to size sampling of clusters, with sampling of
individuals within clusters through compact segment sampling. Selected participants underwent detailed ophthalmic
examinations which included: visual acuity, autorefraction, visual fields, slit lamp assessment of the anterior and
posterior segments, lens grading and fundus photography. In addition, anthropometric measures were taken and
risk factors were assessed through structured interviews. Six years later (2013/2014) all subjects were invited for
follow-up assessment, repeating the baseline examination methodology.
Discussion: The methodology will provide estimates of the progression of eye diseases and incidence of blindness,
visual impairment, and eye diseases in an adult Kenyan population.
Keywords: Cohort study, Longitudinal, Eye disease, Africa, Kenya, Cataract, Glaucoma, Age related macular
degeneration, Diabetic retinopathy, Refractive error, Incidence, Progression
Background
The most recent global estimates suggest 285 million
people worldwide are visually impaired, of whom, 39
million are blind [1]. The WHO defined Africa region
has 26 million people with visual impairment (VI) of
whom 6 million are blind. The continent also has the
greatest disparity between numbers blind and number
of ophthalmologists per million people [2], and therefore
the greatest need for scaling up services.
In recent years several cross-sectional surveys have
been undertaken across Africa to estimate prevalence
and causes of blindness [3-16]. Whilst this information
has been vital in planning services where resources and
provision of healthcare are limited, data on incidence
and rates of progression of eye disease are needed to
allow long-term planning. To date, no longitudinal,
population-based studies of eye disease have been under-
taken in Africa, and there have been only ten worldwide,
predominantly in high-income settings (Table 1) [17-26].
The current study was undertaken in Nakuru district
(now Nakuru County), which is the main district of Kenya’s
largest province, the Rift Valley and has a population of
1.6 million. Nakuru district is broadly representative of
Kenya in terms of ethnic diversity and economic activities.
In 2004, a Rapid Assessment of Avoidable Blindness
(RAAB) was completed in Nakuru district, to estimate
the prevalence and causes of avoidable blindness and VI
in the population of those 50 years and over [7]. A subse-
quent more comprehensive study was planned in the same
region as a consequence of this survey to estimate causes
and risk factors for those with visual impairment as well
as those with non-visually impairing eye disease, with a
particular focus on posterior segment eye disease [6].
Fieldwork was carried out in 2007 and 2008, during
the course of which 4414 participants (a response rate of
* Correspondence: Andrew.bastawrous@lshtm.ac.uk
1International Centre for Eye Health, Department of Clinical Research, Faculty
of Infectious and Tropical Diseases, London School of Hygiene and Tropical
Medicine (LSHTM), Keppel Street, London WC1E 7HT, UK
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88.1%) aged 50 years and above underwent ophthalmic
and/or general examinations.
The prevalence of blindness and visual impairment
[6], glaucoma, age-related macular degeneration (AMD)
[27], diabetic retinopathy (DR), cataract, refractive error
(RE) [28,29] and cardiovascular diseases [30,31] were
assessed. This 2007/08 survey forms the baseline to co-
hort described here.
The overall aim of this cohort is to estimate the inci-
dence, progression and risk factors for the development
of blindness/visual impairment and their leading causes
in a Kenyan adult population.
Objectives
Incidence
To estimate the age- and sex- specific incidence of visual
impairment (VA < 6/12) and blindness (VA < 3/60) (all
causes) in a Kenyan adult population.
To estimate the age- and sex- specific incidence of cata-
ract, RE, glaucoma, AMD and DR.
Causes & risk factors
To identify the causes and risk factors for incident visual
impairment and blindness from specific diseases investigated
(specifically focusing on demographic, anthropometric,
behavioural, and vascular risk factors).
Progression
To estimate the risk of progression of Cataract, RE, Glau-
coma, AMD and DR among cases detected at baseline.
Treatment & progression outcome
To describe the outcome of treatment for cataract, RE,
glaucoma or DR among cases detected at baseline.
To describe the progression of untreated eye disease
among cases detected at baseline.
Table 1 Population-based cohort studies of eye disease (not exhaustive)
Study Location Year commenced Years of follow up No of participants Reference*
Beaver Dam Eye Study USA 1988 Baseline 4926 [17]
5 3684
10 2764
15 2119
Blue Mountain Eye Study Australia 1992 Baseline 3654 [18]
5 2335
10 1952
Rotterdam Study Netherlands 1990 Baseline 6418 [19]
2 4953
6.5 3406
11 2387
Copenhagen City Eye Study Denmark 1986 Baseline 946 [20]
14 359
Barbados Eye Study Barbados 1987 Baseline 4631 [21]
4 3427
9 2793
Pathologies Oculaires Liees a L’Age France 1995 Baseline 2584 [22]
3 1642
Melbourne Visual Impairment Project Australia 1992 Baseline 5147 [23]
5 3271
Hisayama Study Japan 1998 Baseline 1482 [24]
5 961
9 (1401>40 yrs)
Reykjavik Eye Study Iceland 1996 Baseline 1045 [25]
5 846
Los Angeles Latino Eye Study USA 2000 Baseline 6357 [26]
4 4658
*Only one reference per study given.
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Methods/Design
This paper describes the definitions, eligibility criteria,
follow-up procedures, visual acuity (VA) measurements,
anthropometry and clinical examination procedures adopted
for the study.
Baseline study population - sample size
The sample size of 5000 participants required for the
baseline survey was calculated based on an expected
prevalence of VA < 6/12 in the better eye due to posterior
segment eye diseases (PSED) of 3.0% among those
aged ≥50 years, a required precision of 0.5% (i.e. a
95% confidence interval [CI] of 2.5%-3.5%), a design
effect of 1.5, and a response rate of 90%. (Epi Info 6.04,
Centers for Disease Control and Prevention, Atlanta, GA).
We selected 100 clusters each of 50 participants.
Sampling strategy and recruitment
Recent census data for Kenya were not available [32],
and therefore electoral role lists that were renewed in
2006 in preparation for the 2007 general elections were
used as the sampling frame for this baseline survey.
The population size was updated for the year 2007
using a population growth rate of 2.7% per year [33].
One hundred clusters were selected with a probability
proportional to the size of the population (Figure 1). A
cluster was defined as the area served by the polling
station.
Households were selected within clusters using a modi-
fied compact segment sampling method [34]. Each cluster
was divided into segments so that each segment included
approximately 50 people aged ≥ 50 years. For instance,
if a cluster included 200 people aged ≥ 50 years then it
was divided into four segments. One of the segments
was chosen at random by drawing lots and all households
in the segment were sequentially sampled, until 50 people
aged ≥ 50 years were identified. An eligible individual was
defined as someone aged ≥ 50 years living in the house-
hold for at least three months in the previous year. Age
was determined using the subject’s testimony, national
identity cards and a calendar of historic events. If the
segment did not include 50 people aged ≥ 50 years then
another segment was chosen at random and sampling
continued until 50 were reached. If after enumerating
individual number 49 the next household had more than
one person aged ≥50 all were enumerated and invited for
examination.
Baseline findings
In total, 4381 participants underwent complete (ophthalmic
and general) examination at baseline across 100 clusters.
The prevalence of blindness was 1.6% (95% CI: 1.2-2.1%) [6].
Follow-up
A pilot follow up retraced 438 participants from 10 of the
100 clusters in 2008, a mean of 1.5 years from baseline,
and 408 (79%) were successfully retraced to give an
estimated 4.2% loss per year.
Retracing at follow-up - advance team
Approximately one week before the follow-up examination
clinic was planned for a given cluster, a field officer studied
the maps of the village and made phone contact with the
village chief or guide to arrange the visit. At the planning
visit a list of study participants were given to the chief and
a local village guide was recruited to assist location of the
study participants. At this visit the examination site was
established and identification of amenities such as electri-
city, water and road access were made. Two days prior to
the clinic, the field officer reminded chiefs of the visit by
phone and notified them and the guide of the advance
team’s arrival.
On the day prior to the examination clinic, the Advance
Team visited homes of baseline participants and confirmed
their identity using National Identity cards. The two ad-
vance teams comprised of one nurse, one field officer and a
driver or public transport. During this visit they performed
the following duties:
○ Located individuals with assistance from the guide,
phone numbers when available and previously
recorded GPS locations using a Garmin Oregon
450 Satellite Navigation device.
○ Explained details of the exam and obtain written/
thumb print informed consent for examination
○ Informed selected participants about location and
time for examination
Figure 1 Map showing the 100 study locations in the Nakuru
County, Kenya.
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Registration
On the examination day, the advance team confirmed
the identity of participants against their records from
the previous day and against data from baseline (age,
date of birth, name, and identity cards). Each participant
was given a questionnaire, which was completed by the
examiners as they move from station to station.
Examination procedures
Examinations were performed as per baseline unless
otherwise indicated in Table 2.
Details of each examination station are provided below
including differences, if there were any, between baseline
and follow-up.
Anthropometry
A nurse performed and recorded measures of participants:
height; weight; waist and hip circumference, and three
measures of blood pressure, each 5 minutes apart. In
addition, at follow-up, bioimpedence (Tanita Segmental
Body Composition Monitor) was performed.
At baseline, capillary blood was taken from all par-
ticipants for random blood glucose and cholesterol.
At follow-up, no blood for cholesterol was collected
and in addition, subjects with a random blood sugar
greater than 11.1 mmol/L (IDF guidance at time of
baseline study), those with known diabetes (regardless
of random measure), evidence of diabetic retinopathy
on retinal imaging and a subset (chosen randomly
within each cluster) with random glucose between 7-
11 mmol/L had an additional capillary blood HbA1c (A1C
Now+, Bayer).
Interview
An interviewer performed the structured interview in
the participant’s preferred language covering i) demo-
graphic details including; name, year of birth, ethni-
city and education level; ii) past medical and ocular
history including medical or ophthalmic medication
or surgery and relevant family history; iii) relevant
risk factors including; smoking and tobacco consump-
tion and alcohol intake; iv) socioeconomic status
based on job, housing conditions, ownership of ma-
terial goods and livestock which is translated in to a
score based on previous work in the same population
[35]. (See Additional file 1: Appendix for Question-
naire/Data Entry Booklet).
Visual acuity
A clinical officer determined whether the study participant:
a) Attends wearing distance correction glasses
b) Owns distance correction glasses but failed to
bring them
c) Does not have any distance glasses
d) Routinely uses reading glasses
e) Attends wearing aphakic glasses
Visual acuity (VA) was measured using a back-illu-
minated modified LogMAR reduced tumbling E chart
[36,37], which has been used in previous population
based studies [38,39].
Autorefraction
All subjects, regardless of VA underwent autorefraction
using the Topcon® Auto refractor RM8800 at baseline
and the hand held SureSight autorefractor (Welch Allyn)
at follow-up, following manufacturers guidelines. Any sub-
ject recording an acuity of ≤24 optotypes, <6/9 equivalent
(with or without glasses) underwent best corrected visual
acuity. The refraction measure recorded for each eye was
mounted in the trial frames using trial lenses (rounded
up or down to the nearest 0.25 diopters). Visual acuity was
then re-measured to give an estimate of the “corrected
visual acuity” in each eye individually. When autorefraction
results were not available, the pinhole method was used
to estimate corrected visual acuity. A subset of partici-
pants also underwent manual refraction by a visiting
optometrist for five clusters to validate the accuracy of
the autorefractor.
Visual field assessment
At baseline, all individuals with suspect or abnormal discs
on clinical examination underwent automated visual field
testing. The Humphrey® Field Analyzer II - 720i series
(Carl Zeiss Ophthalmic Systems, Inc.) was used. A suspect
or abnormal disc was defined as a vertical cup/disc ratio
(VCDR) of 0.7 or above; optic disc cupping asymmetry
between the eyes of more than 0.2 VCDR; or any other
abnormal features. A random sample of five individuals
per cluster (10%) also underwent visual field testing to
provide normative data.
Participants performed the Swedish Interactive Thresh-
olding Algorithm (SITA) STANDARD 24–2. SITA Fast
was used to determine the threshold level in all partici-
pants having visual field analysis. Appropriate corrective
lenses for refractive errors were used when needed. An
automated fixation monitor was used throughout. If the
SITA fast test was reliable (following manufacturers guide-
lines) the SITA standard test was performed. If the SITA
fast was unreliable then this was repeated once. If it
remained unreliable then no further testing was done.
At follow-up, a different strategy for visual field testing
was used: All subjects with VA equivalent to > =6/60
Snellen underwent automated visual field testing by a
trained visual field technician using the Henson 8000
Visual Field Analyser (TopCon, Inc.) The multiple stimu-
lus suprathreshold test was used following manufacturers
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guidelines (Screening test - 26 test locations). When one
or more spots were missed, the 26-point test was repeated
for that eye. If any missed spots re-occurred on the second
time of testing the test for that eye was extended to 68
test locations. This machine and strategy were used in
preference to the baseline methods due to feedback
from both patient’s and tester at baseline. Patient’s found
the baseline testing protocol difficult to understand and
the time required to complete the test meant only a sub-
sample of the population could be investigated.
Slit lamp biomicroscopy examination
Undilated (anterior segment) and dilated (posterior
segment) slit lamp biomicroscopy examination were
performed on all participants by the study ophthal-
mologists (WM at baseline, AB at follow-up) using a
Table 2 Instruments used at baseline and follow-up for examination, including rationale for change where appropriate
Procedure Baseline Instrument (2007/08) Follow-up instrument
(2013/14)
Rationale for change
Near Vision Test Continuous Text “Read in Style®”
diopter chart
Unchanged N/A
Personal Interview Questionnaire developed by the
survey ophthalmologist (WM)
Questionnaire developed by
the survey ophthalmologist
(AB) see Additional file 1: Appendix
N/A
Weight The Seca 761 Medical Class 4
Scales mechanical ground scale
(Williams Medical Supplies, London)
Tanita Segmental Body
Composition Monitor
Combined weight and bioimpedence
device – approved for medical studies
Bioimpedence Not performed Tanita Segmental Body
Composition Monitor
Combined weight and bioimpedence
device – approved for medical studies
Height Leicester Height Measure
(Stadiometer) (Chasmors Ltd,
London)
SECA Height Measure Better stability on uneven grounds
Waist and Hip
circumference
Chasmors WM02 Body
Tape measure
SECA Measuring tape Availability
Blood pressure Omron® Digital Automatic Blood
Pressure Monitor Model HEM907
Unchanged N/A
Visual Acuity ETDRS LogMAR chart Unchanged N/A
Auto refraction Topcon® Auto refractor RM8800 Welch Allyn SureSight Improved portability
Corrected Visual Acuity Frames and standard
refraction lenses
Unchanged N/A
Undilated eye exam
including imaging (SL-OCT)
Haag-Streit® Slit lamp
BD900 with SL-OCT
Haag-Streit® Slit lamp
BM900 – no SL-OCT
Availability
Tonometry Haag Streit® Goldmann
Applanation tonometer
on above slit lamp
Haag Streit® Goldmann Applanation
tonometer on above slit lamp
N/A
Gonioscopy Not performed Four-mirror non-coupling gonioscopy
lens (Zabby’s)
For glaucoma sub-typing and angle
evaluation in normal population
Visual fields Humphrey Field Analyzer
II -720 i series(Zeiss®)
Henson 8000 Visual Field Analyser
(TopCon, Inc)
Deemed more suitable for
epidemiological data collection
Pupil Dilation Mydriacyl drops (Alcon®) G. Tropicamide 1% + G.
Phenylepherine 2.5% (Minims)
Single units and better shelf life
Blood sugar Accutrend GCT and
test strips (Roche®)
OneTouch Select, Lifescan Availability. Approved for
medical studies
Blood Cholesterol Accutrend GCT and
test strips (Roche®)
Not performed Cost prohibited inclusion
HbA1c Not performed (A1C Now+, Bayer) Increase accuracy of Diabetes Mellitus
diagnosis as participants non-fasted
Examination of anterior
and posterior segments
through a dilated pupil
90D lens and slit lamp(Volk®) Superfield and 60D Lens
(Volk) and Slit Lamp
Study ophthalmologist preference
Retinal Photo Topcon® NW6S Non
Mydriatic camera model
Haag-Streit DRS Retinal Camera Suitability for travel and ease of use.
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Haag-Streit BD 900 Slit Lamp (BM 900 at follow-up)
and Volk condensing lenses (90D at baseline, Superfield
and 66D at follow-up).
Anterior segment
The anterior segment of the eye was assessed for the
presence of signs of trachoma. In addition at follow up
examination included grading of corneal scarring, pte-
rygium, secondary glaucoma, evidence of past or active
uveitis, or evidence of surgery. The angle at baseline
and follow-up was assessed using the Van Herick Test
[40] and direct visualization of the angle using gonioscopy
(performed after intraocular pressure, see below) was
performed at follow-up.
At follow-up, the ophthalmologist using a bright LED
pen torch tested for the Relative Afferent Pupil Defect
(RAPD). RAPD was recorded as present or absent. If
present it was sub-categorised in to “subtle” or “definite”.
Intraocular pressure
Goldmann Applanation Tonometry (GAT) was used to
measure intraocular pressure (IOP). A drop of Proxy-
methacaine and fluorescein (minims) were instilled to each
eye. After 20 seconds the GAT was used in combination
with a slit lamp to measure the IOP in each eye. The GAT’s
calibration was checked as per manufacturers instructions
on a daily basis by the study ophthalmologist, if found to
be inaccurate, the spare GAT was used whilst the original
was returned to the factory for calibration. One reading
was taken from each eye and the GAT was disinfected
between patients.
Gonioscopy
Assessment of the opening angle of participants’ right and
left eyes was made using a four-mirror gonioscopy lens
(Zabbys). This lens does not require coupling fluid and
was chosen to minimize impact on the quality of retinal
photographs. Angles were recorded using standard Shaffer
grading [41] and further classified as “open”, “occludable”
or “closed” based on standard referral criteria. Occludable
angles are defined as: pigmented trabecular meshwork not
visible in 3⁄4 or more of angle circumference in primary
position without manipulation, in presence of low illumin-
ation. If the patient could not cooperate with gonioscopy,
the Van Herick (VH) technique [40] was used for grading.
Dilated slit lamp examination
Pharmacologic dilation of the subject’s pupils was achieved
by using tropicamide 1% (Mydriacyl) with phenylephrine
hydrochloride 2.5% if needed. Dilation was not performed
in subjects deemed at risk of narrow angle closure (inability
to visualise at least 180° of posterior pigmented trabecular
meshwork on non-indentation gonioscopy [42]). At risk
subjects were referred to the Nakuru Eye Unit for prophy-
lactic laser peripheral iridotomies.
Lens
The WHO simplified system for lens grading was used
[43] following standard protocols. The lens was also
examined for position, the presence of hyper mature
(Morgagnian) cataract, and previous lens surgery (aphakic
or pseudophakic). A red reflex lens image was taken when
each participant was having retinal photographs. At
follow-up, pseudophakic participants were assessed for
the presence or absence of posterior capsular opacification
and, if present, whether it entered the visual axis.
Optic disc
The optic nerve head was examined using a 90 Diopter
Lens (Volk) at the slit lamp at baseline and a 66 Diopter
lens (Volk) at follow-up. The clarity of the optic nerve
head was determined and graded as clear, hazy or no
view. Among subjects in whom an adequate view of the
disc was obtained, the VCDR was estimated and recorded
for each eye. Other glaucomatous changes were recorded
and non-glaucomatous characteristics such as optic atro-
phy and optic pits were also recorded.
Macula
The macula was examined using a 90 Diopter Lens (Volk)
at the slit lamp at baseline and a 66 Diopter or Superfield
lens (Volk) at follow-up. The view of the macula was
recorded as clear, hazy or no view. DR was clinically
graded and recorded as absent, non proliferative, prolif-
erative and end stage or maculopathy (macula oedema)
[44]. The presence of drusen, hypo or hyper pigmentation,
dry or geographic atrophy and neovascular changes were
also recorded.
Fundus photography
An Ophthalmic Assistant performed digital photography
of the lens and fundus on all study participants using a
Topcon® NW6S Non Mydriatic camera model at baseline
and DRS Digital Fundus Camera (Haag-Streit) at follow-up.
The study ophthalmologist checked images were of suffi-
cient quality for grading in the absence of prominent media
opacities. An anterior segment co-axial photograph was
taken for lens grading from each eye. Two 45° fundus pho-
tographs were taken in each eye, one optic disc centered
and the other macula centered. Images were then securely
uploaded to the Moorfields Reading Centre for review
and grading for image quality, the presence or absence of
pathology and the severity of pathology when present.
Note: The gold-standard for grading of DR, AMD and
optic disc changes is based on retinal photographs and not
clinical assessment. Clinical examination was performed as
a backup to equipment failure and a comparison of clinical
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and image based grading can be compared in the analysis
stage and factored in the scenario by which a number of
participants only have clinical grading available.
Data management and analysis
A patient record was completed for each participant and
crosschecked for errors by the project field coordinator.
Patient records were scanned to create a digital backup
and then data were entered into an EpiData database (with
built in range and consistency checks) independently by
two data clerks and validated by the study ophthalmolo-
gist to reconcile any differences. Further data cleaning and
all statistical analyses were conducted using STATA 10.0
(StataCorp LP, Texas, USA).
The visual fields PDF print outs and raw data were
sent securely to Moorfields Eye Hospital for grading
along with the fundus and anterior segment images at
baseline and follow-up. All image and visual field data
were backed up on local devices and external hard
drives. All images were first examined for quality and
categorized as excellent, good, fair, borderline and
ungradeable. If the images were ungradeable the clinical
diagnosis was used. For gradable images the retina and
optic disc were reviewed, and a diagnosis made based on
the appearance of the image e.g. diabetic retinopathy,
toxoplasmosis, onchocerciasis, age related macular degen-
eration, myopic fundus, glaucoma, optic atrophy or other
retinal pathology. VCDR was measured and all images
were graded for the absence/presence and stage of DR
and ARMD. The graders graded the images for as many
disease categories as possible, and so if it was feasible to
grade an image for optic disc abnormality but not for
ARMD, then the grader completed the optic disc grading
only. A senior grader verified a random 10% of images
that were graded as normal as well as all abnormal images
to ensure quality assurance. The graders re-graded a ran-
dom selection of images with a minimum of 14-days inter-
val to allow for intragrader reliability to be established.
Definitions used for analysis are detailed in Table 3.
Quality assurance procedures
Training
Inter observer variations (IOV) assessments were per-
formed in the training phase. IOV assessments on anthro-
pometric variables were done by having the two nurses
perform repeat measuring of 50 subjects. IOV of visual
acuity were undertaken by having the ophthalmic clinical
officer (OCO) and ophthalmic nurse repeat measures of
50 subjects (half normal vision and half visual impairment).
IOV of undilated examinations were done by repeat
measure of 50 subjects (half normal vision and half vis-
ual impairment) by a visiting ophthalmologist and study
Table 3 Definitions of disease incidence and progression
Disease Incidence Progression
Definition At risk Cases At risk Cases
Blindness and Visual
Impairment (VI)
Blind: Persons with VA
of ≥3/60 in the better
eye at baseline.
Persons who have VA of <3/60 in the
better eye at follow up who had ≥3/60
in the better eye at baseline
Categorical changes in visual acuity between: Normal;
Mild VI; Moderate VI; Severe VI; Blind, with a minimum
of two line Snellen equivalent change in VA.
Cataract
Persons without evidence
of cataract at baseline
based on WHO simplified
cataract grading systems
Persons with evidence of cataract
at follow-up based on WHO
simplified cataract grading systems
[45] who did not have evidence
at baseline
Persons with evidence
of any grade of cataract
at baseline based on
WHO simplified cataract
grading systems
Persons who increase by
two or more severity grades
in each sub-type of cataract.
Primary open
angle glaucoma
Persons without
glaucoma in either eye at
baseline based on ISGEO
[46] criteria
Persons who develop ISGEO
classification 1, 2 or 3 glaucoma
by the 6-year follow-up point
Glaucoma or glaucoma
suspect case at baseline
Definite, disc or field
progression. See below* [47]
Age-related
macula degeneration
Persons who did not
have any evidence
of AMD at baseline
in both eyes
Persons with evidence
of early, late or specific
AMD lesions
AREDS [48] step 9 or less
(no AMD or early AMD)
at baseline.
2-or-more-step increase in
combined AREDS score from
baseline in persons with gradable
fundus photographs at both
time points.
Diabetic
retinopathy
Persons with diabetes
and free of retinopathy
at baseline and persons
developing DM by
follow up.
Persons with signs of DR
(ETDRS) [49]
Persons with diabetes
and minimal or moderate
DR at baseline
(1) Persons who develop
severe DR by the 6-year
follow-up
CSME and incidence of
proliferative or severe DRϒ (2) Increase by ≥ 3 steps on
the ETDRS Severity Scale or
development of proliferative DR
necessitating photocoagulation
therapy or vitrectomy
*Definite progression will be defined as those with a combination of ≥0.2 VCDR increase in either eye and/or ≥0.2 VCDR asymmetry between the two eyes with a
corresponding progression on the visual field test defined as (TBC – either “expert analysis” or an arbitrary objective measure).
Note: More specific definitions will be provided in subsequent papers.
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ophthalmologist at the beginning of the baseline survey and
again in the middle. IOV of dilated exams were done by
repeat measure of 50 subjects (half normal vision and half
visual impairment) by a visiting ophthalmologist and study
ophthalmologist at baseline. Retraining was done where
IOV scores indicated poor comparability (kappa < 0.5).
At follow-up, four weeks of training in November/
December 2012 was completed for the study team
members on all equipment and study protocols. Three
pilot clusters examining over one hundred people were
completed prior to commencing the study.
Standard Operating Procedures (SOP) detailing follow-
up survey methodology for each examination station were
prepared and read by all study team members. The SOP
was used in training and for reference during fieldwork.
Supervisory visits were made to the field site (HK and
MJB) to monitor practices and ensure standard protocols
were being followed.
Non-responders at follow-up
Participants who were examined at baseline and eligible
for follow-up assessment but who did not attend the
examination clinic were contacted to determine the reason
for their absence. Participants who were not locatable for
the examination were categorized as non-responders and
their reason for absence determined through available
phone contact, neighbors and village guides as, “deceased”,
“moved away”, or “unknown”.
Service provision
All participants identified with treatable disease in the
study were offered appropriate care including free surgery
and transport to the Rift Valley General Provinical Hospital
or St Mary’s mission hospital, Elementita. Specific cases re-
quiring other services were referred to the Kikuyu Eye Unit.
A trained ophthalmic nurse or Ophthalmic Clinical Officer
(OCO) discussed the diagnosis and the treatment options
available to subjects diagnosed with untreatable eye disease.
As well as study participants, non-study attendees were
examined and treated by the study team.
Ethical approval
The study adhered to the tenets of the Declaration of
Helsinki and was approved by the Ethics Committee of
London School of Hygiene and Tropical Medicine at both
baseline and follow-up. Baseline approval was provided by
the Kenya Medical Research Institute and the African
Medical and Research Foundation (AMREF), Kenya at
follow-up. At both phases approval was also granted by
the Rift Valley Provincial Medical Officer and the Nakuru
district Medical Officer of Health. Approval was sought
from the administrative heads in each cluster, usually the
village chief. They were also given a copy of the consent
form to read and pass on to those in the village.
Informed consent
Informed consent was obtained from all participants.
The objectives of the survey and the examination process
were explained to those eligible in the local dialect, in
the presence of a witness. A subject was examined only
after informed consent was obtained. All participants
gave written (or thumbprint) consent to participate.
Discussion
The Nakuru Eye Disease Cohort Study is the first
population-based cohort study of eye disease to have
taken place in Africa. It will provide estimates on the
incidence of blindness and visual impairment, the incidence
and progression of: cataract, refractive error, glaucoma,
ARMD and DR as well other retinal conditions. This data
will be disseminated to eye care providers and programs in
the region to facilitate the provision of eye care services.
Additional file
Additional file 1: Appendix. The Nakuru Eye Disease Cohort Study -
Study Questionnaire 2013.
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The Nakuru Eye Disease 
Cohort Study 
- 
Study Questionnaire  
2013 
 
REFERRALS 
 
DIABETIC ☐ Yes – REFER  READING GLASSES DISPENSED? 
POWER 
 Distance GLASSES ☐ Yes - REFER 
CATARACT ☐ Yes - REFER  Any other treatment? E.g. drops 
GLAUCOMA ☐ Yes - REFER 
DIABETIC RETINOPATHY ☐ Yes - REFER 
OTHER ☐ Yes - REFER 
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!
 
 
 
Mark Tick Boxes using a black biro with a cross “X”, if marked incorrectly, fill in the 
box and mark the correct box. 
 
e.g. ! if incorrect fill the box " #  
 
Answer Questions in the grey boxes 
 
 
 
 
 
 
 
 
 
  
Phase Section Page 
 
Complete? 
 
 
 
1 
 
Registration/Demographic Data [A] 
 3 ☐ 
Autorefraction [B] 
 4 ☐ 
 
Phase 
 
 
Visual Acuity 
[A] 
 
Interview 
[B] 
 
Height/Weight 
etc. 
[C] 
 
Slit Lamp – 
Undilated 
 [D] 
 
Visual 
Fields 
 [E] 
 
 
2 
 
☐ ☐ ☐ ☐ ☐ 
 
Page 
 
5-7 8-12 13 14-16 17 
Phase Section Page 
 
Complete? 
 
 
 
3 
Dilated Slit Lamp Examination 
 18-22 ☐ 
Fundus Camera 
 23 ☐ 
All#tests#above#this#line#must#be#completed#before#pupil#dilation#
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1. A. Demographic data (Registration Desk) 
 
 
 
Cluster Number 3 digit number 001-100  
Individual Number 2 digit number 01-50  
Study ID Number Cluster Number – Individual Number    --   
Date of the examination Day / Month / Year (dd/mm/yyyy)    
First name text  
Last name text  
Common name text  
ID Number from ID Card if available  
Serial Number from ID Card if available  
Village name   
Telephone number   
Whose telephone is 
this?  
 
Sex ☐ Male (1) ☐ Female (2) 
Date of birth Date / Month / Year 
If year only known enter 99/99/19YY 
dd mm 19 yy 
Age in years (55+)  
Ask “mother tongue” ☐ Kikuyu (1) ☐ Kalenjin (2)  
☐ Kisii (3) ☐ Luo (4) 
☐ Luhyia (5) ☐ Masaai (6) 
☐ Kamba (7) ☐ Other (8) 
Highest level of 
Education 
☐ Primary 
(1) 
☐ Secondary 
(2) 
☐ College/University 
(3)  
☐ None 
(4) 
 
 
 
I have recorded the data onto the form: 
 
Name      Date 
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1. B. Refraction (Ophthalmic Nurse) 
Refraction? 
 
(Select ONE only) 
 
Right Eye 
 
 
Left Eye 
☐ AutoRefraction possible ☐ AutoRefraction possible 
☐ AutoRefraction not 
possible  
☐ AutoRefraction not 
possible  
☐ Manual Refraction ☐ Manual Refraction 
Refraction Result  Right Eye 
 
 
Left Eye 
Sphere +/- 00.00 (to 
nearest 0.25)   
Cylinder +/- 00.00 (to 
nearest 0.25)   
Axis 0-180 
   
Reliability score (1 to 9)    
 
Print out Autorefraction and attach to back of booklet 
 
!
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2.A. Presenting Vision (Ophthalmic Nurse) 
Glasses 
(Select ONE only) 
☐ Wearing distance glasses (Go to 2.A.a) 
 
☐ Has no distance glasses   (Go to 2.A.b) 
 
☐ Forgot distance glasses    (Go to 2.A.b) 
 
!
Wears glasses for reading ☐ Yes ☐ No 
Wears aphakic glasses 
(has had cataract surgery) 
☐ Yes 
 
☐ No 
!
2.A.a 
Test!vision!WITH!glasses!if!available.!If!own!glasses!not!available!skip!to!Question!2.A.b!(page!6).!
Vision WITH distance or 
aphakic glasses at 4m 
Number of letters seen at 4 meters (0 to 39) 
 
R L 
 
If Visual Acuity Recorded at 4 meters (greater than 00) in either eye move to next station 
If misses top E at 4m, move to 1m and retest (Record 00 at 4m) 
 
!
Vision WITH distance or 
aphakic glasses at 1m 
Number of letters seen at 1 meter (0 to 39) 
 
R L 
 
If misses top E at 1m, move to next box (Record 00 at 1m) 
 
!
If cannot see at 1m 
 
(Select ONE only) 
 
Right Eye 
 
 
Left Eye 
☐ Counting fingers at 1m ☐ Counting fingers at 1m 
☐ Hand Movements ☐ Hand Movements 
☐ Perception of light ☐ Perception of light 
☐ No light perception (in 
dark) 
 
☐ No light perception (in 
dark) 
 
!
!
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2.A.b (not needed if vision was tested with own glasses) 
Vision WITHOUT glasses 
at 4m 
Number of letters seen at 4 meters (0 to 39) 
 
R L 
 
If Visual Acuity Recorded at 4 meters (greater than 00) in either eye move to next station 
If misses top E at 4m, move to 1m and retest (Record 00 at 4m) 
 
!
Vision WITHOUT glasses 
at 1m (if 00 at 4m) 
Number of letters seen at 1 meter (0 to 39) 
 
R L 
 
If misses top E at 1m, move to next box (Record 00 at 1m) 
 
!
If cannot see at 1m 
 
(Select ONE only) 
 
Right Eye 
 
 
Left Eye 
☐ Counting fingers at 1m ☐ Counting fingers at 1m 
☐ Hand Movements ☐ Hand Movements 
☐ Perception of light ☐ Perception of light 
☐ No light perception (in 
dark) 
☐ No light perception (in 
dark) 
!
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2.A.c 
 
Is Best Corrected 
Visual Acuity 
(Wearing refraction 
results) Indicated 
From Page 4 
(Select ONE only) 
 
 
Vision in Best Eye 
 
☐ Not indicated (could read 25 or more letters in the best eye) 
Move patient to next station (miss page 7) 
 
☐ Indicated (could not read 25 or more letters in the best eye, 
refraction not available therefore use pinhole.  
 
#
NOW#TEST#BEST#CORRECTED/PIN#HOLE#VISUAL#ACUITY#IF#LESS#THAN#25#LETTERS#SEEN#IN#
BETTER#EYE#
 
How was corrected vision tested 
(Select ONE only) 
☐CORRECTED WITH LENSES 
 
☐CORRECTED WITH PINHOLE 
If refraction was not possible 
☐CORRECTED VISION NOT TESTED 
 
!
Using!refraction!result!from!Section!1.B,!page!4.!
BEST CORRECTED VISUAL 
ACUITY at 4m 
Number of letters seen at 4 meters (0 to 39) 
 
R L 
 
Move to next station if Best Corrected Visual Acuity Recorded at 4 meters (greater than 00)  
 If misses top E at 4m, move to 1m and retest (Record 00 at 4m) 
 
!
BEST CORRECTED VISUAL 
ACUITY at 1m 
Number of letters seen at 1 meter (0 to 39) 
 
R L 
 
If misses top E at 1m, Record 00 at 1m 
 
 
 
I have recorded the data onto the form: 
 
Name      Date 
 
!
 
 
 
! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Study!ID !
! 8 
2.B. General Heath (Nurse/Interviewer) 
 
Have you ever been diagnosed 
with diabetes? 
☐ Yes (1) ☐ No (2) 
 
If NO, go to next question 
 
 How long ago were you 
diagnosed with diabetes? 
 
Years (01 – 99) 
If less than one year, enter “01” 
 
 Are you receiving treatment 
for diabetes? (select ALL 
that apply) 
☐ Yes, 
insulin (1) 
☐ Yes, 
tablets (2) 
☐ Yes, 
diet (3) 
☐ Yes, 
traditional (4) 
☐ No 
(5) 
!
Have you ever been diagnosed 
with high blood pressure? 
☐ Yes (1) ☐ No (2) 
 
If NO, go to next question 
 
 How long ago were you 
diagnosed with high blood 
pressure? 
 
Years (if less than 1 year mark “0” 
 
 Are you receiving treatment 
for high blood pressure? 
(select ALL that apply) 
☐ Yes, 
tablets (1) 
☐ Yes, diet 
(2) 
☐ Yes, 
traditional (3) 
☐ No (4) 
!
Have you been diagnosed or 
are you suffering from any of 
the following? (tick all that 
apply) 
☐ Renal 
Disease (1) 
☐ Heart 
Disease (2) 
☐ Foot 
Ulcers (3) 
☐ None (4) 
Did/Do your mother have any 
of the following? 
☐ Diabetes 
(1) 
☐ High Blood 
Pressure (2) 
☐ Blinding 
eye condition 
(3) 
☐ Not 
sure/None (4) 
 
Did/Do your father have any of 
the following? 
☐ Diabetes 
(1) 
☐ High Blood 
Pressure (2) 
☐ Blinding 
eye condition 
(3) 
☐ Not 
sure/None (4) 
 
Did/Do your siblings have any 
of the following? 
☐ Diabetes 
(1) 
☐ High Blood 
Pressure (2) 
☐ Blinding 
eye condition 
(3) 
☐ Not 
sure/None (4) 
 
!
# #
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#
2.B.#continued:#Blood#Pressure#(Nurse)!
 
Take First and Second Blood Pressure Measurements 
 
First Blood Pressure Reading Systolic (00 to 250) Diastolic (00 to 250) Pulse (00 to 250)  
   
Wait ten minutes between readings. Ensure patient is resting, sitting and no talking whilst 
BP being taken 
Second Blood Pressure Reading Systolic (00 to 250) Diastolic (00 to 250) Pulse (00 to 250)  
   
!
Do you drink alcohol? 
 
(Answer ONE only) 
☐ 
Daily/Mos
t days (1) 
☐ 
Weekend
s only (2) 
☐ 1-2 
times per 
month (3) 
☐ 
Special 
occasion
s only (4) 
☐ 
Never 
(5) 
☐ 
Former 
(>6 
months) 
(6) 
!
Have you ever smoked? ☐ Never (1) ☐ Former (stopped > 
6 months ago) (2) 
☐ Current (in last 6 
months) (3) 
 
If “Never”, skip to next question  
 
 Age at starting 
years  
Duration of use 
years  
Number of days 
per week 
days (max 07)  
Number smoked 
per day 
  
!
Have you ever snuffed tobacco? ☐ Never (1) ☐ Former (stopped > 
6 months ago) (2) 
☐ Current (in last 6 
months) (3) 
 
If “Never”, skip to next question  
 
 Age at starting 
years  
Duration of use 
years  
How many days 
used per week 
days (max 07)  
How many times 
used per day 
  
!
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!
2.B.#continued!
Have you ever chewed 
tobacco? 
☐ Never (1) ☐ Former (stopped > 
6 months ago) (2) 
☐ Current (in last 6 
months) (3) 
 
If “Never”, skip to next page  
 
 Age at starting 
years  
Duration of use 
years  
Number of days 
per week 
days (max 07)  
Number chewed 
per day 
  
!
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2.B. Socioeconomic Status (Nurse/Interviewer) 
 
In the last month have you had a job 
other than working in the field owned 
or rented by the household? 
☐ Yes (1) ☐ No (2) 
Major external wall 
material of your home 
(Select ONE only) 
☐ Brick (1) ☐ Concrete Block 
(2) 
☐ Stone (3) 
 
☐ Unbaked brick 
(4) 
☐ Wood/logs (5) ☐ Tin, zinc 
sheeting (6) 
☐ Flattened tin 
cans (7) 
☐ Mud (8) ☐ Stone and Mud 
(9) 
☐ Canvas/Felt 
(10) 
☐ Other (11) 
 
 
Primary Roof Material of 
your home 
(Select ONE only) 
☐ Concrete (1) ☐ Shingles (2) ☐ Asbestos 
Sheets (3) 
☐ Metal Sheets 
(4) 
☐ Tile (5) ☐ Wood (6) 
 
☐ Unbaked bricks 
(7) 
☐ Thatch (8) ☐ Other (9) 
 
Primary Floor Material of 
your home 
(Select ONE only) 
☐ Parquet (1) 
 
☐ Painted wood 
(2) 
☐ Tile (3) 
☐ Linoleum (4) ☐ Concrete (5) ☐ Clay/earthen 
floor (6) 
☐ Other (7) 
 
 
Where is the toilet? 
(Select ONE only) 
If more than one toilet mark 
best one 
☐ Inside dwelling (1) ☐ Outside dwelling – in 
compound (2) 
☐ Outside dwelling – outside 
compound (3) 
☐ Not Applicable/no access 
to a toilet (uses bush etc) (8) 
Type of toilet? 
(Select ONE only) 
If more than one toilet mark 
best one 
☐ Flush Toilet (1) ☐ Traditional 
latrine (2) 
☐ Improved pit 
latrine with 
ventilation (VIP)(3) 
☐ Bowl/Bucket (4) ☐ Other (5) ☐ No toilet (6) 
 
!
!
!
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Household assets  
(Select ALL that apply) 
☐ Radio/Hifi ☐ Sewing machine 
☐ TV/VCR/DVD ☐ Table 
☐ Fridge/Freezer ☐ Bicycle 
☐ Telephone/cell phone ☐ Washing machine 
☐ Cupboard ☐ Motor vehicle/car 
☐ Sofaset/armchair ☐ Motorbike 
How many of the following 
animals do you possess? 
 
Enter “0” if none 
Cows? 
 
 
Sheep? 
 
 
Pigs? 
 
 
Chicken/ducks? 
 
 
 
 
Blood Pressure 
 
 
Third Blood Pressure 
Reading 
Systolic (00 to 250) Diastolic (00 to 250) Pulse (00 to 250) 
 
   
 
Treatment history and barriers to uptake (Nurse/Interviewer) 
 
Previous Eye Surgery  
(Select ALL that apply) 
 
Right Eye 
 
 
Left Eye 
☐ Cataract Surgery ☐ Cataract Surgery 
☐ Eye lid surgery (Trachoma) ☐ Eye lid surgery (Trachoma) 
☐ Glaucoma Surgery ☐ Glaucoma Surgery 
☐ Other ☐ Other 
☐ No Surgery ☐ No Surgery 
Current regular medicine 
for the eyes 
(Select ALL that apply) 
 
Right or Left Eyes 
 
☐ Antibiotics 
☐ Steroids 
☐ Anti-Glaucoma 
☐ Lubricant 
☐ Other 
☐ No medicines 
!
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2.C. Anthropometry (Nurse) 
 
 
Patient Age from page 3: 
 
 
 
 
Height in cm (no dp) 888: unable, 999: refused  
Weight in kg (1 dp) 
 
888: unable, 999: refused 
 
Body Fat % 
 
888: unable, 999: refused 
 
Muscle Mass 
 
888: unable, 999: refused 
 
Bone MASS 
 
888: unable, 999: refused 
 
Metabolic Age 
 
888: unable, 999: refused 
 
Total Body Water % 
 
888: unable, 999: refused 
 
Visceral Fat Level 
 
01-59 
888: unable, 999: refused 
 
Waist circumference in 
cm (no dp)  
 
888: unable, 999: refused 
 
Hip circumference in cm 
(no dp) 
  
888: unable, 999: refused  
 
!
Random blood sugar 
mmol/L 
 
0.0 to 35.0  
 
!
If > 11.1 
mmol/l 
 
HbA1c 
(%) 
 
Enter number on 
screen (<4 or >13 may 
be shown) 
 
 
 
 
I have recorded the data onto the form: 
 
Name      Date  
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2.D. Anterior Segment Examination (Ophthalmologist) 
Relative Afferent Pupil Defect  Right Eye 
 
 
Left Eye 
☐ Definite ☐ Subtle ☐ Definite ☐ Subtle 
☐ No ☐ Not able ☐ No ☐ Not able 
!
Pterygium present and extent  Right Eye 
 
 
Left Eye 
☐ No Pterygium ☐ No Pterygium 
☐ Pterygium – Cornea NOT 
involved 
☐ Pterygium – Cornea NOT 
involved 
☐ Pterygium – Cornea 
Involved 
☐ Pterygium – Cornea 
Involved 
mm in to cornea from limbus (0-12) ☐☐ ☐☐ 
! !
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!
2.D. continued!
Corneal scarring grade 
 
 
Right Eye 
 
 
Left Eye 
☐ NO Opacity ☐ NO Opacity 
☐ Opacity not entering central 
4mm (C1) 
☐ Opacity not entering central 
4mm (C1) 
☐ Opacity within central 4mm 
but not entering within the 
central 1mm of the cornea. 
The pupil margin is visible 
through the opacity (C2a) 
☐ Opacity within central 4mm 
but not entering within the 
central 1mm of the cornea. 
The pupil margin is visible 
through the opacity (C2a) 
☐ Opacity within central 4mm 
but not entering within the 
central 1mm of the cornea. 
The pupil margin is not visible 
through the opacity (C2b) 
☐ Opacity within central 4mm 
but not entering within the 
central 1mm of the cornea. 
The pupil margin is not visible 
through the opacity (C2b) 
☐ Opacity within central 4mm 
and entering the central 1mm 
of the cornea. The pupil 
margin is visible through the 
opacity (C2c) 
☐ Opacity within central 4mm 
and entering the central 1mm 
of the cornea. The pupil 
margin is visible through the 
opacity (C2c) 
☐ Opacity within central 4mm 
and entering within the central 
1mm of the cornea. The pupil 
margin is not visible through 
the opacity (C2d) 
☐ Opacity within central 4mm 
and entering within the central 
1mm of the cornea. The pupil 
margin is not visible through 
the opacity (C2d) 
☐ Opacity large enough and 
dense enough to make whole 
pupil margin invisible (C3) 
☐ Opacity large enough and 
dense enough to make whole 
pupil margin invisible (C3) 
☐ Phthisis (C4) ☐ Phthisis (C4) 
 
 
Anterior Segment 
 
Right Eye 
 
 
Left Eye 
Mark ALL that apply ☐ Pseudoexfoliation ☐ Pseudoexfoliation 
☐ Iris Trans illumination ☐ Iris Trans illumination 
☐ Krukenberg’s Spindle ☐ Krukenberg’s Spindle 
☐ Evidence of previous inflammation ☐ Evidence of previous inflammation 
☐ None of the above ☐ None of the above 
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2.D. continued!
Van Herick’s  Right Eye 
 
 
Left Eye 
☐ ACD = 0 or negligible (0) ☐ ACD = 0 or negligible (0) 
☐ ACD ≤1/4 cornea (1) ☐ ACD ≤1/4 cornea (1) 
☐ ACD = 1/4 cornea (2) ☐ ACD = 1/4 cornea (2) 
☐ ACD =1/4-1/2 cornea (3) ☐ ACD =1/4-1/2 cornea (3) 
☐ ACD >=1/2 cornea (4) ☐ ACD >=1/2 cornea (4) 
☐ not gradable (9) ☐ not gradable (9) 
!
 
Applanation IOP (mmHg) 
 
99 = not 
possible R L 
!
Gonioscopy  Right Eye 
 
 
Left Eye 
☐ Nil (0) 
 
☐ Nil (0) 
☐ Scwalbe’s line and anterior 
meshwork (1) 
 
☐ Scwalbe’s line and anterior 
meshwork (1) 
☐ Posterior pigmented 
meshwork (2) 
 
☐ Posterior pigmented 
meshwork (2) 
☐ Scleral Spur (3) 
 
☐ Scleral Spur (3) 
☐ Ciliary Band (4) ☐ Ciliary Band (4) 
☐ Not gradable (5) ☐ Not gradable (5) 
 
Safe to dilate? ☐ Yes ☐ No 
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2.E. Visual Fields (Visual Field Technician) 
VF completed?  Right Eye 
 
 
Left Eye 
☐ Yes ☐ Yes 
☐ No – uncooperative  ☐ No – uncooperative  
☐ No – poor visual acuity ☐ No – poor visual acuity 
☐ No – machine failure  ☐ No – machine failure  
Classification (in the field – by 
ophthalmologist or OCO) 
 
Right Eye 
 
 
Left Eye 
☐ Normal ☐ Normal 
☐ Abnormal – definite 
Glaucoma 
☐ Abnormal – definite 
Glaucoma 
☐ Abnormal – suspect 
glaucoma 
☐ Abnormal – suspect 
glaucoma 
☐ Abnormal – non-glaucoma ☐ Abnormal – non-glaucoma 
 
Print out Visual Fields and attach to back of booklet 
 
!
I have recorded the data onto the form and printed the visual fields: 
 
Name      Date 
!
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3.A. Dilated Examination (Ophthalmologist) 
 
WHO CATARACT GRADING (See Document for Reference) 
 
Cataract 
 
(Select ONE only) 
 
3.A.1 
 
Right Eye 
 
 
Left Eye 
[0] ☐ No cataract  [0] ☐ No cataract  
[1] ☐ Gradable cataract  [1] ☐ Gradable cataract  
[2] ☐ Mature  [2] ☐ Mature  
[3] ☐ Hypermature  [3] ☐ Hypermature  
[4] ☐ Corneal Opacity  [4] ☐ Corneal Opacity  
[5] ☐ Phythsis  [5] ☐ Phythsis  
[7] ☐ Aphakia  [7] ☐ Aphakia  
[8] ☐ IOL  [8] ☐ IOL  
[9] ☐ Can not grade  [9] ☐ Can not grade  
Nuclear 
 
(Select ONE only)
 
         1                2                 3 
 
Right Eye 
 
 
Left Eye 
☐ Not applicable ☐ Not applicable 
☐ Nuclear 0 [0] ☐ Nuclear 0 [0] 
☐ Nuclear 1 [1] ☐ Nuclear 1 [1] 
☐ Nuclear 2 [2] ☐ Nuclear 2 [2] 
☐ Nuclear 3 [3] ☐ Nuclear 3 [3] 
☐ Aphakia [7] ☐ Aphakia [7] 
☐ IOL [8] ☐ IOL [8] 
☐ Cannot grade [9] ☐ Cannot grade [9] 
!
!
!
!
!
!
!
!
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3.A. continued!
Cortical 
(Select ONE only) 
 
0: <1/8, 1: 1/8 to <1/4, 2: ¼ to 
<1/2, 3: 1/2+ 
 
Right Eye 
 
 
Left Eye 
 
☐ Not applicable ☐ Not applicable 
☐ Cortical 0 [0] ☐ Cortical 0 
☐ Cortical 1 [1] ☐ Cortical 1 
☐ Cortical 2 [2] ☐ Cortical 2 
☐ Cortical 3 [3] ☐ Cortical 3 
☐ Aphakia [7] ☐ Aphakia 
☐ IOL [8] ☐ IOL 
☐ Cannot grade [9] ☐ Cannot grade 
Cortical Central? (central 3mm) ☐ Yes 
[1] ☐ No [2] 
☐ N/A 
[3] 
☐ Yes 
[1] 
☐ No [2] ☐ N/A 
[3] 
!
Posterior Subcapsular (PSC) 
 
(Select ONE only) 
0: <1mm 
1: >=1mm, <2mm 
2: >=2mm, <3mm 
3: >=3mm 
 
Right Eye 
 
 
Left Eye 
 
☐ Not applicable ☐ Not applicable 
☐ PSC 0 [0] ☐ PSC 0 [0] 
☐ PSC 1 [1] ☐ PSC 1 [1] 
☐ PSC 2 [2] ☐ PSC 2 [2] 
☐ PSC 3 [3] ☐ PSC 3 [3] 
☐ Aphakia [7] ☐ Aphakia [7] 
☐ IOL [8] ☐ IOL [8] 
☐ Cannot grade [9] ☐ Cannot grade [9] 
Posterior Capsular Opacification 
(PCO) with IOL  
 
Right Eye 
 
 
Left Eye 
 
☐ Yes  - within central 3mm [1] ☐ Yes  - within central 3mm [1] 
☐ No – Clear capsule [2] ☐ No – Clear capsule [2] 
☐ Not sure [3] ☐ Not sure [3] 
☐ Evidence of capsulotomy [4] ☐ Evidence of capsulotomy [4] 
☐ Yes – outside central 3mm [5] ☐ Yes – outside central 3mm [5] 
☐ N/A [9] ☐ N/A [9] 
! !
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3.A. continued!
POSTERIOR SEGMENT EXAMINATION (1 in 10 participants and those in whom imaging not possible) 
☐ 1 in 10 ☐ Imaging not possible ☐ Not applicable (skip to 3B) 
!
View of PSED at slit lamp  Right Eye 
 
 
Left Eye 
 
☐ Clear ☐ Clear 
☐ Hazy ☐ Hazy 
☐ No view 
 
☐ No view 
 
!
Vertical Cup to Disc Ratio 0.0 to 1.0  R   ☐Can not assess L  ☐Can not assess 
VCDR asymmetry (>=0.2)  Both Eyes 
 
 
☐ Yes [1] 
☐ No [2] 
☐ Can not assess [3] 
Disc Haemorrhage  Right Eye 
 
 
Left Eye 
 
☐ Yes [1] ☐ Yes [1] 
☐ No [2] ☐ No  [2] 
☐ Can not assess [3] ☐ Can not assess [3] 
Disc Notch   Right Eye 
 
 
Left Eye 
 
☐ Yes [1] ☐ Yes [1] 
☐ No [2] ☐ No [2] 
☐ Can not assess [3] ☐ Can not assess [3] 
Disc Atrophy  Right Eye 
 
 
Left Eye 
 
☐ Yes [1] ☐ Yes [1] 
☐ No [2] ☐ No [2] 
☐ Can not assess [3] ☐ Can not assess [3] 
!
!
! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Study!ID !
! 21 
3.A. continued!
Diabetic Retinopathy 
(Select ONE only) 
 
Right Eye 
 
 
Left Eye 
 
☐ No diabetic retinopathy ☐ No diabetic retinopathy  
☐ Non-proliferative  ☐ Non-proliferative  
☐ Proliferative/end stage  ☐ Proliferative/end stage  
☐ Cannot assess ☐ Cannot assess 
Diabetic Maculopathy 
(Select ONE only) 
☐ Diabetic Maculopathy  ☐ Diabetic Maculopathy  
☐ No Diabetic Maculopathy ☐ No Diabetic Maculopathy 
☐ Cannot assess ☐ Cannot assess 
Age Related Maculopathy 
(ARM) 
 
Right Eye 
 
 
Left Eye 
 
☐ No ARM [1] ☐ No ARM [1] 
☐ Drusen [2] ☐ Drusen [2] 
☐ Hypo/hyper pigmentation [3] ☐ Hypo/hyper pigmentation [3] 
☐ Can not assess [4] ☐ Can not assess [4] 
Age Related Macular 
Degeneration (ARMD) 
 
Right Eye 
 
 
Left Eye 
 
☐ No ARMD ☐ No ARMD 
☐ Dry or Geographic ☐ Dry or Geographic 
☐ Wet/Neovascular/Disciform ☐ Wet/Neovascular/Disciform 
☐ Can not assess ☐ Can not assess 
Other PSED Pathology  Right Eye 
 
 
Left Eye 
 
☐ Yes ☐ Yes 
☐ No  ☐ No  
☐ Can not assess ☐ Can not assess 
 If Yes - Specify  
(free text) 
 
R L 
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3.B. Fundus Photography  
 
Participant details entered on home screen 
 
☐ Yes ☐ No 
 
Participant Study ID Number 
 
 
XXX-XX 
    
- 
  
Camera Failure? ☐ Yes ☐ No 
 
ANTERIOR SEGMENT & LENS PHOTO 
SIT PATIENT BACK SLIGHTLY ON CHIN REST (3cm) 
 
Image clarity  Right Eye 
 
 
Left Eye 
 
☐ Clear ☐ Clear 
☐ Hazy ☐ Hazy 
☐ No view 
 
☐ No view 
 
 
FUNDUS PHOTOGRAPH 
AUTOMATIC MODE  
MANUAL IF UNABLE 
 
Posterior Segment Image clarity  Right Eye 
 
 
Left Eye 
 
☐ Clear ☐ Clear 
☐ Hazy ☐ Hazy 
☐ No view 
 
☐ No view 
 
! !
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Participant information sheet – to be translated in to Kiswahili and read to participants  
THE INCIDENCE AND PROGRESSION OF POSTERIOR SEGMENT EYE DISEASE IN NAKURU COUNTY IN 
RESIDENTS AGED 55 YEARS AND ABOVE 
You are being invited to take part in a research study. Before you decide to take part, it is important for you to 
understand why the research is being done and what it will involve. I will read information to you about this 
study. Please ask me if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part 
What is the purpose of the study? 
In the world today there are about 39 million blind people. Approximately half of these people are blind due to cataract, 
making this the single largest cause of global blindness. In 2007/8 we undertook a survey to investigate how common 
eye diseases are among older people in Nakuru. This information helps us to plan health services more efficiently. We 
now want to follow-up the people we examined to see how quickly eye disease progresses and how often new eye 
disease occurs.  
Why have I been chosen? 
Every person who was randomly selected for the study 5 years ago (in 2007/2008) is being invited to take part again 
in the study so we can see what has happened to you over this time, 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you decide to take part you will be asked to sign a consent 
form. If you decide to take part you are still free to withdraw at any time and without giving a reason.  
What is involved in the study? 
We will give you a very complete eye examination to look for any problem at the front and inside the eye using several 
machines. We will also check the pressure in your eye. Some of the examinations will involve contact with your eye. 
Some drops will be put in your eye so that you feel no pain. We will also put drops in your eyes to make the pupils as 
big as possible so we can see inside clearly. This will cause blurring of your near vision for a few hours afterwards and 
so you will not be able to drive or operate dangerous machinery for the rest of the day. The risks and likelihood of 
side-effects from this procedure is extremely small. We will also collect information about your history of diabetes, high 
blood pressure, eye diseases, smoking and alcohol all of which affect your eyes.  
Your height, weight and blood pressure will be measured. A finger prick blood sample will be taken to check for 
diabetes, and a swab from the inside of your cheek will be taken to measure genetic material (DNA).  This genetic 
material carries information for making up our bodies and is different in all people. Having DNA samples  helps us to  
understand whether diseases run in the family. The results are unlikely to have any implications for you personally. 
We will store the DNA for future laboratory research that may be needed.  
All information which is collected about you during the course of the research will be kept strictly confidential and your 
name will never be released.  
 
Should we find that you could benefit from ant further eye treatment we will arrange an appointment for you to have 
treatment done at Nakuru eye unit. If you are found to be diabetic or have high blood pressure we will arrange for you 
be seen at the Nakuru provincial hospital. You will have to pay normal hospital fees for some of the treatment at the 
hospital. It is up to you to decide whether you would like to take up the offer of treatment or not.  
!
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CONSENT!FORM! ! ! ! ! ! ! ! ! ! !
!
The!information!sheet!concerning!this!study!has!been!read!to!me,!and!I!understand!what!will!be!expected!
of!me!if!I!take!part!in!this!study.!
My!questions!concerning!this!study!have!been!answered!by!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!!I!understand!that!
participation!in!this!study!is!voluntary.!!I!also!understand!that!I!may!withdraw!from!this!study!at!any!time!
without!giving!a!reason!and!that!this!will!not!affect!my!normal!care.!!I!agree!to!take!part!in!this!study.!I!agree!to!have!a!sample!of!genetic!material!(DNA)!taken:!Yes/No!!Name!of!study!subject:!! ! ! ! ! ! ! ! ! ! !!Signature!or!thumbprint! ! ! ! ! ! ! ! ! ! !!Witness! ! ! ! ! ! ! ! ! ! ! ! !!Date! ! ! ! ! ! ! ! ! ! ! ! ! !
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!
*!Witness:!!By!signing!in!this!column!I!warrant!that!I!have!read!this!form!and!the!information!form!to!the!persons!against!whose!
names!my!signature!appears.!!I!am!sure!that!each!of!these!persons!has!understood!what!is!required!of!him/her!and!has!agreed!
to!take!part!in!the!study.!
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PURPOSE. To describe the cumulative 6-year incidence of visual impairment (VI) and blindness
in an adult Kenyan population. The Nakuru Posterior Segment Eye Disease Study is a
population-based sample of 4414 participants aged ‡50 years, enrolled in 2007–2008. Of
these, 2170 (50%) were reexamined in 2013–2014.
METHODS. The World Health Organization (WHO) and US definitions were used to calculate
presenting visual acuity classifications based on logMAR visual acuity tests at baseline and
follow-up. Detailed ophthalmic and anthropometric examinations as well as a questionnaire,
which included past medical and ophthalmic history, were used to assess risk factors for study
participation and vision loss. Cumulative incidence of VI and blindness, and factors associated
with these outcomes, were estimated. Inverse probability weighting was used to adjust for
nonparticipation.
RESULTS. Visual acuity measurements were available for 2164 (99.7%) participants. Using WHO
definitions, the 6-year cumulative incidence of VI was 11.9% (95%CI [confidence interval]:
10.3–13.8%) and blindness was 1.51% (95%CI: 1.0–2.2%); using the US classification, the
cumulative incidence of blindness was 2.70% (95%CI: 1.8–3.2%). Incidence of VI increased
strongly with older age, and independently with being diabetic. There are an estimated 21
new cases of VI per year in people aged ‡50 years per 1000 people, of whom 3 are blind.
Therefore in Kenya we estimate that there are 92,000 new cases of VI in people aged ‡50
years per year, of whom 11,600 are blind, out of a total population of approximately 4.3
million people aged 50 and above.
CONCLUSIONS. The incidence of VI and blindness in this older Kenyan population was
considerably higher than in comparable studies worldwide. A continued effort to strengthen
the eye health system is necessary to support the growing unmet need in an aging and
growing population.
Keywords: Kenya, Africa, visual impairment, blindness, incidence, cohort, population-based
Global estimates based on recent population-based surveyssuggest that approximately 191 to 285 million people live
with visual impairment (VI; defined as visual acuity of <6/18 or
<20/60 in the better eye), of whom 32 to 39 million people are
bilaterally blind (visual acuity < 3/60 or < 20/400 in the better
eye).1,2 Overall, VI is ranked sixth in the global burden of
disease in terms of disability-adjusted life-years (DALYs)3 and is
associated with increased mortality.4,5 Despite a reduction in
the prevalence of blindness in sub-Saharan Africa over the last
two decades, the numbers with VI have risen due to an increase
in population and longevity,6 though data are sparse.
Longitudinal studies provide the opportunity to investigate
the natural history of disease, which is essential to plan health
services. However, despite a large body of data globally on the
prevalence and causes of eye disease, data on incident visual
loss from population-based cohorts are limited, due to
prohibitive costs and complex logistical and planning challeng-
es. Consequently, to date, no longitudinal, population-based
studies of eye disease have been undertaken in sub-Saharan
Africa, and there have been only a small number worldwide,
predominantly in high-income settings.7–10 Inferring data from
high-income cohorts is not appropriate for low-income settings,
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and data are required from low-income countries for effective
planning of eye care services.
The aim of this study was to estimate the 6-year incidence
and risk factors for incident VI and blindness (both bilateral
and unilateral) in a cohort of adult Kenyans.
MATERIALS AND METHODS
The methodology of the Nakuru Eye Disease Cohort Study has
been reported in detail previously11 and is summarized here.
Ethical Approval
The study adhered to the tenets of the Declaration of Helsinki
and was approved by the Ethics Committee of London School
of Hygiene and Tropical Medicine at both baseline and follow-
up (LSHTM Ref. 6192). Baseline approval was provided by the
Kenya Medical Research Institute Ethics Committee and by the
African Medical and Research Foundation (AMREF) Ethics
Committee, Kenya, for the follow-up (AMREF-ESRC P44/12).
For both phases, approval was granted by the Rift Valley
Provincial Medical Officer and the Nakuru District Medical
Officer of Health. Approval was sought from the administrative
heads in each cluster. Informed written (or thumbprint)
consent was obtained from all participants after the objectives
of the survey and the examination process were explained to
those eligible in the local dialect, in the presence of a witness.
Participants identified with eye conditions, or other health
conditions, were referred to local services.
Baseline Study Population
The baseline population-based survey was conducted in 2007–
2008. The sample size of 5000 participants aged ‡50 years was
calculated based on an expected prevalence of visual acuity
(VA) < 20/40 in the better eye due to posterior segment eye
diseases (PSED, the primary outcome for the baseline survey)
of 3.0% in this age group, precision of 0.5%, design effect of
1.5, and a response rate of 90%.
A total of 100 clusters each of 50 participants were selected
with a probability proportional to the size of the population
across Nakuru district. Households were selected within
clusters using a modified compact segment sampling meth-
od.12 An eligible individual was defined as someone aged ‡50
years living in the household for at least 3 months in the
previous year. All participants were invited to undergo a
comprehensive ophthalmic examination at a screening clinic
(details below).
In total, 4381 (response rate 87.4%) participants underwent
complete (ophthalmic and general) examination at baseline.
Among those aged ‡50 years at baseline, the prevalence of
blindness was 1.6% (95%CI [confidence interval]: 1.2–2.1%),
and prevalence of VI was 13.6% (95%CI: 11.8–16.0%).13
Follow-up
Follow-up was conducted from January 2013 to March 2014.
Retracing at Follow-up: Advance Team. One week
before the follow-up examination clinic was planned for a given
cluster, a field officer studied the maps of the village including
Global Positioning System (GPS) coordinates recorded at
baseline and made phone contact with the village chief or
guide to arrange the visit. At the planning visit, a list of study
participants was given to the chief, and a local village guide was
recruited to assist location of the study participants. At this visit,
the examination site was established. Two days prior to the
clinic, the field officer reminded chiefs of the visit by phone and
notified them and the guide of the advance team’s arrival.
On the day prior to the examination clinic, the advance
team visited homes of baseline participants, confirmed their
identity using National Identity cards, and invited them to
attend the examination clinic the following day. All identified
participants were also asked to help locate baseline partici-
pants who had not been found.
Examination Clinic. The following procedures were
undertaken for all participants who attended the examination
clinic at both baseline and follow-up, and further details are
available elsewhere.11 Procedures undertaken but not included
in these analyses are not described in this report (e.g., visual
field assessment).
Registration. On the examination day, the advance team
confirmed the identity of participants against data from
baseline (age, date of birth, name, and identity cards). In cases
of uncertain identity, confirmation was made based on retinal
examination verified by comparison of retinal photos with
baseline photo (n ¼ 12).
Visual Acuity Assessment. Presenting VA was measured
using a back-illuminated modified logMAR reduced tumbling E
chart (Sussex Vision, Inc., Rustington, UK),14,15 which has
been used in previous population-based studies.16,17 Present-
ing VA was measured on all participants, that is, the patient’s
own correction was used if normally worn.
If the subject’s vision was too poor to read any letters on the
chart at 4 m, the subject was tested at 1 m, then as follows:
" Counting fingers (CF): ability to count fingers at 1-, 2-, or
3-m distance
" Hand motion (HM): ability to distinguish if a hand is
moving or not in front of the patient’s face
" Light perception (LP): ability to perceive any light
" No light perception (NLP): inability to see any light or
total blindness
Those who did not read 24 letters (VA < 20/40) at 4 m were
scheduled for correction and to undergo a repeat VA measure-
ment with the correction in place unless the vision was worse
than CF, in which case no correction was undertaken.
Anthropometry. A nurse performed and recorded measures
of participants: height (Leicester Height Measure; Chasmors
Ltd, London, UK); weight (Seca 761 Medical Class 4 Scales
mechanical ground scale; Williams Medical Supplies, London,
UK); waist and hip circumference (Chasmors Ltd WM02 Body
Tape measure); and three measures of blood pressure (Omron
Digital Automatic Blood Pressure Monitor Model HEM907;
Omron, Hoofddorp, The Netherlands), each 10 minutes apart.
In addition, at follow-up, bioimpedence (Tanita Segmental
Body Composition Monitor; Tanita, Amsterdam, The Nether-
lands) was performed.
At baseline, capillary blood was taken from all participants
for random blood glucose. Random blood glucose was also
taken at follow-up with the addition of glycosylated hemoglo-
bin (HbA1c) in all with a self-reported history of diabetes or
random blood glucose of ‡7.0 mM, and a further 10% of
nondiabetics (based on history and random blood glucose).
Interview. An interviewer performed a structured inter-
view in the participant’s preferred language covering demo-
graphic details; past medical and ocular history; known risk
factors (e.g., smoking and tobacco consumption and alcohol
intake); and socioeconomic status (e.g., job, housing condi-
tions, ownership of material goods and livestock).18
Definitions and Statistical Analyses
All participants who had complete examinations at baseline
who were not visually impaired or blind were considered ‘‘at
risk’’ for incident VI or blindness, respectively. Follow-up status
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at 6 years was categorized as Found and examined; Found and
not examined; Deceased; Moved away; or Unknown.
Statistical analysis was performed using STATA v13 (Stata
Corp, College Station, TX, USA). All analysis accounted for the
cluster survey design using Taylor linearized variance estima-
tion to calculate standard errors.
Preparation of Cohort for Analysis
Pearson v2 tests corrected for the survey design were used to
calculate P values in order to assess differences between
participants seen and those lost to follow-up (LTFU), and
between those known to have died and with unknown
outcome status. P < 0.1 was considered to represent a
statistically significant difference.
Those who were deceased were then excluded. Those
followed up but without complete records for all covariates at
baseline were also excluded.
An inverse probability weighting (IPW) model19 was
developed to allow estimation of cumulative incidence while
accounting for those LTFU. Multivariable logistic regression
was used to identify independent baseline covariates associat-
ed with LTFU. Covariates for which there was evidence of
univariable association with the outcome (P < 0.1) were kept
in a multivariable model. From this final model, the probability
of being followed was estimated, based on the presence or
absence of each of these baseline covariates. The inverse of
this probability formed the weighting to be applied in order to
account for those LTFU.
The final step was to remove those individuals LTFU from
the cohort, so that all subsequent analysis would be performed
on only those with complete outcome records, with IPW
applied to account for those LTFU. A sensitivity analysis for this
approach involved a complete records analysis (i.e., including
only those people who had complete records for outcome and
all variables in the analysis).
Estimation of Absolute and Relative Effects. The 6-year
cumulative incidence of each outcome was calculated by
dividing the number of events identified at 6-year follow-up by
the number of people at risk at the beginning of follow-up; 95%
confidence intervals were estimated assuming a Poisson
distribution of events. This analysis was done for the
population overall, and stratified by key covariates.
Age-adjusted risk ratios of the outcomes (VI and blindness,
respectively) were estimated for each covariate using a Poisson
regression model with robust error variance to allow for the
clustered design and including IPW. For multivariable analysis,
an initial model was fitted that included those variables
associated with outcome in age-adjusted analysis (Wald P value
< 0.05). A backward stepwise approach was applied to obtain a
final multivariable model, removing variables with P > 0.05.
Definitions. Visual acuity: WHO definitions of VI and
blindness were used throughout.20 Monocular VI was defined
as VA < 6/18 (20/60) in either eye. Visual impairment was
defined as a VA of <6/18 in the better eye. Monocular
blindness was defined as a VA of <3/60 (20/400) in either eye.
A person was considered to be blind if the VA in the better eye
was <3/60. The definition of VI also includes those who were
blind. An estimate of incident monocular and bilateral
blindness using the US definition was also calculated. The US
definition of monocular blindness is a Snellen acuity of !6/60
in either eye and !6/60 in the better eye for person
blindness.13
Diabetes: Diabetes was defined as self-reported in the
history, or random glucose ‡ 11.0 mM, or (3) HbA1c ‡ 7.0.
Socioeconomic status: A socioeconomic status (SES) score
was developed based on information collected on job, housing
conditions, and ownership of material goods and livestock,
based on previous work in the same population.18
Extrapolation of Data. Estimates of annual cumulative
incidence were extrapolated to estimate the number of adults
over the age of 50 with incident VI or blindness in Kenya each
year. This was calculated by taking the 2015 population
estimate from Kenya (Census Bureau of Kenya; Supplementary
Table S2) by age category and sex and multiplying this by the
age- and sex-specific estimates of annual cumulative incidence.
RESULTS
At baseline 4381 participants were examined (Fig.). Of these,
2645 (60%) were reidentified at the 6-year follow-up. The
reasons for non–follow-up were migration (n ¼ 321, 7%),
deceased (n ¼ 407, 10%), and unknown (n ¼ 1008, 23%). Of
the baseline participants, 2170 (50%) were reexamined. The
large number of unknowns is thought to be due to mass
displacement during the postelection violence in Kenya in
2007–2008.21 Of the 2170 participants followed up, 2164
(99.7%) had complete data. Those with complete data available
FIGURE. Flowchart of participants and nonparticipants.
The Incidence of Blindness in Kenya IOVS j November 2016 j Vol. 57 j No. 14 j 5976
were used in the model for missing data and adjustment of
estimates. The mean follow-up time of all participants was 5.6
years (SD 0.6) and the median was 5.5 years (inter quartile
range, 5.0–6.1), expressed as a ‘‘6-year cumulative incidence’’
from here on. The Supplementary Figure includes the visual
status of participants at both time points in the cohort study.
Table 1 provides the baseline characteristics of partici-
pants who were reexamined at follow-up and those who were
LTFU. In comparison to participants, there was strong
evidence that those who had died during follow-up were
older, were more likely to be male, and had lower education
and SES. Compared with participants seen, those LTFU were
less likely to be Kikuyu or Kalenjin speakers, had lower levels
of education, were more likely to be from urban areas, and
had higher SES.
In those followed up, the prevalence of VI was higher at
follow-up (23%) than at baseline (13%), suggesting an overall
shift toward VI in this aging cohort (Table 2). Of the 45 blind at
follow-up, the majority were incident cases (n ¼ 29, 64%).
Eight of 24 blind persons at baseline were no longer blind at
follow-up, having received treatment in the interim period;
however, only 2 had achieved normal vision (Table 2).
Incidence of Blindness and Visual Impairment
Of the 2164 participants with complete follow-up data, 24
were blind at baseline and were therefore excluded from the
group considered at risk of becoming blind. We analyzed 2140
subjects at risk for incident blindness, of whom 29 participants
(1.36%, 95%CI: 0.9–1.9%) were blind at the follow-up visit
(Table 3). All subsequent results presented here have been
calculated based on the at-risk population and take account of
clustering, and also account for missing data via IPW, unless
otherwise stated.
The cumulative incidence, in participants aged 50 years and
over, of WHO-defined bilateral and unilateral VI was 119.4/
1000 (95%CI 103.1–137.9) and 228.0/1000 (95%CI 206.0–
251.6), respectively (Table 3). The cumulative incidence of
WHO-defined bilateral and unilateral blindness was 15.1/1000
(95%CI 10.4–21.7) and 54.6/1000 (95%CI 43.7–68.0), respec-
tively. Unweighted estimates using only those participants with
complete records of incidence were similar: WHO-defined
(Supplementary Table S3) bilateral and unilateral VI was 118.0/
1000 (95%CI 102.0–136.2) and 226.6/1000 (95%CI 204.8–
250.0), respectively (Supplementary Table S1), with estimates
TABLE 1. Baseline Characteristics in Nonblind Participants of the Nakuru Eye Disease Cohort Study: Participants and Nonparticipants (n¼ 4310)
Baseline Characteristics
Missing
Values
Participants Nonparticipants or Not Included in Analysis
Followed Up,
n ¼ 2140, 49.7%
Not Followed Up Alive/
Unknown/DM Status Missing,
n ¼ 1782, 41.3% P Value*
Deceased,
n ¼ 388, 9.0% P Value†
Age, y, mean (SD) 0 62.5 (9.3) 62.3 (10.1) 0.743 70.8 (12.4) <0.001
Sex, n (%)
Female 0 1011 (47.2) 821 (46.1) 0.521 223 (57.5) <0.001
Male 1129 (52.8) 961 (53.9) 165 (42.5)
Vision status impaired,
presenting <6/12
better eye, n (%)
Normal 0 1983 (92.7) 1646 (92.4) 0.734 307 (79.1) <0.001
Impaired 157 (7.3) 136 (7.6) 81 (20.9)
Tribe, n (%)
Kikuyu 0 1378 (64.4) 1064 (59.7) <0.001 272 (70.1) 0.059
Kalenjin 530 (24.8) 365 (20.5) 84 (21.6)
Other 232 (10.8) 353 (19.8) 32 (8.2)
Education, n (%)
None 11 192 (9.0) 203 (11.4) 0.030 25 (6.5) 0.001
Primary 668 (31.2) 568 (32.0) 163 (42.1)
Secondary 1061 (49.6) 793 (44.7) 170 (43.9)
Higher 217 (10.1) 210 (11.8) 29 (7.5)
Residence, n (%)
Rural 0 1612 (75.3) 995 (55.8) <0.001 288 (74.2) 0.696
Urban 528 (24.7) 787 (44.2) 100 (25.8)
SES quartile, n (%)
Lower 31 499 (23.4) 432 (24.5) 0.008 125 (32.3) 0.004
Middle lower 587 (27.6) 394 (22.3) 91 (23.5)
Middle upper 550 (25.8) 429 (24.3) 94 (24.3)
Upper 493 (23.2) 508 (28.8) 77 (19.9)
4381 individuals had a baseline measure of visual acuity. Of these, 71 were classified as blind, so the 4310 individuals who had a visual acuity
measure and were nonblind contributed to this table. DM, diabetes mellitus.
* P value for association between the baseline characteristic and the odds of having a valid VI observation at follow-up, among all participants
identified as nonblind at baseline and not known to be deceased at follow-up.
† P value for association between the baseline characteristic and the odds of dying during the follow-up period, among all participants identified
as nonblind at baseline and either followed up or known to be deceased at follow-up (i.e., excluding the group who were not followed up).
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of blindness being slightly lower at 13.6/1000 (95%CI 9.5–
19.4).
The cumulative incidence using the US definitions of
blindness was estimated to enable comparison with other
cohorts, and was higher than for WHO estimates (Table 3). All
further analyses are based on WHO definitions.
There was strong evidence of an increase in 6-year
cumulative incidence of VI and blindness by age (Table 4).
Overall differences in sex across all age categories were not
evident; however, a significant difference was found between
male and females aged ‡80 years for cumulative incidence of
both VI and blindness.
Extrapolations based on recent census data were used to
calculate the number of individuals aged ‡50, by age and sex,
estimated to become visually impaired or blind in Kenya each
year (Table 5, Supplementary Table S4). There are an estimated
21 new cases of VI in people aged ‡50 years per 1000 total
population per year, of whom 3 (2.7) are blind. Therefore in
Kenya we estimate that there are 92,000 new cases of VI per
year in people aged ‡50 years, of whom 11,600 are blind, out
of a total population of approximately 4.3 million people aged
‡50 (Supplementary Table S5).
Data from other similar populations indicate that 85% of
blindness prevalence is among those aged ‡50 years.22
Assuming that the relative incidence of blindness in the under-
and over-50s is comparable to the prevalence (i.e., 85% of
incidence is also in the over-50s), extrapolating to all ages, we
estimate that there are 1.66 new cases of blindness per 1000
per year in all ages in Kenya, approximately 76,000 new cases
annually out of a total population of 46 million.
Multivariable analysis for incident bilateral blindness and VI,
respectively, showed only diabetes and increasing age to be
associated (Table 6). However, low numbers of incident cases
of blindness and wide confidence intervals make drawing
conclusions limited for this group. There was no evidence of
an association with all other risk factors.
DISCUSSION
There are few longitudinal population-based studies describing
the incidence of blindness and VI worldwide, and data from
sub-Saharan Africa are particularly sparse (Table 7). The data
build on our previously reported population-based estimates of
prevalence in the same population.13
We found that the annual incidence of blindness in those
aged 50 years and over was 2.2 per 1000 people per year using
the WHO definition (VA < 20/400 Snellen in the better-seeing
eye) and 4.3 per 1000 for the US definition (VA ! 20/200 in the
better-seeing eye). The annual incidence of VI (VA < 6/18
Snellen in the better-seeing eye) was 20.9 per 1000 people per
year. These estimates are substantially higher annual incidence
rates of VI and blindness when compared with other cohort
studies (Table 7). It should be noted that comparable studies
had varying follow-up periods and thus comparison is made
based on annual incidence.
As expected, the incidence of VI and blindness increased
significantly with age, as seen in all previous comparable
cohort studies. This reflects age-related changes to the
crystalline lens and age-related retinal and nerve diseases.
TABLE 3. Six-Year Adjusted Cumulative Incidence of Unilateral and Bilateral Visual Impairment by WHO and US Criteria Among the Nakuru Eye
Disease Cohort Study Participants
Incidence of
WHO Criteria US Criteria
Incident Cases/
At Risk Cases
Cumulative
Incidence,
n per 1000
of Population
(95% CI)
Cumulative Incidence
per Million of Population,
n per 1 Million
of Population
(95% CI)
Incident Cases/
At Risk Cases
Cumulative
Incidence,
n per 1000
of Population
(95% CI)
Bilateral blindness 29/2140 15.1 (10.4–21.7) 15,100 (10,400–21,700) 53/2122 25.9 (19.4–34.4)
Bilateral visual impairment 234/1983 119.4 (103.1–137.9) 119,400 (103,100–137,900) – –
Unilateral blindness 111/1984 54.6 (43.7–68.0) 54,600 (43,700–68,000) 154/1937 79.9 (68.2–93.4)
Unilateral visual impairment 390/1721 228.0 (206.0–251.6) 228,000 (206,000–251,600) – –
WHO definition: blind, Snellen acuity < 3/60 (<20/400); visually impaired, Snellen acuity < 6/12 (<20/40). US definition: blind, Snellen acuity
! 6/60. Cumulative incidence adjusted for missing data. 2164 individuals had VA measurements at baseline and follow-up, but 24 of these had WHO
bilateral blindness at baseline, hence 2164" 24¼ 2140 at risk; 181 had WHO bilateral visual impairment at baseline, hence 2164" 181¼ 1983 at
risk; 180 had WHO unilateral blindness at baseline, hence 2164" 180¼ 1984 at risk; 443 had WHO unilateral visual impairment at baseline, hence
2164" 443¼ 1721 at risk; 42 had US-defined bilateral blindness, hence 2164" 42¼ 2122 at risk; 227 had US-defined unilateral blindness, hence
2164" 227 ¼ 1937 at risk.
TABLE 2. Change in Presenting Visual Acuity Category From Baseline to Follow-Up in Cohort With Visual Acuity Data From Both Time Points (n¼
2164)
Baseline
Follow-Up
‡6/12 <6/12–6/18 <6/18–6/60 <6/60–3/60 <3/60 Total
‡6/12 1474 227 166 4 10 1881, 86.9%
<6/12–6/18 18 30 51 1 2 102, 4.7%
<6/18–6/60 15 22 82 16 15 150, 6.9%
<6/60–3/60 0 0 5 0 2 7, 0.3%
<3/60 2 1 4 1 16 24, 1.1%
Total 1509, 69.7% 280, 12.9% 308, 14.2% 22, 1.0% 45, 2.0% 2164, 100%
2164 individuals had both a baseline measure of visual acuity and a follow-up measure of visual acuity. All are included in this table. Visual acuity
categories are presenting visual acuity in the better of eye of the individual.
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The disease-specific incidence rates will be presented and
discussed in separate reports.
One previous study from Uganda assessed the incidence of
VI and blindness in an African population from a population-
based cohort that was established to assess the dynamics of
human immunodeficiency virus (HIV) infection through annual
censuses and serologic surveys,29 and incorporated an
assessment of vision at two time points. The sample was a
general population cohort and not designed specifically for eye
disease, measuring only VA (modified Snellen chart).30 Only
one case of incident bilateral blindness was reported and 21
cases of incident VI in the study sample (aged 13 and above),
providing an age-standardized incidence rate of bilateral VI of
13.2 persons per 1000 persons per year (in a different age
group from that presented from this population).31 In
comparison, this study estimated an incidence of VI at 20.9
persons per 1000 per year.
There are data from comparable population-based studies of
eye disease worldwide (Table 7). There are some variations in
the age group considered for inclusion, although the majority
sampled those 40 or 50 years and above. Most studies
presented incident data using the WHO and US definitions of
VI or blindness, but some included only one definition, limiting
comparability across studies. The incidence of bilateral VI in
the Nakuru Eye Disease Cohort Study was found to be higher
than anywhere else in the world. The annual incidence rate
(persons per 1000 per year) for the majority of studies (eight)
was between 0.2 and 0.9 (US classifications) and 0.1 and 0.5
(WHO classifications).8–10,23,25–28 Only two studies were
higher, at 1.1 (US) and 2.1 (WHO) for the Barbados Eye
Study24 and 1.2 (US) and 2.4 (WHO) for the Nakuru Eye
Disease Cohort Study, respectively.
The high incidence in this study most likely reflects a
combination of low access to ophthalmic services and health
services in general32; there was only one ophthalmologist in the
region of the study for a population of approximately 1.6 million
people. Other explanations include environmental risk factors
including geography, diet, ethnic origin, and ultraviolet light
exposure. Other barriers to eye care provision in the region
include a low awareness of treatable sight loss, available services
that are unaffordable and far away, and fear of treatment.
The data in this study indicated that of 29 new cases of
blindness at follow-up, 12 had VA of 6/18 or better, and 17
were worse than 6/18 (see Table 2). Of the 24 who were blind
at baseline, 16 were still blind at follow-up. Further analysis
will disaggregate incident VI and blindness by cause, enabling
TABLE 5. Extrapolated Number of Adults per Year, Aged 50 Years and Over, in Kenya With New Visual Impairment and Blindness Based on
Weighted Incidence Data and Estimates of the Population in Kenya by Age Group in 2015
Age Group,
Years
Male Female Overall
Extrapolated
Number
Lower,
95%CI
Upper,
95%CI
Extrapolated
Number
Lower,
95%CI
Upper,
95%CI
Extrapolated
Number
Lower,
95%CI
Upper,
95%CI
Visual impairment
50–59 11,480 7,620 17,080 10,130 6,910 14,740 21,340 16,090 28,160
60–69 9,710 6,830 13,600 13,030 9,490 17,660 22,670 17,760 28,710
70–79 7,700 5,380 10,650 13,670 10,260 17,680 20,720 16,920 25,040
80þ 2,200 1,310 3,340 4,470 2,920 6,200 6,490 4,830 8,350
All age groups 34,550 27,580 43,000 42,230 35,430 50,120 76,740 66,240 88,650
Blindness, <3/60 better eye
50–59 400 50 2,890 – – – 350 50 2,550
60–69 1,350 560 3,190 1,160 350 3,810 2,560 1,250 5,200
70–79 1,200 430 3,280 1,340 530 3,330 2,580 1,280 5,120
80þ 680 200 2,070 2,190 1,160 3,900 2,680 1,520 4,580
All age groups 4,870 2,690 8,780 5,740 3,550 9,240 10610 7,340 15,300
TABLE 4. Age- and Sex-Specific 6-Year Adjusted Cumulative Incidence of Visual Impairment and Blindness by WHO Definition Among the Nakuru
Eye Disease Cohort Study Participants
Age Group,
Years
Male Female Overall
n, Cases/
At Risk
Risk per
1000/6 Years
(95%CI) n
Risk per
1000/6 Years
(95%CI) n
Risk per
1000/6 Years
(95%CI)
Visual impairment, <6/18 better eye
50–59 27/402 66.5 (44.2–99.0) 30/556 53.3 (36.3–77.5) 57/958 58.8 (44.4–77.6)
60–69 35/328 110.4 (77.6–154.7) 37/314 119.8 (87.2–162.3) 72/642 115.1 (90.2–145.8)
70–79 34/156 218.4 (152.8–302.3) 39/137 283.8 (213.1–367.1) 73/293 249.9 (204.1–302.0)
80þ 13/43 308.5 (183.6–469.5) 19/47 411.4 (268.9–570.5) 32/90 363.2 (270.6–467.3)
All age groups 109/929 118.6 (94.6–147.5) 125/1054 120.1 (100.8–142.6) 234/1983 119.4 (103.1–137.9)
Blindness, <3/60 better eye
50–59 1/407 2.3 (0.3–16.5) 0/568 – 1/975 0.9 (0.1–6.9)
60–69 5/353 14.4 (6.0–34.3) 3/337 9.8 (3.0–32.3) 8/690 12.1 (5.9–24.7)
70–79 4/183 28.6 (10.1–77.8) 4/157 24.0 (9.4–59.7) 8/340 26.4 (13.1–52.4)
80þ 3/68 58.4 (17.4–178.7) 9/67 129.7 (68.6–231.6) 12/135 94.6 (53.7–161.5)
All age groups 13/1011 15.2 (8.4–27.4) 16/1129 15.0 (9.3–24.1) 29/2140 15.1 (10.4–21.7)
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further data to support planning (e.g., estimation of need for
cataract surgery).
Strengths of the study include the following characteristics:
a representative population-based sample in an area of ethnic,
socioeconomic, and educational diversity; a large sample size;
comprehensive assessment of risk factors; high-quality assess-
ment of vision; and utilization of the same tools at baseline and
follow-up. The methodology used to assess ophthalmic disease
was consistent with studies performed in well-developed
health systems in high-income countries such as the United
States23 and Australia,8 with use of the latest available
equipment,11 thus making the data highly comparable to those
in other population-based cohort studies of eye disease.
The major limitation of this study was low participation rate
(50%) at 6 years; however, having the baseline characteristics
of nonparticipants is a strength that enabled weighting to
ensure better estimates of cumulative incidence. This loss to
follow-up may have led to an under- or overestimation of
incident VI and blindness, depending on the general charac-
teristics of the nonrespondents. The predominant risk factor
for incident VI or blindness was age; and given that this was
closely matched between participants and nonparticipants
(62.7 years [SD 9.4] and 62.5 years [SD 10.4], respectively), the
estimates are likely to be an acceptable reflection. This
assessment is further supported in that minimal changes were
apparent after adjusting estimates for missing data (Supple-
mentary Table S1).
Reasons for the low participation included ethnic violence
and displacement of large numbers of people in the study
sample area. Postelection violence in 2007 and 2008 led to up
to 600,000 people being internally displaced and 1300
fatalities.21 In a number of study clusters, entire ethnic groups
present at baseline were no longer available or traceable.
Great efforts were made to locate individuals. Further
limitations include restricting the inclusion criteria at baseline
to those 50 years and above, thereby reducing the generaliz-
ability of our results to the entire population. This is, however,
comparable to the majority of population-based studies of eye
disease that restrict inclusion to 40 or 50 years and above
(Table 7). Furthermore, the majority of prevalent and incident
vision loss is in this age group, making the sample size
feasible.22 The definition of blindness and VI in this study did
not include peripheral vision loss and was based solely on
presenting central logMAR VA. This potentially underestimates
the incident VI and blindness (particularly from glaucoma)
when compared to studies that include these criteria.
Our results suggest that there are 86,000 new cases of VI in
people aged ‡50 years per year in Kenya, of whom 8100 are
blind. Recent estimates suggest that there are 86 ophthalmol-
ogists in Kenya33 for a population of approximately 45 million,
with the majority (50%) being based in the capital city of
Nairobi. This leaves 92% of the population (approximately 40
million people) being served by 43 ophthalmologists. Overall,
Kenya is better resourced than many other African countries in
terms of human resources, despite still being well below
recommended targets.34 Continued effort to strengthen the
eye health system is necessary to support the growing unmet
need of this aging and growing population.
In conclusion, the incidence of VI and blindness in this
adult Kenyan population was considerably higher than in
comparable studies worldwide. Further analyses on the causes
of incident blindness will help in setting priorities for
preventing avoidable blindness in this population.
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^ƵƉƉůĞŵĞŶƚĂƌǇDĂƚĞƌŝĂů 
Data cleaning and management 
All raw data collected during the fieldwork was imported from Excel into STATA and the 
variables and categories of the collected variables were labelled appropriately, before 
checking for missing data and likely input errors. Any issues identified were discussed within 
the study team, in order to identify whether the issue was expected based upon the study 
design and data collection approach used in the field. Unexpected issues were resolved by 
checking the source data. Outcome variables were then generated, based on the collected 
field data. These included blindness and visual impairment (at follow-up) outcome variables 
per person and per eye (i.e. monocular) according to the WHO (for both blind and 
visual impairment) and the U.S. (for blind only) standards (see ^ƵƉƉůĞŵĞŶƚĂƌǇTable ^1).  
Co-variate (recorded at baseline) variables were then set up for age, gender, education, 
diabetes, socioeconomic status (SES) and hypertension. A categorical age variable was 
created (10 year age categories from 50 onwards). Education was defined as none, primary, 
secondary and higher. SES included lower, middle lower, middle upper and upper quartile 
categories. All other co-variates were setup as binary variables (i.e. male/female or no/yes, 
with male and no as baseline categories). A dedicated cohort analysis dataset was then 
created that contained the unique study ID for each individual, the village of residence 
(which   defined   the   cluster   in   subsequent   analysis),   the   individual’s   follow   up   status (i.e. 
participant vs non-participant), whether the person died or not, the outcome variables and 
the covariates. 
Table ^1. Baseline Characteristics in Nakuru Eye Disease Cohort Study: Participants 
and Non-participants   
Participants Non-participants 
Baseline Characteristics (n=2,171, 
49.2%) 
Alive/Unknown 
n=1,834, 
(41.5%) 
p-value Deceased 
(n=409, 
9.3%) 
p-value
Age (yrs), mean +/- SD 62.7 (9.4) 62.5 (10.4) 0.50 71.6 (12.8) <0.001 
Male % (n) 47.3% 
(1,026) 
46.4% (851) 0.59 57.7%  
(236) 
<0.001 
Vision status Normal 
(≥6/12 both 
eyes) 
91.6% 
(1,988) 
91.0%  
(1,641) 
0.47 75.4 % 
(307) 
<0.001 
Impaired 
(<6/12 
better eye) 
8.4%  
(182) 
9.0%  
(163) 
24.6% 
(100) 
Tribe % (n) Kikuyu 64.2% 
(1,393) 
59.1% (1,084) <0.001 69.2% 
(283) 
0.10 
Kalenjin 25.1% (544) 20.6% (378) 22.7%(93) 
Other 10.8% (234) 20.3% (372) 8.1% (33) 
Education % 
(n) a
None 8.9% (193) 11.1% (204) <0.001 6.4% (26) <0.001 
Primary 31.7% (689) 32.0% (586) 43.8% 
(179) 
Secondary 49.3% 
(1,070) 
43.9% (805) 42.5% 
(174) 
Higher 10.0% (217) 11.7% (215) 7.1% (29) 
Urban % (n) 24.5%  (532) 44.1% (808) <0.001 25.9% 
(106) 
0.54 
SES Quartile % 
(n)b
Lower 23.8% (517) 23.9% (439) <0.001 33.3% 
(136) 
0.002 
Middle 
lower 
27.2% (591) 22.0% (404) 23.5% (96) 
Middle 
upper 
25.7% (557) 23.9% (438) 23.7% (97) 
Upper 22.8% (495) 28.2% (517) 19.3% (79) 
P values represent the difference between participants and non-participants (deceased and 
alive/unknown), results of a chi-squared test of overall association of the variable. 
a. Missing data on 27 participants, b. missing data on 48 participants
Note 24 participants followed up were blind at baseline, therefore n= 2,160 – 24 = 2,136 
Table ^2͘ Estimates of Population of Kenya in 2015 
Age Both Sexes Population Male Population Female Population 
All 
ages 45,925,301 22,907,500 23,017,801 
50-59 2,231,660 1,061,476 1,170,184 
60-69 1,278,899 565,224 713,675 
70-79 594,118 258,604 335,514 
80+ 187,131 78,468 108,663 
50+ 4,291,808 1,963,772 2,328,036 
Table^3͘ Six-Year unweighted Cumulative Incidence of Unilateral and Bilateral 
Visual Impairment by World Health Organization and United States Criteria among 
the Nakuru Eye Disease Cohort Study Participants. 
WHO criteria US criteria 
Incidence of Incident 
cases / 
At risk 
cases 
Cumulative 
incidence (n / 
per 1000 of 
population, 
95% CI) 
Cumulative 
incidence per 
million of 
population (n / 
per 1m of 
population, 95% 
CI) 
Incident 
cases / 
At risk 
cases 
Cumulative 
incidence (n / 
per 1000 of 
population, 
95% CI) 
Bilateral 
blindness 
29 / 2140 13.6(9.5,19.4) 13,600 (9,500-19,400) 53 / 2122 25.0(18.9,33.0) 
Bilateral Visual 
Impairment 
234 / 1983 118.0(102.0,136.2) 118,000 (102,000-136,200) - - 
Unilateral 
blindness 
111 / 1984 55.9(45.3,68.8) 55,900 (45,300-68,800) 154 / 1937 79.5(68.2,92.4) 
Unilateral 
Visual 
Impairment 
390 / 1721 226.6(204.8,250.0) 226,600 (204,800-250,000) - - 
Table ^4͘ Age-Gender–Specific 6-Year unweighted cumulative incidence of Visual 
Impairment and Blindness by World Health Organization definition among the 
Nakuru 
Male Female Overall 
Age Group 
(years) 
n 
(Cases / at 
risk) 
Risk per 1,000/6yrs 
(95%CI) 
n Risk per 1,000/6yrs 
(95%CI) 
n Risk per 1,000/6yrs 
(95%CI) 
Visual Impairment (<6/18 better eye) 
50-59 27 / 402 67.2(47.5,94.1) 30 / 556 54.0(37.7,76.6) 57 / 958 59.5(46.1,76.4) 
60-69 35 / 328 106.7(74.9,149.9) 37 / 314 117.8(85.4,160.5) 72 / 642 112.1(87.2,143.1) 
70-79 34 / 156 217.9(151.6,303.0) 39 / 137 284.7(212.2,370.3) 73 / 293 249.1(202.8,302.0) 
80+ 13 / 43 302.3(183.8,454.8) 19 / 47 404.3(264.1,562.0) 32 / 90 355.6(264.7,458.2) 
All age groups 109 / 929 117.3(94.3,145.0) 125 / 1054 118.6(99.3,141.1) 234 / 1983 118.0(102.0,136.2) 
Blindness (<3/60 better eye) 
50-59 1 / 407 2.5(0.3,17.7) 0 / 568 - 1 / 975 1.0(0.1,7.5) 
60-69 5 / 353 14.2(6.0,33.2) 3 / 337 8.9(2.9,27.4) 8 / 690 11.6(5.8,23.0) 
70-79 4 / 183 21.9(8.1,57.6) 4 / 157 25.5(10.1,62.7) 8 / 340 23.5(12.1,45.2) 
80+ 3 / 68 44.1(13.7,133.0) 9 / 67 134.3(73.1,233.9) 12 / 135 88.9(50.2,152.6) 
All age groups 13 / 1011 12.9(7.3,22.4) 16 / 1129 14.2(8.9,22.5) 29 / 2140 13.6(9.5,19.4) 
Table ^5͘ Extrapolated number of new adults per year, aged 50 years and over in 
Kenya with visual impairment and blindness based on unweighted incidence data 
and estimates of the population in Kenya by age group in 2015. 
Male Female Overall 
Age 
Group 
(years) 
Extrapolated 
number 
Lower 
(95%CI) 
Upper 
(95%CI) 
Extrapolated 
number 
Lower 
(95%CI) 
Upper 
(95%CI) 
Extrapolate
d number 
Lower 
(95%CI) 
Upper 
(95%CI) 
Visual Impairment  
50-59 11590 8200 16230 10260 7180 14560 21580 16740 27710 
60-69 9380 6580 13180 12820 9290 17450 22090 17180 28180 
70-79 7680 5340 10680 13710 10220 17840 20660 16820 25040 
80+ 2150 1310 3240 4390 2870 6110 6350 4730 8190 
All age 
groups 34190 27500 42260 41680 34880 49600 75830 65530 87510 
Blindness (<3/60 better eye) 
50-59 430 60 3110 #VALUE! #VALUE! #VALUE! 380 50 2760 
60-69 1320 560 3100 1050 340 3230 2450 1230 4860 
70-79 920 340 2430 1420 560 3500 2300 1180 4420 
80+ 510 160 1540 2260 1230 3940 2520 1420 4330 
All age 
groups 4120 2350 7190 5430 3410 8630 9540 6660 13640 
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Abstract
Background: The epidemic rise of diabetes carries major negative public health and economic consequences
particularly for low and middle-income countries. The highest predicted percentage growth in diabetes is in the
sub-Saharan Africa (SSA) region where to date there has been no data on the incidence of diabetic retinopathy
from population-based cohort studies and minimal data on incident diabetes. The primary aims of this study were
to estimate the cumulative six-year incidence of Diabetes Mellitus (DM) and DR (Diabetic Retinopathy), respectively,
among people aged ≥50 years in Kenya.
Methods: Random cluster sampling with probability proportionate to size were used to select a representative
cross-sectional sample of adults aged ≥50 years in 2007-8 in Nakuru District, Kenya. A six-year follow-up was
undertaken in 2013–14. On both occasions a comprehensive ophthalmic examination was performed including
LogMAR visual acuity, digital retinal photography and independent grading of images. Data were collected on
general health and risk factors. The primary outcomes were the incidence of diabetes mellitus and the incidence of
diabetic retinopathy, which were calculated by dividing the number of events identified at 6-year follow-up by the
number of people at risk at the beginning of follow-up. Age-adjusted risk ratios of the outcomes (DM and DR
respectively) were estimated for each covariate using a Poisson regression model with robust error variance to
allow for the clustered design and including inverse-probability weighting.
Results: At baseline, 4414 participants aged ≥50 years underwent complete examination. Of the 4104 non-diabetic
participants, 2059 were followed-up at six-years (50 · 2%). The cumulative incidence of DM was estimated at 61 · 0
per 1000 (95% CI: 50 · 3–73 · 7) in people aged ≥50 years. The cumulative incidence of DR in the sample population
was estimated at 15 · 8 per 1000 (95% CI: 9 · 5–26 · 3) among those without DM at baseline, and 224 · 7 per 1000
(116.9–388.2) among participants with known DM at baseline. A multivariable risk factor analysis demonstrated
increasing age and higher body mass index to be associated with incident DM. DR incidence was strongly
associated with increasing age, and with higher BMI, urban dwelling and higher socioeconomic status.
Conclusions: Diabetes Mellitus is a growing public health concern with a major complication of diabetic
retinopathy. In a population of 1 · 6 million, of whom 150,000 are ≥50 years, we estimated that 1650 people aged
≥50 develop DM per year, and 450 develop DR. Strengthening of health systems is necessary to reduce incident
diabetes and its complications in this and similar settings.
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Background
The number of adults with Diabetes Mellitus (DM) in
Africa is predicted to double from 12 · 1 million in 2010
to 23 · 9 million in 2030 based on projections from
prevalence data [1]. The epidemic rise of DM carries
major public health and economic consequences for the
continent, particularly given it is home to some of the
fastest growing economies and most rapid transitions in
lifestyles conducive to DM ([http://unstats.un.org/unsd/
methods/m49/m49regin.htm - least]). Currently, there
are few incidence data from low and middle-income set-
tings, particularly sub-Saharan Africa (SSA), making it
difficult to plan screening and treatment services [2, 3].
DM causes visual impairment through cataract and
diabetic retinopathy (DR) [4], a progressive disease of
the retinal microvasculature. DR is not yet a leading
cause of blindness in sub-Saharan Africa, responsible for
just 2.8% of blindness [5]. However, it is likely to become
an increasingly important cause of blindness and visual
impairment, with the increasing prevalence of DM in
SSA, and improving control of other leading causes of
visual impairment such as cataract, uncorrected refract-
ive error and trachoma. Population-based incidence data
for DR are lacking for SSA, although some clinical
follow-up data are available [6].
Current strategies to control DM in SSA focus on health
system strengthening to enable a public health approach
to both prevent the onset of DM and create awareness of
the consequences of DM, including sight loss [7]. In
addition, efforts are also being scaled-up for the identifica-
tion of people with DM , and their enrolment in treatment
programmes [8]. Systematic DR screening in SSA is cur-
rently very limited, with only a small number of locations
having an active programme [9].
Data on the incidence and progression of DM and
DR are needed to estimate the current and future
burden of these conditions in order to inform service
development, and future research. The primary aims
of this study were to estimate the cumulative six-year
incidence of DM and DR in people aged ≥50 years in
Kenya. A secondary aim was to identify risk factors
for each of these outcomes.
Methods
The fieldwork was carried out in Nakuru district, Kenya,
which has a population of 1.6 million [accurate as of
2009], one third of which is urban. Nakuru is broadly
representative of Kenya in terms of ethnic diversity and
economic activities. The baseline survey took place from
January 2007 to November 2008, and the follow-up
survey from November 2012 to March 2014. Full details
of the methods at baseline and follow-up are presented
elsewhere [10–12].
Sampling strategy and recruitment at baseline
We selected 100 clusters of 50 people aged ≥50 years
through probability proportionate to size sampling,
using the electoral roll as the sampling frame. House-
holds were selected within clusters using a modified
compact segment sampling method [13]. The village
leaders produced a sketch map of the polling area. The
polling area was divided into segments each including
approximately 50 people aged ≥50 years. One segment
was chosen at random by drawing lots and all house-
holds in the segment were included in the sample
sequentially, until 50 people aged ≥50 years were identi-
fied. If the segment did not include 50 people aged
≥50 years then an additional segment was chosen at
random and sampling continued.
The enumeration team visited households, assisted by
a village guide, and invited all eligible participants aged
≥50 years to the examination clinic, held at a convenient
place in the cluster over the subsequent two days.
Eligible participants were defined as those aged ≥50 years
resident in the cluster (i.e. living there at least 6 months
per year) who had slept in the house either the night
before or were planning on sleeping in the house that
night. If an eligible person was absent then the survey
team revisited the household at least twice.
The six-year follow-up assessment was initiated by an
Advance Team who visited homes of baseline partici-
pants and confirmed their identity using National
Identity cards. The two advance teams comprised of one
nurse, one field officer and a driver or public transport.
During this visit they located individuals with assistance
from the guide, phone numbers when available and pre-
viously recorded GPS locations using a Garmin Oregon
450 Satellite Navigation device. In addition, the team ex-
plained details of the examination and obtained written/
thumb print informed consent as well as informing par-
ticipants about location and time of examination [11].
Data collection
Comprehensive data were collected at baseline and
follow-up, using comparable methods, including slit
lamp examination by an ophthalmologist at both time
points. Details of data collection are available elsewhere
[11, 14] with specific details provided here for the
current analyses.
Diabetes mellitus
A single random finger-prick blood sample was taken to
measure glucose (Accutrend GC system) at baseline and
at follow-up. At follow-up, in addition, subjects with a
random blood sugar greater than 11.1 mmol/L (Inter-
national Diabetes Federation (IDF) guidance at time of
baseline study), those with known DM (regardless of
random measure), evidence of DR on retinal imaging
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and a subset (chosen randomly within each cluster) with
random glucose between 7 and 11 mmol/L had an add-
itional capillary blood HbA1C (A1C Now+, Bayer).
Visual acuity (VA)
Two ophthalmic nurses measured presenting VA, which
was defined as the number of letters read correctly with-
out glasses if the participant did not have glasses or with
distance glasses if they had them. Each eye was tested
separately at 4 m using a reduced Logarithm of the Min-
imal Angle of Resolution (LogMAR) tumbling ‘E’ chart
[15] in a well illuminated area. If the subject’s vision was
too poor to read any letters on the chart at four meters,
then the subject was tested at one meter, then counting
fingers, hand movements, light perception or no light
perception.
Fundus photography
Pupil dilation was performed using one drop of tropica-
mide 1% and one drop of phenylephrine 2.5%. The par-
ticipants had two non-stereoscopic digital 450 fundus
photographs taken per eye by an ophthalmic clinical of-
ficer using a TRC-NW6S Non-Mydriatic Retinal Camera
with 10 megapixel Nikon D80 (TopCon®) at baseline and
a Haag-Streit DRS CentreVue + at follow-up. One image
was centred on the optic disc while the other was
centred on the macula.
Anthropometric data collection
At baseline and follow-up, a nurse recorded the blood
pressure of participants three times on the right arm of
the participant, at least five minutes apart after an initial
period of five minutes of rest using the Omron digital
automatic monitor (model HEM907). Weight was mea-
sured to the nearest kilogram using standard scales (Seca
761 scales) after the participant had removed all heavy
clothing and shoes. Height was measured to the nearest
centimetre while the participant stood without shoes
using a standardized stadiometer (Leicester Height
Measure). For weight and height the average of two
readings was recorded. Waist and hip circumferences
were measured with a tape to the nearest centimetre.
Interviews
Participants were interviewed by trained nurses. Infor-
mation was collected on demographic data, education
and asset ownership. People were asked whether their
mother tongue was “Kikuyu”, “Kalenjin” (the two largest
ethnic group in Nakuru County) or “other” to assign
ethnicity. Information was also collected on health
behaviour (smoking, alcohol use) and health status
(diagnosis of diabetes or hypertension, family history
and their treatment).
Grading of retinal images
Retinal images were forwarded to the Retinal Grading
Centre at Moorfields Eye Hospital Reading Centre
(MEHRC) London for grading DR. All images supplied by
the Nakuru Eye Study Group, regardless of quality, were
sent for grading. No manipulation of the images was
allowed while grading, other than using grey-scale for
viewing the images. All images were first categorized for
quality as excellent, good, borderline and ungradeable.
Next, the photographs were graded for DR based on
the UK National Guidelines on Screening for Diabetic
Retinopathy [16]. Each eye was classified for all people
with diabetes as: no DR, mild NPDR, moderate NPDR,
severe NPDR or proliferative DR, based on the following
criteria:
! No DR - no changes characteristic of diabetic
retinopathy visible on the images.
! Mild non-proliferative DR (NPDR) - micro
aneurysms (MAs) and retinal haemorrhages only
were seen.
! Moderate NPDR - in addition to MAs multiple
deep, round or blot haemorrhages were noted.
! Severe NPDR - the presence of features of NPDR
plus cotton wool spots. In this scenario the grader
was asked to search for vascular features of DR,
such as venous loop, venous beading and
Intra-retinal micro-vascular abnormality (IRMA). If
these were found, severe NPDR was graded.
! Proliferative DR (PDR) – as above, with new vessels
on the disc (NVD) new vessels elsewhere (NVE),
pre-retinal or vitreous haemorrhage or pre-retinal
fibrosis ± tractional retinal detachment were seen.
All images were graded by the senior grader. In case of
difficulties, the adjudicator (TP) adjudicated the images.
The adjudicator also looked at a random selection of 5% of
images to ensure quality control. Data were entered onto
Excel and checked for consistency by a data monitor.
Grading methods were the same at baseline and follow-up.
Data analysis
Definitions and statistical analyses
DM was defined as per WHO standards for population-
based studies: reported current medication (tablets or
insulin) or; diet control for diabetes or; random blood
glucose level ≥11 · 1 mmol/L [17]. At follow up the def-
inition included HbA1C when a result was possible.
HbA1C of > =7 · 0 was taken as confirmation of DM and
if <7 · 0 DM was excluded. An HbA1C result superseded
other measures of DM apart from self-reported and on
medication, in which case an HbA1C of <7 · 0 was taken
as well controlled DM and HbA1C > =7 · 0 of poorly
controlled DM.
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A continuous socio-economic score (SES) was pro-
duced for each participant using principal component
analysis based on asset ownership, household type and
education [18]. The score was divided into quartiles to
categorize the study participants into four socioeco-
nomic groups with a higher score representing higher
SES. Body Mass Index (BMI) was calculated as height
(meters)/weight (kilograms)2. The clusters were defined
as rural or urban according to the classification used by
the District Health Statistics office [19].
All participants who had complete examinations at
baseline who did not have DM or did not have DR were
considered “at-risk” for incident DM or DR, respectively.
Follow-up status at 6 years was categorised as i) Found
and examined; ii) Found and not examined; iii)
Deceased; iv) Moved away; or v) Unknown.
Statistical analysis was performed using STATA v13
(Stata Corp). All analysis accounted for the cluster
survey design using Taylor linearized variance estimation
to calculate standard errors.
Pearson chi-squared tests, corrected for the survey-
design were used to calculate p-values in order to assess
differences between participants seen and those lost to
follow-up (LTFU), and between those known to have
died and with unknown outcome status. Those who
were deceased were then excluded. Those followed up
but without complete records for all covariates at base-
line were also excluded. An inverse probability-
weighting (IPW) model [20] was developed to allow
estimation of cumulative incidence while accounting for
those LTFU. Multivariable logistic regression was used
to identify independent baseline covariates associated
with LTFU. Covariates for which there was evidence of
univariable association with being LTFU (p < 0.1) were
kept in a multivariable model. From this final model, the
probability of being followed-up was estimated, based
on the presence or absence of each of these baseline co-
variates. The inverse of this probability formed the
weighting to be applied in order to account for those
LTFU. The final step was to remove those individuals
LTFU from the cohort, so that all subsequent analysis
would be performed on only those with complete out-
come records, with IPW applied to account for those
LTFU. A sensitivity analyses for this approach involved a
complete records analysis (i.e. only including those
people who had complete records for outcome and all
variables in the analysis).
The six-year cumulative incidence of each outcome
was calculated by dividing the number of events identi-
fied at 6-year follow-up by the number of people at risk
at the beginning of follow-up. 95% confidence intervals
were estimated assuming a Poisson distribution of
events. This analysis was done for the population overall,
and stratified by key covariates. Age-adjusted risk ratios
of the outcomes (DM and DR respectively) were estimated
for each covariate using a Poisson regression model with
robust error variance to allow for the clustered design and
including IPW. For multivariable analysis, an initial model
was fitted that included those variables associated with
outcome in age-adjusted analysis (Wald p-value <0.05). A
backward stepwise approach was applied to obtain a final
multivariable model, removing variables with p > 0.05. Es-
timates were weighted to allow for any bias due to loss to
follow up by weighting using inverse probability weights
as described above. The six-year cumulative incidence was
then used to estimate the expected number of new DR
cases per year by multiplying the six-year incidence by the
estimated Kenyan population and dividing by six, with the
assumption that cumulative incidence was constant over
time. Annual cumulative incidence was also estimated
separately for men and women and in ten-year age
categories (50–59, 60–69, 70–79 and 80 + .
Results
Diabetes mellitus
At baseline, 4414 participants aged ≥50 years underwent
complete examination (response rate of 88 · 1%) and 4388
(99 · 4%) had DM status data available, of whom 287 (6 ·
5%) were diagnosed with DM (Fig. 1). Of the 4,101who had
no DM at baseline, 2059 (50 · 2%) were followed-up at six-
years. Complete DM status data at follow-up were available
on 2056 (99 · 9%) participants, of whom 123 (6 · 0%) were
newly diagnosed with DM at six-year follow-up (Fig. 1).
Baseline characteristics of individuals with known
baseline DM status data who were re-examined at
follow-up (participants) and those who were LTFU are
shown in Table 1. There was strong evidence that those
who were LTFU were less likely to be Kikuyu or Kalenjin
speakers and more likely to be from urban areas (p <
0.001). The mean follow-up time of all participants was
5 · 6 (SD 0 · 6) years and the median was 5 · 5 (interquar-
tile range (IQR): 5 · 0–6 · 1) years (referred to as “six-year
cumulative incidence” from here on).
Of the 123 participants who developed incident DM
by six-years, 64 diagnoses were self-reported and 59
were based on blood sugar readings. Of the 64 self-
reported subjects with DM, 35 (54 · 7%) had random and
HbA1C readings within normal limits and were consid-
ered “controlled DM”, and the remaining 29 were
“uncontrolled DM” (10 had high HbA1C only, three had
elevated random glucose data only (no HbA1C data)
and 16 had both a high random glucose and HbA1C).
Consequently, the cumulative incidence of DM was esti-
mated at 61 · 0 per 1000 (95% CI: 50 · 3,73 · 7) in people
aged ≥50 years when corrected for loss to follow-up.
The incidence of DM decreased with age in both men
and women, and was similar across the sexes (Table 2).
Based on recent census data, the number of incident
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cases was estimated by extrapolating to the Kenyan
population aged ≥50 years (Table 3), assuming an equal
incidence per year over the study period. In the popula-
tion of 1 · 6 million people in Nakuru, Kenya, approxi-
mately 150,000 individuals are aged ≥50 years, and of
these approximately 1650 will develop DM each.
Of the 287 participants with known DM from baseline,
54 (18.8%) were known to have died, 110 (38.3%) were
re-assessed and 123 (42.8%) were LTFU. All 110 people
with known DM at baseline were defined as having
known DM at follow-up regardless of self-report. Of
these, 70 (63 · 6%) self-reported as DM at follow-up, of
whom 20 (28 · 6%) were controlled. Of the 40 with
known DM at baseline who did not report as having
DM at follow-up, 32 (80 · 0%) were controlled. Of these,
25 had a normal random blood sugar at baseline but
self-reported as DM, four did not self-report but had a
high random blood sugar and three both self-reported
and had a high blood sugar.
Increased risk of incident DM was associated with the
following baseline variables: higher body mass index, urban
dwelling, higher socioeconomic status, hypertension, and
having no previous formal education (Table 4). A lower
incidence was found with increasing age, former alcohol
consumption and Kalenjin ethnicity. After adjustment for
confounding, increasing age and higher body mass index
remained associated with incident DM (Table 4).
Diabetic retinopathy
At baseline, 4414 participants aged ≥50 years underwent
complete examination (response rate of 88 · 1%) and
3281 (74 · 3%) had DR image data available, of whom
195 (5 · 9%) were diagnosed with DM at baseline (Fig. 2).
Of these 195 participants, 70 had DR at baseline. At
Fig. 1 Flowcharts of participant Diabetes Mellitus status in the Nakuru Eye Disease Cohort Study
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follow-up, 78 (40 · 0%) of the 195 participants with base-
line DM were seen, and 1562 (50 · 6%) of the 3086
participants without DM at baseline.
The baseline characteristics of those with complete
data for analysis (participants with a known DR status at
follow-up, based on retinal images), and those for whom
data was incomplete were similar. However a higher
proportion of those who had impaired vision at baseline
were not included in the DR incidence analysis, either
due to LTFU or ungradeable retinal images (Table 5).
Table 1 Baseline characteristics of all individuals with a known baseline DM status subdivided by their follow-up category
(participant, non-participant) at 6-year follow-up (N = 4388)
Participants Non-participants or not included in analysis
Baseline characteristics Missing values Followed-up
n = 2166 (49.4%)
Not followed-up Alive/Unknown/DM
status missing n = 1814 (41.3%)
p-value* Deceased
n = 408 (9.3%)
p-value**
Age in years, mean (SD) 0 62.7 (9.4) 62.6 (10.4) 0.84 71.6 (12.8) <0.001
Systolic BP in mmHg, mean (SD) 12 139.5 (23.5) 140.8 (24.8) 0.16 147.4 (30.3) <0.001
Diastolic BP in mmHg , mean (SD) 12 82.6 (13.0) 83.3 (13.6) 0.19 82.7 (16.5) 0.94
Random Blood Glucose, mean (SD) 92 5.1 (2.3) 5.3 (2.3) 0.12 5.7 (3.7) <0.001
Sex, % (n) Female 0 1025 (47.3%) 841 (46.4%) 0.59 236 (57.8%) <0.001
Male 1141 (52.7%) 973 (53.6%) 172 (42.2%)
BMI, % (n) Underweight
(<18.5 kg/m2)
42 267 (12.4%) 250 (14.0%) 0.52 99 (25.0%) <0.001
Normal
(18.5–24.99 kg/m2)
1091 (50.5%) 882 (49.2%) 199 (50.3%)
Overweight
(25–29.99 kg/m2)
506 (23.4%) 419 (23.4%) 66 (16.7%)
Obese
(30 + kg/m2)
295 (13.7%) 240 (13.4%) 32 (8.1%)
Vision status
impaired
(<6/12 better eye),
% (n)
Normal 17 1985 (91.7%) 1635 (90.8%) 0.36 306 (75.4%) <0.001
Impaired 180 (8.3%) 165 (9.2%) 100 (24.6%)
Tribe, % (n) Kikuyu 0 1393 (64.3%) 1079 (59.5%) <0.001 283 (69.4%) 0.09
Kalenjin 540 (24.9%) 380 (20.9%) 92 (22.5%)
Other 233 (10.8%) 355 (19.6%) 33 (8.1%)
Education, % (n) None 1 193 (8.9%) 204 (11.3%) 0.03 26 (6.4%) <0.001
Primary 687 (31.7%) 588 (32.4%) 179 (43.9%)
Secondary 1069 (49.4%) 806 (44.5%) 174 (42.6%)
Higher 217 (10.0%) 215 (11.9%) 29 (7.1%)
Residence, % (n) Rural 0 1636 (75.5%) 1014 (55.9%) <0.001 302 (74.0%) 0.59
Urban 530 (24.5%) 800 (44.1%) 106 (26.0%)
SES Quartile, % (n) Lower 22 514 (23.8%) 442 (24.5%) 0.01 136 (33.3%) 0.003
Middle lower 591 (27.4%) 404 (22.4%) 96 (23.5%)
Middle upper 557 (25.8%) 438 (24.3%) 97 (23.8%)
Upper 495 (22.9%) 517 (28.7%) 79 (19.4%)
Smokers, % (n) Never 0 1503 (69.4%) 1322 (72.9%) 0.007 255 (62.5%) 0.02
Former 163 (7.5%) 145 (8.0%) 33 (8.1%)
Current 500 (23.1%) 347 (19.1%) 120 (29.4%)
Alcohol, % (n) Never 5 882 (40.8%) 704 (38.9%) 0.10 117 (28.7%) <0.001
Former 942 (43.6%) 772 (42.6%) 221 (54.2%)
Current 339 (15.7%) 336 (18.5%) 70 (17.2%)
*P-value for association between the baseline characteristic and the odds of having a known DM status observation at follow up, amongst all participants
identified as non-diabetic at baseline and not known to be deceased at follow up
**P-value for association between the baseline characteristic and the odds of dying during the follow up period, amongst all participants identified as
non-diabetic at baseline and either followed up or known to be deceased at follow up (i.e. excluding the group who were not followed up)
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Of the 1562 people without either DM or DR at base-
line, 1377 (88 · 1%) had complete follow-up DR status
data. Of these, 89/1377 (6 · 5%) were newly diagnosed
with DM; and 9 (10 · 1%) had incident DR. A further 11
incident cases of DR were seen in the 44 participants
with DM but no DR at baseline (Fig. 2). Therefore, in
total, 20 participants developed DR during follow up,
giving a corrected cumulative incidence of 15 · 8 per
1000 (95% CI: 9 · 5–26 · 3), Table 2. This equates 15,800
cases in the population aged ≥50 years per year per
million. In the population of 1 · 6 million people in
Nakuru, Kenya, approximately 150,000 individuals are
aged ≥50 years, and of these approximately 1650 will de-
velop DM each year and 450 will develop DR each year.
Among subjects with known DM at baseline, the cor-
rected cumulative incidence of DR is 224 · 7 per 1000
(95% CI: 116 · 9–388 · 2) (Table 2). Similarly to DM, the
incidence of DR decreased with increasing age (Table 2).
Of the 20 incident cases of DR, seven had sight-
threatening DR (STDR) of whom two cases were prolif-
erative DR (five with severe retinopathy), four cases had
moderate DR and nine mild DR (Table 2).
In total 23 participants with known DR at baseline
were followed up and had a gradable retinal image. Of
these, 15 still had signs of DR, while eight no longer had
evidence of DR. Of nine with background DR at baseline,
one progressed to pre-proliferative DR and the remainder
either remained BDR (n = 2) or had no signs of DR at
follow-up (n = 6). Of seven participants with moderate
non-proliferative DR (NPDR) at baseline, three progressed
to proliferative DR (PDR). One participant with severe
NPDR at baseline developed PDR and one remained
Severe NPDR. Of five with PDR at baseline, one regressed
to Moderate NPDR (having undergone pan-retinal photo-
coagulation) and the other four remained PDR, of whom
two had evidence of laser treatment.
Multivariable analysis of incident DR (Table 6) was not
conducted due to the small number of participants in
the category (n = 20). However, the age-adjusted risk
ratio suggested a correlation between increasing inci-
dence of DR and higher BMI, urban dwelling and higher
socioeconomic status. No conclusions can be drawn
from this due to the wide 95% confidence intervals.
Discussion
This population-based cohort study of people aged 50+
in rural Kenya is the first, to our knowledge, to assess
the incidence of DM and DR in SSA. The six-year
Table 2 Age-gender–specific 6-year cumulative incidence of diabetes mellitus among the Nakuru eye disease cohort study
participants
Male Female Overall
Age group
(years)
N
(Cases / at risk)
Risk per 1000/6 years
(95% CI)a
N Risk per 1000/6 years
(95% CI)a
N Risk per 1000/6 years
(95% CI)a
Diabetes Mellitus (N = 2056)
50–59 24 / 393 63.7(43.0,93.3) 37 / 544 69.6(49.2,97.7) 61 / 937 67.1(52.2,85.8)
60–69 19 / 328 62.3(39.2,97.6) 22 / 326 67.0(42.6103.8) 41 / 654 64.7(46.3,89.5)
70–79 8 / 180 48.2(22.2101.5) 9 / 151 57.5(29.9107.8) 17 / 331 52.6(33.0,82.7)
80+ 3 / 66 40.3(12.3123.9) 1 / 68 11.9(1.6,84.9) 4 / 134 25.8(9.6,67.5)
All ages 54 / 967 58.6(44.7,76.4) 69 / 1089 63.0(48.8,81.1) 123 / 2056 61.0(50.3,73.7)
Diabetic Retinopathy – among those without DM and without DR at baseline (N = 1421)
50–59 5 / 297 24.6(8.5,68.9) 7 / 394 20.0(7.8,50.3) 12 / 691 22.0(11.0,43.4)
60–69 5 / 237 22.9(9.8,53.0) 1 / 229 3.9(0.5,28.5) 6 / 466 13.3(5.4,32.8)
70–79 2 / 123 15.2(3.6,61.4) 0 / 89 – 2 / 212 8.6(2.1,34.8)
80 + b 0 / 29 – 0 / 23 – 0 / 52 –
All ages 12 / 686 20.5(10.9,38.2) 8 / 735 11.5(4.8,27.1) 20 / 1421 15.8(9.5,26.2)
Diabetic Retinopathy – among those with DM at baseline, but without DR at baseline (N = 44)
50–59 3 / 8 400.4(83.3830.7) 3 / 14 198.9(46.8556.8) 6 / 22 278.3(111.7541.7)
60–69 4 / 10 409.8(130.2763.1) 0 / 4 – 4 / 14 268.8(78.8612.2)
70–79 1 / 4 175.5(2.7943.6) 0 / 2 – 1 / 6 126.8(6.3770.0)
80 + b 0 / 1 – 0 / 1 – 0 / 2 –
All ages 8 / 23 337.7(162.1573.3) 3 / 21 118.8(29.7372.5) 11 / 44 224.7(116.9388.2)
aEstimated using inverse probability weights to account for loss to follow up
bNo-one with DR at follow up among 80+ group
Risk of the outcome in the 6-year follow up, adjusted for loss to follow up using inverse probability weightings
Sample sizes are small for the DR analyses, so estimates have a wide confidence interval
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cumulative incidence of DM in this study was 61 cases
per 1000, equating to approximately 10 new cases per
1000 of population aged ≥50 per year. Longo-Mbenza et
al. investigated the incidence of type 2 DM in a pro-
spective cohort of 807 subjects of Central Africans aged
≥40 years over a four-year period, all of whom had no
DM at basline [2]. During the follow up, there were 93
incident DM cases (11 · 5%), corresponding to an inci-
dence of 29 (95% CI 15-43) per 1000 persons per year,
considerably higher than our estimated cumulative inci-
dence. Motola et al. investigated the incidence of DM in
a prospective cohort of 563 South African Indians with
no-DM aged 15 years or greater over a ten-year period.
During the follow up period there were 91 (16.2%) inci-
dent cases of DM, corresponding to an incidence (age
and sex-adjusted) cumulative incidence of 8.3 per 1000
persons per year [21]. This latter estimate was more in
line with ours, but included a much younger population.
The six-year cumulative incidence of DR among per-
sons, 50 years and over, with known DM was 225 cases
per 1000 (95%CI: 116 · 9388 · 2). There is minimal com-
parable data available for SSA. One systematic review of
62 studies that reported the prevalence or incidence of
DR in SSA [6] found few high-quality population-based
studies and the majority were hospital or clinic based
surveys. Two cohort studies of DR have been conducted
in SSA. Sixty-four patients with insulin-dependent (Type
1) DM (IDDM) in Soweto, South Africa were followed
over a 10-year period between 1982 and 1992. In those
subjects seen at 10 years, prevalence of DR had in-
creased from 6 to 52% and PDR from 0 to 3%, but no
incidence data was reported [22]. In a two-year pro-
spective cohort study of DR in Malawi, 357 subjects
were systematically sampled from two primary care dia-
betes clinics, and 295 participants were followed up. The
incidence of any DR over the follow-up period was 380
Table 3 Extrapolated number of new adults, per year, aged 50 years and over in Kenya with diabetes mellitus and diabetic
retinopathy based on incidence data (adjusted to take account of loss to follow up) and estimates of the population in Kenya by
age group in 2015
Male Female Overall
Age group
(years)
Extrapolated
number
Lower
(95% CI)
Upper
(95% CI)
Extrapolated
number
Lower
(95% CI)
Upper
(95% CI)
Extrapolated
number
Lower
(95% CI)
Upper
(95% CI)
Diabetes Mellitus
50–59 10,710 7230 15,690 12,760 9020 17,910 23,570 18,340 30,140
60–69 5350 3370 8390 7400 4700 11,460 12,690 9080 17,560
70–79 1950 900 4100 3010 1570 5650 4880 3060 7680
80+ 490 150 1500 200 30 1430 750 280 1950
All ages 17,910 13,660 23,350 22,860 17,710 29,390 40,780 33,630 49,270
Diabetic Retinopathy – among those without DM and those without DR
50–59 4230 1460 11,860 3850 1500 9690 8020 4020 15,840
60–69 2090 890 4820 450 60 3300 2760 1110 6770
70–79 640 150 2610 – – – 840 200 3410
80+ – – – – – – – – –
All ages 6520 3460 12,160 4390 1850 10,340 11,100 6670 18,370
Diabetic Retinopathy – among those without DR at baseline
50–59 1650 340 3430 1850 430 5170 3790 1520 7390
60–69 2090 660 3880 – – – 2840 830 6470
70–79 370 10 1980 – – – 620 30 3780
80+ – – – – – – – – –
All ages 4300 2070 7310 2260 570 7100 7080 3690 12,240
All are based on 2015 estimates of population
Diabetes Mellitus: Population at risk are all adults over 50 who do not have DM. To estimate the size of the population at risk the 2008 DM prevalence is used.
Expected number of new DM diagnoses in 50+ year old individuals per year is (population at risk x risk per 1000/6 years)/(6 × 1000)
Diabetic Retinopathy among those with no DM and without DR at baseline: Population at risk are all adults over 50 who do not have DR. To estimate the size of the
population at risk the 2008 DR prevalence is used. Expected number of new DR diagnoses in 50+ year old individuals per year is (population at risk x risk
per 1000/6 years)/(6 × 1000)
Diabetes Retinopathy among those with DM out without DR at baseline: Population at risk are all adults over 50 who have DM but do not have DR. To estimate the
size of the population at risk the 2008 DR prevalence is used. Expected number of new DR diagnoses in those 50+ year old with DM per year is (population at risk
x risk per 1000/6 years)/(6 × 1000)
Sample sizes are small for the DR analyses, so estimates have wide confidence intervals
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Table 4 Age-adjusted and multivariable analysis of a number of baseline co-variables and incident diabetes mellitus in the
Nakuru eye disease cohort study
Study sample, n = 2056
No at risk of diabetes
mellitus
Incident diabetes
mellitus
Risk per 1000/6 years
(95% CI)
Age adjusted risk ratio
(95% CI)
Multivariable adjusted risk ratio
(95% CI)a
Age
50–59 937 61 67.1 (52.2–85.8) Baseline Baseline
60–69 654 41 64.7 (46.3–89.5) 0.96 (0.64–1.45) 1.10 (0.74–1.63)
70–79 331 17 52.6 (33.0–82.7) 0.78 (0.47–1.30) 1.05 (0.64–1.72)
80+ 134 4 25.8 (9.6–67.5) 0.38 (0.14–1.05) 0.58 (0.21–1.59)
Gender
Male 967 54 58.6 (44.7–76.4) Baseline –
Female 1089 69 63.0 (48.8–81.0) 1.06 (0.74–1.51) –
BMI (5 missing values)
Underweight 260 5 17.5 (6.1–49.2) Baseline Baseline
Normal 1050 29 27.4 (18.5–40.4) 1.54 (0.50–4.79) 1.54 (0.50–4.79)
Overweight 465 54 120.4 (91.6–156.8) 6.69 (2.26–19.81) 6.69 (2.26–19.81)
Obese 276 34 123.3 (85.9–173.8) 6.83 (2.28–20.49) 6.83 (2.28–20.49)
Location
Rural 1571 79 48.6 (39.2–60.1) Baseline –
Urban 485 44 87.0 (63.5–118.2) 1.75 (1.20–2.56) –
SES Quartile (9 missing values)
Lower 504 15 28.9 (17.9–46.5) Baseline –
Lower middle 576 26 46.8 (31.4–69.3) 1.59 (0.87–2.89) –
Upper middle 520 40 75.4 (54.7–103.2) 2.54 (1.47–4.36) –
Upper 447 41 94.3 (71.7–123.1) 3.12 (1.80–5.40) –
Smoker
Never 1426 88 62.6 (49.9–78.2) Baseline –
Former 161 4 31.4 (9.4–100.2) 0.50 (0.15–1.63) –
Current 469 31 66.8 (47.8–92.7) 1.08 (0.73–1.62) –
Hypertension (7 missing values)
No 1084 44 43.3 (31.6–59.2) Baseline –
Yes 965 78 80.3 (64.1–100.3) 1.94 (1.33–2.82) –
Alcohol (3 missing values)
Never 835 60 73.0 (55.6–95.2) Baseline –
Former 891 42 47.5 (35.3–63.7) 0.68 (0.46–1.00) –
Current 327 20 66.7 (41.8–104.9) 0.94 (0.55–1.61) –
Ethnic group
Kikuyu 1308 86 68.2 (53.5–86.6) Baseline –
Kalenjin 530 23 42.6 (28.3–63.6) 0.62 (0.40–0.98) –
Other 218 14 60.5 (35.6–101.1) 0.84 (0.45–1.54) –
Education level
No education 173 14 88.9 (56.1–13.8) 1.77(1.01–3.12) –
Primary 665 32 45.7 (31.8–65.4) Baseline –
Secondary 1009 61 61.6 (46.9–80.5) 1.25 (0.80–1.95) –
College/Uni 209 16 80.0 (48.4–129.4) 1.58 (0.85–2.95) –
aFor multivariable analysis, an initial model was fitted that included those variables shown to be associated with outcome in age-adjusted analysis (using a Wald
test threshold p-value of <0.05 to indicate association). A backward stepwise approach was then applied in order to obtain a final
multivariable model, removing variables with p > 0.05 one-by-one
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Fig. 2 Flowcharts of participant Diabetic Retinopathy status in the Nakuru Eye Disease Cohort Study. DM: Diabetes Mellitus, DR: Diabetic Retinopathy
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per 1000 of population over two years [23]. Two of the
leading cohort studies of eye disease from high-income
settings, the Blue Mountains Study in Australia and The
Wisconsin Epidemiologic Study of Diabetic Retinopathy
(WESDR) in the United States in which comparable
methodology was used show estimates of incident DR
from Nakuru, Kenya are more than twice that of the
findings from Wisconsin and three times that of the
Blue Mountains Study. The Blue Mountains Study
reported 222 cases per 1000 over five years (44 per
Table 5 Baseline characteristics of all individuals with a known baseline DR status, subdivided by their follow-up category
(participant, non-participant) at 6-year follow-up (N = 3281)
Participants Non-participants or not included in analysis
Baseline characteristics Missing values Followed-up
n = 1444 (44.0%)
Not followed-up Alive/Unknown/DM
status missing n = 1555 (47.4%)
p-value* Deceased
n = 282 (8.6%)
p-value**
Age in years, mean (SD) 0 61.4 (8.6) 62.7 (10.2) 0.015 69.6 (11.8) <0.001
Systolic BP in mmHg, mean (SD) 8 138.6 (23.6) 140.4 (24.1) 0.084 145.2 (29.6) 0.001
Diastolic BP in mmHg , mean (SD) 8 82.9 (13.0) 82.9 (13.1) 0.865 82.6 (16.4) 0.72
Random Blood Glucose, mean (SD) 69 5.1 (2.3) 5.2 (2.3) 0.10 5.5 (3.0) 0.04
Sex, % (n) Female 0 701 (48.5%) 746 (48.0%) 0.78 172 (61.0%) <0.001
Male 743 (51.5%) 809 (52.0%) 110 (39.0%)
BMI, % (n) Underweight
(<18.5 kg/m2)
11 166 (11.5%) 220 (14.2%) 0.07 68 (24.2%) <0.001
Normal
(18.5-24.99 kg/m2)
738 (51.2%) 757 (48.9%) 138 (49.1%)
Overweight
(25-29.99 kg/m2)
343 (23.8%) 360 (23.3%) 51 (18.1%)
Obese
(30 + kg/m2)
194 (13.5%) 211 (13.6%) 24 (8.5%)
Vision status
impaired (<6/12
better eye), % (n)
Normal 4 1375 (95.3%) 1415 (91.1%) <0.001 233 (82.9%) <0.001
Impaired 68 (4.7%) 138 (8.9%) 48 (17.1%)
Tribe, % (n) Kikuyu 0 912 (63.2%) 891 (57.3%) 0.001 191 (67.7%) 0.28
Kalenjin 358 (24.8%) 354 (22.8%) 63 (22.3%)
Other 174 (12.0%) 310 (19.9%) 28 (9.9%)
Education, % (n) None 1 129 (8.9%) 168 (10.8%) 0.004 20 (7.1%) 0.001
Primary 425 (29.4%) 518 (33.3%) 116 (41.1%)
Secondary 739 (51.2%) 685 (44.1%) 121 (42.9%)
Higher 151 (10.5%) 183 (11.8%) 25 (8.9%)
Residence, % (n) Rural 0 1062 (73.5%) 863 (55.5%) <0.001 199 (70.6%) 0.43
Urban 382 (26.5%) 692 (44.5%) 83 (29.4%)
SES Quartile, % (n) Lower 16 310 (21.6%) 385 (24.9%) 0.003 87 (30.9%) 0.03
Middle lower 399 (27.7%) 354 (22.9%) 63 (22.3%)
Middle upper 386 (26.8%) 380 (24.6%) 72 (25.5%)
Upper 343 (23.9%) 426 (27.6%) 60 (21.3%)
Smokers, % (n) Never 0 981 (67.9%) 1115 (71.7%) 0.02 167 (59.2%) 0.02
Former 113 (7.8%) 139 (8.9%) 23 (8.2%)
Current 350 (24.2%) 301 (19.4%) 92 (32.6%)
Alcohol, % (n) Never 3 586 (40.6%) 584 (37.6%) 0.06 82 (29.1%) 0.001
Former 624 (43.2%) 664 (42.8%) 147 (52.1%)
Current 233 (16.1%) 305 (19.6%) 53 (18.8%)
*P-value for association between the baseline characteristic and the odds of having a valid DM observation at follow up, amongst all participants identified as
having no diabetes at baseline and not known to be deceased at follow up
**P-value for association between the baseline characteristic and the odds of dying during the follow up period, amongst all participants identified as no-DM at
baseline and either followed up or known to be deceased at follow up (i.e. excluding the group who were not followed up)
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1000/year) and the WESDR study reported 327 cases
per 1000 over a four-year period (82 per 1000/year).
In a prospective cohort in southern Malawi, sampled
from two primary care diabetes clinics, the 2-year inci-
dence of sight-threatening DR (STDR) amongst 357 sub-
jects for subjects with no DR, BDR, and PDR at baseline
was 2 · 7% (95% confidence interval [CI], 0 · 1–5 · 3), 27 ·
3% (95% CI, 16 · 4–38 · 2), and 25 · 0% (95% CI, 0–67 · 4),
respectively [23].
The sample of participants with DR at both study time
points in the Nakuru cohort was too small to draw con-
clusions on the progression of DR. However, 23 partici-
pants over the six year follow up period had a DR
assessment at baseline and follow-up, of whom four pro-
gressed from non-STDR to STDR and of five with STDR
at baseline, one recovered to non-STDR and the other
four remained with STDR [23].
Strengths
This study is one of the first reports of DM and DR from
a population-based sample in SSA. The sampling meth-
odology ensures that the data is representative for the
population over 50 and minimised bias by sampling
from the community rather than from hospitals or
clinics. Retinal image data were collected for DR analysis
and images were independently graded at Moorfields
Eye Hospital Reading Centre.
Limitations
The definition of DM used in this study was based on a
single, non-fasting, capillary blood sample and did not
include fasting blood glucose samples and HbA1C mea-
sures were only available at follow-up. There was a high
loss to follow-up which creates potential for selection
bias however statistical methods were used to adjust for
this. This high LTFU was largely due to post-election
violence in the region between the two study time points
which led to mass displacement. The population under
Table 6 Age-adjusted analysis the association between a
number of baseline co-variables and incident DR amongst those
DR free at baseline in the Nakuru eye disease cohort study
Study sample, n = 1421
No at risk of
diabetic
retinopathy
Incident
diabetic
retinopathy
Risk per
1000/6 years
(95% CI)
Age adjusted
risk ratio
(95% CI)
Age
50–59 691 12 22.0 (11.0–43.4) Baseline
60–69 466 6 13.3 (5.4–32.8) 0.6 (0.2–2.0)
70–79 212 2 8.6 (2.1–34.8) 0.4 (0.1–1.9)
80+ 52 0 – –
Gender
Male 686 12 20.5 (10.9–38.2) Baseline
Female 735 8 11.5 (4.8–27.1) 0.5 (0.2–1.5)
BMI (2 missing values)
Underweight
166 1 5.3 (0.7–36.6) Baseline
Normal 727 5 8.1 (3.3–19.5) 1.5 (0.2–13.0)
Overweight 336 11 39.6 (20.3–75.9) 6.4 (0.8–53.6)
Obese 190 3 12.9 (4.1–40.2) 2.0(0.2–21.9)
Location
Rural 1053 12 11.6 (6.6–20.4) Baseline
Urban 368 8 23.5 (10.3–52.7) 1.8 (0.7–4.4)
SES Quartile (6 missing values)
Lower 309 1 3.0 (0.4–21.8) Baseline
Lower
middle
394 2 4.9 (1.2–19.4) 1.6 (0.4–6.9)
Upper
middle
380 9 25.1(13.1–47.5) 7.5 (1.0–58.1)
Upper 332 8 29.3 (13.3–63.3) 8.3 (1.0–66.9)
Smoker
Never 964 16 18.3 (10.0–33.1) Baseline
Former 113 0 – –
Current 344 4 14.3 (5.4–37.5) 0.8 (0.3–2.6)
Hypertension (2 missing values)
No 764 8 15.0 (6.0–36.7) Baseline
Yes 655 12 16.9 (9.3–30.3) 1.2 (0.4–3.6)
Alcohol (1 missing value)
Never 580 8 15.3 (6.5–35.6) Baseline
Former 611 9 15.0 (7.4–30.1) 1.1 (0.4–3.3)
Current 229 3 19.0 (4.1–83.5) 1.3 (0.2–7.9)
Ethnic group
Kikuyu 895 14 16.9 (10.3–27.8) Baseline
Kalenjin 357 3 8.5 (1.9–36.9) 0.5 (0.1–2.3)
Other 169 3 22.6 (7.2–69.1) 1.1 (0.4–3.0)
Table 6 Age-adjusted analysis the association between a
number of baseline co-variables and incident DR amongst those
DR free at baseline in the Nakuru eye disease cohort study
(Continued)
Education level
No
education
123 4 42.8 (15.3–114.2) Baseline
Primary 422 0 – –
Secondary 726 14 21.7(11.9–39.0) 0.6(0.2–1.9)
College/
Uni
150 2 12.6(3.0–51.6) 0.3(0.0–1.8)
For multivariable analysis, an initial model was fitted that included those
variables shown to be associated with outcome in age-adjusted analysis (using
a Wald test threshold p-value of <0.05 to indicate association). A backward
stepwise approach was then applied in order to obtain a final multivariable
model, removing variables with p > 0.05 one-by-one
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observation were ≥50 years and therefore the study does
not estimate the incidence of DM or DR in the popula-
tion under age 50 years.
Implications
As the diabetes epidemic continues, a greater under-
standing is required of the resources needed and level of
deployment of those resources within the health system
to respond appropriately. This includes primary
prevention of DM in the community, high treatment
coverage of persons with DM in primary care, and inclu-
sion of eye screening for people with DM as standard
practice. With good prevalence data on DM available in
many countries and regions in SSA and a growing
understanding of the natural history of the diseases in
different populations it should now be possible (within a
wide range of confidence and based on several assump-
tions) to estimate the conversion in the over 50s of those
without DM developing DM and DR.
Overall, DM is increasing in Africa probably related to
environmental factors such as increased access to proc-
essed foods and more sedentary lifestyles; this is likely to
increase in the next decade. The awareness of DM in the
community is still low [3] and public campaigns to raise
awareness as well as provide locally available DM
screening and counselling facilities is needed. It is also
important to consider detection of VTDR in the com-
munity and resourcing eye care providers with the
knowledge and tools to manage patients with STDR is
essential to ensure a high quality service and avoid sight
loss from DM. Specific planning data for the region
under investigation is provided in Table 7.
Conclusions
In a population of 1 · 6 Million in Nakuru County, Kenya:
150,000 are 50 years and over, we estimated that 1650
people over the age of 50 develop DM per year, and 450
develop DR. The management of DM and DR is complex
and requires different approaches at different levels of the
healthcare system with considerable variation depending
on location. For effective planning at any level, high qual-
ity information is required to effectively plan the services.
This cohort provides some data to support planning and
is indicative of areas that need further research.
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Table 7 Population summary for programme planning based
on prevalence and incidence data from a Kenyan cohort over
50 years of age
Population at risk
Place Nakuru
County
Kenya
(National)
Total Population 1.6 Million 46 Million
Population 50 years and over 0.15 Million 4.3 Million
Diabetes Mellitus (DM)
Prevalence (%) of DM 6.5
Number of people over 50 with
DM (needing examination of the
retina every 1–2 years)
26,100 279,500
Awareness of DM within the
population over 50 (%)
85
Number of people over 50 with
known DM
22,185 237,575
Number over 50 who develop new
DM per 1000 of population per year
11/1000
Number over 50 who develop new
DM per sample population per year
1650 47,300
Diabetic Retinopathy (DR)
Proportion (%) of people over 50
with DM who have DR
35.9
Number of people over 50 with DR 9400 100,340
Number over 50 who develop new
DR per 1000 of population per year
3/1000
Number over 50 who develop new
DR of the sample population per year
450 12,900
Vision Threatening Diabetic Retinopathy (VTDR)
Proportion of people over 50 with
DM who have VTDR
13.4
Number of people over 50 with VTDR
(needing treatment)
1260 13,450
Number over 50 who develop new
VTDR per 1000 of population per year
1.6/1000
Number over 50 who develop new
VTDR of the sample population per year
240 6880
Further research needs to be done to assess gaps in the patient care pathway
which include:
• awareness of DM in the population;
• access / availability to relevant diagnostic and treatment services ;
• quality of diagnostic and treatment services;
• availability of screening for DR within diabetes and eye care;
• protocols and referral thresholds for people with or without DR;
• barriers to receiving treatment for STDR in those with known STDR
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IMPORTANCE The incidence of age-relatedmacular degeneration (AMD) is unknown in Africa.
OBJECTIVE To estimate the 6-year cumulative incidence and progression of AMD in older
adults (!50 years old) in Nakuru, Kenya.
DESIGN, SETTING, AND PARTICIPANTS This study assessed a population-based cohort with
6-year follow-up of 4414 participants who had a complete assessment. Random cluster
sampling with probability proportionate to size procedures was used to select a
representative, cross-sectional sample of adults 50 years and older from January 26, 2007,
through November 11, 2008. A 6-year follow-up was undertaken from January 7, 2013,
throughMarch 12, 2014. On both occasions, a comprehensive ophthalmic examination was
performed that included logMAR visual acuity, digital retinal photography, and grading of
images at Moorfields Eye Hospital Reading Centre. Data were collected on general health and
risk factors.
MAIN OUTCOMES ANDMEASURES Incident AMD in participants with no AMD at baseline and
progression from early to late AMD.
RESULTS A total of 1453 of the 2900 individuals (50.1%) at risk for AMDwere followed up
after 6 years (mean [SD] age, 60.7 [8.2] years; 635 female [49.5%]; 799 Kikuyu [62.3%], 324
Kalenjin [25.3%], and 159 other [12.4%]); 1282 had data on AMD status at follow-up. Of these,
202 developed early AMD, and no participants developed late AMD. The 6-year weighted (for
loss to follow-up) cumulative incidence of early AMDwas 164.2 per 1000 persons (95% CI,
136.7-195.9 per 1000 persons). Two individuals with baseline early AMD from the 142 at risk
had developed late AMD at follow-up, with a 6-year cumulative incidence of progression from
early to late AMD of 24.5 per 1000 persons (95% CI, 5.0-111.7 per 1000 persons). Cumulative
incidence of AMD increased with age (!80 years old vs 50-59 years old: 1.8; 95% CI, 0.9-3.5)
and was higher in women (female vs male: 1.6; 95% CI, 1.2-2.1) and persons with diabetes
(diabetes vs no diabetes: 1.7; 95% CI, 1.0-2.8).
CONCLUSIONS AND RELEVANCE In Kenya, more than 100000 estimated new cases of AMD,
mainly early AMD, will develop every year in individuals 50 years or older, although a 50%
loss to follow-up and wide CIs for progression to late AMD limit definitive conclusions from
these findings.
JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2017.1109
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A ge-related macular degeneration (AMD) is a progres-sivedegenerativedisease that affects the central retinaand is highly associatedwith age.1AdvancedAMD, in-
cluding geographic atrophy (late dry) and neovascular AMD
(wet), leads to central vision loss. In the early dry form of the
disease, deposits known as drusen are layered between the
retina and choroid, and subtypes of drusen (basedon size and
morphologic features) form part of the more detailed classi-
fications. Although AMD is a leading cause of visual impair-
ment and blindness in populations living in high-income
countries,2 there is a paucity of available data from low- and
middle-incomecountries,3 includingsub-SaharanAfrica.How-
ever, a systematic review4 found that overall posterior-
segment disease is a common cause of visual impairment in
sub-Saharan Africa, and a survey5 in Kenya found that 1 in 10
persons 50 years and older had signs of AMD.
Estimation of the incidence and progression of AMD and
associatedsight loss is important forplanningofservices.Treat-
ment of neovascular AMD is currently possible in well-
established health care systems but infrequently available in
low- and middle-income countries. It is therefore important
to be able to identify individuals at high risk for AMD to con-
sider targetedapproaches forpreventionand/or treatment.Fur-
thermore, rehabilitation services need to be planned for indi-
vidualsdevelopingvisual lossasaresultofAMD.Unfortunately,
data to plan these services are currently lacking. The inci-
dence of AMDhas been investigated in 7 cohort studies of eye
disease worldwide,6-16 with no data from the African conti-
nent. There are large variations in the prevalence, pheno-
types, and incidenceofAMDindifferentpopulations,6-16mak-
ing extrapolation of findings from studies in other regions of
the world to an African setting difficult. The aims of the cur-
rent study were to estimate the 6-year cumulative incidence
of AMD in Nakuru, Kenya, and to identify risk factors for in-
cident disease.
Methods
We studied a population-based cohort with 6-year follow-up
of 4414 participants who had a complete assessment. Ran-
dom cluster sampling with probability proportionate to size
procedures was used to select a representative, cross-
sectional sample of adults 50 years and older from January
26, 2007, through November 11, 2008. A 6-year follow-up
was undertaken from January 7, 2013, through March 12,
2014. The following examination protocols were imple-
mented at baseline and follow-up, with detailed methods
available elsewhere17 and in the eMethods in the Supple-
ment. The London School of Hygiene & Tropical Medicine
Ethics Committee and the African Medical Research Founda-
tion granted ethical approval for the study, which was also
approved by the provincial medical officer for Nakuru
County. Written approval was sought from the administra-
tive heads in each cluster, usually the village chief. All par-
ticipants gave written or thumbprint consent to participate.
People requiring medical treatments were referred to the
appropriate center. All data were deidentified.
Ophthalmic and General Examination
All participants underwent logMAR visual acuity testing on
eacheye separately andcorrectedvisual acuitywhen less than
20/40 Snellen equivalent. Detailed interviews were under-
taken in the local language on demographic details, informa-
tiononrisk factors, socioeconomic status, and fullmedicalhis-
tory.Anurse recorded thebloodpressure,weight, height, and
waist and hip circumferences. Participants had 2 nonstereo-
scopic, digital, 45° fundus photographs (1 disc and 1macula
centered) takenper eyeby anophthalmic clinical officer. Digi-
tal imageswere graded at an approved grading center. The se-
nior grader (N.S.) graded all images for the presence of AMD.
All eyes classified as having late-stage AMDwere adjudicated
by theMoorfieldsEyeHospital ReadingCentre clinician (T.P.).
Theadjudicator (T.P.) alsograded5%of randomly selected im-
ages to ensure quality control.
Definitions of AMDUsed
Amodifiedversionof the international classificationandgrad-
ing systemfor age-relatedmaculopathyandAMDwasused for
image grading at baseline and follow-up.18 Drusen were cat-
egorized based on size, uniformity of color, and margins. Pa-
tientswere classified intohardor soft drusen categories: small
drusen (<63μm)wereconsidered tobehard.Largedrusenwith
a uniform density, sharp margins, and a nodular surface tex-
ture were placed in the soft distinct category, whereas those
without sharpmarginswereclassifiedas indistinct.Whenend-
stage disease was apparent, patients were classified as hav-
inggeographic atrophy in thepresenceofwell-demarcated re-
gionswith diameters greater than 175 μm,withinwhich large
choroidalvesselswereclearlyvisible to theatrophyof theover-
lying choriocapillaris and retinal pigment epithelium. Neo-
vascular AMD was graded as present when exudative fea-
tures, such as serous fluid, hemorrhage, lipid exudates, or
fibrosis, were seen to be originating primarily from the sub-
retinal, pigment, and epithelial tissue layers.
Case definitions were based on the eye with more severe
status ifbotheyesweregradableandonthegradableeye ifonly
one was gradable. Early AMD was defined as the presence of
large, soft drusen and pigmentation greater than 63 μm, and
late AMD was defined as the presence of geographic atrophy
or neovascular AMD.
Incident AMDwas defined on the basis of the absence of
AMD features at baseline on retinal images and the subse-
Key Points
Question What is the incidence of age-relatedmacular
degeneration in Kenya?
Findings A 6-year, population-based cohort study of 4414 adult
Kenyans (!50 years of age) was conducted, and the 6-year
weighted cumulative incidence of early age-relatedmacular
degeneration was 164.2 per 1000 persons.
Meaning These results suggest that age-relatedmacular
degenerationmay become a greater public health concern in
Kenya and similar countries in the future with population aging in
these regions.
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quent presence of these features at follow-up. Incident late
AMD was defined as the combination of no or early AMD at
baseline and signs of late AMD at follow-up.
DealingWith Loss to Follow-up
Logistic regressions corrected for the surveydesignwereused
to calculate P values to assess differences between partici-
pants seenand lost to follow-upand thoseknowntohavedied.
An inverse probability weighting (IPW)model was used to al-
low estimation of cumulative incidence while accounting for
those lost to follow-up. Those who had died between base-
line and follow-up were excluded from the analysis. Multi-
variable logistic regressionwas used to identify independent
baseline covariates associated with loss to follow-up. Covari-
ates forwhich therewas evidence of associationwith the out-
come (P < .10) were kept in a multivariable model. Individu-
alswithout a complete set of the baseline covariates included
in the final multivariable model were excluded from any es-
timations based on the weighted analysis. From this final
model, the probability of being followed up was estimated
basedon thepresence or absence of eachof these baseline co-
variates. The inverse of this probability formed theweighting
to be applied to account for those lost to follow-up.
The final stepwas to exclude those individuals lost to fol-
low-upfromtheanalysisandapply the IPWtoaccount for those
lost to follow-up. A sensitivity analysis for this approach in-
volved a complete records analysis (ie, including only indi-
viduals who had complete records for outcome and all vari-
ables in the analysis).
Cumulative Incidence Estimation
The 6-year cumulative incidence of AMDwas estimated by di-
vidingthetotal (weighted)numberof individualswhowereclas-
sified ashavingAMDat follow-upby the (weighted)numberof
individuals who were AMD free at baseline and examined at
follow-up.The6-yearcumulative incidencewasthenusedtoes-
timatetheexpectednumberofnewAMDcasesperyear.Thesize
of theat-riskpopulation inKenyawasestimatedusing thebase-
line prevalence of AMD from this cohort and the 2015 Kenyan
populationestimates for those50yearsorolder. The6-year in-
cidence was thenmultiplied by this at-risk population and di-
videdby6,with theassumption that cumulative incidencewas
constant over time. Annual cumulative incidence was also es-
timated separately formen andwomen and in 10-year age cat-
egories (50-59,60-69, 70-79, and ≥80 years). The incidence of
progression from early to late AMDwas calculated by examin-
ingparticipantswith earlyAMDatbaselinewhowere followed
up and had a valid AMD status at follow-up.
Assessing Risk Factors AssociatedWith AMD Incidence
Theage-adjustedassociationbetweenAMDincidenceandeach
covariate was estimated using a Poisson regression model. A
multivariablemodel was createdwith backward stepwise se-
lectionusing the likelihoodratio test anda thresholdof2-tailed
P < .05 for retention of a variable in the model.
Results
At baseline, 4414 participants had a complete assessment, of
whom 3304 (74.9%) had an AMD assessment from retinal
imaging (Figure). Of these participants,404 (12.2%)hadAMD
at baseline,with 366 (90.6%)having earlyAMDand 38 (9.4%)
having lateAMD.Anadditional2900participantsdidnothave
AMDatbaselineandwere thereforeat risk fordevelopingAMD
at follow-up.5
Figure. Participant Flowchart
4414 Baseline participants
3304 Had baseline AMD status
1080 No AMD at follow-up
171 Missing AMD data
(no gradable image)
202 Early AMD at follow-up
1453 Followed up
2900 WIth no AMD
173 Followed up with early
AMD at risk of progression
140 Nonprogressor 2 Progressor to late AMD
404 With AMD
366 With early AMD
38 With late AMD
1110 Missing AMD status
1027 Camera not available
83 Images not gradable
1447 Lost to follow-up
225 Deceased
1222 Other
193 Lost to follow-up
52 Deceased
141 Other
31 Missing AMD data
(no gradable image)
AMD indicates age-relatedmacular
degeneration.
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Characteristics of participants and nonparticipants at
6-year follow-upare given inTable 1. Nonparticipantsweredi-
vided into thosewhohaddiedand thosewho livedbutdidnot
attend the examination clinic (eg, because of mass displace-
ment in the period of postelection violence after the baseline
study period) and/or those without a valid AMD assessment
(eg, cataract obstructing a viewof the retina). Comparedwith
those followed up, participants who had died during fol-
low-up were older and more likely to be female, have lower
educational level,havehighersystolicbloodpressure,andhave
diabetes but lower body mass index. Compared with partici-
pants seen, those lost to follow-upwere less likely tobeKikuyu
or Kalenjin speakers, had lower levels of education, andwere
more likely tobe fromurbanareas and fromthehighestor low-
Table 1. Baseline Characteristics of All 2900 IndividualsWith No AMD at Baseline According to Availability
of AMD Status at 6-Year Follow-upa
Baseline Characteristic
Missing
Values
Participants
Nonparticipants or Not Included in
Analysis
Followed Up
(n = 1282)
Not Followed Upb
(n = 1393)
Deceased
(n = 225)
Age, mean (SD), y 0 60.7 (8.2) 61.8 (9.8) 68.5 (12.0)c
BP, mean (SD), mm Hg
Systolic 26 138.4 (23.6) 139.3 (23.6) 143.3 (28.7)c
Diastolic 26 83.1 (13.0) 82.6 (13.1) 82.4 (16.0)
Random blood glucose level,
mean (SD), mg/dL
79 5.2 (2.3) 5.2 (2.2) 5.6 (3.3)c
Sex
Male 0 647 (50.5) 707 (50.8) 86 (38.2)
Female 0 635 (49.5) 686 (49.2) 139 (61.8)c
BMId
Underweight (<18.5) 29 139 (10.9) 188 (13.7) 52 (23.2)c
Normal (18.5-24.99) 0 648 (50.7) 674 (49.2) 113 (50.4)
Overweight (25-29.99) 0 307 (24.0) 321 (23.4) 40 (17.9)
Obese (≥30) 0 184 (14.4) 186 (13.6) 19 (8.5)
Vision status impaired,
<6/12 better eye
Normal 18 1233 (96.3) 1279 (93.0)e 195 (86.7)c
Impaired 0 48 (3.7) 97 (7.0) 30 (13.3)
Tribe
Kikuyu 0 799 (62.3) 782 (56.1)e 152 (67.6)
Kalenjin 0 324 (25.3) 313 (22.5) 52 (23.1)
Other 0 159 (12.4) 298 (21.4) 21 (9.3)
Educational level
None 21 119 (9.3) 163 (11.9)e 15 (6.7)c
Primary 0 345 (26.9) 432 (31.4) 91 (40.6)
Secondary 0 677 (52.8) 608 (44.3) 94 (42.0)
Higher 0 140 (10.9) 171 (12.4) 24 (10.7)
Residence
Rural 0 937 (73.1) 763 (54.8)e 161 (71.6)
Urban 0 345 (26.9) 630 (45.2) 64 (28.4)
SES quartile
Lower 34 266 (20.9) 324 (23.7)e 66 (29.5)
Middle lower 0 347 (27.2) 304 (22.2) 55 (24.6)
Middle upper 0 345 (27.1) 342 (25.0) 60 (26.8)
Upper 0 317 (24.9) 397 (29.0) 43 (19.2)
Smoker
Never 15 861 (67.2) 980 (71.1)e 134 (59.6)
Former 104 (8.1) 124 (9.0) 22 (9.8)
Current 317 (24.7) 274 (19.9) 69 (30.7)
Alcohol use
Never 23 524 (40.9) 512 (37.3) 61 (27.2)c
Former 0 549 (42.9) 595 (43.3) 116 (51.8)
Current 0 207 (16.2) 266 (19.4) 47 (21.0)
Abbreviations: AMD, age-related
macular degeneration; BMI, body
mass index; BP, blood pressure;
SES, socioeconomic status.
a Data are presented as number
(percentage) of participants unless
otherwise indicated.
b Participants not followed up were
alive, unknown, or had AMD status
missing.
c P < .05 for association between the
baseline characteristic and the odds
of dying during the follow-up period
among all participants identified as
non-AMD at baseline, excluding the
group whowere not followed up.
dCalculated as weight in kilograms
divided by height in meters
squared.
e P < .05 for association between the
baseline characteristic and the odds
of being followed up among all
participants identified as non-AMD
at baseline and not known to be
deceased at follow-up.
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est socioeconomicquartile. Individuals seenat follow-upwere
less likely tohave impairedvision at baseline (48 [3.7%]) com-
pared with those who died before follow-up (30 [13.3%]) or
those not seen at follow-up (97 [7.0%]).
In total, 1453 persons (50.1%) at risk for AMD were fol-
lowed up after 6 years (Figure), and 1282 had data on AMD at
follow-up. Of these, 202 developed early AMD, and no par-
ticipants developed late AMD. The 6-year cumulative inci-
dence of early AMD, after taking account of loss to follow-up
by using IPW, was 164.2 per 1000 persons (95% CI, 136.7-
195.9 per 1000 persons).
In addition, 366 participants with early AMDwere at risk
of progressing to lateAMDat follow-up, ofwhom 173were fol-
lowed up and 142 had a valid AMD assessment (25 of 31who
did not have an AMD assessment had a lens opacity that ob-
scured the retinal images). Two individuals with early AMD
from the 142 at risk had developed late AMD at follow-up
(Figure), giving a 6-year cumulative incidence of progression
from early to late AMDof 24.5 per 1000 persons (95%CI, 5.0-
111.7 per 1000 persons).
Of the 38 individualswith lateAMDatbaseline, 17 (44.7%)
were followed up, 5 (13.2%) died, and 16 (42.1%) were not lo-
cated for follow-up. Of the 17 individuals who were followed
up, 4 (23.5%) did not have a valid AMD assessment (because
of obstructing lens opacities), 11 (64.7%) remained classified
as having late AMD, and 2 (11.8%) had a critical eye that was
difficult to grade because of imagequality butmost likely had
stable end-stage AMD. The visual status at baseline and fol-
low-up is given in eTable 1 in the Supplement.
Cumulative incidence of AMD (≥80 vs 50-59 years of
age: 243.8 per 1000 persons [95% CI, 115.8-442.4 per 1000
persons] vs 139.3 per 1000 persons [95% CI, 105.3-181.9 per
1000 persons]) strongly correlated with age (Table 2). The
cumulative incidence of AMD was higher among women
than men in each age group (197.0 per 1000 persons [95%
CI, 156.7-244.7 per 1000 persons] vs 130.5 per 1000 persons
[95% CI, 104.1-162.4 per 1000 persons]), with an overall
6-year cumulative incidence of 197 new cases per 1000 per-
sons (95% CI, 157-245 per 1000 persons) among women
compared with 131 new cases per 1000 persons (95% CI,
104-162 per 1000 persons) among men, giving an unad-
justed risk ratio of 1.51 (95% CI, 1.14-2.00). For each increase
in age category, the risk ratio was estimated to be 1.19 (95%
CI, 1.00-1.42).
On the basis of extrapolations of these results to census
dataandpopulationestimates in2015 (assuming incidentcases
annually is proportional to the cumulative incidence), we es-
timate that, in Kenya, 103070 new cases of AMD (at any se-
verity)developeveryyear inpersons50yearsorolder,ofwhom
65 720 (63.8%) are women (Table 3).
Specific features ofAMD that appear or regress during the
studyperiodwere recorded (eTable2 in theSupplement). Small
drusen were noted to have a 6-year cumulative incidence of
59.1% (95% CI, 53.7%-64.3%) and a cumulative risk of 24.1%
(95%CI,20.6%-28.0%)for regression.Hyperpigmentationand
hypopigmentationhadahighcumulativeriskof resolutiondur-
ing the 6-year follow-up period (hyperpigmentation: 77.0%;
95% CI, 59.5%-88.4%; hypopigmentation: 58.1%; 95% CI,
39.7%-74.4%)but a low incidence (hyperpigmentation: 3.5%;
95% CI, 2.5%-5.0%; hypopigmentation: 5.0%; 95% CI, 3.5%-
7.1%).
Multivariable analysis of factors associatedwith incident
AMD indicated an increasing incidenceofAMDwitholder age
(P for trend = .02), female sex (P = .001), anddiabetes (P = .04)
(Table 4).
Of the 234 individuals in the cohort who developed inci-
dent vision impairment, 162 (69.2%)hadanavailableAMDas-
sessment at follow-up. Of the 162 individuals, 52 (32.1%) had
AMD, and 3 of these patients were classified as blind. It was
notpossible to inferwhethervision losswasattributable solely
toAMDoracombinationofotherocular comorbidities.Change
in vision category frombaseline to follow-up in all thosewith
Table 3. Extrapolated Number of NewAdults 50 Years andOlder in Kenya Developing Age-RelatedMacular
Degeneration per Yeara
Age Group, y
Extrapolated No. (95% CI)
Males Females Overall
50-59 16 460 (10 860-24 500) 31 520 (23 630-41 360) 48 770 (36 890-63 700)
60-69 12 280 (8680-17 040) 21 800 (15 450-29 860) 33 450 (26 540-41 690)
70-79 6650 (4370-9750) 7720 (4370-12 710) 14 550 (10 700-19 400)
≥80 1520 (520-3710) 4550 (1590-8520) 5520 (2620-10 020)
All ages >50 38 280 (30 530-47 650) 65 720 (52 270-81 620) 103 070 (85 800-123 020)
a On the basis of incidence data
(adjusted for loss to follow-up) and
estimates of the population in
Kenya by age group in 2015.
Table 2. Age- and Sex-Specific 6-Year Cumulative Incidence of Age-RelatedMacular Degeneration Among the Nakuru Eye Disease Cohort
Study Participants
Age Group, y
Males Females Overall
No. of Cases/No.
at Risk
Risk per 1000 at
6 Years (95% CI)
No. of Cases/No.
at Risk
Risk per 1000 at
6 Years (95% CI)
No. of Cases/No.
at Risk
Risk per 1000 at
6 Years (95% CI)
50-59 29/288 98.2 (64.8-146.1) 60/369 172.7 (129.4-226.6) 89/657 139.3 (105.3-181.9)
60-69 33/221 146.6 (103.6-203.4) 38/197 214.5 (152.0-293.7) 71/418 179.9 (142.8-224.3)
70-79 20/104 184.6 (121.3-270.9) 13/66 193.0 (109.3-318.0) 33/170 188.0 (138.2-250.6)
≥80 4/22 148.1 (51.0-360.0) 5/15 378.8 (132.6-708.7) 9/37 243.8 (115.8-442.4)
All ages 86/635 130.5 (104.1-162.4) 116/647 197.0 (156.7-244.7) 202/1282 164.2 (136.7-195.9)
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Table 4. Age-Adjusted andMultivariable Analysis of Baseline Covariables and Incident AMD in the Nakuru Eye Disease Cohort Study Sample
of 1282 Individuals
Covariable
No. at Risk
of AMDa
No. With
Incident AMDb
Risk per 1000
at 6 Years (95% CI)
Age-Adjusted Risk
Ratio (95% CI)
Baseline
P Value
Multivariable-Adjusted
Risk Ratio (95% CI)c
Baseline
P Value
Age group, y
50-59 657 89 139.3 (105.3-181.9) 1 [Reference]
.16
1 [Reference]
.07
60-69 418 71 179.9 (142.8-224.3) 1.3 (1.0-1.7) 1.3 (1.0-1.7)
70-79 170 33 188.0 (138.2-250.6) 1.4 (0.9-1.9) 1.5 (1.0-2.1)
≥80 37 9 243.8 (115.8-442.4) 1.8 (0.8-3.7) 1.8 (0.9-3.5)
Sex
Male 635 86 130.5 (104.1-162.4) 1 [Reference]
.002
1 [Reference]
.001
Female 647 116 197.0 (156.7-244.7) 1.6 (1.2-2.1) 1.6 (1.2-2.1)
BMId (4 missing values)
Underweight (<18.5) 139 25 191.3 (127.2-277.4) 1 [Reference]
.84
NA
NA
Normal (18.5-24.99) 648 98 160.1 (129.9-195.7) 0.8 (0.5-1.3) NA
Overweight (25-29.99) 307 49 159.4 (113.0-220.1) 0.9 (0.6-1.4) NA
Obese (≥30) 184 30 169.1 (119.0-234.6) 0.9 (0.6-1.6) NA
Location
Rural 937 146 160.0 (131.9-192.8) 1 [Reference]
.55
NA
NA
Urban 345 56 171.2 (116.8-244.0) 1.1 (0.8-1.7) NA
SES quartile
(7 missing values)
Lower 266 50 216.0 (154.0-294.2) 1 [Reference] .07 NA NA
Lower middle 347 43 128.5 (94.4-172.4) 0.6 (0.4-0.9) NA
Upper middle 345 59 169.1 (128.1-219.8) 0.8 (0.5-1.3) NA
Upper 317 48 148.5 (105.9-204.4) 0.7 (0.5-1.1) NA
Smoker
Never 861 142 173.6 (141.6-211.1) 1 [Reference]
.12
NA
NAFormer 104 9 83.5 (39.5-167.9) 0.5 (0.2-1.0) NA
Current 317 51 165.7 (125.5-215.7) 0.9 (0.7-1.2) NA
Hypertension
(2 missing values)
No 664 95 149.1 (113.3-193.6) 1 [Reference]
.37
NA
NA
Yes 616 106 178.0 (143.1-219.2) 1.2 (0.8-1.6) NA
Diabetes (1 missing value)
No 1223 188 157.8 (131.7-187.9) 1 [Reference]
.07
1 [Reference]
.04
Yes 58 14 263.9 (136.3-448.9) 1.7 (1.0-2.8) 1.7 (1.0-2.8)
Alcohol use
(2 missing values)
Never 524 85 171.6 (133.7-217.5) 1 [Reference]
.59
NA
NAFormer 549 81 155.2 (117.5-202.2) 0.8 (0.6-1.2) NA
Current 207 36 169.6 (116.3-240.6) 1.0 (0.6-1.4) NA
Ethnic group
Kikuyu 799 126 164.7 (130.5-205.6) 1 [Reference]
.51
NA
NAKalenjin 324 46 148.5 (107.4-201.7) 0.9 (0.6-1.3) NA
Other 159 30 184.4 (119.2-274.3) 1.2 (0.8-2.0) NA
Educational level
(1 missing value)
No education 119 12 111.3 (58.2-202.5) 1 [Reference]
.16
NA
NA
Primary 345 66 215.8 (161.8-281.7) 1.8 (0.9-3.4) NA
Secondary 677 104 152.8 (123.7-187.4) 1.3 (0.7-2.5) NA
College or university 140 20 128.5 (80.7-198.4) 1.2 (0.5-2.6) NA
Abbreviations: AMD, age-relatedmacular degeneration; BMI, bodymass index;
NA, not applicable; SES, socioeconomic status.
a At risk indicates no AMD at baseline.
b Incident AMD indicates early or late AMD at follow-up.
c For multivariable analysis, an initial model was fitted that included those
variables associated with outcome in age-adjusted analysis (using aWald test
threshold P < .05 to indicate association). A backward stepwise approach was
then applied to obtain a final multivariable model, removing variables with
P > .05 one by one.
dCalculated as weight in kilograms divided by height in meters squared.
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avalidAMDstatus at baseline and follow-up is given in eTable
3 in the Supplement.
A total of 202 participants in the cohort developed inci-
dent AMD, of whom 192 (95.0%) had normal vision at base-
line. A total of 27 (14.1%) of the 192 developed visual impair-
mentby follow-up.A total of 1080participantsdidnotdevelop
AMD, with 1040 (96.3%) in this group having normal vision
atbaseline.Of these 1040 individuals,83 (8.0%)developedvi-
sion impairment.
Discussion
The Nakuru Eye Disease Cohort Study provides longitudinal
data on AMD in sub-Saharan Africa from a population-based
cohort. Although there is 50% loss to follow-up and few
cases of late AMD (resulting in wide CIs for that outcome),
there are limited data on these outcomes from this region.
With those caveats in mind, during 6 years, 1 in 6 adults 50
years or older developed early manifestations of AMD, with
women having a higher incidence than men. Increasing age
was strongly related to the prevalence and incidence of
AMD. Most incident cases of AMD were defined on the basis
of the development of large drusen (>64 μm). Late AMD was
infrequent at baseline, and consistent with this pattern, only
2 cases of incident late AMD were found at follow-up. Both
incident cases developed in individuals with early AMD at
baseline, and no case was identified that progressed from no
AMD to late AMD.
Our data estimate a higher incidence of AMD than other
(non-African) cohort studies of eye disease (eTable 4 in the
Supplement). A likely explanation is that the Nakuru cohort
includes only persons 50 years or older, similar to the next 2
highest cumulative annual incidence estimates, which were
also from samples of older individuals in Copenhagen6 and
Reykjavik.11 Furthermore, in the Nakuru study, there was a
higher incidence of early AMD and a lower incidence of late
AMD compared with other populations. This observation is
consistent with the baseline finding, which indicated a com-
paratively high prevalence of early AMD but low prevalence
of late AMD.5-16 The 2 participants who progressed from
early to late AMD were older than 80 years; the reduced
number of individuals in this age group in the Nakuru
cohort may explain the low incidence of late AMD because
age is the leading risk factor for incident AMD.
A high prevalence of early AMD at baseline and a high
incidence of early AMD at follow-up may suggest that the
population under investigation has a higher risk of develop-
ing AMD. The relatively high prevalence and incidence may
possibly be attributed to greater UV light exposure, earlier
biological aging, greater genetic predisposition, or greater
susceptibility to inflammatory processes, which have been
attributed to AMD.19 The proportion of persons with vision
loss attributable to AMD is relatively low because overall
vision loss primarily attributable to conditions such as cata-
ract is largely under control in more developed health care
systems. Of those with AMD, 14% developed vision impair-
ment during the 6-year study period compared with 9%
during 14 years in a well-developed health care system in
Copenhagen. However, vision impairment cannot be attrib-
uted to AMD alone.
Strengths and Limitations
This study was conducted under challenging circumstances
with limited infrastructure. It provides independently
graded, digital image–based analysis of AMD in an East Afri-
can cohort that is diverse and largely representative of the
population from which it was sampled. Detailed ophthal-
mic, demographic, and anthropometric assessment of each
participant has enabled valuable analyses of associations
and risk factors.
Despite these strengths, limitations of the current study
may have contributed to an underestimation of the true
incidence of AMD and AMD lesions. First, the main limita-
tion of our study is the large loss of participants at follow-
up. Of the 4414 persons who participated in the baseline
study, only 2171 persons participated in the follow-up
examination, of whom 1424 had gradable images at baseline
and follow-up, with most being excluded from analysis as a
result of camera failure at baseline, lack of electricity access,
and/or ungradable images attributable to media opacities.
Only those who had gradable images at both time points
were included in the analysis. A complete case record analy-
sis was conducted without weighting for loss to follow-up
(eTable 5 in the Supplement), with results similar to those
using the IPWmodeling (Table 2), with a possible underesti-
mation of the incidence in women when loss to follow-up is
not taken into account.
Second, changes in procedures between the baseline and
follow-upexamination (different retinal camera)mayhave in-
troducedbias.Change incamerasmayhavecaused imageswith
different color profiles and saturation levels, resulting in dif-
ferent abilities to detect AMD features (eg, drusen and pig-
ment).Furthermore, the lackofstereophotographsmeantcases
of retinal elevationmay have been overlooked. These factors
may have resulted in bias toward an underestimation of the
incidence of subtle early AMD lesions, such as small drusen,
or anoverestimationofpigmentationattributed toAMD.Com-
parison images between cameras of the same study partici-
pants at baseline and follow-up are given in eTable 6 in the
Supplement. Overall image quality was considered to be
equivalent at the 2 time points in those with clear media (ie,
no lens or corneal opacity).
Third, survival bias may have caused an underestima-
tion of the true incidence of late AMD if those who died
before the follow-up had experienced advanced AMD
lesions after the first examination, and it is possible that
those with worsening disease were more likely to attend
follow-up visits. The low prevalence of late AMD at baseline
and low incidence can, in part, be attributed to a lack of
older individuals in this study population, with an expected
shorter life span than other populations with data on AMD
incidence. Classification bias may also have contributed
to the estimates, and histologic studies would be required to
confirm whether the manifestations being attributed
to AMD are consistent with those in other populations.
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Conclusions
We estimate that, in Kenya, more than 100000 new cases of
AMD, mainly early AMD, will develop every year in persons
50 years and older, although a 50% loss to follow-up and
wide CIs for progression to late AMD limit definitive conclu-
sions from these findings. The AMD in this population was
found to be phenotypically different from that in a prior
study.5 However, because the relatively high incidence was
restricted to occurrence of early AMD, the high incidence of
early AMD may not have major implications for clinical
practice given the low number of individuals with associ-
ated visual loss.
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 eMethods. Ethics Statement, Sampling Strategy, and Inverse Probability Weighting 
 
Ethics Statement 
The London School of Hygiene & Tropical Medicine (LSHTM) Ethics committee and 
the African Medical Research Foundation (AMREF) granted ethical approval for the 
study and by the Provincial Medical Officer for Nakuru County. Written approval was 
sought from the administrative heads in each cluster, usually the village chief. All 
participants gave written or thumbprint consent to participate. People requiring 
medical treatments were referred to the appropriate centre. 
 
Sampling Strategy and Recruitment 
The study baseline fieldwork was carried out at baseline between January 2007 and 
November 2008. The follow-up study took place between October 2012 and March 
2014.  
 
At baseline, 100 clusters were selected across Nakuru County with a probability 
proportional to the size of the population using the electoral roll as the sampling 
frame. A cluster was defined as the area served by a polling station. Households 
were selected within clusters using a modified compact segment sampling method.1 
Each cluster was divided into segments so that each segment included 
approximately 50 people aged ш50 years. One segment was selected at random, and 
all eligible people were included sequentially until 50 had been examined.  
 
The sample size of 5000 people at baseline (2007-2008) was sufficient to estimate a 
prevalence of AMD of 3.0% among those aged ш50 years, with a required precision 
of 0.5%, 95% confidence, a design effect to account for clustering of 1.5, and a 
response rate of 90%. (Epi Info 6.04, Centers for Disease Control and Prevention, 
Atlanta, GA). In total, 4,381 participants were recruited at baseline (response rate 
81%). 
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All participants were invited to attend an examination clinic at a central location 
within the cluster (see below). 
 
Follow-up 
One week before the follow-up examination clinic was carried out a field officer 
studied the maps of the village including GPS coordinates recorded at baseline and 
made phone contact with the village chief or guide to arrange a planning visit. A list 
of study participants were given to the chief and a local village guide was recruited 
to assist locating the study participants. On the day prior to the examination clinic, a 
study team visited homes of baseline participants and confirmed their identity using 
National Identity cards and invited them to attend the examination clinic the 
following day.   
 
On the examination day, the advance team confirmed the identity of participants 
against data from baseline (age, date of birth, name, and identity cards). In cases of 
uncertain identity, confirmation was made based on retinal examination verified by 
comparison of retinal photos with baseline photo (n=12). 
 
Visual Acuity 
All participants underwent visual acuity (VA) testing on each eye separately at four 
meters using a reduced LogMAR tumbling ‘E’ chart2 in a well illuminated area as 
described elsewhere.3,4 Presenting VA was defined as the number of letters read 
correctly without glasses if the participant did not have glasses or with glasses if they 
had them. 
All participants underwent Autorefraction and those with a presenting acuity of <24 
LogMAR letters (<20/40 Snellen Equivalent) had a corrected VA assessed in addition 
to presenting (uncorrected, under corrected or corrected). More detailed 
methodology is available elsewhere.5  
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Fundus photography 
The participants had two non-stereoscopic digital 450 fundus photographs taken per 
eye by an ophthalmic clinical officer using a TRC-NW6S Non-Mydriatic Retinal 
Camera with 10 megapixel Nikon D80 (Top Con®) at baseline and a DRS CentreVue+ 
(Haag-Streit) Retinal Camera at follow-up. One image was centred on the optic disc 
while the other was centred on the macula. The digital images were forwarded to 
the Retinal Grading Centre at Moorfields Eye Hospital Reading Centre (MEHRC) 
London for grading and confirming the clinical diagnosis of posterior segment 
disease.  
 
Questionnaire and anthropometry 
Detailed interviews were undertaken in the local language covering demographic 
details, information on risk factors, socio-economic status (SES) and full past medical 
history. SES was evaluated using a continuous asset score, which was produced for 
each participant, using a scoring system derived through principal component 
analysis in an earlier study in this setting.6,7 The scale included assessment of 17 
asset items and five measures of household characteristics. 
 
A nurse recorded the blood pressure of participants three times on the right arm of 
the participant, at least five minutes apart after an initial period of five minutes of 
rest using the Omron digital automatic monitor (model HEM907). Weight was 
measured to the nearest kilogram using standard scales  (Seca 761 scales) after the 
participant had removed all heavy clothing and shoes. Height was measured to the 
nearest centimetre while the participant stood without shoes using a standardized 
stadiometer (Leicester Height Measure). For weight and height the average of two 
readings was recorded. Waist and hip circumferences were measured with a tape to 
the nearest centimetre. 
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 Image Grading 
The senior grader (NS) graded all images for the presence of AMD. All images were 
first categorized for quality as excellent, good, fair, borderline and ungradeable. All 
questionable lesions and all eyes classified as having late-stage AMD were 
adjudicated by the MEHRC clinician (TP). Any lesions considered to be due to other 
causes such as myopia and inflammatory disease were not graded for AMD, and 
these were also verified by TP. The adjudicator also graded 5% of randomly selected 
images to ensure quality control. Data were single entered onto Excel and checked 
for consistency by an independent data monitor from MEHRC who was not involved 
in the study.  
 
Data Handling & Statistical Analyses Methods 
Data entry 
Image data were double entered into a specially developed dataset (EpiData Entry 
v2.1). Consistency checks were performed each evening and inconsistencies 
corrected the same day.  
 
Data analysis 
Individuals in the study who were classified as AMD free at baseline were defined as 
being at risk of developing AMD during the follow-up period of the study.  
 
Inverse Probability Weighting 
Of the 2900 individuals at risk of AMD at baseline, 225 were confirmed as deceased 
during the follow up period. This left 2675 individuals eligible for follow up. Of these 
1393 (52%) did not have a valid AMD status at follow up, leaving 1282 individuals 
eligible for inclusion in the incidence study. To take account for any bias due to this 
loss to follow up, inverse probability weights were estimated for individuals who 
© 2017 American Medical Association. All rights reserved.   
were not confirmed as deceased, then this weighting was applied to the estimates of 
incidence. 
Variables found to be associated with loss to follow up were: age group, residence, 
socio-economic status, smoking status, alcohol status, tribe, education level and 
baseline diabetes status. Of those that were followed up, socio-economic status was 
missing for 7 individuals. So these individuals were excluded from the weighted 
estimates, as the number missing was small and socio-economic status was a strong 
predictor of missingness. 
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eTable 1. Change in Presenting Visual Acuity Category in Those With Late AMD at 
Baseline in Those With an AMD Status Available at Both Time Points 
Follow-up 
Baseline 
 
Normal 
Mild 
VI 
Mod 
VI 
Severe 
VI 
Blind Total 
Normal 2 4 1 0 0 7 
Mild VI 0 0 0 0 0 0 
Mod VI 0 0 4 2 3 9 
Severe VI 0 0 0 0 0 0 
Blind 0 0 0 0 1 1 
Total 2 4 5 2 4 17 
The proportion in brackets after each number is the proportion that report either 
baseline or incident AMD (total N=17).  
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eTable 2. Incidence of Appearance and Regression of Individual Features of AMD 
Between Baseline and Follow-up 
 Featur
e 
measur
ed at 
baselin
e and 
follow 
up 
(n) 
Featu
re 
absen
t at 
baseli
ne 
(n) 
Featu
re 
prese
nt at 
follo
w-up 
(n) 
6 year 
cumulativ
e 
incidence 
of feature 
appearanc
e 
(Adjusted 
for LTFU 
using IPW) 
Featu
re 
prese
nt at 
baseli
ne 
(n) 
Featu
re 
abse
nt at 
follo
w-up 
(n) 
6 year 
cumulativ
e 
incidence 
of feature 
regression 
(Adjusted 
for LTFU 
using IPW) 
Small drusen 
1220 446 261 
59.1% 
(53.7%,64.
3%) 
774 188 
24.1% 
(20.6%,28.
0%) 
Large drusen 
1134 1039 196 
19.6% 
(16.3%,23.
5%) 
95 8 
6.8% 
(3.3%,13.5
%) 
GA 
1083 1077 1 
0.3% 
(0.0%,2.0
%) 
6 1 
19.2% 
(0.7%,89.2
%) 
CNV 
1083 1075 2 
0.2% 
(0.0%,0.7
%) 
8 2 
24.6% 
(3.4%,75.4
%) 
Hyperpigment
ation 1090 1050 36 
3.5% 
(2.5%,5.0
%) 
40 30 
77.0% 
(59.5%,88.
4%) 
Hypopigmenta
tion 1088 1053 48 
5.0% 
(3.5%,7.1
%) 
35 21 
58.1% 
(39.7%,74.
4%) 
RPE 
detachment 
1081 1080 0 - 1 1 100.0% 
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LTFU: Loss to follow-up, IPW: Inverse Probability Weighting 
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eTable 3. Change in Presenting Visual Acuity Category From Baseline to Follow-up 
in Cohort With Visual Acuity Data and AMD Status Available at Both Time Points   
Follow-up 
Baseline 
 
Normal Mild VI Mod VI 
Severe 
VI 
Blind Total 
Normal 
1,058 
(21.6%) 
153 
(30.7%) 
103 
(35.0%) 0 (N/A) 
3 
(66.7%) 
1,317 
(23.8%) 
Mild VI 
13 
(23.1%) 
16 
(31.3%) 
22 
(31.8%) 0 (N/A) 0 (N/A) 
51 
(29.4%) 
Mod VI 
9 
(33.3%) 
9 
(55.6%) 
34 
(41.2%) 
7 
(42.9%) 
1 
(0.0%) 
60 
(41.7%) 
Severe 
VI 0 (N/A) 0 (N/A) 
2 
(50.0%) 0 (N/A) 0 (N/A) 
2 
(50.0%) 
Blind 
0 (N/A) 0 (N/A) 
1 
(100.0%) 0 (N/A) 
4 
(50.0%) 
5 
(60.0%) 
Total 
1,080 
(21.7%) 
178 
(32.0%) 
162 
(36.4%) 
7 
(42.9%) 
8 
(50.0%) 
1,435 
(24.9%) 
The proportion in brackets after each number is the proportion that report either 
baseline or incident AMD (total N=1,435) 
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eTable 4. Population-Based Cohort Studies of AMD 
Study 
Locat
ion 
Year 
comm
enced 
Year
s of 
Foll
ow 
up 
No of 
partici
pants 
Age 
at 
Base
line 
Cumul
ative 
incide
nce of 
Early 
AMD 
(%) 
Cumul
ative 
annua
l 
incide
nce of 
Early 
AMD 
(%)* 
Cumul
ative 
(study 
period
) 
Incide
nce of 
Late 
AMD 
(%)** 
Refer
ence 
Nakuru Keny
a 
2007 Base
line 
6 
4414 
2171 
50+  
16.4 
 
2.9 
 
0.2 
This 
paper 
Studies of equivalent age groups 
Blue 
Mount
ain Eye 
Study  
Austr
alia 
1992 Base
line 
5 
10 
3654 
2335 
1952 
49+  
 
14.1 
 
 
1.4 
 
 
3.7 
8 
          
Reykja
vik Eye 
Study  
Icela
nd 
1996 Base
line 
5 
1045 
846 
50+  
10.7 
 
2.1 
 9 
Studies of different age groups 
Beaver 
Dam 
Eye 
Study 
USA 1988 Base
line 
5 
10 
15 
4926 
3684 
2764 
2119 
43-
86 
 
 
12.1 
14.3 
 
 
 
1.0 
 
 
2.1 
3.1 
10-12 
Copen Den 1986 Base 946 60-    13 
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hagen 
City 
Eye 
Study  
mark line 
14 
359 80 31.5 2.3 14.8 
Barbad
os Eye 
Study  
Barb
ados 
1987 Base
line 
4 
9 
4631 
3427 
2793 
40+  
5.2 
12.6 
 
 
1.4 
 
Negligi
ble 
0.7 
14,15 
Hisaya
ma 
Study  
Japa
n 
1998 Base
line 
5 
9 
1482 
961 
1401(>
40yrs) 
40+  
8.5 
10.0 
 
 
1.1 
 
0.8 
1.4 
16,17 
Los 
Angele
s 
Latino 
Eye 
Study  
USA 2000 Base
line 
4 
6357 
4658 
40+  
7.5 
 
1.9 
 
0.2 
18 
*Annual cumulative incidence is calculated as the overall cumulative incidence 
divided by the number of years of follow up, where more than one follow-up visit 
was conducted, the longest one is used. 
**Incident Late AMD considered as those without Late AMD (no AMD or Early AMD 
at baseline). 
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eTable 5. Unweighted for Missing Data (Complete Case Records Only) Age-and 
Sex-Specific 6-Year Cumulative Incidence of AMD Among the Nakuru Eye Disease 
Cohort Study Participants 
 Male Female Overall 
Age 
Grou
p 
(years
) 
N 
(Case
s / at 
risk) 
Risk per 
1,000/6yrs 
(95%CI)* 
N Risk per 
1,000/6yrs 
(95%CI)* 
N Risk per 
1,000/6yrs 
(95%CI)* 
50-59 29 / 
288 
100.7(66.0,150.7
) 
60 
/ 
36
9 
162.6(123.5,211.
1) 
89 / 
657 
135.5(103.5,175.
3) 
60-69 33 / 
221 
149.3(107.2,204.
2) 
38 
/ 
19
7 
192.9(141.9,256.
7) 
71 / 
418 
169.9(137.6,207.
9) 
70-79 20 / 
104 
192.3(128.5,277.
7) 
13 
/ 
66 
197.0(113.2,320.
4) 
33 / 
170 
194.1(144.8,255.
2) 
80+ 4 / 22 181.8(70.6,394.0
) 
5 / 
15 
333.3(137.5,610.
6) 
9 / 
37 
243.2(131.3,406.
0) 
All 
ages 
86 / 
635 
135.4(108.0,168.
5) 
11
6 / 
64
7 
179.3(145.3,219.
2) 
202 
/ 
128
2 
157.6(132.3,186.
6) 
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eTable 6.  Side by Side Image Comparison Between Baseline and Follow-up  
Baseline – TopCon NRW6  Followup – Haag Streit DRS 
CentreVue 
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Abstract 
Background 
Glaucoma is a leading cause of blindness in low and middle-income countries with 
people of African descent being at higher risk of early onset glaucoma and 
subsequent vision loss. Minimal data is available from African population-based 
cohort studies. The primary aims of this study were to describe the normative 
distribution of glaucoma features to enable glaucoma classification and to assess risk 
factors for those with glaucoma at follow-up among people aged ≥50 years in Kenya. 
 
Methods 
Random cluster sampling with probability proportionate to size was used to select a 
representative cross-sectional sample of adults aged ≥50 years in 2007-8 in Nakuru 
District, Kenya. A six-year follow-up was undertaken in 2013-14. On both occasions 
a comprehensive ophthalmic examination was performed including LogMAR visual 
acuity, digital retinal photography, visual fields, intraocular pressure, anterior 
chamber OCT and independent grading of optic nerve images. Data were collected 
on general health and risk factors. We report glaucoma features, prevalence and 
predictors for glaucoma based on the ISGEO criteria at follow-up. These measures 
were estimated for each covariate using a Poisson regression model with robust 
error variance to allow for the clustered design and including inverse-probability 
weighting for loss to follow up.  
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Results 
At baseline, 4,414 participants aged ≥50 years underwent examination. Anterior 
chamber OCT findings: mean anterior chamber angle of 36.6°, mean central corneal 
thickness of 508.1µm and a mean anterior chamber depth of 2.67mm. 2,171 
participants were examined at follow-up. Only five eyes (0.2%) having occludable 
angles based on Scheie grading using gonioscopy. The mean baseline IOP in those 
examined at baseline and follow up was 15.4mmHg and 14.6mmHg in the right and 
left eyes, respectively. The VCDR distribution based on images in those with normal 
visual fields at follow up was 0.7 and 0.8 at the 97.5th and 99.5th percentiles, 
respectively. A total of 88 (4.3%, 95% CI, 3.5-5.9%) of participants at follow-up had 
glaucoma consistent with ISGEO criteria. A RAPD and raised IOP were associated 
with the diagnosis.  
Conclusions 
Glaucoma is a challenging disease to diagnose and treat in low-resource settings and 
it remains a public health concern with the lack of cost-effective treatments Further 
research in to the natural history and risk for progression of glaucoma in Africa is 
required, as well as the development and testing of treatment modalities. 
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Introduction 
Glaucoma is a leading cause of blindness globally. [1] The proportion of the 
worldwide magnitude of blindness attributable to glaucoma increased by 50% 
between 1990 and 2010 from 4.4% to 6.6%.[2] This trend is expected to continue 
over coming decades, with the estimated numbers with glaucoma predicted to rise 
from 60.5 million people in 2010 to 79.6 million by the year 2020 [3] and then to 
111.8 million by 2040 [4] Glaucoma is the second most common cause of blindness 
in sub-Saharan Africa (SSA), [5] with estimates suggesting that there were 6.5 million 
people with glaucoma in SSA in 2010 projected to increase to 8.4 million by 2020, 
though data are sparse.[6] 
Whilst blindness from glaucoma may be preventable, this is dependent upon early 
diagnosis and delivery of long-term effective treatment. Glaucoma poses a particular 
problem in sub-Saharan Africa due to both higher age-specific prevalence, higher risk 
for open-angle glaucoma, [7-10], late presentation [11] and low levels of coverage 
and adherence with treatment. [12, 13] Adherence to topical treatment is 
sufficiently poor that the primary treatment of choice in SSA is often surgery [5] in 
the hope that a single intervention achieves long term control of intra-ocular 
pressure (IOP) as the main modifiable risk factor. [11-13] Furthermore, clinical 
features of glaucoma may be different in a sub-Saharan African setting compared to 
elsewhere, necessitating different therapeutic approaches. 
The objectives of this study were therefore, within the context of a population-
based cohort study in Nakuru, Kenya: i) to describe normative features of glaucoma 
in this cohort, ii), to describe the prevalence of glaucoma or specific glaucoma 
features at baseline and at follow up, iii) to assess baseline risk factors for having 
 6 
glaucoma  at follow up and iv) to describe clinical signs predictive of glaucoma at 
follow up. [14] The distribution of key features of glaucoma (optic nerve 
morphology, intraocular pressure, visual acuity, angle morphology) and the risk 
factors associated with changing optic disc morphology that occurred over the six 
year follow up period will also be described.  
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Methods 
Ethics Statement 
The London School of Hygiene & Tropical Medicine (LSHTM) Ethics committee and 
the African Medical Research Foundation (AMREF) granted ethical approval for the 
study. Approval was also granted by the Provincial Medical Officer for Nakuru 
County. Written approval was sought from the administrative heads in each cluster, 
usually the village chief. All participants gave written or thumbprint consent to 
participate. People requiring medical treatments were referred to the appropriate 
health care service. 
 
Sampling Strategy and Recruitment 
The study baseline fieldwork was carried out between January 2007 and November 
2008. The follow-up study took place between October 2012 and March 2014. At 
baseline, 100 clusters were selected across Nakuru County with a probability 
proportional to the size of the population using the electoral roll as the sampling 
frame. A cluster was defined as the area served by a polling station. Households 
were selected within clusters using a modified compact segment sampling method 
[15]. Each cluster was divided into segments so that each segment included 
approximately 50 people aged ≥50 years. One segment was selected at random, and 
all eligible people were included sequentially until 50 had been examined.  
The sample size of 5000 people was sufficient to estimate a prevalence of disease at 
3.0% among those aged ≥50 years, with a required precision of 0.5%, 95% 
confidence, a design effect to account for clustering of 1.5, and a response rate of 
90% (Epi Info 6.04, Centers for Disease Control and Prevention, Atlanta, GA). In 
 8 
total, 4,381 participants were recruited at baseline (response rate 81%). All 
participants were invited to attend an examination clinic at a central location within 
the cluster (see below). 
 
Follow-up 
Approximately one week before the follow-up examination clinic was carried out 
for a given cluster, a field officer studied the maps of the village including GPS 
coordinates recorded at baseline and made phone contact with the village chief or 
guide to arrange the visit. At the planning visit a list of study participants were given 
to the chief and a local village guide was recruited to assist locating the study 
participants. Two days prior to the clinic, the field officer reminded chiefs of the visit 
by phone and notified them and the guide of the advance team’s arrival. On the day 
prior to the examination clinic, a study team visited homes of baseline participants 
and confirmed their identity using National Identity cards and invited them to attend 
the examination clinic the following day.  All identified participants were also asked 
to help locate baseline participants that had not been found. 
On the examination day, the advance team confirmed the identity of participants 
against data from baseline (age, date of birth, name, and identity cards). In cases of 
uncertain identity, confirmation was made based on retinal examination verified by 
comparison of retinal photos with baseline photo (n=12). 
In both baseline and follow-up, an examination clinic was established at a central 
location where there were appropriate amenities such as electricity, water and road 
access. The following examination protocols were implemented at both baseline and 
follow-up. [14, 16] 
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Ophthalmic and General Examination 
 
Visual Acuity 
All participants at baseline and follow-up underwent visual acuity testing on each eye 
separately at four meters using a reduced LogMAR tumbling ‘E’ chart [17] in an 
appropriately illuminated area, as described elsewhere.[18, 19] The presenting visual 
acuity was defined as the number of letters read correctly without glasses if the 
participant did not have glasses, or with glasses if they had them. 
 
Anterior Segment Examination 
At baseline the anterior segment assessment was made on the slit lamp by a single 
ophthalmologist (WM). The Van Herick angle assessment was performed. [20]  
 
Anterior Chamber OCT 
Gonioscopic assessment of the angle was not undertaken, however a Heidelberg Slit 
Lamp-adapted Optical Coherence Tomography (SL-OCT) (Heidelberg Engineering, 
Heidelberg, Germany) was used at baseline to examine the anterior segment to 
provide population normative data on the Angle Opening Distance (AOD), Anterior 
Chamber Angle (ACA), Central Corneal Thickness (CCT) and Anterior Chamber 
Depth (ACD). These normative data analyses excluded eyes that were 
pseudophakic. Furthermore, eyes with trachomatous or non-trachomatous corneal 
opacities and those with disorganized globes (phthisis, staphyloma) were excluded 
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from the corneal thickness analysis. All measurements were obtained from scans 
using the interactive distance measurement of the SL-OCT proprietary software 
(Heidelberg Eye Explorer v1.5.9.0; Heidelberg Engineering, Heidelberg, Germany). 
Analyses based on naso-temporal (horizontal) meridians. Anterior chamber depth 
was assessed using peaks of the corneal reflectivity profile to identify the central 
cornea as well as the anterior and posterior boundaries of the cornea. Calipers 
were aligned from the posterior border of the central cornea. Two measurements 
were averaged for each eye. Anterior chamber angle opening distance was taken as 
posterior cornea and opposite peripheral iris with the apex lying in the angle recess.  
All anterior segment measurements were taken with the pupil undilated.  
 
Gonioscopy 
At follow-up, an assessment of the opening angle of participants’ right and left eyes 
using direct visualisation was made using a four-mirror gonioscopy lens (Zabbys).  
This lens does not require coupling fluid and was chosen to minimize impact on the 
quality of retinal photographs. Angles were recorded using standard Shaffer grading  
and further classified as “open”, “occludable” or “closed” based on standard referral 
criteria. [21] Angle OCT was not performed at follow-up. Occludable angles were 
defined at follow up as: pigmented trabecular meshwork not visible in 3⁄4 or more 
of angle circumference in primary position without manipulation, in presence of low 
illumination. If the patient could not cooperate with gonioscopy, the Van Herick 
(VH) technique [20] was used for grading with an anterior chamber depth of less 
than quarter of the corneal thickness being considered occludable.  
 11 
 
Intraocular Pressure (IOP) 
At baseline and follow-up participant’s eyes were anesthetized using tetracaine 1% 
eye drops (Kenya Society for the Blind, Eye Drop Production Unit, Nairobi, Kenya) 
and the tear film stained with fluorescein-impregnated paper. IOP was measured 
using a Goldmann Applanation Tonometer. One reading was taken from each eye 
and analysed independently. The tonometer was checked for calibration weekly and 
disinfected between patients. 
 
Visual Field Assessment  
At baseline, all individuals with suspect or abnormal discs on clinical slit-lamp 
examination underwent automated visual field testing. The Humphrey® Field 
Analyzer II - 720i series (Carl Zeiss Ophthalmic Systems, Inc.) was used. A suspect 
or abnormal disc was defined as a vertical cup to disc ratio (VCDR) of 0.7 or above; 
optic disc cupping asymmetry between the eyes of more than 0.2 VCDR; or any 
other abnormal features including notching, disc haemorrhages or disc pallor. A 
random sample of five individuals per cluster (10%) also underwent visual field 
testing to provide normative data.  
Participants performed the Swedish Interactive Thresholding Algorithm (SITA) 
STANDARD 24-2. SITA Fast was used to determine the threshold level in all 
participants having visual field analysis. Appropriate corrective lenses for refractive 
errors were used when needed. An automated fixation monitor was used 
throughout. If the SITA fast test was reliable the SITA standard test was performed. 
If the SITA fast was unreliable (false-positives, ≥20%; false-negatives, ≥33%; fixation 
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losses, ≥33%), then this was repeated once. If it remained unreliable then no further 
testing was done. 
 
At follow-up, a different strategy for visual field testing was used due to challenges at 
baseline: All subject’s eyes with VA equivalent to >=6/60 Snellen underwent 
automated visual field testing by a trained visual field technician using the Henson 
8000 Visual Field Analyser (TopCon, Inc.) The multiple stimulus suprathreshold test 
was used following manufacturers guidelines (Screening test - 26 test locations). 
When one or more spots were missed, the 26-point test was repeated for that eye. 
If any missed spots re-occurred on the second time of testing the test for that eye 
was extended to 68 test locations. This machine and strategy were used in 
preference to the baseline methods due to feedback from both patient’s and tester 
at baseline as well as unreliable visual field data from baseline. Patient’s found the 
baseline testing protocol difficult to understand and the time required to complete 
the test meant only a sub-sample of the population could be investigated. 
 
Visual fields were considered consistent with glaucoma at baseline and follow-up if: 
(1) The test was reliable according to performance indices 
(2) The glaucoma hemifield test was outside normal limits, and 
(3) The test showed three or more abnormal contiguous points clustering in the 
same hemi field.   
Visual Fields were graded at the Moorfields Eye Hospital Reading Centre.  
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Fundus photography and grading 
The participants had two non-stereoscopic digital 45o fundus photographs taken per 
eye by an ophthalmic clinical officer using a TRC-NW6S Non-Mydriatic Retinal 
Camera with 10 megapixel Nikon D80 (TopCon®) at baseline and a DRS 
CentreVue+ (Haag-Streit) Retinal Camera at follow-up. One image was centered on 
the optic disc while the other was centered on the macula.  
The digital images were forwarded to the Retinal Grading Centre at Moorfields Eye 
Hospital Reading Centre (MEHRC) London for grading and confirming the clinical 
diagnosis of posterior segment disease.  
The senior grader graded all discs considered abnormal on clinical examination at 
the slitlamp at baseline and all optic nerve images at follow-up. Images were first 
categorized for quality as excellent, good, fair, borderline or ungradeable. They were 
then graded for vertical cup disc ratio (VCDR). The scleral ring was identified to 
determine the margins of the disc and delineating the rim identified the cup. The rim 
was defined as the area between the border of the optic disc and the position of 
blood vessel bending and the area within the rim as the cup. A vertical measure of 
both the cup and disc were taken to calculate the VCDR. Discs images were also 
examined for any abnormality and were graded as normal, suspicious or abnormal. A 
disc was deemed abnormal if any of neuro-retinal rim (NRR) thinning, notching or 
disc hemorrhage(s) were present, if VCDR was ≥0.7. A suspicious disc was one 
where adjudication was necessary to determine if its appearance was abnormal. 
In case of difficulties, the adjudicator (TP) decided on the grading of the images. The 
adjudicator also graded 5% of randomly selected images to ensure quality control.  
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At baseline only a subset (10%) of optic discs were graded based on images with all 
participant’s receiving a clinical slit lamp grading and estimation of VCDR. At follow-
up, all participants’ discs were estimated based on image grading.  
 
Data Handling & Statistical Analyses Methods 
Data entry 
Image data were double entered into a specially developed dataset (EpiData Entry v 
2.1) at both baseline and follow up. Consistency checks were performed each 
evening and inconsistencies corrected the same day.  
Data analysis 
The International Society for Geographical & Epidemiological Ophthalmology 
(ISGEO) categorises glaucoma in to Primary Open Angle Glaucoma (POAG) and 
Primary Angle Closure (PAC) based on direct viewing of the angle. POAG is defined 
in three categories based on the optic nerve VCDR, visual fields, IOP, VA and the 
presence or absence of previous glaucoma surgery (clinically or from medical 
records). [22] The mean, 97.5th and 99.5th percentiles were calculated for optic disc 
VCDR and IOP for the participants at follow-up. Based on baseline normative data 
the cut off points required for ISGEO POAG classifications were used to classify 
accordingly: [22] 
• Category 1 with structural and functional evidence: Eyes with a 
VCDR or VCDR asymmetry ≥97.5% for the normal population that showed 
a definite visual field defect consistent with glaucoma 
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• Category 2 (advanced structural damage with unproven field loss): 
Eyes of those without any or with no valid visual field testing but with a 
VCDR or asymmetry ≥99.5th percentile for the normal population. 
• Category 3 (no view of optic disc and field testing impossible): Eyes 
of those with VA<3/60 and the IOP>99.5th percentile, or VA<3/60 and 
evidence of glaucoma filtering surgery, or previous diagnosis of glaucoma 
confirmed from medical records. 
Glaucoma suspects were defined as: 
! field suspects: those with abnormal visual fields consistent with glaucomatous 
changes but no raised IOP, disc damage or features consistent with 
trabecular obstruction,  
! disc suspects: those with VCDR ≥97.5th percentile for the population but less 
than the 99.5th percentile and no other feature of glaucoma and no 
documented field defect. It also included those with optic disc hemorrhages 
accompanied by no other feature of glaucoma  
! Ocular Hypertensives: IOP ≥97.5th percentile with normal optic disc and 
normal visual field 
 
A normative sample was used to calculate the 97.5th and 99.5th percentiles of VCDR 
and IOP from those participants examined at follow-up with normal visual fields. 
 
Baseline to follow-up changes 
It was not possible to produce an annual glaucoma incidence due to the lack of 
reliable visual field data and optic discs graded from images at baseline and therefore 
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it was not possible to define an “at-risk” baseline group. Individuals at follow-up 
were classified as suspect or definite glaucoma based on ISGEO criteria using graded 
images of the optic disc and visual fields. Participants at follow up were then 
classified in a binary manner as normal or glaucoma (glaucoma if ISGEO categories 1, 
2 or 3 were fulfilled for that participant). Multivariable logistic regression analyses 
were conducted to compare those with and without features of glaucoma at follow-
up in terms of baseline demographic, anthropometric and ocular features as 
potential risk factors of glaucoma.   
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Results 
Follow up rates 
At baseline, 4,414 participants had a complete assessment and 2,171 participants 
were seen at follow up. Characteristics of participants and non-participants at six-
year follow-up are described in detail elsewhere.[23, 24] In summary, compared 
with those followed-up, participants who had died during follow-up were older, 
more likely to be male, to have lower education levels and higher systolic blood 
pressure and be diabetic, but had lower BMI. Compared with participants seen, 
those lost to follow-up (not known to be deceased) were less likely to be Kikuyu or 
Kalenjin speakers, had lower levels of education, and were more likely to be from 
urban areas and be from either the highest or lowest socioeconomic quartile.  
 
Anterior Chamber OCT 
Anterior)segment)findings)at)baseline)using)OCT)are)described)in)Table)1,)the)mean)
angle)opening)distance)(n=6,259))was)631µm)(SD:167),)the)mean)anterior)chamber)
angle) (n=3,484)) was) 36.6°) (SD:7.6),) the)mean) central) corneal) thickness) (n=6,365))
was) 508.1) µm) (SD:36.9),) and) the) ) mean) anterior) chamber) depth) (n=6,358)) was)
2.67mm)(SD:0.32))
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Table 1. OCT Summary of normative findings of the anterior segment at baseline 
 Right Eye Left Eye Both eyes 
N 3115 3144 6259 
Mean Angle 
Opening Distance 
(µm)  (SD) 
620(164.5) 637(179.5) 631(167.3) 
N 1774 1807 3484 
Mean Anterior 
Chamber Angle 
(SD) 
36.3(7.7) 37.0(7.5) 36.6(7.6) 
N 3179 3186 6365 
Central Corneal 
Thickness (µm) 
(SD) 
507.7(35.7) 508.5(38.1) 508.1(36.9) 
N 3177 3181 6358 
Anterior 
Chamber Depth 
(mm) (SD) 
2.66(0.32) 2.68(0.32) 2.67(0.32) 
 
Gonioscopy 
Anterior Segment OCT was not available at follow-up, however 2,111 right eyes and 
2,107 left eyes had a direct visualisation of the angle using a 4-mirror gonioscope, 
with only five right and five left eyes (0.2%) considered to have occludable angles 
(based on visualisation of Schwalbe’s line and the anterior meshwork or less). Table 
2. 
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Table 2. Gonioscopic grading of the angle in the follow-up of the Nakuru Eye 
Disease Cohort Study 
Gonioscopic visualisation (Grade) Right Eye Left Eye 
Nil (0) 0 (0%) 2 (0.1%) 
 Schwalbe’s line and anterior meshwork (1) 5 (0.2%) 3 (0.1%) 
Posterior pigmented meshwork (2) 90 (4.3%) 98 (4.7%) 
Scleral Spur (3) 797 (37.8%) 809 (38.4%) 
 Ciliary Band (4) 1219 (57.8%) 1195 (56.7%) 
  
 
Intraocular Pressure 
The mean IOP at baseline based on 3,745 observations (right eye only) was 
15.3mmHg (SD 3.4, Range 2-46mmHg). Of these, there were 1,775 observations 
(right eyes only) for whom IOP was measured at both baseline and follow-up. 
Among these, at baseline mean IOP was 15.4 (SD 3.4) for the right eye, and at 
follow-up (right eyes) was 15.0mmHg (SD 3.2, Range = 1-34mmHg), providing 
evidence of a lower IOP at follow up compared to baseline among right eyes 
(p<0.001). IOP was significantly higher in the right eye than the left eye at both 
baseline (p<0.001) and follow-up (p=0.02). See Table 3 
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Table 3. Intraocular Pressure in the Nakuru Eye Disease Cohort 
 Baseline (whole 
sample) 
Baseline who 
were followed up 
Follow up 
 Right Eye 
(n=3,745) 
Left Eye 
(n=3,746) 
Right Eye 
(n=1,784) 
Left Eye 
(n=1,776) 
Right Eye 
(n=1,784) 
Left Eye 
(n=1,776) 
Mean 
pressure 
(mmHg) 
15.3 14.5 15.4 14.6 15.0 14.9 
Sample 
Standard 
Deviation 
3.4 3.0 3.4 2.9 3.3 3.2 
Confidence 
Interval for 
Estimate 
15.2-15.4 14.4-14.6 15.2-
15.6 
14.5-
14.7 
14.9-15.2 14.7-15.0 
97.5th 
Percentile 
(95% CI) 
22.0 
(20.0-
22.0) 
20.0 
(20.0-
20.0) 
22.0  
(20.0-
23.0) 
20.0 
(20.0-
20.0) 
22.0 
(21.0-
23.0) 
21.0 
(21.0-
22.0) 
99.5th 
Percentile 
(95% CI) 
28.0  
(27.0-
28.0) 
24.0 
(23.5-
28.0) 
28.0 
(25.3 -
29.9)  
25.1 
(22.3-
27.9) 
27.1 
(25.0-
28.9) 
26.0 
(24.0-
28.9) 
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Optic discs 
At baseline, due to camera failure preventing image acquisition in one third of 
clusters, a slit lamp based clinical assessment of the optic disc vertical cup to disc 
ratio (VCDR) was made in two ways:  
1. Through undilated pupils with +90D lenses using slit lamp biomicroscopy 
(n=5,917 eyes) 
2. After dilating pupils with +90D lenses using slit lamp biomicroscopy (n=7,821 
eyes) 
 
Baseline optic disc assessment is summarised in Table 4.1,063 (25.7%) Right Eye 
discs and 1,078 (25.8%) Left Eye Discs could not be visualised with undilated pupils. 
There was a statistically significant difference between the mean VCDR for eyes with 
pupils dilated and non dilated pupils where the disc was visible in both instances, 
with the dilated eyes having higher VCDR ratios (0.23, SD 0.15) than non dilated 
eyes (0.21, SD 0.13) (paired t test<0.001). Using undilated CDR 1.5% of eyes had 
CDR≥0.7 while using dilated CDR, 2.8% of eyes had VCDR≥0.7 (X2=13.8 p=0.002). 
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Table 4. Baseline clinical (undilated and dilated) optic disc assessment made at the 
slit lamp  
 
 
  
 Undilated assessment Dilated assessment 
 
Right 
VCDR 
(95%CI) 
Left     
VCDR 
(95%CI) 
Right 
and Left 
(95%CI) 
Right   
VCDR 
(95%CI) 
Left 
VCDR 
(95%CI) 
Right and 
Left 
(95%CI) 
Number 2958 2959 5917 3906 3915 7821 
0.5th 
Percentile 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
2.5th 
Percentile 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
0.1(0.1-
0.1) 
Mean(SD) 0.21 (0.14) 0.22 (0.13) 0.21(0.13) 
0.23 
(0.16) 
0.23 
(0.15) 
0.23(0.15) 
97.5th 
Percentile 
0.6(0.5-
0.6) 
0.6(0.5-
0.6) 
0.6(0.5-
0.6) 
0.7(0.6-
0.7) 
0.6(0.6-
0.7) 
0.7(0.6-
0.7) 
99.5th 
Percentile 
0.8(0.8-
0.9) 
0.8 (0.7-
0.9) 
0.8(0.8-
0.8) 
0.9(0.8-
1.0) 
0.84(0.8-
0.9) 
0.9(0.8-
0.9) 
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At follow up, the VCDR for right and left eyes from image grading were available in 
all clusters from 3,658 of a possible 4,342 eyes (2,171 people). The median VCDR 
was 0.3 and at the 97.5th and 99.5th percentile it was 0.7 and 0.8 respectively. See 
Figure 1. 
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Figure 1. The distribution of VCDRs at follow up from retinal images 
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The VCDR percentiles at follow-up in those with a normal visual field (n=1062) 
remained at 0.7 and 0.8 at the 97.5th and 99.5th percentiles respectively.  
 
At baseline, 3,251 participants had a clinical assessment (i.e. no image grading) of the 
optic discs, of which 40 (1.2%) were considered abnormal, 536 (16.5%) suspicious 
and 2,675 (82.3%) normal. At follow-up, 2,003 participants had an image-based 
assessment of the optic discs, of which 64 (3.2%) were graded as abnormal, 234 
(11.7%) suspicious and 1,705 (85.1%) were normal. 89 of 1,255 (7.1%) participants 
who had a baseline (clinical) and follow-up (image) assessment went from “normal” 
to either “suspicious” or “abnormal”. Of the 1,499 participants who had optic discs 
graded at both baseline (clinical) and follow-up (image)17l (1.1%) were considered 
abnormal, 236 (15.7%) suspicious and 1246 (83.1%) as normal at baseline. At follow 
up there were 53 (3.5%) considered abnormal, 174 (11.6%) suspicious and 1272 
(84.9%) normal. 
 
Visual Fields 
Interpretation based on visual fields was not possible at baseline. A total of 508 
participants (glaucoma suspects and non-glaucoma suspects) were indicated for 
visual field testing at baseline of whom 342 (67.3%) completed the test on the 
Humphrey Visual Field Analyser. Of these, 63.2% and 69.1% of normal and glaucoma 
suspects had abnormal visual field results despite good reliability indices. These 
baseline results were therefore discarded. 
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 At follow-up, 1,309 (60.3%) participants successfully completed fields on the 
Henson 8000 Field Analyser with reliable results. 1,074 (82.0%) were normal in both 
eyes, 122 (9.3%) had one or both eyes with suspicious fields and 113 (8.6%) had an 
abnormal field in one or both eyes.  
Based on gradable optic disc images at follow-up in those with normal visual fields, 
the 97.5th and 99.5th percentile VCDRs were 0.7 and 0.8 respectively (Fig 1).  
 
Signs of glaucoma 
At follow-up, 1,246 individuals had a VF measurement and a disc grading. Of these, 
895 (71.8%) had both a normal VF and a normal disc, 141 (11.3%) had a normal VF 
and suspicious or abnormal disc, 182 (14.6%) had a suspicious or abnormal VF and 
normal discs and 28 (2.2%) had both suspicious or abnormal VFs and suspicious or 
abnormal discs.  
Using the ISGEO classification 88 participants were considered to have glaucoma 
based on meeting either the ISGEO 1 (n= 64), 2 (n=22) or 3 (n=2) criteria, 1,973 
participants did not meet ISGEO criteria and were deemed non-glaucoma, 110 could 
not be classified. (Figure 2) 
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Figure 2. The ISGEO Classification of the Nakuru Eye Disease Cohort follow-up 
group 
 
No ISGEO status due to missing data 
Based on follow up optic disc grading from images, visual fields, IOP and visual 
acuity, participants were defined as glaucoma positive or negative based on the 
ISGEO criteria.  Vision status comparing participants with and without ISGEO 
glaucoma are described in Table 5 showing participants with glaucoma were more 
likely to have visual impairment. 85.2% of the non-glaucoma group classified as 
normal vision, compared to 72.7% in the glaucoma group. Blindness and VI were 
more prevalent in the glaucoma group, 5.7% and 21.6% respectively compared to 
those without glaucoma, 1.2% and 13.6% respectively.  
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Table 5 . Visual status of participants at follow-up with and without glaucoma  
ISGEO 
Normal 
vision 
(6/12) 
[%] 
Visually 
impaired 
(<6/12-
3/60) 
[%] 
Blind 
(<3/60) 
[%] 
Negative 
(N=1972) 1680 [85.2] 269 [13.6] 23 [1.2] 
Positive 
(N=88) 64 [72.7] 19 [21.6] 5 [5.7] 
 
 
Baseline and follow-up risk analyses was conducted and is summarised in Table 6. 
Associations with glaucoma was evident for several baseline factors.  
Moderate association was found with participants being more likely to be 
categorised with glaucoma if they were of male gender (Male as baseline, Female 
OR: 0.69, 0.45-1.06, p=0.097).  
No association was found between baseline IOP and BMI (p=0.49), height (p=0.58) 
and weight (p=0.28). Associations with ophthalmic signs at follow up were seen for 
both IOP (IOP>21mmHG OR: 4.10 (95%CI, 2.08-8.08), p<0.001) and a relative 
afferent pupillary defect (RAPD) showing a particularly strong association with being 
categorised as glaucoma (Confirmed RAPD OR: 7.39 (4.20-13.01), p<0.001).  
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Table 6.Association of anthropometric risk factors at baseline and ophthalmic risk factors at 
follow-up with glaucoma at follow-up 
  
  
* Follow-up risk factor 
 
 
Category 
N 
total Abnormal 
Percent
age 
Odds 
Ratio 
Lower 
95% 
CI 
limit 
Upper 
95% 
CI 
limit p-value 
Gender Male 989 50 5.1% 1.00 ) ) 
0.10   Female 1072 38 3.5% 0.69 0.45 1.06 
Location Rural 1559 60 3.8% 1.00  ) 
0.13   Urban 502 28 5.6% 1.48 0.93 2.34 
Socio 
Economic 
Status Poorest 464 23 5.0% 1.00 ) ) 
0.53 
  Poorer 574 20 3.5% 0.69 0.38 1.28 
  Richer 532 27 5.1% 1.03 0.58 1.81 
  Richest 480 17 3.5% 0.70 0.37 1.34 
Tribe Kikuyu 1336 58 4.3% 1.00  ) 
0.19 
  Kalenjin 507 16 3.2% 0.72 0.41 1.26 
  Other 218 14 6.4% 1.51 0.83 2.76 
BMI 
Category Underweight 195 9 4.6% 1.00 ) ) 
0.69 
  Normal 913 36 3.9% 0.85 0.40 1.79 
  Overweight 540 27 5.0% 1.09 0.50 2.36 
  Obese 340 12 3.5% 0.76 0.31 1.83 
Hypertensive No 1250 54 4.3% 1.00  ) 
0.84   Yes 799 33 4.1% 0.95 0.61 1.49 
Diabetic No 1839 77 4.2% 1.00 ) ) 
0.58   Yes 221 11 5.0% 1.20 0.63 2.29 
Education 
level 
reported None 186 6 3.2% 1.00  ) 
0.49 
  Primary 624 26 4.2% 1.30 0.53 3.22 
  Secondary 1034 50 4.8% 1.52 0.64 3.61 
  College/Uni 215 6 2.8% 0.86 0.27 2.72 
CCT 
  <=550 1484) 55) 3.71%) 1.00) )) )) 0.44)
 >550 160) 4) 2.50%) 0.67) 0.24) 1.86) )
RAPD* No 1,831 57 3.11% 1.00 ) ) 
<0.001   Yes 99 19 19.19% 7.39 4.20 13.01 
IOP* <=21 1,920 75 3.91% 1.00 ) ) 
<0.001   >21 77 11 14.29% 4.10 2.08 8.08 
Gonioscopy* Open 2040 87 4.26% 1.00   0.28 
 Occludable 8 1 12.50% 3.21 0.39 26.35  
  ) ) ) ) ) )  
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Discussion 
In this study we have described the population distributions and normative ranges 
from an epidemiological survey of glaucoma in an East African population in Kenya. 
Structural damage manifest by optic nerve changes was comparable in terms of the 
population distribution to other studies (described below). In those with glaucoma 
at follow-up, the strongest predictors were the presence at follow-up of an RAPD 
and IOP above 21mmHg. No demographic or anthropometric risk factors were 
associated with glaucoma.  
The prevalence of glaucoma on those followed up was 4.3% (CI, 3.5-5.9) which is 
comparable to other population based studies in Africa which range from 4.2% (3.5-
4.9) to 7.3% (5.5-9.1)[25, 26] with a higher prevalence in west African populations 
(Nigeria 5.0% (4.6-5.5) and 7.3% (5.5-9.1),[26] Ghana 6.5% (5.8-7.1)[27]) than is East 
and Southern African populations (Tanzania 4.2% (3.5-4.9),[25] South Africa 4.5% 
(3.2-6.1)[28] and 5.3% (3.9-7.1)[29]). 
The basis of the diagnosis of glaucoma in the majority of cases, both in clinical 
settings and in population based surveys, is correlation of structural optic nerve 
damage and loss of function demonstrated by visual field testing.[30] However, in 
SSA, where equipment constraints are considerable,[31] visual field testing is not 
widely available. A survey in Lagos State, Nigeria identified one visual field analyser 
for every 2,380,000 population including private and governmental facilities. [32] 
Even where field analysers are available, they are of much less importance in the 
diagnosis and treatment decision making process than in more resource intense 
settings; visual field changes were a factor in only 4% of treatment decisions in a 
review of 344 patients attending a glaucoma clinic in South African.[33] 
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additional problem due to lack of availability; Population based studies have 
demonstrated that there are substantial difficulties in achieving adequate field testing 
in SSA populations. [34] 
The lack of a reliable visual field in the baseline of this cohort is consistent with 
other studies in the region that have faced similar challenges such as the Nigerian 
National Blindness Survey that used a relatively simple testing modality, the 
Humphrey Frequency Doubling Technology test, where adequate testing was only 
available for 60% of 4,538 Nigerian patients.[34] Furthermore, the logistical 
problems obtaining reliable visual field tests mean that they were not included in the 
flow chart for community diagnosis of glaucoma in a recently published West 
African algorithm; relative afferent pupillary defect testing was the chosen test of 
nerve function,[35] which the findings of this study concur with. 
  
Diagnosis and management of glaucoma in SSA, therefore, centres very much 
around IOP and optic nerve assessment, the latter through direct visualisation and 
pupil assessment. Very little data from longitudinal population-based cohorts exist, 
with none to date from SSA, on glaucoma. This cohort study of people aged 50+ 
undertaken in Nakuru, Kenya, with baseline in 2007-8 and follow-up in 2013-14 was 
an opportunity to estimate the normative range of various features of glaucoma as 
well as potential features that are important for clinical decision making in a context 
where availability of equipment is limited.  
The percentile distributions of optic nerve VCDR and IOP in the Nakuru Cohort 
follow-up subgroup in whom image grading was available was very similar to the 
Nigeria National Blindness survey, a nationally representative survey of adults 40 
 32 
years and older, which is to our knowledge the only National survey in SSA to 
derive percentile values for defining glaucoma in population-based surveys. [36].  At 
the 97.5th and 99.5th percentiles the VCDR in Kenya was 0.7 and 0.8 respectively and 
0.75 and 0.95 in Nigeria (in all the population with gradable disc images). The median 
VCDR was lower in Kenya at 0.23 compared to 0.4 in Nigeria. [36]. Our findings are 
also consistent with other population-based studies in the region where a VCDR of 
0.7 was consistent at the 97.5th percentile however greater variation is found at the 
99.5th from 0.7 in Tanzania to 0.9 in South Africa. [27, 29, 37, 38] 
The IOP distribution in Kenya was similar at baseline and follow-up with a higher 
median than in Nigeria (15 vs. 14mmHg) but lower IOP at the 97.5th and 99.5th 
percentiles (Kenya: 22, 27mmHg vs. Nigeria: 24, 34mmHg).[36]  
 
Changes over the period of the cohort were difficult to define conclusively due to 
the clinical nature of a glaucoma diagnosis, however a strong association between 
optic discs and visual fields considered to be outside of normal range was 
demonstrated, in particular with the relative afferent pupil defect (RAPD) test. An 
IOP over 21mmHg was also less strongly associated with glaucoma as defined by the 
ISGEO criteria in this study. The findings suggest a combination of optic nerve 
assessment by both visualisation including VCDR grading as well assessing function 
through the RAPD test are practical means for identifying individuals who have or 
are at risk of sight loss from glaucoma. Portable tools for assessing vision [39] and 
optic disc imaging [40] may make this more accessible with IOP being a suitable 
method to monitor an effect from treatment and various handheld tools now 
available for accurate IOP assessment independent of a slit lamp.  
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Management of glaucoma remains a major challenge in SSA with limited availability 
and poor adherence to medical treatment when available. A primary surgical 
approach has problems also, in that patients presenting due to visual loss in one eye 
need to be persuaded to undergo surgery, most frequently with direct financial costs 
to them, in the other eye which they do not as yet consider to have a problem. [11, 
41] The operation of choice, trabeculectomy augmented by anti-metabolites, does 
not improve the vision in most cases, but in fact can lead to visual acuity reduction. 
Identification of new treatment options in Africa therefore remains a priority. 
 
Strengths of this study included it being a large, population-based sample, 
representative of a population on which there is minimal data. A senior 
ophthalmologist examined all study participants at baseline and follow up. High 
quality, modern, equipment was used throughout.  
Limitations included a high loss to follow up (50%) at six years, this was primarily 
due to post-election violence affecting the study population with large numbers of 
people displaced or killed. Major variations in baseline and follow-up data collection 
protocols were employed, in part due to challenges at baseline such as unreliable 
visual field data, retinal camera break down and due to a lack of availability of all 
baseline equipment at follow-up, e.g. no repeat AC-OCT was undertaken. Key 
measurement differences and therefore potential measurement bias were in the 
following tests: i) optic nerve grading at baseline was primarily based on clinical 
assessment at the slit-lamp with only a minority having image grading, optic nerve 
grading at follow-up was based on images only, ii) visual fields at baseline were 
completed for glaucoma suspects (n=165) and a sub-set of normal participants 
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(n=343) (11.6% of all baseline participants) using a Humphrey field analyser with 
outputs that could not be confidently used to make an assessment of glaucoma, the 
Henson 8000 was used at follow-up, iii) anterior chamber angle assessment at 
baseline was based on AC-OCT and on 4-mirror gonioscopy at follow-up, iv) a 
statistically significant variation between right and left eye IOP at baseline and follow 
up. IOP was on average higher in the right than the left eye at both baseline and 
follow-up. This may have arisen because the right eye was tested first and/or 
because the majority of the population was assumed to be right-handed, and IOP 
measurement is associated with hand dominance. [42, 43]  
  
In conclusion, glaucoma remains a public health concern. However, the lack of cost-
effective treatments and challenges identifying high-risk individuals means that 
population-based screening for open-angle glaucoma should not currently be 
recommended. [44] Further research in to the risk factors, natural history and 
aetiology of glaucoma in Africa and the barriers to effective sight loss prevention are 
required.  
 
  
 35 
References 
 
1. Pascolini D, Mariotti SP: Global estimates of visual impairment: 
2010. The British journal of ophthalmology 2011. 
2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, 
Jonas JB, Keeffe J, Leasher J, Naidoo K et al: Causes of vision loss 
worldwide, 1990-2010: a systematic analysis. The Lancet Global 
health 2013, 1(6):e339-349. 
3. Quigley HA, Broman AT: The number of people with glaucoma 
worldwide in 2010 and 2020. The British journal of ophthalmology 
2006, 90(3):262-267. 
4. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY: Global 
prevalence of glaucoma and projections of glaucoma burden 
through 2040: a systematic review and meta-analysis. 
Ophthalmology 2014, 121(11):2081-2090. 
5. Cook C: Glaucoma in Africa: size of the problem and possible 
solutions. J Glaucoma 2009, 18(2):124-128. 
6. Quigley HA, Broman AT: The number of people with glaucoma 
worldwide in 2010 and 2020. Br J Ophthalmol 2006, 90(3):262-267. 
7. Abu-Amero KK, Gonzalez AM, Osman EA, Larruga JM, Cabrera VM, 
Al-Obeidan SA: Mitochondrial DNA lineages of African origin 
confer susceptibility to primary open-angle glaucoma in Saudi 
patients. Mol Vis 2011, 17:1468-1472. 
8. Friedman DS, Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S, 
Leske MC, Mitchell P, Congdon N, Kempen J: Prevalence of open-
angle glaucoma among adults in the United States. Archives of 
ophthalmology (Chicago, Ill : 1960) 2004, 122(4):532-538. 
9. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D: Variations in 
primary open-angle glaucoma prevalence by age, gender, and 
race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci 2006, 
47(10):4254-4261. 
10. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J: Racial 
variations in the prevalence of primary open-angle glaucoma. The 
Baltimore Eye Survey. JAMA 1991, 266(3):369-374. 
11. Abdull MM, Gilbert CC, Evans J: Primary open angle glaucoma in 
northern Nigeria: stage at presentation and acceptance of 
treatment. BMC Ophthalmol 2015, 15:111. 
12. Mehari T, Giorgis AT, Shibeshi W: Level of adherence to ocular 
hypotensive agents and its determinant factors among glaucoma 
patients in Menelik II Referral Hospital, Ethiopia. BMC 
ophthalmology 2016, 16:131. 
13. Santos MA, Ayena DK, Kuaovi KR, Vonor K, Djagnikpo A, Balo KP: 
[Compliance with medical treatment in primary open-angle 
glaucoma in Lome]. J Fr Ophtalmol 2016, 39(5):459-466. 
14. Bastawrous A, Mathenge W, Peto T, Weiss HA, Rono H, Foster A, 
Burton M, Kuper H: The Nakuru eye disease cohort study: 
methodology & rationale. BMC Ophthalmol 2014, 14:60. 
 36 
15. Turner AG, Magnani RJ, Shuaib M: A not quite as quick but much 
cleaner alternative to the Expanded Programme on Immunization 
(EPI) Cluster Survey design. Int J Epidemiol 1996, 25(1):198-203. 
16. Mathenge W, Bastawrous A, Foster A, Kuper H: The Nakuru 
Posterior Segment Eye Disease Study: Methods and Prevalence 
of Blindness and Visual Impairment in Nakuru, Kenya. 
Ophthalmology 2012, 119(10):2033-2039. 
17. Rosser DA, Laidlaw DA, Murdoch IE: The development of a 
"reduced logMAR" visual acuity chart for use in routine clinical 
practice. The British journal of ophthalmology 2001, 85(4):432-436. 
18. Dineen B, Gilbert CE, Rabiu M, Kyari F, Mahdi AM, Abubakar T, 
Ezelum CC, Gabriel E, Elhassan E, Abiose A et al: The Nigerian 
national blindness and visual impairment survey: Rationale, 
objectives and detailed methodology. BMC Ophthalmol 2008, 8:17. 
19. Bastawrous A, Rono HK, Livingstone IA, Weiss HA, Jordan S, Kuper 
H, Burton MJ: Development and Validation of a Smartphone-Based 
Visual Acuity Test (Peek Acuity) for Clinical Practice and 
Community-Based Fieldwork. JAMA ophthalmology 2015, 
133(8):930-937. 
20. Van Herick W, Shaffer RN, Schwartz A: Estimation of width of angle 
of anterior chamber. Incidence and significance of the narrow 
angle. American journal of ophthalmology 1969, 68(4):626-629. 
21. Shaffer RN, Schwartz A: Gonioscopy. Survey of ophthalmology 1957, 
2(5):389-409. 
22. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ: The definition and 
classification of glaucoma in prevalence surveys. The British 
journal of ophthalmology 2002, 86(2):238-242. 
23. Bastawrous A, Mathenge W, Wing K, Bastawrous M, Rono H, Weiss 
HA, Macleod D, Foster A, Peto T, Blows P et al: The incidence of 
diabetes mellitus and diabetic retinopathy in a population-based 
cohort study of people age 50 years and over in Nakuru, Kenya. 
BMC endocrine disorders 2017, 17(1):19. 
24. Bastawrous A, Mathenge W, Wing K, Rono H, Gichangi M, Weiss HA, 
Macleod D, Foster A, Burton MJ, Kuper H: Six-Year Incidence of 
Blindness and Visual Impairment in Kenya: The Nakuru Eye 
Disease Cohort Study. Invest Ophthalmol Vis Sci 2016, 57(14):5974-
5983. 
25. Buhrmann RR, Quigley HA, Barron Y, West SK, Oliva MS, Mmbaga 
BB: Prevalence of glaucoma in a rural East African population. 
Invest Ophthalmol Vis Sci 2000, 41(1):40-48. 
26. Ashaye A, Ashaolu O, Komolafe O, Ajayi BG, Olawoye O, Olusanya B, 
Adeoti C: Prevalence and types of glaucoma among an indigenous 
African population in southwestern Nigeria. Invest Ophthalmol Vis 
Sci 2013, 54(12):7410-7416. 
27. Budenz DL, Barton K, Whiteside-de Vos J, Schiffman J, Bandi J, Nolan 
W, Herndon L, Kim H, Hay-Smith G, Tielsch JM et al: Prevalence of 
glaucoma in an urban West African population: the Tema Eye 
Survey. JAMA ophthalmology 2013, 131(5):651-658. 
 37 
28. Rotchford AP, Johnson GJ: Glaucoma in Zulus: a population-based 
cross-sectional survey in a rural district in South Africa. Arch 
Ophthalmol 2002, 120(4):471-478. 
29. Rotchford AP, Kirwan JF, Muller MA, Johnson GJ, Roux P: Temba 
glaucoma study: a population-based cross-sectional survey in 
urban South Africa. Ophthalmology 2003, 110(2):376-382. 
30. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ: The definition and 
classification of glaucoma in prevalence surveys. Br J Ophthalmol 
2002, 86(2):238-242. 
31. Razai MS, Jackson DJ, Falama R, Mongwa M, Mutapanduwa MG, 
Baemisi C, Josiah E, Nkomazana O, Lehasa A, Brealey E et al: The 
Capacity of Eye Care Services for Patients with Glaucoma in 
Botswana. Ophthalmic epidemiology 2015, 22(6):403-408. 
32. Adekoya BJ, Shah SP, Adepoju FG: Managing glaucoma in Lagos 
State, Nigeria - availability of Human resources and equipment. 
The Nigerian postgraduate medical journal 2013, 20(2):111-115. 
33. Lenake M, Cook C, Mustak H, Du Toit N: How useful is visual field 
testing in an African glaucoma clinic? Clin Ophthalmol 2014, 
8:1767-1771. 
34. Kyari F, Entekume G, Rabiu M, Spry P, Wormald R, Nolan W, Murthy 
GV, Gilbert CE, Nigeria National B, Visual Impairment Study G: A 
Population-based survey of the prevalence and types of 
glaucoma in Nigeria: results from the Nigeria National Blindness 
and Visual Impairment Survey. BMC Ophthalmol 2015, 15:176. 
35. Kyari F, Gilbert C, Blanchet K, Wormald R: Improving services for 
glaucoma care in Nigeria: implications for policy and 
programmes to achieve universal health coverage. Br J 
Ophthalmol 2017. 
36. Kyari F, Abdull MM, Sallo FB, Spry PG, Wormald R, Peto T, Faal HB, 
Gilbert CE, Nigeria National B, Visual Impairment Study G: Nigeria 
normative data for defining glaucoma in prevalence surveys. 
Ophthalmic Epidemiol 2015, 22(2):98-108. 
37. Buhrmann RR, Quigley HA, Barron Y, West SK, Oliva MS, Mmbaga 
BB: Prevalence of glaucoma in a rural East African population. 
Investigative ophthalmology & visual science 2000, 41(1):40-48. 
38. Rotchford AP, Johnson GJ: Glaucoma in Zulus: a population-based 
cross-sectional survey in a rural district in South Africa. Archives 
of ophthalmology 2002, 120(4):471-478. 
39. Bastawrous A, Rono HK, Livingstone IA, Weiss HA, Jordan S, Kuper 
H, Burton MJ: Development and Validation of a Smartphone-Based 
Visual Acuity Test (Peek Acuity) for Clinical Practice and 
Community-Based Fieldwork. JAMA ophthalmology 2015. 
40. Bastawrous A, Giardini ME, Bolster NM, Peto T, Shah N, Livingstone 
IA, Weiss HA, Hu S, Rono H, Kuper H et al: Clinical Validation of a 
Smartphone-Based Adapter for Optic Disc Imaging in Kenya. 
JAMA ophthalmology 2015:1-8. 
41. Abdull MM, Gilbert C, McCambridge J, Evans J: Adapted 
motivational interviewing to improve the uptake of treatment for 
glaucoma in Nigeria: study protocol for a randomized controlled 
trial. Trials 2014, 15:149. 
 38 
42. Dane S, Gumustekin K, Yazici AT, Baykal O: Correlation between 
hand preference and intraocular pressure from right- and left-
eyes in right- and left-handers. Vision research 2003, 43(4):405-408. 
43. Pekmezci M, Chang ST, Wilson BS, Gordon MO, Bhorade AM: Effect 
of measurement order between right and left eyes on intraocular 
pressure measurement. Arch Ophthalmol 2011, 129(3):276-281. 
44. Cook C, Foster P: Epidemiology of glaucoma: what's new? Can J 
Ophthalmol 2012, 47(3):223-226. 
 
 
 
 
40 
Chapter 11. Six-Year Incidence of Visually Impairing 
Cataracts in Kenya. The Nakuru Eye Disease Cohort 
Study 
!!! !
216 
  
 
 
 
 
 
 
RESEARCH PAPER COVER SHEET 
 
PLEASE NOTE THAT A COVER SHEET MUST BE COMPLETED FOR EACH RESEARCH PAPER INCLUDED 
IN A THESIS. 
 
SECTION A – Student Details 
 
Student       
Principal Supervisor       
Thesis Title       
 
If the Research Paper has previously been published please complete Section B, if not please move to 
Section C 
 
SECTION B – Paper already published 
 
Where was the work published?       
When was the work published?       
If the work was published prior to 
registration for your research degree, 
give a brief rationale for its inclusion 
      
Have you retained the copyright for the 
work?*  
Was the work subject to 
academic peer review?  
 
 
*If yes, please attach evidence of retention. If no, or if the work is being included in its published format, please 
attach evidence of permission from the copyright holder (publisher or other author) to include this work. 
 
SECTION C – Prepared for publication, but not yet published 
 
Where is the work intended to be 
published?       
Please  list  the  paper’s  authors  in  the  
intended authorship order:       
Stage of publication  
 
SECTION D – Multi-authored work 
 
For multi-authored work, give full details of your role in 
the research included in the paper and in the preparation 
of the paper. (Attach a further sheet if necessary) 
      
 
 
Student Signature:        Date:      
 
 
Supervisor Signature:       Date:      
Andrew'Bastawrous
Hannah'Kuper
The'Nakuru'Eye'Disease'Cohort'Study
10'May,'2017
Yes
Study'design,'data'collecEon,'analysis,'
write'up,'review,'overall'lead.'
T
12,'April'2017
Ophthalmology
Wanjiku Mathenge, John Nkurikiye, Tunde Peto, Hillary Rono,  Michael Gichangi, Helen A. 
Weiss,  David Macleod, Allen Foster, Matthew Burton, Hannah Kuper
Final draft, ready for review by co-authors then peer-review
12, April 2017
! 1 
Six-Year Incidence of Visually Impairing Cataracts in Kenya.  
The Nakuru Eye Disease Cohort Study 
 
 
Authors: 
 
Andrew Bastawrous BSc (Hons) MRCOphth1     [Corresponding Author] 
Wanjiku Mathenge PhD2 
John Nkurikiye MD2  
Kevin Wing PhD3 
Hillary Rono MMed, MPHEC1,5 
Michael Gichangi MPHEC6 
Helen A. Weiss MSc DPhil7 
David Macleod7 
Allen Foster FRCS1 
Matthew Burton PhD, FRCOphth1,8 
Hannah Kuper ScD1 
 
1. International Centre for Eye Health, Clinical Research Department, London 
School of Hygiene & Tropical Medicine, United Kingdom 
2. Rwanda International Institute of Ophthalmology and Dr Agarwal’s Eye Hospital, 
Rwanda 
3. Department of Non-Communicable Disease Epidemiology, London School of 
Hygiene & Tropical Medicine, United Kingdom  
4. Kitale Eye Unit and Trans Nzoia County, Kenya 
5. Ministry of Health, Nairobi, Kenya 
6. MRC Tropical Epidemiology Group, Dept of Infectious Disease Epidemiology, 
London School of Hygiene & Tropical Medicine, United Kingdom 
7. Moorfields Eye Hospital, London, United Kingdom 
 
 
 
Word Count:  3,984 
Tables:  7 
Figures: 1 
References: 43 
 
Keywords: Kenya, Africa, Visual Impairment, Blindness, Incidence, Cataract Surgical 
Rate, Cohort, Population-based, Cataract 
 
 
 
 
 
 
! 2 
Abstract 
Objective: To provide six-year cumulative incidence of visually impairing cataract in 
an older age Kenyan population 
Design: Population based cohort study with six-year follow-up (n=2,171; 50% 
participation) 
Main outcome measures: Six-year cumulative incidence of visually impairing 
cataract, risk factors for incidence, population estimates and required cataract 
surgical rates to manage incident visually impairing cataract. 
Results: The six-year cumulative incidence of visually significant cataract in either 
eye was 251.9 per 1000 (95%CI: 228.5 – 276.8) with an increase with age from 128.9 
per 1000 (107.9-153.2), to 624.5 per 1000 (493.1-739.9) in the 50-59 years and 80 
years and over groups respectively. This equates to an annual incidence of visually 
significant cataract of 45.0 per 1000 people over 50 years. Multivariable analysis 
showed alcohol consumption, diabetes, education level and increasing age to be 
associated with incident visually impairing cataract. Extrapolations to all people aged 
50 years and older in Kenya indicate that 148,280 (95%CI: 134,510-162,950) 
individuals are developing new visually impairing cataract in either eye (<6/18 in 
worst seeing eye), and 9,540 (6,610-13,750) are becoming cataract blind in both eyes 
(<3/60 better seeing eye).  
This indicates that a cataract surgical rate of 232 operations per million of population 
is required to match the annual new cases of cataract blind persons and a CSR of 
2,000 for unilateral cataract with visual acuity of <6/60. This goes up as the threshold 
for surgery goes down. 
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Conclusions: This six-year follow-up of a cohort indicates a high incidence of 
visually impairing cataract that remains the priority for prevention of blindness 
programmes in the region.  
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Introduction 
The prevalence and incidence of cataract is known to rise with increasing age, and 
consequently the magnitude of visually impairing cataract is expected to continue to 
grow with population ageing and increases in life expectancy.(1) Half of all cases of 
blindness worldwide are attributed to cataract.(2) Cataract disproportionately 
affects people living in low and middle-income countries and persons of African 
descent.(2, 3) Multiple population-based studies have been conducted examining the 
prevalence of cataract in sub-Saharan Africa (4) with a considerable variation in 
prevalence across the continent. However, surveys routinely show that cataract is 
the leading cause of blindness in sub-Saharan Africa, (4) and a leading cause of visual 
impairment.  
 
Management of cataract involves surgical removal of the lens and insertion of an 
intraocular lens and is considered one of the most cost-effective health interventions 
worldwide.(5) Determining the cataract surgical rate needed to control cataract 
blindness depends on being able to estimate the incidence of cataract. However, the 
only incidence data on cataract from populations of African descent comes from 
outside the African continent. The best estimates come from the Barbados Eye 
Studies in which a  nine-year follow up of an adult population, 40 years and over, of 
African descent were completed, and showed incidence rates of any cortical and any 
nuclear opacities over nine years were 33.8% and 42.0%, respectively and were 
higher in participants of African descent than Caucasians (Risk Ratio: 1.8; 95% 
confidence interval,1.2–2.8), .(6-9) Incidence data are urgently needed for Africa, to 
ensure appropriate planning and allocation of scarce human resources and 
equipment. 
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We aimed to estimate the six-year cumulative incidence of visually impairing and 
blinding cataract in an East African adult cohort of people 50 years and above in 
Nakuru, Kenya. 
 
 
Methods 
 
The methodology of the Nakuru Eye Disease Cohort Study has been reported in 
detail previously (10), and is summarised here.  
 
Ethical Approval 
The study adhered to the tenets of the Declaration of Helsinki and was approved by 
the Ethics Committee of London School of Hygiene & Tropical Medicine at both 
baseline and follow-up (LSHTM Ref 6192). Baseline approval was provided by the 
Kenya Medical Research Institute Ethics Committee and by the African Medical and 
Research Foundation (AMREF) Ethics Committee, Kenya for the follow-up (AMREF-
ESRC P44/12). For both phases approval was granted by the Rift Valley Provincial 
Medical Officer and the Nakuru District Medical Officer of Health. Approval was 
sought from the administrative heads in each cluster, usually the village chief. They 
were also given a copy of the consent form to read and pass on to those in the 
village.  
Informed Consent 
The objectives of the survey and the examination process were explained to those 
! 6 
eligible in the local dialect, in the presence of a witness. A subject was examined only 
after informed written (or thumbprint) consent was obtained. Participants identified 
with eye conditions, or other health conditions, were referred to local services. 
 
Baseline Study Population  
The initial population based survey was conducted in 2007/08. The sample size of 
5000 participants aged ≥ 50 years was calculated based on an expected prevalence of 
VA<6/12 in the better eye due to posterior segment eye diseases (PSED, the 
primary outcome for the baseline survey) of 3.0% in this age group, precision of 
0.5%, design effect of 1.5, and a response rate of 90%.  
A total of 100 clusters each of 50 participants were selected with a probability 
proportional to the size of the population across Nakuru district. Households were 
selected within clusters using a modified compact segment sampling method (11). An 
eligible individual was defined as someone aged ≥50 years living in the household for 
at least three months in the previous year. All participants were invited to undergo a 
comprehensive ophthalmic examination at a screening clinic (details below). 
 
Follow-up 
Follow-up of the cohort was conducted from January 2013 to March 2014.  
Retracing at Follow-up - Advance Team 
Approximately one week before the follow-up examination clinic was planned for a 
given cluster, a field officer studied the maps of the village including GPS coordinates 
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recorded at baseline and made phone contact with the village chief or guide to 
arrange the visit. At the planning visit, a list of study participants were given to the 
chief and a local village guide was recruited to assist location of the study 
participants. At this visit the examination site was established and identification of 
amenities such as electricity, water and road access were made. Two days prior to 
the clinic, the field officer reminded chiefs of the visit by phone and notified them 
and the guide of the advance team’s arrival. 
 
On the day prior to the examination clinic, the Advance Team visited homes of 
baseline participants and confirmed their identity using National Identity cards and 
invited them to attend the examination clinic the following day.  All identified 
participants were also asked to help locate baseline participants that had not been 
found. 
 
Examination Clinic (Baseline and Follow-up) 
The following procedures were undertaken for all participants who attended the 
examination clinic at baseline and follow-up and further details are available 
elsewhere.(10) Further procedures were undertaken that are not included here as 
they are not relevant to the outcomes being reported (e.g. visual field assessment). 
1. Registration 
On the examination day, the advance team confirmed the identity of participants 
against data from baseline (age, date of birth, name, and identity cards). In cases of 
uncertain identity, confirmation was made based on retinal examination verified by 
comparison with the baseline photo. 
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2. Visual Acuity Assessment 
A clinical officer determined whether the study participant: 
a) Was wearing distance correction glasses 
b) Owns distance correction glasses but failed to bring them 
c) Does not own any distance correction glasses 
d) Routinely uses reading glasses  
e) Was wearing aphakic glasses 
 
Visual acuity (VA) was measured using a back-illuminated modified LogMAR reduced 
tumbling E chart (Sussex Vision Inc) (12, 13), which has been used in previous 
population based studies. (14, 15)  
 
VA was used to define eye and person level (based on the better seeing eye) 
categories of vision as follows: Normal (≤6/12 Snellen, LogMAR ≤0.3), Mild VI 
(<6/12-6/18, <0.3-0.48), Moderate VI (<6/18-6/60, <0.48-1.0), Severe VI (<6/60-3/60, 
<1.0-1.3), Blind (<3/60, <1.3). The term “Visual Impairment (VI)” is used to define all 
those with a VA <6/18 to “no perception of light” and is therefore inclusive of 
moderate VI, severe VI and Blind.  
 
 
3. Lens Assessment !
Pharmacologic dilation of the subject’s pupils was achieved by using tropicamide 1% 
(Mydriacyl) with phenylephrine hydrochloride 2.5% if needed. The anterior segment 
was examined by the study ophthalmologist (WM at baseline, AB at follow-up) using 
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slitlamp biomicroscopy. The WHO simplified system for lens grading was used (16) 
following standard protocols. The lens was also examined for position, the presence 
of hypermature (Morgagnian) cataract, and previous lens surgery (aphakic or 
pseudophakic). A red reflex lens image was taken when each participant was having 
retinal photographs. Pseudophakic participants were assessed for the presence or 
absence of posterior capsular opacification and, if present, whether it entered the 
visual axis. 
 
4. Anthropometry 
A nurse performed and recorded measures of participants: height (Leicester Height 
Measure, Chasmors Ltd, London); weight (Seca 761 Medical Class 4 Scales 
mechanical ground scale, Williams Medical Supplies, London); waist and hip 
circumference (Chasmors WM02 Body Tape measure), and three measures of blood 
pressure (Omron® Digital Automatic Blood Pressure Monitor Model HEM907), 
each ten minutes apart. In addition, at follow-up, bioimpedence (Tanita Segmental 
Body Composition Monitor) was performed.    
 
At baseline, capillary blood was taken from all participants for random blood glucose, 
in addition at follow-up glycosylated haemoglobin was taken in all with a self-
reported history of diabetes, or random blood glucose of ≥7.0mmol/L and a further 
10% of non-diabetics (based on history and random blood glucose).   
 
5. Interview 
An interviewer performed a structured interview in the participant’s preferred 
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language covering i) demographic details including; name, year of birth, ethnicity and 
education level; ii) past medical and ocular history including medical or ophthalmic 
medication or surgery and relevant family history; iii) known risk factors, including 
smoking and tobacco consumption and alcohol intake; iv) socioeconomic status 
based on job, housing conditions, ownership of material goods and livestock which is 
translated in to a score based on previous work in the same population.(17)  
 
Definitions and Statistical Analyses 
Visually impairing cataract was defined as an individual with vision in the better 
seeing eye of <6/18 and the presence of a gradable cataract (nuclear, cortical, 
posterior capsular or mixed using the WHO Simplified Cataract Grading System 
(16)), mature cataract or hypermature cataract. Definitions of incidence are 
described in table 1. 
All participants who had complete examinations at baseline who were not classified 
as having a visually impairing cataract were considered to be “at-risk” for incident 
visually impairing cataract. Follow-up status at 6 years was categorised as i) Found 
and examined; ii) Found and not examined; iii) Deceased; iv) Moved away; or v) 
Unknown.  
 
Statistical analysis was performed using STATA v13 (Stata Corp). All analysis 
accounted for the cluster survey design using Taylor linearized variance estimation 
to calculate standard errors.   
 
Preparation of cohort for analysis 
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Pearson Chi-squared tests corrected for the survey-design were used to calculate p-
values in order to assess differences between participants seen and those lost to 
follow-up (LTFU), and between those known to have died and with unknown 
outcome status.  
 
Those who were deceased and therefore did not have outcome data were then 
excluded, as they were not eligible for follow-up. Those followed up but without 
complete records for all covariates at baseline were also removed from the cohort 
at this stage. 
 
An inverse probability-weighting (IPW) model (18) was then developed, in order to 
allow estimation of cumulative incidence while accounting for those LTFU. 
Multivariable logistic regression was used to identify independent baseline covariates 
associated with LTFU. Covariates for which there was evidence of univariable 
association with the outcome (p<0.1 across all categories of the variable) were kept 
in a multivariable model, those with p>0.1 were excluded from the model. From this 
final model, the probability of being followed was estimated, based on the presence 
or absence of each of these baseline covariates. The inverse of this probability 
formed the weighting to be applied in order to account for those LTFU. 
 
The final step was to remove those individuals LTFU from the cohort, so that all 
subsequent analysis would be performed on only those with complete outcome 
records, with IPW applied to account for those LTFU.  A sensitivity analyses for this 
approach involved a complete records analysis (i.e. only including those people who 
had complete records for outcome and all variables in the analysis). 
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Estimation of absolute and relative effects 
The six-year cumulative incidence of each outcome was calculated by dividing the 
number of events identified at 6-year follow-up by the number of people at risk at 
the beginning of follow-up. 95% confidence intervals were estimated assuming a 
Poisson distribution of events.  This was done for the population overall, and 
stratified by each covariate.  
 
To estimate age-adjusted associations between each outcome (visual impairment and 
blindness respectively), with baseline covariates, age-adjusted risk ratios for each 
covariate were estimated using a Poisson regression model with robust error 
variance to allow for the clustered design and including IPW. For multivariable 
analysis, an initial model was fitted that included those variables shown to be 
associated with outcome in age-adjusted analysis (using a Wald test threshold p-
value of <0.05 to indicate association). A backward approach was then applied in 
order to obtain a final multivariable model, removing variables with p>0.05 one-by-
one. 
 
Visual Acuity Definitions 
WHO definitions of visual impairment and blindness were used throughout (19). 
Monocular visual impairment is defined as visual acuity <6/18 (20/60) in either eye. 
Visual impairment is defined as a visual acuity of <6/18 in the better eye. Monocular 
blindness was defined as a visual acuity of <3/60 (20/400) in either eye. A person was 
considered to be blind if the visual acuity in the better eye was <3/60. The definition 
of visual impairment also includes those who were blind.  
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Diabetes Definition 
Diabetes was defined as (1) Self-reported in the history, or (2) random glucose of 
≥11.0mmol/L, or (3) HbA1c ≥7.0. 
 
Extrapolation of data 
Estimates of cumulative incidence were extrapolated to estimate the number of 
adults over the age of 50 with incident visual impairment or blindness in Kenya. This 
was calculated by taking 2015 population estimate from Kenya (Census Bureau of 
Kenya) by age category and gender and multiplying this by the age and gender 
specific estimates of annual cumulative incidence.  
 
Cataract Surgical Rate 
The estimated number of cataract operations per million of population (all ages) was 
estimated at different thresholds for surgery based on three levels of vision (blind, 
severely VI, moderate VI) and whether for person or individual eye. To give an 
estimated annual cataract surgical rate per million of population.: the annual 
incidence rate for all ages 50 and above was multiplied by 1,000 and by the 
proportion of the population who are aged 50 years and above in Kenya (4.3M of 
45M in 2015), The CSR calculation assumes there are no cases of blinding or visually 
impairing cataract in people aged under 50 years, and is therefore likely to 
underestimate the true incidence by a small amount.  
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Results 
 
Baseline estimates of prevalence 
 
4,414 participants were recruited at baseline in 2007-2008. 4,364 (98.9%) of these 
had an examination of the lens and given a lens status. 
 
Out of the 4,364 individuals who had complete eye examinations, 669 had VA<6/12 
in the better seeing eye. Of these, 180 subjects were visually impaired (<6/18) from 
cataract with 32 of them blind, 11 with severe VI (SVI) and 137 with moderate VI.  
Cataract was the commonest cause of blindness and SVI, being responsible for 45.1% 
and 61.1%, respectively. 3,591 (82.3%) participants did not have visual impairment or 
visually significant cataract, i.e. they either had no cataract and vision of 6/18 or 
better, the presence of cataract but vision 6/18 or better, or vision at worse than 
6/18 but no evidence of cataract (Table 1).  
 
The types of lens opacities associated with the level of visual impairment were 
examined, table 2, with the most common finding being mixed followed by nuclear 
only, cortical only and posterior subcapsular (PSC) only in all vision categories.  
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Estimates of incidence 
A total of 2,159 (49.5%) participants were followed up in 2013-2014 of whom 2,129 
(98.6%) had a complete examination including lens status.  
At baseline there were 3,591 participants without visually significant cataract and, 
1,821 (50.7%) were followed up with 1,799 (98.8%) having a complete lens 
examination. Therefore 1,799 participants were at-risk of incident visually impairing 
cataract of whom 449 (24.7%) in the six-year follow-up period developed a visually 
significant cataract (the participant newly developed VA of worse than 6/18 with the 
presence of a cataract), and seven of these had become cataract blind. 
 
1,944 study participants had a cataract on clinical examination at baseline, of whom 
773 had a visually significant cataract at baseline with proportionally fewer available 
for follow up examination (n=330, 42.7%). The majority, 302 individuals (91.5%), of 
this group had a visually significant cataract at follow-up, while 28 (8.5%) no longer 
had a visually significant cataract at follow up despite not reporting having had 
surgery (figure 1). 18 of 284 (6%) individuals at baseline who were referred for 
cataract surgery had undergone surgery at follow-up.  
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Figure1. Study participants and visually significant cataract (<6/18 Snellen) 
 
LTFU: Loss to follow up, Vis Sig Cataract: Visually Significant Cataract [VA <6/18 and proven 
cataract], BL: Baseline 
 
Due to the high loss to follow up (50.5%) a comparison of baseline features between 
participants who were followed up and those who were not was undertaken (Table 
3). There were notable differences between those followed-up and those who were 
not (and not known to be deceased) (n=1,524, 42.4%), these were: tribal group 
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[proportionally less Kikuyus and Kalenjins, the two major tribes in those not 
followed up] and residence [proportionally more rural than urban dwellers followed 
up]. Notable differences between those followed up and those known to have been 
deceased included [followed up vs. deceased]: younger mean age [60.9 vs. 67.1years], 
lower systolic blood pressure [139.1mmHg vs. 145.1mmHg], lower random blood 
sugar [5.2mmol/L vs. 5.6mmol/L], higher body mass index [10.4% vs. 23.4% 
underweight at baseline] and lower alcohol consumption.  
 
The six-year cumulative incidence of visually significant cataract in either eye after 
adjusting for LTFU using the IPW model, was 251.9 per 1000 (95%CI: 228.5 – 276.8) 
with an increase with age from 128.9 per 1000 (107.9-153.2), 290.5 per 1000 (249.6-
335.2), 565.3 per 1000 (489.3-638.3) to 624.5 per 1000 (493.1-739.9) with each 
decade of life, 50-59 years, 60-69 years, 70-79 years and 80 years and over 
respectively. (Table 4). This equates to an annual incidence of visually significant 
cataract of 45.0 per 1000 people over 50 years.  
 
The six-year incidence of persons (better seeing eye) becoming cataract visually 
impaired, severely visually impaired or blind from cataract was: 134.9 per 1000 
(95%CI: 117.1-154.9), 66.6 per 1000 (54.9-80.6) and 13.6 per 1000 (9.4-19.5) 
respectively. Table 4. 
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When the cumulative incidence is extrapolated to all people aged 50 years and older 
in Kenya, the estimated number of individuals developing new visually impairing 
cataract in either eye, becoming cataract visually impaired (better seeing eye), 
severely visually impairing cataract in either eye, becoming cataract severely visually 
impaired (better seeing eye), new cataract blind in either eye and cataract blind 
(better seeing eye) per year is: 148,280 (95%CI: 134,510-162,950); 86,690 (75,240-
99,570); 88,630 (78,140-100,280); 46,690 (38,500-56,480); 44,260 (36,700-53,240) 
and; 9,540 (6610-13750) respectively (Table 5).  
This indicates that a cataract surgical rate of 232 is required to match the annual 
new cases of cataract blind persons. This goes up as the threshold for surgery goes 
down, Table 6 and Figure 2. 
 
Figure 2a. Estimated minimal cataract surgical rate (CSR) needed to meet the current annual 
incidence of visually impairing cataract at different operating thresholds (based on presenting acuity in 
either the better or worse seeing eye). Horizontal text = annual CSR, vertical text = annual number 
of new cases in Kenya 
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Figure 2b. Simplified CSR pyramid  
 
 
Multivariable analysis showed alcohol consumption, diabetes, education level and 
increasing age to be associated with incident visually impairing cataract; With a 1.4 
(95%CI: 1.1-1.8) increase risk in current alcohol drinkers vs. never drinkers, former 
drinkers were not at increased risk; diabetics had a 1.7 (95%CI: 1.3-2.3) fold risk 
versus non-diabetics; a trend towards less incident cataract with higher education 
level; and 2.0 (95%CI: 1.6-2.6), 3.7 (95%CI 2.9-4.7), 3.8 (95%CI: 2.6-5.5) increased 
adjusted relative risks in the 60-69, 70-70 and ≥80 year age categories with 50-59 
years as the baseline (table 7).  
! !
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Discussion !
 
This is, to our knowledge, the first longitudinal population-based study on eye 
disease in Africa. The annual incidence of visually impairing cataract (<6/18) in either 
eye in those aged 50 years and over was 45.0 per 1000 people per year and 2.5 per 
1000 per year were cataract blind (<3/60 both eyes).  
Increasing age, diabetes, alcohol consumption and low education were associated 
with incident visually impairing cataract. Ageing is a well described risk factor for 
incident cataract throughout the world. (8, 9, 20, 21) Diabetes is also known to be 
associated with incident cataract, (22, 23) most cohort studies have not found an 
association with alcohol consumption however a “u” shaped association was found in 
an Australian cohort with moderate consumption being seemingly protective 
compared to abstinence or heavy consumption.(24) There is some evidence of an 
inverse relationship between education level and incident cataract (25, 26) as 
demonstrated in this population, notably education level affects incidence of cataract 
surgery more commonly than cataract formation.(27)  
 
Blindness and VI due to cataract is associated with reduced quality of life (28) and 
visual function, which can be reversed following low-cost surgical management.(29) 
Considerable social and economic disadvantages can result from cataract, especially 
in low-income communities and it contributes to the perpetual cycle of poverty.(30) 
Conversely, poverty can be alleviated with the provision of cataract surgery.(31) 
Management of cataract is recognised as a priority of the VISION2020: The Right for 
Sight global initiative that targets avoidable blindness however, to our knowledge, 
incidence data including risk factors for incidence of visually impairing cataract has 
! 21 
not previously been available from the African continent limiting the ability to 
effectively plan and resource services. 
 
Based on a presenting visual acuity of VA <6/18 (Snellen equivalent) in either eye 
with a cataract verified by dilated slit lamp examination, or the participant being 
newly pseudophakic, we found the incidence of cataract in this population to be high. 
As expected, the incidence of visual impairing cataract increased significantly with 
age. Comparison with other cohorts is limited in part due to a lack of other data 
from the region and variations on the definition of “visually impairing cataract”, 
however, the estimates from Nakuru show a higher incidence than most other 
cohort studies outside Africa. (26, 27, 32-34) The high prevalence of untreated 
cataract in this study may reflect a combination of low access to ophthalmic services 
and health services in general with the high incidence. (35) 
This study also highlighted the low uptake of services in those needing cataract 
surgery. All participants at baseline identified by the lead ophthalmologist with an 
operable cataract were offered referral to the regional eye unit. However very few 
accessed the service with only 18 of 284 (6%) of individuals followed-up after six 
years having had surgery. Barriers to cataract surgery have been previously 
described in this population and include: awareness; cost; distance from services; fear 
and lack of felt need for treatment. (36, 37) Ultimately, these factors mean that 
visually significant cataract remains untreated.(38)!
 
Strengths of the study include it being a representative population-based sample in 
an area of ethnic, socioeconomic and educational diversity; a large sample size; 
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comprehensive assessment of risk factors; high-quality assessment of vision and 
utilising the same tools at baseline and follow up. The methodology used to assess 
ophthalmic disease was consistent with studies performed in well-developed health 
systems in high-income countries such as the USA (39) and Australia (40), with use 
of the latest available equipment. (10)  
The major limitation of this study was low-participation rate at follow-up (50%), 
however having the baseline characteristics of non-participants is a strength that 
enabled weighting to ensure better estimates of cumulative incidence. This loss to 
follow-up may have led to an under or over estimation of incident cataract visual 
impairment and blindness, depending on the general characteristics of the non-
respondents. The predominant risk factor for incident VI or blindness was age and 
given this was closely matched between participants and non-participants (62.7 years 
(SD 9.4) and 62.5 years (SD 10.4) respectively) the estimates are likely to be an 
acceptable reflection. This is further supported by minimal changes being apparent 
after adjusting estimates for missing data.  
Reasons for the low-participation included ethnic violence with displacement of large 
numbers of people in the study sample area. Post-election violence in 2007 and 2008 
led to up to 600,000 people being internally displaced and 1,300 fatalities.(41, 42) In a 
number of study clusters, entire ethnic groups present at baseline were no longer 
available or traceable. Great efforts were made to locate individuals on two or three 
pre-examination visits. We tried to promote attendance by providing transport 
support and notification of alternative dates to attend clinics in the same locality. 
Further limitations include restricting the inclusion criteria at baseline to those 50 
years and above, reducing the generalizability of our results to the entire population. 
! 23 
This restriction is, however, comparable with the majority of population-based 
studies of eye disease that restrict inclusion to 40 or 50 years and above. Sampling 
people aged 50 and above was appropriate for the outcomes of interest given the 
highest prevalence and incidence is in this age group, making this appropriate both 
epidemiologically (sample size considerations) and for public health and policy 
planning purposes.(43) The definition of blindness and visual impairment in this study 
was based solely on presenting central LogMAR visual acuity and did not include 
peripheral vision loss. This potentially underestimates the incident visual impairment 
and blindness when being compared to studies that include these criteria, though this 
is of less concern with the focus of the paper being on cataract. 
Our results suggest that there are 148,280 new cases of eyes with VI  (<6/18) due to 
cataract in people aged 50 years and above per year in Kenya, of whom 9,540 are 
blind.  Extrapolating these estimates suggests that between 232 cataract surgeries 
(only one eye of people who have less than <3/60 in both eyes); 2305 (all eyes <6/60 
with cataract) and 4,298 (all eyes <6/18 with cataract) need to be conducted per 
million population per year (cataract surgical rate – CSR) to manage the new 
cataract cases depending on which vision threshold for surgery is used. The current 
estimate of CSR in Kenya is 550. Recent estimates suggest there are 100 
ophthalmologists in Kenya for a population of approximately 45 million, with the 
majority (50%) being based in the capital city of Nairobi. This leaves 92% of the 
population (approx. 40 million people) being served by 50 ophthalmologists. Overall 
Kenya is better resourced than many other African countries in terms of human 
resources, despite still being well below recommended targets.(44) Continued effort 
to strengthen the eye health system is necessary to support the growing unmet need 
of this aging and growing population.   
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In conclusion, the incidence of visually impairing cataract in this adult, Kenyan 
population was considerably higher than comparable studies worldwide and remains 
the priority condition for the prevention of avoidable blindness and visual 
impairment. High quality, high volume surgery and an increased awareness and 
demand for services at the community level are required to lower the burden of 
visual impairment and blindness.  
!
!
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The aim of this thesis was to estimate the incidence of visual impairment (VI) and 
blindness, as well as the incidence of the leading visually impairing eye diseases, in an 
elderly population in Nakuru, Kenya. Overall we demonstrated that this population 
has a high incidence of visual impairment and blindness, higher than any documented 
population elsewhere in the world with key differences in disease aetiology to 
populations in other settings.  
 
The results of this cohort study among older people in Nakuru, Kenya are 
summarised below 
 
 
Table. Key finding from the Nakuru Eye Disease Cohort Study 
 
Incidence of Incident cases / At 
risk cases 
Six year cumulative 
incidence (N / per 1000 of 
population, 95% CI) 
Bilateral blindness 29 / 2140 15.1 (10.4 – 21.7) 
Bilateral Visual Impairment 234 / 1983 119.4 (103.1 - 137.9) 
Unilateral blindness 111 / 1984 54.6 (43.7- 68.0)  
Unilateral Visual Impairment  390 /1721 228.0 (206.0 – 251.6)  
Diabetes  
Mellitus 
123 / 2056 61.0 (50.3 - 73.7) 
Diabetic Retinopathy* 20 / 1421 15.8 (9.5 - 26.2) 
Diabetic Retinopathy** 11 / 44 224.7 (116.9 - 388.2) 
Age Related Macular 
Degeneration 
202 / 1282 164.2 (136.7 - 195.9) 
Visually significant cataract 
(either eye) 
422 / 1799 235.6 (213.5 – 259.3) 
*At risk = those without diabetes mellitus or diabetic retinopathy at baseline 
**At risk = those with diabetes mellitus and no diabetic retinopathy at baseline 
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The systematic reviews we conducted on the prevalence of eye diseases in sub-
Saharan Africa (SSA) confirmed that there is a wide variation in estimates across the 
continent and that as a whole, yet overall the prevalence is one of the highest in the 
world with only Asia having a higher prevalence of visually impairing eye diseases.(1, 
2) The per capita human resources to tackle this huge magnitude of disease is lower 
in SSA than anywhere in the world.(3) Despite Kenya having proportionally more 
human resources then many of its neighbours, it remains hugely under served and 
large areas of the country have minimal access to services.  
 
Secondary aims included establishing risk factors for incident VI or blindness and 
describing the natural history of several eye diseases. We found age and diabetes 
(independently) to be positively associated with incident VI and blindness. Diabetic 
Retinopathy (DR) incidence was strongly associated with increasing age, and with 
higher BMI, urban dwelling and higher socioeconomic status.  Incident AMD 
increased with age as well as independently being higher in persons with diabetes and 
females. Incident visually impairing cataract was associated with alcohol consumption, 
diabetes, education level and increasing age. No systemic or anthropometric 
associations with prevalent glaucoma in the cohort follow up were found, however 
both a relative afferent pupil defect and high intraocular pressure (>21mmHg) were 
strongly associated.  
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The main strengths and limitations of the study have already been discussed in the 
individual papers. Some key features of the study design are considered here in 
further detail.  
 
A population-based cohort study in Nakuru, Kenya was chosen for the study.  
Population-based studies are the most effective designs for establishing reliable 
estimates of prevalence and incidence and extrapolating that data to the sampled 
population and other similar populations. Nakuru itself was chosen as it was believed 
to be relatively representative of Kenya in terms of: the diverse ethnic mix, the mix 
of rural and urban dwellers, the socioeconomic and educational spread and the age 
spread of participants. It was also chosen as there had been a previous Rapid 
Assessment of Avoidable Blindness (RAAB)(4) which showed posterior segment eye 
diseases to be a leading cause of VI and blindness, as with other studies in the region. 
Dr Wanjiku Mathenge, who led the RAAB in Nakuru was based in the government 
hospital in Nakuru and was well placed to lead a comprehensive study of eye disease, 
which formed the baseline for this cohort.  
 
The large sample size (n = 5,000) at baseline provided accurate estimates (with 
narrow confidence intervals) for the prevalence of VI, blindness, (5) diabetes, 
diabetic retinopathy, (6) age related macula degeneration (7) and refractive errors. 
(8), which were assessed with gold-standard clinical methods, and so provided a 
strong foundation for a cohort study.  
 
The sampling frame used data from the electoral role (2005) as the most recent 
census data at the time was from the 1990s. A limitation of this was that estimation 
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of the proportion of adults aged 50 years and over were taken from the out-dated 
census resulting in less confidence that the sample probability was proportionate to 
size although this was not thought to alter the overall findings significantly.  
 
Much of the study design at baseline was repeated at follow-up, which was an 
important strength. However certain limitations of the baseline study were used to 
change specific aspects of the follow-up. This included using a difference fundus 
camera and different visual field analyser. Although the quality of retinal images at 
baseline was high, the consistency was low with almost one in three clusters having 
camera failure that meant no images were captured for grading. This considerably 
reduced the available sample at follow-up for sub-analyses, which required 
independent image grading at both time points. The visual field analyser used at 
baseline was found to be unsuitable for this study population. Participants found it 
difficult to complete with no opportunity for learning or repetition. The test time 
meant it was only delivered on a 10% sub-set of the sample population and the 
reliability of these was very low. Despite multiple attempts to assess the raw data 
from these visual field tests, the entire baseline visual field analysis was reluctantly 
discarded due to the low confidence in the findings. As a consequence, using the 
preferred ISGEO classification for glaucoma was not possible and no prevalence data 
on glaucoma from this baseline sample has been published to date, nor was it 
possible to estimate the incidence. Another concern with the data at baseline was 
the use of the WHO definition of diabetes mellitus based on a single random blood 
sugar of ≥11.1mmol/L. (9) Although this was a suitable choice for this study 
environment, it incurred limitations around the confidence of a diagnosis from a 
single, capillary reading done without fasting.  
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At follow-up, multiple retinal cameras were evaluated which included visiting 
different manufacturers and discussing the use of these in settings that they are not 
typically designed for. In the end, the Haag-Streit DRS Centre Vue camera was 
chosen. This choice was made based on the several key factors: the required power 
consumption, on-board hard disk for auto-saving and labelling of images, limited 
moving parts, dust seal and packaged size (suitable for air transport to Kenya and 
transportation to over 100 sites across Nakuru County). As with the retinal camera, 
multiple visual field analysers were reviewed, including novel laptop based tests. 
After discussion with multiple leading experts (thank you to Dr Wormald and Prof 
Henson), the Henson 8000 was chosen. A final change was made to the baseline 
protocol in order to further support a diagnosis of diabetes mellitus at follow-up; 
portable HbA1c kits (Bayer) were used on a sub-set of participants (limited to a sub-
set due to cost) as a means of confirming diagnosis in those with a random sugar and 
evaluating for false negatives.   
 
As expected, the logistical and personal challenges of undertaking such a study were 
considerable. These ranged from moving to a new country with a young family to 
having no place to live or team to work with. We had to adapt quickly and prepare 
carefully. Despite months of preparation there were many things we couldn’t 
prepare for including the national elections that took place mid-way in the study. 
The tensions leading up to the elections were considerable and many of the clusters 
we visited had been deeply affected by the post-election violence in 2008. This 
included entire ethnic groups being untraceable in several clusters, with nobody 
available to know if they had moved away, died or otherwise. This had a dramatic 
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effect on the follow-up rate with us only being able to successfully locate 50% of the 
baseline participants. Huge efforts were undertaken to minimise loss to follow-up. 
This included several calls to the village chief or senior person in the cluster to 
explain we were coming and the purpose of our visit. This was followed up by a visit 
by one of our team members to meet the village chief, gain permission for the study 
and the allocation of a local guide. The chief and guide would review the list of 
participants from that cluster marking those they knew and making announcements 
for the others at local meetings such as church services or farmers markets. A few 
days later, two of the study’s advance team would meet the guide and go together 
on foot, door-to-door, visiting all the participants known to still be located there. 
Each confirmed participant was asked to review the list to confirm if they knew 
others on the list, if they were still alive, where they were or if they were known to 
have moved away. A clinic site was established on the first visit to ensure all 
participants were aware of where to come. On the clinic day, the advance team 
would arrange collection with the team driver of all those who were a considerable 
distance from the clinic or had limited mobility and/or time. Subsequent clusters 
were located as close as possible to previous ones to provide a further chance for 
those who were known to still be alive and located in the cluster to attend a 
neighbouring cluster had they not been able to make it to their own. Further 
additional clinics were put on at the end of the study period with all clusters re-
contacted and free transport to and from the town based clinics offered. 
 
Despite these efforts, only 50% follow-up was achieved causing potential sampling 
bias. Comparable studies worldwide (10-24) have had four to six-year follow up 
rates varying between 53-81% as summarised in the table below. Advice was sought 
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from several statisticians on how best to handle this loss to follow up including 
Professor Helen Weiss, Dr Jonathan Bartlett, Dr Kevin Wing and Dr David Macleod 
at the LSHTM. The model chosen in the end was the “inverse probability weighting” 
model (IPW), which is detailed in the data papers. Reassuringly, the estimates when 
using complete case studies and IPW modelling were similar, indicating the lack of 
important bias in the estimation of incidence. Furthermore, the differences between 
those followed-up and those who were not were described in detail for each paper.  
 
Table. Comparable cohort studies with follow-up rates indicated 
Study Location Year commenced 
Years of 
Follow up 
Follow-up 
rate (%) 
Age at 
Baseline 
Reference 
 
Nakuru Eye 
Disease Cohort 
Study 
 
Kenya 
 
2007 
 
Baseline 
6 
 
- 
50 
 
50 
 
(25) 
Beaver Dam Eye 
Study 
USA 1988 Baseline 
5 
10 
15 
- 
75 
56 
43 
43-86 (10-12) 
Blue Mountain 
Eye Study  
Australia 1992 Baseline 
5 
10 
- 
64 
53 
49+ (13) 
Rotterdam Study  Netherlands 1990 Baseline 
2 
6.5 
11 
- 
77 
53 
37 
55+ (14, 15) 
Copenhagen City 
Eye Study  
Denmark 1986 Baseline 
14 
- 
38 
60-80 (16) 
Barbados Eye 
Study  
Barbados 1987 Baseline 
4 
9 
- 
74 
60 
40+ (17, 18) 
Pathologies 
Oculaires Liees a 
L’Age  
France 1995 Baseline 
3 
- 
64 
60+ (19) 
Melbourne Visual 
Impairment 
Project  
Australia 1992 Baseline 
5 
- 
64 
40+ (20) 
Hisayama Study  Japan 1998 Baseline 
5 
9 
- 
65 
- 
40+ (21, 22) 
Reykjavik Eye 
Study  
Iceland 1996 Baseline 
5 
- 
81 
50+ (23) 
Los Angeles 
Latino Eye Study  
USA 2000 Baseline 
4 
- 
73 
40+ (24) 
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The major strengths of this study include the study design and use of state-of-the-art 
ophthalmic equipment for the examinations. All participants underwent testing on 
each station, regardless of visual status (a limitation of RAABs, the Nigeria National 
Survey and some aspects of the baseline study). This included: 
• LogMAR Presenting Visual Acuity 
• Autorefraction 
• LogMAR Corrected Visual Acuity 
• Visual Fields 
• Anterior Segment Slit Lamp examination 
• Goldmann Applanation Tonometry for Intraocular Pressure 
• Gonioscopy 
• Visual Fields 
• Retinal photography 
• Slit Lamp lens assessment (mydriatic) 
• Anthropometry (height, weight, hip circumference, waist circumference, 
bioimpedance, blood sugar, HbA1c, blood pressure) 
• Risk factor analysis (detailed questionnaire in the local language) 
Furthermore, an ophthalmologist was available at both baseline (WM) and follow-up 
(AB) to confirm diagnoses, with independent verification through the Moorfields 
Grading Centre where image data was available. Methodological rigour of this cohort 
study is therefore on a par with existing ophthalmic cohort studies.  
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Much of the data from this cohort is now in the public domain and more will 
become so in the near future. This adds to our collective understanding of the 
epidemiology of eye disease in SSA, however further questions remain unanswered 
and for completion this data needs to be summarised and provided to the Ministry 
of Health in Kenya. A workshop has been proposed for 2018, which will bring 
together leading eye health researchers and policy makers in Kenya to discuss the 
findings and their implication for practice going forward. 
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Public Health Implications for Kenya 
 
In line with the aims of the VISION2020 initiative, there has been major success 
reducing blindness from communicable diseases in the region, however cataract 
remains the leading cause of blindness.(26) The incidence of visually impairing 
cataract demonstrates the need to increase the current provision of eye services to 
meet the growing numbers of people losing sight from cataract and preventing the 
prevalence from growing as well as number of people who die never having had 
treatment.  
 
Based on the data from this cohort study, the CSR needs to be between 232 and 
4,298 cataract operations per million per year depending on those in the population 
for whom services are targeted. It should be noted that when targeting the most 
severely impaired group (bilaterally blind) those less severely impaired are identified 
also and so the case mix will usually include a variety of different levels of 
impairment (from experience, for every bilaterally blind person there will be 5-10 
non blind persons on the operating list). Current estimates are that the CSR is 
around 550 / million / year. A target CSR of 2,000 has been set and for this to be 
achievable a long-term strategy to increase and retain ophthalmologists and cataract 
surgeons is needed as well as short and medium term solutions to maximise the 
reach and efficiency of existing human resources.  
 
 
Posterior segment eye diseases are growing with the aging population and will 
contribute more to the burden of sight loss as measures to control cataract 
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strengthen.(26) These diseases are more complex in their presentation and 
management and will require a different approach to that alone of establishing strong 
cataract services.  
 
Posterior segment eye diseases (PSED) are becoming more prevalent with the aging 
population with the need for cost-effective methods for identification and 
intervention to prevent sight loss becoming urgent.(2) Well resourced health 
systems are struggling to meet the growing demand of these non-communicable, 
chronic diseases that require frequent follow-up, intensive use of specialist 
equipment and personnel. The challenge is compounded as these diseases do not 
have interventions that restore or improve sight, but rather prevent progression to 
significant sight loss.  
 
Diabetic retinopathy (DR) is a growing concern and whilst the prevalence and 
incidence is relatively low compared to other conditions in this population this is 
likely to change with the rapid epidemiological transition that is underway. (27) 
Effective management of DR must be tackled at the source, i.e. prevention of 
diabetes, rather than approaching it solely as an ophthalmic issue. A lack of 
awareness of risk factors for diabetes and an increasingly obesogenic environment 
are becoming critical issues that for a minority result in end stage organ damage 
including sight-threatening diabetic retinopathy. Greater demand is likely to be felt by 
eye care services as those in urban areas and of higher socioeconomic status are 
both more likely to become diabetic and more likely to have access to services. This 
perceived increase in demand by service providers needs to be balanced by the 
public health concerns and in particularly the large groups of the population for 
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whom accessing any services is difficult. Three key areas of systems strengthening is 
required to meet the growing number of people with potential sight loss from their 
diabetes, these are, but not limited to: (1) increasing service capacity (human 
resources and appropriate equipment for diagnosis and treatment), (2) increasing 
demand for services by creating awareness in those known to have diabetes about 
the risk of sight loss and potential for sight saving treatment with regular screening 
and follow-up, and (3) great efforts need to be made to reduce the incidence of 
diabetes by creating public awareness and policy changes that encourage a healthy 
environment.  
 
Age related macula degeneration (AMD) is more prevalent in this population than 
many anticipated (7) however it is yet to be a major contributor to vision loss, in 
part due to the life expectancy of the population meaning many do not reach the age 
groups in which vision loss begins to manifest from AMD. AMD is not a priority 
public health concern yet as the prevalence of sight loss from AMD is low and 
effective treatments that prevent and restore vision are limited. This is likely to 
change in decades to come as cataract and refractive errors are better controlled 
and treatment options become more readily available.   
 
Glaucoma identification continues to prove to be challenging to identify, even with 
modern equipment such as was available in this cohort. The standardisation of 
classifying glaucoma using the ISGEO criteria (28) for prevalence surveys has enabled 
comparative data across populations, however there is a need to develop a practical 
set of standards for identifying patients with, and monitoring progression of, 
glaucoma in settings where access to modern equipment is not feasible. This might 
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include a combination of simple tools to measure structural and functional optic 
nerve damage such as optic disc imaging, visual acuity testing, relative afferent pupil 
defect assessment and portable intraocular pressure measurement.  
 
Effective reduction of blindness and visual impairment should also focus on reducing 
the barriers that currently exist, as demonstrated (Chapter 11) by the low uptake of 
services in those identified at baseline with operable cataract. (29-32) This should 
include a focus on: 
• Awareness – many visually impaired people are not aware they have a 
treatable condition and therefore do not consider accessing services 
• Bad Service – poor outcomes and limited availability of services  
• Costs – the lowest socioeconomic groups are the most likely to be affected 
and both direct costs of treatment and indirect costs are unaffordable 
• Distance – the location of services is often prohibitively far both in terms or 
time and cost to travel 
• Escort – the need to have a carer take the potential beneficiary to the 
services creates a dependence on a family or community member 
• Fear – potential beneficiaries are afraid of being in an alien environment 
when they already have lost their independence. Certain ideas around what 
happens at surgery can result in the rejection of services 
• Gender – females are disproportionally more likely to not access services 
 
Overall, the combination of cataract and PSED challenges requires a health system 
strengthening approach with the priority being the immediate issue of cataract visual 
impairment and longer-term concern of PSED. Both supply (treatment services) and 
! 15 
demand (improved access to those services) needs targeted changes including 
consideration of novel approaches such as task-sharing and task-shifting (33) to 
create efficiencies that enable a higher volume and quality of services. This includes 
empowering community workers and volunteers to be involved in sensitization and 
case finding and providing more basic eye services closer to the patient’s homes to 
increase access and raise demand as well as establishing policies that are supportive 
of new cadres delivering tasks previously limited to the scope of established cadres. 
Sensitivity is needed to ensure that those from established cadres do not feel 
threatened and in fact support these initiatives and are provided with assurance that 
their roles are protected and will in all likelihood become more demanding due to 
the increased workforce closer to the population who remain off the medical grid.  
 
Based on the finding of this body of work, it is recommended that the focus of 
VISION2020 remains that of tackling avoidable blindness and visual impairment 
through delivery of high volume, high quality cataract and refractive error services 
and that the emerging posterior segment eye diseases should not distract from this 
focus. Health care system strengthening, including eye health systems is required of 
PSEDs are to be managed once cataract and refractive errors come under better 
control.  
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Future work 
This population-based cohort study from Nakuru, Kenya, has huge amounts of 
untapped information that warrants analysis, interpretation and sharing.  
 
Outside the scope of this thesis, many other manuscripts are being prepared and 
several others will be developed in due course.  
 
The list below is a summary of these. 
 
Manuscripts under review or in preparation: 
 
1. Reference values for body composition and associations with blood pressure 
in Kenyan adults [under review] 
 
2. Changes in the magnitude and pattern of socioeconomic inequality in 
blindness and visual impairment in Nakuru County, Kenya between 2007/08 
and 2013/14 
 
3. The incidence and risk factors for hypertension in a population-based cohort 
of older people in Kenya 
 
4. The incidence of obesity and potential risk factors in a population-based 
cohort of older people in Kenya 
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5. The incidence of sub-types of lens opacity in a population-based cohort of 
older people in Kenya 
 
6. The incidence of posterior capsular opacification in a population-based 
cohort of older people in Kenya 
 
7. The prevalence and incidence of pterygium and corneal opacities in a 
population-based cohort of older people in Kenya 
 
8. Risk factors for mortality from a population-based cohort of older people in 
Kenya 
 
9. Mortality and visual impairment in a population-based cohort of older people 
in Kenya 
 
10. Comparing various models of calculating incidence from prevalence data and 
its validity in the Nakuru Eye Disease Cohort 
 
11. HbA1c in population-based sample of Kenyan adults. 
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Peek 
Multiple challenges were faced throughout this cohort study such as a lack of 
infrastructure (poor roads, unavailability of electricity) and dependence on highly 
skilled personnel to deliver the examinations and data demonstrating the big gap 
between accessible services and need for services.  
 
Peek was designed to overcome, or reduce some of these challenges by enabling 
task shifting to more available cadres of the workforce and create the possibility for 
roles to be performed by people who do not typically have a role in health service 
delivery (e.g. community volunteers and teachers).  The design and validation of 
these tools was nested within the cohort study and included the validation of a 
smartphone visual acuity test, Peek Acuity (34) and a smartphone retinal imaging 
adapter, Peek Retina. (35) The acceptability of these tools was assessed and found to 
be highly acceptable by patients, examiners and key stakeholders. (36) 
 
Peek could potentially be used to help overcome three major challenges identified in 
this thesis: 
1. Increase the availability of data on the prevalence of PSED in Africa 
These tools are now being embedded into survey tools, including mRAAB, an 
evolution of the Rapid Assessment of Avoidable Blindness methodology (4) to 
increase the quality of data being collected in surveys to support understanding the 
eye health needs at a district level including disaggregated PSED and planning 
modules that combine a needs assessment (prevalence) with a resource assessment 
(capacity) to deliver achievable plans.  
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2. Identify people in the community who need eye services and lower barriers 
to them accessing them 
Tools and methodologies are also in development and implementation to lower 
many of the barriers to accessing services experienced in this cohort study, 
including Community Screening, School Screening (37) and Diabetic Retinopathy 
Screening.(38) These systems utilise connected Peek tools to connect those 
identified in the community with appropriate services as well as enabling real-
time feedback to all those involved in the patient care pathway including carers, 
local opinion leaders and programme managers. Further information is available 
from: https://www.peekvision.org/peek-systems/ 
 
Table. Summary of locations at which key activities (identification, triage and 
treatment) take place in the different models 
 
System Identify Triage  Treat 
School Schools Local camps or in 
the school 
Local 
camp/refractive 
service/hospital 
Community Households Primary health care 
facilities 
Hospital 
Diabetes Primary health care 
facilities 
Cloud based Hospital  
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3. Increase the capacity in ophthalmic institutions  
Many ophthalmic institutions in SSA are poorly resourced. Peek tools such as the 
smartphone based visual acuity test, Peek Acuity, and Peek Retina for assessing the 
fundus can be used to provide additional capabilities. They can also be used in end-
to-end solutions that mean less time is spent by highly-trained specialists performing 
tasks that can be performed by other cadres.  
 
Further information on Peek is available in the appendix.  
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Conclusions 
The incidence of visual impairment and blindness in Nakuru Kenya is high and the 
majority of people in who are blind are avoidably so. Strengthening of the health 
system is required if sustainable change is to be delivered.  
Short-term efforts should continue the efforts of VISION 2020 to focus on 
controlling cataract visual impairment. In the long-term, the focus must shift to 
whilst building capacity to identify and manage posterior segment eye diseases early.   
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Page 1 of 1 
       
Observational / Interventions Research Ethics Committee  Dr Andrew Bastawrous International Centre for Eye Health CRD/ITD LSHTM  26 June 2012   Dear Dr Bastawrous,  
Study Title: The Incidence and Progression of Posterior Segment Eye Diseases in Nakuru, 
Kenya 
LSHTM ethics ref: 6192  Thank you for your email of 20 June 2012, responding to the Observational Committee’s  request  for  further  information on the above research and submitting revised documentation.  The further information has been considered on behalf of the Committee by the Chair.   
Confirmation of ethical opinion On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation as revised, subject to the conditions specified below.  
Conditions of the favourable opinion Approval is dependent on local ethical approval having been received, where relevant.    
Approved documents The final list of documents reviewed and approved by the Committee is as follows:   
Document Version Date LSHTM ethics application  V2 13/06/2012 Protocol V3 14/06/2012 Information Sheet V2 13/06/2012 Consent form  V2 13/06/2012  
After ethical review Any subsequent changes to the application must be submitted to the Committee via an E2 amendment form.   All studies are also required to notify the ethics committee of any serious adverse events which occur during the project via form E4.   At the end of the study, please notify the committee via form E5.    Yours sincerely,   
 
 
 
Professor Andrew J Hall 
Chair ethics@lshtm.ac.uk  http://intra.lshtm.ac.uk/management/committees/ethics/  
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Appendix II. Peek 
 
 
In the two years prior to commencing the fieldwork required for this PhD study I 
began reviewing all the equipment, personnel and training that would be required to 
deliver the study effectively. As preparation for the application and subsequent 
interview with the Medical Research Council and Fight for Sight (who went on to 
fund the PhD Fellowship) I began assessing any alternative ways the follow-up could 
be done given the half decade of progress since the baseline study. Although there 
were some updates and marginal changes in equipment available, the fundamental 
challenges that were present at baseline remained true at follow up: most of the 100 
clusters did not have access to a stable power supply, three-quarters were not 
accessible on tarmac road and the equipment required specialist training to use 
appropriately and was all at risk of failure as they were designed for use in an 
environment that is dust free, with minimal temperature variation and stable power 
supply. Furthermore, most of the equipment was designed to be stationary rather 
than moved, unpacked and repacked several times per week.  
I had received feedback that the cohort was unlikely to be funded, although the work 
was of high scientific importance the challenges delivering it meant this was 
considered a high-risk study. Fortunately the Medical Research Council and Fight for 
Sight were convinced that the study could be delivered, nonetheless, I continued to 
explore ways it may be less logistically challenging to deliver.  
 
While writing my first draft of the PhD application I purchased my first smartphone 
and like the many early adopters before me soon realised I had something that was 
going to fundamentally change the way we communicated. I also realised that the 
impressive computing power, high resolution screen, in-built camera and constant 
“connectedness” meant this could be harnessed for delivering ophthalmic 
examinations. Assuming this is something that had already been done I began 
downloading as may “eye test” apps as I could find, hoping there may be something I 
could use as an alternative to all the equipment I was going to need to buy. To my 
disappointment they were all unsuitable. With some colleagues we began 
systematically reviewing every one of the apps available at the time concluding that 
they were almost all unvalidated and not suitable for use in clinical practice. (1) 
Searching the wider mHealth landscape, beyond eye health there were several 
examples of effective mHealth apps, hardware or services being used. (2) These 
included a mobile phone base clinical microscopy tool (3) which led me to believe it 
must be possible to image the retina with a smartphone.  
Given the anticipated logistical challenges that lay ahead for my PhD and those who 
might attempt to replicate it, I began prototyping smartphone vision tests and 
hardware adaptions for retinal imaging. My first successful attempt to view the retina 
with my smartphone was adapting the indirect technique, which uses a co-axial light 
source mounted on a hat between the examiner’s eyes and a condensing lens. By 
using a smartphone in video mode with the flash on I was able to get fundus views 
effectively. (4) Its use was limited to only being effective in the hands of an 
ophthalmologist and so I begun working on several other prototypes with help from 
engineers with specialist experience. After several unsatisfactory attempts to make 
something usable by a non-specialist, an engineering colleague in the university 
collaboration we had established, successfully 3D printed a device that was easy to 
use and provided satisfactory images in the hands of a non-specialist. (5) We 
developed multiple further prototypes before establishing a nested study within the 
cohort to validate its use in the hands of a non-physician against the reference 
standard desktop retinal camera being operated by an ophthalmic technician. Images 
from both were independently graded at Moorfields Eye Hospital Reading Centre. 
When performing an optic disc grading the two techniques were found to be 
comparable. (6) In parallel multiple prototypes of a visual acuity Android app had 
been tested and improved with a similar ambition of making it possible to accurately 
measure visual acuity in the hands of a non-physician. As with retinal examinations, 
this was nested within the cohort study and examiners were asked to measure 
participant’s vision at home and repeated again in the clinic the following day where 
they also underwent the reference standard vision test on an ETDRS chart. An 
experienced clinical officer undertook the reference standard vision test in 
controlled conditions. The visual acuity app, in the hands of a lay-user, was found to 
be as accurate as ETDRS, as repeatable as Snellen and quicker than both. (7)  
As well as validity testing both the acuity app (Peek Acuity) and the retinal hardware 
(Peek Retina), the adoptability and acceptability of these tools were assessed through 
qualitative interviews with patients, examiners and stakeholders. The conclusions 
from the in-depth interviews were that, “Peek is an acceptable solution, as it 
provides a beneficial service, supports patients' needs, and fulfils health care 
providers' roles, overall contributing to strengthening eye health”. (8) 
 
 
The app has consequently been released globally and is now been using in 126 
countries. It’s use has been independently validated in several settings, including 
Aravind Eye Hospital in India where it was chosen as the acuity app of choice for use 
within in a local trial (personal correspondence).  
 The ambition was not to create stand-alone tools such as a vision test or 
smartphone ophthalmoscope, it was to create tools that could be integrated in to 
digital data collection tools enabling greater access to services for those most in 
need and least likely to receive services, and to make research more straight-
forward than it was anticipated to be and without question proved to be. The 
integration of these tools could be specifically for remote interpretation of retinal 
images or more comprehensive workflow integration. (9, 10) 
 
The fist scenario in which integrating these tools were applied, was within a school 
screening program in Kitale, Kenya. It was estimated that one on 20 children in 
school had an undetected visual impairment and most schools had no active school 
screening facility. The only active program required an eye nurse to leave the 
hospital and travel to neighbouring schools to conduct basic eye and vision 
assessments. It was found to be ineffective for several reasons: the ophthalmic 
nurses workload at the hospital increased in their absence as there was no back up 
provision; the majority of children screened in the schools, 19 in 20, did not have a 
vision problem but still required a specialist nurse assessment to discover this; and 
those were positively identified as needing review in the hospital were unlikely to 
attend despite referral (estimated at 10% attendance). Peek Acuity was tested in the 
hands of teachers and shown to be an effective way of positively identifying school 
children with visual impairment (data in preparation for publication). A screening 
system was developed to pull data on children who had screened positive and 
automating text messaging to their parents notifying them of assessment and need 
for hospital follow up. A cluster randomised control trial including over 20,000 
children equally divided in to two arms, the Peek School Screening System and 
standard care (Card based vision assessment in the hands of the same teachers and 
letter referral). The adherence to referral in the intervention arm was 52% 
compared to 21% in the control arm (data in preparation for publication). The 
program has subsequently been adopted in Trans Nzoia County and is now scaling 
to reach 300,000 children. The program has also been replicated in Botswana with a 
recent pilot completed and plans underway for a national program to commence 
next year. A further cluster randomised control trial of Peek School Screening is 
underway in India. (11) Further work is underway developing or collaborating on the 
development of: 
• Contrast sensitivity 
• Red desaturation 
• Visual fields 
• Colour vision 
And systems that use Peek Acuity, Peek Retina and potential other Peek developed 
or third party apps in connected systems for: 
• School screening  
• Community screening 
• Population surveys 
• Diabetic Retinopathy screening 
 
 
In the course of this PhD, Peek has grown from an idea to a suite of software apps, 
hardware and systems, (12) some globally available and other continuing validation 
and trials. A spin out from the London School of Hygiene & Tropical Medicine was 
established in 2015. The Peek Vision Foundation, a UK Charity to mission lock the 
purpose of Peek as an organisation that represents the millions of people avoidably 
visually impaired. A wholly owned subsidiary trading company, Peek Vision Ltd has 
been established as a legal manufacturer of medical devices and is working to 
become a sustainable provider of products and services that radically increase access 
to eye care services. Profits from the company are gifted to the Foundation to 
further build eye care capacity in low and middle-income countries.  
  
The following short essay was submitted to and was selected as the winner of the Medical 
Research Council, Max Perutz Science Writing Award: 
 
 
 
Why Does My Research Matter? – Max Perutz Science Writing 
Award 
 
Everything is hazy; He keeps his eyes closed; it doesn’t seem to make much 
difference opening them. His hand clumsily feels around the bedside table reaching 
for his mobile phone and knocking last night’s cold mug of tea to the floor. Today is 
the day he hopes he’ll get his sight back  
 
Losing sight is the sense most people fear losing most. I am privileged to be in a 
profession (ophthalmology) where centuries of research and practice have brought 
us to a time when so much of blindness is now curable or preventable. There is no 
feeling like it when the eye patch comes off someone who hasn’t seen for years, the 
sheer wonder as they take in their surroundings and their anticipation to see faces 
that have become voices and places that have become memories.  
 
Incredibly, despite 80% of blindness being curable or preventable, the majority of 
blind people with treatable eye conditions live in developing countries and have no 
access to suitable healthcare. Africa has the greatest disparity in numbers needing 
treatment and specialists available to provide it. For example, in the UK we have 
3,600 ophthalmologists (eye surgeons/doctors) compared to only 86 in Kenya where 
I will be moving to later this year.   
 
There are many factors that can lead to blindness, and many complexities that lead 
to a society unable to deal with the burden that comes with a disability. Although 
each individual goes blind very much alone, there are shared stories and features, the 
understanding of which can enable prevention or access to curative treatment. Some 
of the major questions include knowing how many people are blind? Who are they? 
Where do they live? Why are they blind? At what rate are people becoming blind? All 
this information is vital for planning a health service and using limited resources in a 
way that will allow the maximum number of people to receive treatment and restore 
or preserve their vision.  
 
Gathering this type of information is known as epidemiological research, it is a 
method of describing the characteristics of a population. This information is then 
used in practice to inform policy makers and health workers to benefit individuals on 
a large scale.  
 
Performing such a study can be a logistical nightmare, it is also extremely time 
consuming and expensive. My study involves the retracing and examination of 5,000 
people across a district in Kenya known as Nakuru. Taking what is effectively a fully 
staffed eye hospital (team of 15 people), fully equipped (over £100,000 worth of 
heavy and fragile equipment) to remote villages, many of which have no road access 
or electricity supply is extremely challenging yet absolutely vital if provision to 
prevent needless blindness is to be put in place.  
 
As I’ve pondered and planned for the challenges that lay ahead, I’ve had the continual 
thought that there must be an easier way to gather this information, a way that is 
less expensive, less resource hungry and therefore could be used on a much wider 
scale. Then it dawned on me… I use my smartphone for everything nowadays, from 
checking train times, navigating in the car, taking and sharing photos, not to mention 
using it as a phone and speaking to people.  This has led me to develop a set of 
gadgets and applications making it possible to use a modified smartphone (I call it the 
Eye Phone) to measure someone’s vision, check their refractive error (glasses 
prescription), take photos of the back of the eye for diseases such as diabetic 
retinopathy, macula degeneration and glaucoma and check for the presence of a 
cataract. All the data is then stored on the phone and can be shared with specialists 
anywhere in the world to provide expert diagnosis and treatment plans in even the 
most remote locations. Individuals are locatable on an interactive Google Map, and 
can be retraced and contacted to arrange treatment or follow up.  
 
It is important to check the new device works and doesn’t miss people who need 
help. To see how accurate the new device is, I will test it on the same 5,000 
individuals undergoing the detailed examinations that use the gold-standard state-of-
the-art hospital equipment with the phone also. We will then be able to compare 
the two methods and see how many of the study population we would have 
correctly picked up as having sight loss (as well as the reasons why) and if we would 
have missed anyone.  At one-fiftieth of the price and only one non-specialist needed 
to perform the test, the examiner can go to the patient rather than the patient 
waiting for someone to never come.  It could mean those in difficult to reach places, 
silently losing their sight, could be a text message away from help.  
 
 
 
 !!
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Development and Validation of a Smartphone-Based
Visual Acuity Test (Peek Acuity) for Clinical Practice
and Community-Based Fieldwork
Andrew Bastawrous, MRCOphth; Hillary K. Rono, MBBS; Iain A. T. Livingstone, FRCOphth; Helen A. Weiss, PhD;
Stewart Jordan, BSc; Hannah Kuper, ScD; Matthew J. Burton, PhD
IMPORTANCE Visual acuity is the most frequently performedmeasure of visual function in
clinical practice andmost people worldwide living with visual impairment are living in low-
andmiddle-income countries.
OBJECTIVE To design and validate a smartphone-based visual acuity test that is not
dependent on familiarity with symbols or letters commonly used in the English language.
DESIGN, SETTING, AND PARTICIPANTS Validation study conducted fromDecember 11, 2013, to
March 4, 2014, comparing results from smartphone-based Peek Acuity to Snellen acuity
(clinical normal) charts and the Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR
chart (reference standard). This study was nested within the 6-year follow-up of the Nakuru
Eye Disease Cohort in central Kenya and included 300 adults aged 55 years and older
recruited consecutively.
MAIN OUTCOMES ANDMEASURES Outcomemeasures weremonocular logMAR visual acuity
scores for each test: ETDRS chart logMAR, Snellen acuity, and Peek Acuity. Peek Acuity was
compared, in terms of test-retest variability andmeasurement time, with the Snellen acuity
and ETDRS logMAR charts in participants’ homes and temporary clinic settings in rural Kenya
in 2013 and 2014.
RESULTS The 95% CI limits for test-retest variability of smartphone acuity data were ±0.029
logMAR. Themean differences between the smartphone-based test and the ETDRS chart and
the smartphone-based test and Snellen acuity data were 0.07 (95% CI, 0.05-0.09) and 0.08
(95% CI, 0.06-0.10) logMAR, respectively, indicating that smartphone-based test acuities
agreed well with those of the ETDRS and Snellen charts. The agreement of Peek Acuity and
the ETDRS chart was greater than the Snellen chart with the ETDRS chart (95% CI, 0.05-0.10;
P = .08). The local Kenyan community health care workers readily accepted the Peek Acuity
smartphone test; it requiredminimal training and took no longer than the Snellen test (77
seconds vs 82 seconds; 95% CI, 71-84 seconds vs 73-91 seconds, respectively; P = .13).
CONCLUSIONS AND RELEVANCE The study demonstrated that the Peek Acuity smartphone
test is capable of accurate and repeatable acuity measurements consistent with published
data on the test-retest variability of acuities measured using 5-letter-per-line retroilluminated
logMAR charts.
JAMA Ophthalmol. 2015;133(8):930-937. doi:10.1001/jamaophthalmol.2015.1468
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V isual acuity (VA) is themost frequentlyperformedmea-sureofvisual function in clinical practice.Visual acuitymeasurementsareusedtoestablish theneedforclinical
investigation andquantify changes in central visionover time.
Four percent of those who attend general practice in the
UnitedKingdomdosowithaneyeproblem1 anda formalmea-
sureofVAshouldbepart of eachof these consultations.2Glob-
ally, 285millionpeoplehavevisual impairment,with80%hav-
ing diseases with known curative or preventive treatment.
However,most live in low-income countrieswithminimal ac-
cess to detection and subsequent treatment.3
The Snellen chart4 is the most common method for the
measurement of VA in ophthalmic and general practice; how-
ever, it is limitedby thenongeometric progression in letter siz-
ing from line to line and the inconsistent number of letters per
line.5 Different letters or optotypes (standardized symbols for
testingvision) havevarying legibility at the same size and sec-
ondary effects, such as crowding, are known to affect the abil-
ity of the patient to determine optotypes correctly and there-
fore could lead to measurement bias.
The limitationsof theSnellencharthave largelybeenover-
comewith the development of logMAR acuity charts,6 which
are now frequently used in clinical research, such as theEarly
Treatment Diabetic Retinopathy Study (ETDRS) charts. De-
spite this improvement, the Snellen chart remains the domi-
nant method for acuity testing in clinical practice.7 This may
be owing to several factors including familiarity, a well-
recognized scoring system, smaller chart size, and the speed
of performing the test relative to the ETDRS chart test.
Mobile telephone technology has evolved rapidly in re-
cent years. In 2013, an estimated 280 million (20%) of the 1.4
billionmobile telephones soldwere smartphonesand thispro-
portion is expected to increase, particularly in low-income
settings,8 where fixed-line technology has been leapfrogged
straight to mobile technology,9 providing the potential to ac-
cesshealthcarewithoutthepreviouslyrequiredinfrastructure.10
The medical community is embracing mobile technolo-
gieswith its potential in health care informationdelivery, real-
time patient monitoring, research data collection, andmobile
telemedicinefortheprovisionofexpertisetoremotelocations.10
We hypothesized that a logMAR-style smartphone-based
vision test (PeekAcuity),with a fast-testing algorithm,would
allowmeasurements tobemade inaclinically acceptable time,
with greater precision and reliability than is possible with
Snellen charts. Visual acuity results canbedisplayed in famil-
iar Snellen chart notation (imperial or metric) or logMAR.
The Peek Acuity test was developed and compared, in
terms of test-retest variability (TRV) andmeasurement time,
with the Snellen chart and the ETDRS-based tumbling E
logMAR chart (reference standard) in controlled and uncon-
trolled (real-world) settings in rural Kenya.
Methods
Participants
This study, conducted from December 11, 2013, to March 4,
2014, was nested within the 6-year follow-up of the Nakuru
Eye Disease Cohort in central Kenya, a population-based
study that recruited 5000 individuals from 100 clusters in
2007 selected through probability proportionate to the size
of the clusters, with individuals sampled within clusters
through compact segment sampling.11,12 Follow-up of the
participants was undertaken in 2013 and 2014.12 Three hun-
dred consecutive participants from the final 21 survey clus-
ters who were undergoing reference measures of VA as part
of the cohort follow-up were invited to enroll into this addi-
tional study of alternative VA measures. A temporary mobile
eye clinic was set up in the center of each cluster. All partici-
pants examined in the study were aged 55 years and older.
Ethics Approval
The study adhered to the tenets of the Declaration of
Helsinki13 and was approved by the ethics committees of the
London School of Hygiene and Tropical Medicine and the
African Medical and Research Foundation, Kenya. Approval
was sought from administrative heads in each cluster, usu-
ally the village chief, who were given a copy of the consent
form to read and pass on to those in the village.
Informed consent was obtained from all participants.
The objectives of the study and examination process were
explained in the local dialect in the presence of a witness.
All participants gave written (or thumbprint) consent to par-
ticipate.
Peek Acuity Test
The Peek Acuity application was written in Android and, for
thepurposes of this study,wasusedonaGalaxy SIII GT-I9300
(SamsungC&TCorp) runningAndroid4.0.Theapplicationwas
directly installed onto the test devices. Screenbrightnesswas
set to 100% within the application and all other options de-
tailed here are built in.
Peek Acuity follows the standard ETDRS chart design
with a 5 × 5 grid optotype letter E displayed in 1 of 4 orienta-
tions (90°, 180°, 270°, and 0°). The participant points in the
direction they perceive the arms of the E to be pointing and
the tester uses the touch screen to swipe accordingly, trans-
lating the gestures from the patient. The tester is masked to
the presented optotype and is unaware whether the partici-
pant is providing the correct response. This method reduces
verbal or nonverbal clues, which may bias the result. Single
At a Glance
• Visual acuity is an important measure of visual function,
necessary for decisionmaking with ophthalmic patients. This
research aimed to develop and validate a smartphone-based
visual acuity application.
• Peek Acuity appeared to be comparable in repeatability and
speed with Snellen acuity.
• Peek Acuity appeared to be comparable with Early Treatment
Diabetic Retinopathy Study logMAR for measuring visual acuity.
• Peek Acuity appeared to be reliable for in-home and in-clinic
assessment of visual acuity.
• Accurate measures of visual acuity can be performed
by nonhealth care personnel using Peek Acuity.
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optotypes are shown to reduce confusion; however, a bound-
ing box is used to simulate the crowding effect of a standard
ETDRS chart using a crowding bar, with thickness equivalent
to the limb of the optotype, and spacing between optotype
and crowding bar equal to that of half the total optotype size.
This contour interaction format matches that used by the ref-
erence standard ETDRS chart. A stair-casing algorithm is used
to simulate clinical practice for time efficiency.
Peek Acuity offers standardized alternatives to count fin-
gers, hand movements, and light perception. For count fin-
gers, the application randomly presents between 1 and 4 bars
and a correct or incorrect response is recorded on screen. For
handmovement, a solidblackbox,half thewidthof thescreen,
moves backward and forward across the screen. For percep-
tionof light,PeekAcuityswitchesonthe telephone’sLEDflash-
light and the participant is asked to identify if andwhen they
see the light comeonandoff,with theoption to assess for per-
ception of projection direction. Test completion is indicated
by a sound and vibration alert.
Visual acuity results can be displayed in logMAR or met-
ric or imperial Snellen units based on user preference. An ad-
ditional option, SightSim, presents a live video feed with a
gaussian blur equivalent to the outcome of the vision test
(eFigure 1 in the Supplement),which is of value in sharing the
information with those not familiar with acuity scoring.
Visual AcuityMeasurement
PairedVAmeasuresweremade inboth theparticipant’s home
and in the central clinic on2 consecutivedays. For all tests, the
presenting acuity was measured, with habitual correction if
worn. Onday 1, a health careworkerwith basic eye care train-
ing and a fieldworkerwithout formal health care training vis-
ited participants in their homes. The participantswere tested
using (1) Peek Acuity (logMAR units) at 2 m and (2) a reduced
3-m tumbling E Snellen chart (Sussex Vision) inside or close
to the participant’s home (eFigure 2 in the Supplement). The
order of the test was determined randomly by coin toss. The
detailed testing procedures are described in the eAppendix in
the Supplement.
On day 2, the participants seen on day 1 were reassessed
in the cluster’s central clinic. The same personnel retested
the study participants using (1) Peek Acuity (logMAR units)
at 2 m and (2) a reduced 3-m tumbling E Snellen chart to
allow for measures of TRV. The order of the test was deter-
mined randomly by coin toss. The ETDRS VA was measured
using a back-illuminated 4-m ETDRS chart (Precision Vision
Inc) (eFigures 3 and 4 in the Supplement) by an ophthalmic
clinical officer, which is the reference standard for this
study. All testing (ETDRS, Snellen, and Peek Acuity) at the
different cluster clinic sites was standardized: conducted
indoors, the test area was screened with blackout curtains,
and there were controlled ambient light levels within a range
of 80 to 300 lux (ISO-TECH: ILM1332A light meter), in accor-
dance with British standards for acuity assessment.14
Statistical Analysis
In total, 8 comparisons of the various VAmeasures in the dif-
ferent settings were made (Figure 1).
For any pairwise comparison of methods, the TRV was
estimated as 95% CI limits of agreement (mean paired differ-
ence between measures ±1.96 SD). Histograms of the distri-
bution of the test-retest and between-test method variability
data suggested that the data were consistent with a normal
distribution. Scatterplots of the observed TRV plotted
against the average of the difference between the test and
retest measurements suggested that there were no system-
atic associations between TRV and the underlying bias relat-
ing to level of acuity. Therefore, the Bland and Altman15
methods were used for (1) bias (mean and 95% CI of the
mean) between ETDRS (reference test) and both Snellen and
Peek Acuity scores and (2) TRV for the paired Snellen acuity
and Peek Acuity scores. Mean time scores between Snellen
and Peek Acuity tests were compared using paired t tests.
Acuity scores were converted into a logMAR for data analy-
sis. In the Supplement, eTable 1 outlines the logMAR scores
used including where acuity was too poor to measure with
optoytypes.16
Results
The Peek Acuity study took place between December 2013
and March 2014. Of the 300 participants selected, 293
enrolled (98%; 135 men and 158 women). In total, 272 people
(91%; mean age, 65 years; range, 55-97) were examined and
completed all 3 tests in the central clinic on day 2. Of these,
233 (86%) were available and had also taken both VA tests at
home on day 1.
Figure 1. Testing Regimen of Peek Acuity, Snellen, and LogMAR
in the Participants’ Homes and in Clinics
Home Clinic
4
5
6
8
1
2
3
7
1 represents Early Treatment Diabetic Retinopathy Study (ETDRS) in the clinic
(reference standard) vs Snellen in the clinic; 2, ETDRS in the clinic vs Peek
Acuity in the clinic; 3, Snellen in the clinic (clinical norm) vs Peek Acuity in the
clinic; 4, Snellen at home vs Peek Acuity at home; 5, ETDRS in the clinic vs
Snellen at home; 6, Snellen at home vs Snellen in the clinic (test-retest
variability); 7, Peek Acuity at home vs Peek Acuity in the clinic (test-retest
variability); and 8, ETDRS in the clinic vs Peek Acuity at home.
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The median VAmeasured by the ETDRS chart for all eyes
tested (all levels of vision including those unable to read the
ETDRS chart) was 0.23 logMAR, with a range of −0.2 to 4.0
logMAR (Snellen equivalents: median, 20/32; range, 20/12.5
to no light perception).
The results of the 8 pairwise comparisons of the right
eye VA described here are presented in Table 1 and Figure 2,
with results for the left eye available in the eAppendix in the
Supplement (no difference between the right and left eyes
was found; eTable 2 in the Supplement). The comparisons
of clinic-based Snellen and clinic-based Peek Acuity mea-
sures with the ETDRS chart under the standardized clinic
conditions indicated that Snellen tests showed a high
degree of correlation with the ETDRS chart but that this was
higher still with Peek Acuity (95% CI, 0.05-0.10; P = .08).
The mean difference between the Peek Acuity measure in
the clinic and the ETDRS chart measure was 0.011 logMAR
units (95% CI, −0.014 to 0.035) and 0.032 logMAR units (95%
CI, 0.010 to 0.054) for the right and left eyes, respectively.
This was equivalent to less than 3 letters on a line difference
when taking the upper confidence limit of the mean differ-
ence. The correlation (scatter) plots and Bland-Altman dif-
ference plots for these comparisons in the right eye are
shown in Figure 3A.
Comparing Peek Acuity tested at home with ETDRS test-
ing in the clinic, the mean difference between the Peek Acu-
ity score athomeand theETDRSscorewas0.055 logMAR (95%
CI, 0.023-0.088) and 0.072 logMAR (95% CI, 0.039-0.105) for
the right and left eyes, respectively, which is equivalent to
5 letters or 1 line of difference (Table 1; Figure 3B).
ThePeekAcuityTRV(comparison7as indicated inFigure1)
performedby the sameexaminer onday 1 at homeandonday
2 in the clinic had a high correlation and a small difference of
averages (Table 1; Figure 3C).17
Mean testing time for both eyes on 126 study participants
in whom testing timewasmeasuredwas 82 seconds (95% CI,
73-91 seconds)withSnellen and77 seconds (95%CI, 71-84 sec-
onds) with Peek Acuity, showing no difference (P = .13).
Peek Acuity used at home by a community health care
worker was 85% sensitive and 98% specific (eTable 3 in the
Supplement) at detecting eyeswith severe visual impairment
(deemed locally as the surgical cutoff point for operable cata-
ract; Snellen equivalent of ≤6/60) when compared with the
ETDRS testing in controlled conditions. In addition, therewas
excellent agreement acrossWorldHealthOrganization vision
categoriesbetweenETDRSandPeekAcuitywhenusedathome
(eTable 4 in the Supplement).
No adverse events fromperforming anyof the acuity tests
were reported.
Table 1. Results of the 8 Pairwise Comparisons of the Right Eye Showing Bland-Altman and Pearson Correlation Analysis
Comparison
Participants,
No. Description
Difference
of Average
95% CI
Mean
Difference
95% Limits
of Agreement
Pearson
Correlation
Coefficient
(95% CI)
1 272 ETDRS vs Snellen in the clinic 0.088 0.063 to 0.114 −0.329 to 0.506 0.932
(0.914 to −0.946)
2 272 ETDRS vs Peek Acuity in the clinic 0.011 −0.014 to 0.035 −0.396 to 0.417 0.936
(0.919 to 0.949)
3 272 Snellen in the clinic vs Peek Acuity in the clinic −0.078 −0.100 to −0.056 −0.439 to 0.283 0.950
(0.937 to 0.960)
4 233 Peek Acuity at home vs Snellen at home 0.029 −0.007 to 0.065 −0.517 to 0.575 0.902
(0.875 to 0.923)
5 233 ETDRS vs Snellen at home 0.084 0.043 to 0.125 −0.541 to 0.709 0.865
(0.828 to 0.894)
6 233 Snellen in the clinic vs Snellen at home −0.004 −0.038 to 0.030 −0.523 to 0.515 0.907
(0.881 to 0.927)
7 233 Peek Acuity at home vs Peek Acuity in the clinic −0.054 −0.083 to −0.025 −0.498 to 0.390 0.933
(0.914 to 0.948)
8 233 ETDRS vs Peek Acuity at home 0.055 0.023 to 0.088 −0.438 to 0.549 0.917
(0.893 to 0.935)
Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.
Figure 2. Difference of the Average
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The graph shows 8 outcomes (right eye), with difference of the average in
logMAR on the y-axis and comparisons on the x-axis. 1 represents Early
Treatment Diabetic Retinopathy Study (ETDRS) in the clinic (reference
standard) vs Snellen in the clinic; 2, ETDRS in the clinic vs Peek Acuity in the
clinic; 3, Snellen in the clinic (clinical norm) vs Peek Acuity in the clinic;
4, Snellen at home vs Peek Acuity at home; 5, ETDRS in the clinic vs Snellen at
home; 6, Snellen at home vs Snellen in the clinic (test-retest variability);
7, Peek Acuity at home vs Peek Acuity in the clinic (test-retest variability);
and 8, ETDRS in the clinic vs Peek Acuity at home.
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Figure 3. Scatter and Bland and Altman Plots
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Discussion
Theubiquityofsmartphonesamonghealthcareprofessionals18
and increasing penetration, particularly in low- and middle-
income countries, provide potential for delivering high-
quality, objective, repeatable, and acceptable vision testing
throughout the world.
With most of the world’s blind people living in low-
income countries, the need for tools to increase early detec-
tion and appropriate referral are vital if the prevalence of
blindness and visual impairment is to be reduced. In high-
income settings, where primary care consultations are time
pressured and confidence in diagnosing ophthalmic prob-
lems is low,19 accessible tools to provide reliable measures to
guide management are vital. The referral of patients with
ophthalmic symptoms from primary care, such as in general
practice or accident and emergency, to specialist care should
include a measure of acuity that is reliable and accessible
and further testing in these contexts is encouraged.
In this study, we aimed to develop and validate a smart-
phone-based VA test appropriate for use in challenging cir-
cumstances, such as rural Africa, as well as being reliable
enough for use in routine clinical practice inwell-established
health care systems.Overall, PeekAcuity performedwell and
the testing timewasno sloweror less repeatable thanwith the
Snellen test,while being comparable in accuracy to theETDRS
chart.Forclinical andpopulationscreeninguse, theTRVofacu-
ity should be consistent across the acuity range and measur-
able in terms of lines or letters of change;measurement error
obscures true clinical changeand reduces the statistical power
of clinical trials using acuity as a primary outcomemeasure.20
PeekAcuity testingproved tobe repeatableandconsistent.Our
findings also indicated that the reduced Snellen chart is a re-
peatable and time-efficientVA test that still has application in
clinical and field settings.
In our study, theTRVof the Snellen chartwas higher than
incomparablestudies,5,21whichmayhavebeenowingtotightly
definedendpoints (nopart scoreswere given for part comple-
tion of a line).
Although multiple applications for the testing of VA on
smartphones are available, to our knowledge, most have not
been tested for repeatability or reliability against a reference
standard.22ThisstudyfoundPeekAcuity tobecomparablewith
ETDRS-style chart, with similar TRV to that previously re-
ported for other tests.23,24Key attributes andbenefits for Peek
Acuity are outlined in Table 2.
LowVision
Low vision in participants who have VA below the level that
can be measured on a chart are subject to assessment of
vision that lacks a standardized approach and is open to con-
siderable variability. In standard practice, if no optotypes are
visible at the reduced distance, counting fingers is per-
formed, followed by hand movements and finally differenti-
ating between perception of light and no perception of light.
In practice, this crucial measure of vision that may differen-
tiate poor and good prognosis for treatment is often over-
looked owing to these nonstandardized measures. Peek Acu-
ity offers a standardized approach to testing such low levels
of vision, which could be also performed on a tablet but was
not assessed formally in this study.
Limitations
The study population comprised older-aged Kenyan adults,
who may not be representative of other populations and age
groups, limiting the generalizability. Other studies are ongo-
ing to determine the suitability of this tool in different con-
texts across a range of different handsets and operating sys-
tems (this studyonlyassessed thedeviceonmultiplehandsets
of the same telephone model and operating system), includ-
ing a school-aged population. Reflection from smartphone
Table 2. Key Attributes and Potential Benefits of Peek Acuity
Key Attribute Potential Benefits
Use of E optotype widens accessibility
to those unable to read letters
Increased objectivity of test
Use of E optotype rather than letters
ensures acuity is resolution based
rather than recognition based
Random optotype direction prevents
learning effect from one eye
to the other
Automated visual acuity
score calculation
End-of-test indicator (vibration
and sound alert)
Gesture-based recording of responses,
making the test more objective
by swiping in the direction indicated
while not seeing the letter and shake
to record not seen
Standardized low-vision measurement
tools for count fingers, hand
movements, and perception of light
Standardized testing and
prompts for control
of conditions
Ambient light sensor used for adjusting
screen brightness and detecting
threshold ambient light levels above
which acuity measurements decrease
in accuracy
Use of ETDRS-based optotype with
result available in all the standard units:
decimal, logMAR, metric Snellen,
and imperial Snellen
Easy interpretation
of the results
Live video feed demonstrating
appropriate level of gaussian blur
according to outcome of the vision test
(eFigure 1 in the Supplement), which is
of value in sharing the information with
those not familiar with acuity scoring
Downloadable from the Google
Play Store
Accessible and validated
CE marked (class I)
Smartphone based Potential to store data to
an electronic patient record,
increasing efficiency of data
management and limiting
potential recording error
Data can be shared remotely
with other health care
professionals for feedback
The electronic patient record
can be geotagged, which is
of particular value in
resource-limited settings
where addresses may not be
available and patient follow-up
is challenging
Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.
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screens owing to bright sunlight can be problematic, al-
thoughantiglare screenshavebeen shown to reduce this limi-
tation on other platforms.25 Smartphones are on the whole
more expensive than a basic Snellen chart but less expensive
than a retroilluminated logMARor Snellen chart.With the in-
creasedavailabilityof low-cost smartphonesand tablets,many
health care workers may already own a device suitable for
downloading multiple applications.26
Concerns exist about data sharing and misuse with mo-
bile health platforms, which should be integrated with sys-
tems compliant with approved standards for data sharing.
Owing to the size,weight, andpower requirements, itwas
not possible to perform the ETDRS chart test in participants’
homes and, therefore, TRV of the ETDRS test was not as-
sessed as with the Snellen and Peek Acuity tests. Therefore,
we were unable to assess ETDRS TRV in this environment.
Nonhealthcareworkerswhoreceivedspecifictraininginhow
to use PeekAcuity performed the testing; further investigation
ofPeekAcuity’susabilitywithonlyinbuilt instructionsisrequired.
Testing Distance
During the early development phase, Peek Acuity was per-
formed at 3 m. However, in the study setting, it was often not
possible to find an indoor spaceof 3m to conveniently perform
the test. In conditionswhere the ambient lightmeasure on the
telephonewas greater than 1000 lux, measures of Peek Acuity
did not correlate well with the reference standard. With a 4.8-
inch screen, 720 × 1280pixels, and a viewingdistance of 2m, it
ispossibletomeasureacuityof1.0 logMARand1.3 logMAR(Snel-
lenequivalentof20/200and20/400,respectively)whenthetest-
ing distance is reduced to 1 m. Therefore, the testing distance
and software algorithm were changed to 2 m. Following this
change, more than 90% of participants were tested indoors in
their homes. The smartphone’s inbuilt ambient light detector
(whichwasaccessedinthePeekAcuityapplicationtogiveamean
lux readingperVA test) provides awarning that test conditions
are not suitable if more than 1000 lux is detected.
Implications
Themorewidespread testingofVA in low- andmiddle-income
countries is likely to lead to greater awareness of treatable eye
diseasewithanincreaseduptakeofpreventiveandcurativetreat-
ments.Innonophthalmicdepartments,aneasilyaccessible,easy-
to-use, accurate, andreliablevision test could lead to increased
assessment of vision testing in routine practice.27
Conclusions
Additional applications to assess visual function and imaging
of the eyemake smartphones an attractive option for deliver-
ing ophthalmic assessment.28,29 In settings where ophthal-
mic instrumentationorophthalmic-trainedpersonnel are lim-
ited, the ability to reliablymeasure a change invisionordetect
abnormal vision, automation of stair-casing, masking of pre-
sented information, and generation of a jargon-free result
greatly improveefficacy in thehandsofminimally trainedper-
sonnel. The inherent connectivity and global positioning sys-
tem features of thedevicemayultimately lead tomorepeople
receiving timely and appropriate treatment.
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Clinical Validation of a Smartphone-Based Adapter
for Optic Disc Imaging in Kenya
Andrew Bastawrous, MBChB, BSc(Hons), FHEA, MRCOphth; Mario Ettore Giardini, PhD; Nigel M. Bolster, MEng;
Tunde Peto, MD, PhD; Nisha Shah, MSc; Iain A. T. Livingstone, FRCOphth; Helen A. Weiss, PhD; Sen Hu, MSc;
Hillary Rono, MBBS; Hannah Kuper, ScD; Matthew Burton, PhD, MA, MBBCh, MRCP, MRCOphth, DTM&H
IMPORTANCE Visualization and interpretation of the optic nerve and retina are essential parts
of most physical examinations.
OBJECTIVE To design and validate a smartphone-based retinal adapter enabling image
capture and remote grading of the retina.
DESIGN, SETTING, AND PARTICIPANTS This validation study compared the grading of optic
nerves from smartphone images with those of a digital retinal camera. Both image sets were
independently graded at Moorfields Eye Hospital Reading Centre. Nested within the 6-year
follow-up (January 7, 2013, to March 12, 2014) of the Nakuru Eye Disease Cohort in Kenya,
1460 adults (2920 eyes) 55 years and older were recruited consecutively from the study. A
subset of 100 optic disc images from bothmethods were further used to validate a grading
app for the optic nerves. Data analysis was performed April 7 to April 12, 2015.
MAIN OUTCOMES ANDMEASURES Vertical cup-disc ratio for each test was compared in terms
of agreement (Bland-Altman and weighted κ) and test-retest variability.
RESULTS A total of 2152 optic nerve images were available from bothmethods (also 371 from
the reference camera but not the smartphone, 170 from the smartphone but not the
reference camera, and 227 from neither the reference camera nor the smartphone).
Bland-Altman analysis revealed amean difference of 0.02 (95% CI, −0.21 to 0.17) and a
weighted κ coefficient of 0.69 (excellent agreement). The grades of an experienced retinal
photographer were compared with those of a lay photographer (no health care experience
before the study), and no observable difference in image acquisition quality was found.
CONCLUSIONS AND RELEVANCE Nonclinical photographers using the low-cost smartphone
adapter were able to acquire optic nerve images at a standard that enabled independent
remote grading of the images comparable to those acquired using a desktop retinal camera
operated by an ophthalmic assistant. The potential for task shifting and the detection of
avoidable causes of blindness in themost at-risk communities makes this an attractive public
health intervention.
JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2015.4625
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A total of285millionpeople arevisually impairedworld-wide (Snellen acuity <6/18) of whom 39 million areblind (<3/60 better eye). Low-income countries carry
approximately 90% of the burden of visual impairment, and
80% of this can be prevented or cured.1
There is awideninggapbetween thenumberof eyehealth
careprofessionalsworldwide andan increasingneedaspopu-
lations enlarge and age. Blinding eye disease is most preva-
lent in older people, and in many regions the population 60
years and older is increasing at twice the rate of the number
of health care professionals.2,3
Diseases of the posterior segment are responsible for up
to 37%of blindness in sub-SaharanAfrica.4However, diagno-
sis, monitoring, and treatment are challenging in resource-
poor countries because of a lack of trained personnel and the
prohibitive cost of imaging equipment.
Retinal imaging is frequently used in the diagnosis and
monitoring of diseases, such as diabetic retinopathy, glau-
coma and age-related macular degeneration, retinopathy of
prematurity,5 and systemic diseases, such as hypertension,6
malaria,7 human immunodeficiency virus or AIDS,8 and
syphilis.9
Ophthalmologists, physicians, andeye-careworkershave
used ophthalmoscopes of varying types for more than 150
years, with the first reported use by Dr William Cumming in
1846.10The development of fundus cameras hasmade it pos-
sible to record and share images to collect evidence of dis-
ease presence, severity, and change.
The advent of digital imaging has made recording, pro-
cessing, and sharing of images far quicker and cheaper than
previous film-basedmethods.11However, retinal cameras re-
main impractical in many low-income countries and in pri-
mary care settings throughout the world where early detec-
tionofeyedisease isprohibitedbecauseofhighcost, large size,
lowportability, infrastructure requirements (eg, electricityand
road access), and difficulty of use.
Mobile telephoneaccesshas reachednear-ubiquitous lev-
els worldwide,12 with the highest worldwide increase in the
rateofmobile telephoneownership inAfrica.Telemedicinehas
in recent years begun to favorwireless platforms, with newer
smartphonedeviceshavinghigh-poweredcomputational func-
tions, cameras, image processing, and communication
capabilities.13Mobile telephone cameras are promisingwhen
attached to imaging devices, such as microscopes14 and slit-
lamp biomicroscopes15; however, they remain impractical in
many remote settings because of the size and expense of the
equipment to which the smartphone is attached. The devel-
opment of a handheld smartphone device used in clinicalmi-
croscopy has proven successful.16
Retinal imaging is inprinciplesimilar tousingamicroscope;
however, it ismorecomplexbecauseof the interactionbetween
thecameraopticswith theoptics and illuminationof theeye.17
Thegoalof thesmartphone-basedadapter (PortableEyeExami-
nationKit [PeekRetina])prototypewas todemonstrate the fea-
sibility of creating a portablemobile telephone retinal imaging
systemthat isappropriate for fielduse inKenyaandsimilarcon-
texts, characterized by portability, low cost, and ease of use by
minimally trained personnel. Our primary aimwas to validate
such a smartphone adapter for optic nerve imaging in the con-
text of a population-based study inNakuru, Kenya.18
Methods
Participants
Participants included in the study were from the follow-up
phase of a population-based cohort study on eye disease in
Kenya (January7,2013, toMarch 12,2014).18Onehundredclus-
ters were selected at the baseline (January 26, 2007, to No-
vember 11, 2008), with a probability proportional to the size
of the population.19 Households were selected within clus-
ters using a modified compact segment sampling method.20
Each cluster was divided into segments so that each segment
included approximately 50 people 50 years or older. An eli-
gible individualwas defined as someone 50 years or older liv-
ing in the household for at least 3months in the previous year
at baseline and who was found and consented to follow-up
assessment 6 years later (2013-2014).
Thesmartphone-basedadapterwasavailable foruse in the
final 75 of the 100 clusters revisited, and all available partici-
pants in those clusters were examined. All participants were
examinedwithboth thesmartphone-basedadapterandadesk-
top retinal camera (CentreVue+Digital Retinal System,Haag-
Streit), which acted as the reference standard.
Ethics Approval
The study adhered to the tenets of the Declaration of Helsinki
and was approved by the ethics committees of the London
SchoolofHygieneandTropicalMedicineandtheAfricanMedi-
calandResearchFoundation,Kenya.Approvalwasalsogranted
bytheRiftValleyprovincialmedicalofficerandtheNakuruDis-
trict medical officer for health. Approval was sought from the
administrative heads in each cluster, usually the village chief.
Informed Consent
Informedconsentwasobtainedfromallparticipants.Theobjec-
tives of the study and the examinationprocesswere explained
in the localdialect to thoseeligible in thepresenceof awitness.
All participants gavewritten (or thumbprint) consent.
TestMethods
Pharmacologicdilationinthepupilsofall studyparticipantswas
achieved using tropicamide, 1%, with phenylephrine, 2.5%, if
At a Glance
• Feasibility of a smartphone adapter for optic nerve imaging to
desktop retinal camera was evaluated in Kenya.
• Differences in quality from image acquisition with a smartphone
adapter by photographers not trained in health care compared
with photographers trained in eye care were not identified.
• Images from the smartphone adapter appeared comparable to
images from a desktop camera when independently graded by
experts.
• These imaging systemsmaymake such data collectionmore
feasible in similar settings.
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needed. Dilationwas not performed in participants deemed at
risk fornarrowangleclosure (inability tovisualize>180°ofpos-
terior pigmented trabecularmeshwork on nonindentation go-
nioscopyat theslitlampby thestudyophthalmologist [A.B.]21).
Examination with the reference camera and the smart-
phone-based adapterwasperformed in adimly lit room;how-
ever, conditions slightly varied among clusters. An ophthal-
mic assistant took retinal images with the reference camera,
and 1 of 2 operators or photographers used the smartphone-
basedadapter; all usersweremasked to the alternative exami-
nation. The 2 examinations took place in different rooms as
availability allowed (Figure 1).
Reference Retinal Photography
An ophthalmic assistant digitally photographed the lens and
fundus on all study participants with the reference camera,
which is approved for national diabetic retinopathy screen-
ing in the United Kingdom (https://www.gov.uk/government
/collections/diabetic-eye-screening-commission-and-
provide). Two45° fundusphotographswere taken ineacheye:
one optic disc centered and the other macula centered. Im-
ages were then securely uploaded to theMoorfields Eye Hos-
pital Reading Centre (MEHRC) for review and grading.
Smartphone-Based Photography of the Optic Disc
Anexperiencedophthalmicclinicalofficeroralaytechnicianwith
no health care background used a digital retinal camera (Sam-
sung SIII GT-I9300; Samsung C&T Corp) and its native 8.0-
megapixel camera with the smartphone-based adapter (Peek
Retina) (eFigure 1 in theSupplement) toperformdilated retinal
examinations on study participants. Images were recorded as
video (approximate3-10 secondsat3-7MBpereye)with single
frames (<0.5MB)usedfordiscanalysis.Bothexaminers,hence-
forth termedphotographers, receivedbasic training inanatomy
and the identificationof retinal features (includingopticnerve
and optic cup) at the beginning of the study.
Thesmartphone-basedadapterconsistsofaplasticclip that
covers the telephonecameraandflash (whiteLED)withaprism
assembly. Theprismdeflects light from the flash tomatch the
illumination path with the field of view of the camera to ac-
quire imagesof the retina. Thephone camera andclip areheld
in front and close to the eye, which allows the camera to cap-
ture images of the fundus.22 A video sweep of the optic disc
was performed using the adapter on a smartphone with the
native camera app on each eye and securely uploaded to the
MEHRC for review and grading. A 1-hour training session on
how touse the smartphone-based adapterwas performedbe-
fore the study commenced.
In a random subset of 100 optic nerve examinations per-
formedwith the smartphone-basedadapter, bespoke software
(PeekGrader, PeekVision) (Figure 2) was used by 2 local study
examiners (onenonophthalmologist experienced in retinal ex-
aminationandonewithnohealthcare training, independentof
theoriginalphotographers) toselect still imagesof theopticdisc
fromthevideosweepanduseon-screencalipers tomeasure the
vertical cup-disc ratio (VCDR)withnotrainingprovidedbeyond
that in the app instructions on caliper placement.
DataManagement and Analysis
All imageswere initially examinedona large screendisplay for
quality.Forgradableimages,2 independentgradersreviewedop-
ticdiscpairs. Incaseofgradingdifficulties, theadjudicator (T.P.)
determinedtheimagegradeandverifiedarandomsampleof10%
of images forquality assuranceandcontrol.Graders regradeda
random selection of 100 images after aminimumof 14 days to
assess intragrader reliability.Theadjudicator alsograded5%of
randomly selected images to ensure quality control. Datawere
checked for consistencybyadatamonitor (N.S.).Opticdisc im-
agesweregradedasnormal, suspicious,orabnormal.Adiscwas
considered abnormal if therewas neuroretinal rim thinning as
definedbythe ISNTrule (normaleyeshaveacharacteristic con-
figuration fordisc rimthicknessof inferiorgreater thanorequal
to superior greater than or equal to nasal greater than or equal
to temporal),23notchingordischemorrhagewaspresent,or the
VCDRwas0.7orgreater.Asuspiciousdiscwasoneforwhichad-
judicationwasnecessary todeterminewhether its appearance
was abnormal.
Service Provision
All participants identified as having treatable disease in this
studywereofferedappropriatecare, including freesurgeryand
transport to the Rift Valley General Provincial Hospital or St
Mary’s Mission Hospital, Elementaita. A trained ophthalmic
nurseorophthalmicclinicalofficerdiscussedthediagnosisand
Figure 1. Examination Using the Reference Desktop Retinal Camera (A) and the Smartphone-Based Adapter (B)
A B
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providedcounseling to thestudyparticipants. Inaddition,non-
studyattendeeswereexaminedand treatedby thestudy team.
Statistical Analysis
WeusedtheBland-Altmanmethod24 toanalyzeagreementand
repeatabilitybetweenandwithindiagnostic testsandweighted
κscores tocompare theVCDRmeasurementsmadeondifferent
image sets or on regrading.24,25 For κ weighted agreement of
VCDRbetween observers and imagingmethods, the following
weightswereapplied: 1.0 fora0.0difference,0.95 fora0.05dif-
ference,0.90 fora0.10difference,0.50 fora0.15difference,0.20
for a 0.20 difference, and 0.00 for all differences greater than
0.20asused inapreviousanalysisofdiscagreement.25Weper-
formed the following specific comparisons:
1. Referencedesktopretinalcamera imagerepeatability: subset
of 100 optic disc images randomly selected for repeat grad-
ing by anMEHRCgrader to assess intraobserver agreement.
2. Smartphone-based adapter repeatability: subset of 100op-
tic disc images randomly selected for repeat grading by an
MEHRCgrader to assess intraobserver agreement (the same
individuals used for reference image intraobserver repeat-
ability assessment).
3. Reference desktop retinal camera images by expert grader
on large screenvs smartphone-based adapter imagesusing
the on-screen calipers in Peek Grader (Figure 2): the same
100 images as comparisons 1 and 2.
4. Smartphone-based adapter images by anMEHRCgrader on
the large screen vs smartphone-based adapter images by a
field ophthalmologist or layperson using Peek Grader: the
same 100 images as comparisons 1 and 2.
5. ReferencedesktopretinalcameraimagesbyanMEHRCgrader
vssmartphone-basedadapter imagesbyanMEHRCgraderon
a large screen: all 2152 image pairs analyzed together.
6. Reference desktop retinal camera images by an MEHRC
grader vs smartphone-based adapter images by anMEHRC
grader on a large screen: 2152 image pairs subdivided by
whether the imageswere collected by an experiencedpho-
tographer or a lay photographer.
Results
Participants
Recruitment tookplace fromJanuary7,2013, toMarch 12,2014.
A total of 1460 individuals from 75 clusters participated. Their
mean (SD) age was 68 (9) years (range, 55–99 years), and 700
(47.9%)werefemale.Participantsunderwentretinalexamination
using the smartphone-basedadapter and the standarddesktop
retinal camera.A total of2920eyeswere imaged,ofwhich2152
eyes (73.7%) had gradable images from both the smartphone-
basedadapterand the referencecamera. In 170eyes, agradable
imagewasobtainablewiththesmartphone-basedadapterbutnot
thereferencecamera,and,conversely, in371eyes,agradable im-
agewas obtainablewith the reference camera but notwith the
smartphone-basedadapter. In227eyesadisc imagewasnotpos-
sible fromeithermodality (eFigure 2 in the Supplement).
Figure 2. Peek Grader Being Used toMeasure Vertical Cup-Disc Ratio on the Telephone
Disc Grading NEXT Disc Grading NEXT
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Reference Image Disc Parameters
TheVCDRparametersderived fromtheanalysisof the2152 ref-
erence desktop retinal camera images from this population
(eFigure 3 in the Supplement), using the definitions in the In-
ternational Society forGeographical andEpidemiologicalOph-
thalmology classification,were as follows:meanVCDR,0.38;
97.5th percentile VCDR,0.7; and99.5th percentile, VCDR0.9.
Intraobserver Repeatability
A set of images from 100 eyes were used to assess intraob-
server repeatability. Bland-Altmananalysis andκ scores found
excellent intraobserver repeatability for the MEHRC graders
for both the reference desktop retinal camera images (Table,
comparison 1) and the smartphone-based adapter images
(Table, comparison 2).
Comparison of Expert and Field Grading
For the same 100 eyes, we compared the VCDRmeasured on
the reference desktop retinal camera images by the MEHRC
grader and the images of the same eye taken with the smart-
phone-based adapter with the VCDR graded on the tele-
phone screen (Figure 2) by an ophthalmologist (Table, com-
parison 3a) or a layperson (Table, comparison 3b). Although
themeandifferenceof themeanby theBland-Altmanmethod
was less than 0.1, the weighted κ scores were relatively low.
We performed a similar analysis with the smartphone-based
adapter image graded by the MEHRC grader compared with
the VCDR measured with the Peek Grader (Table, compari-
sons4aand4b).Weagain founda small difference in themean
difference but low κ scores.
Comparison of Reference and Smartphone-Based
Adapter Images
We compared (Table, comparison 5) the VCDRmeasured by an
expertgrader (MEHRC)fromthesmartphone-basedadapterand
reference digital retinal camera images for 2152 eyes (eTable in
theSupplement).TheBland-Altmananalysis foundadifference
in themeanof−0.02 (95%CI,−0.21 to0.17) (Figure 3).
Interexaminer Variability
Twomembersofthefieldteamcollectedretinal imagesusingthe
smartphone-based adapter. The first was a trained eye care
workerexperiencedintheassessmentof theretina(experienced
photographer). The secondhadnopriorhealth careor eyecare
experiencebutwasproficientintheuseofasmartphone(laypho-
tographer).Bland-Altmananalysiswasperformedcomparingthe
reference images and smartphone-basedadapter images, both
graded at theMEHRC. For the 1239 eyes that had smartphone-
basedadapter imagescollectedby theexperienced retinalpho-
tographer, thedifference in themeanwas−0.02 (95%CI,−0.22
to 0.17) (Table, comparison 6a). For the 913 eyes that had
smartphone-basedadapter imagescollectedby the layphotog-
rapher, thedifference inthemeanwasalso−0.02 (95%CI,−0.20
to0.16) (Table, comparison6b).Therewasnoobservablediffer-
ence in imageacquisitionqualitybetweentheexperiencedreti-
nal photographer and lay photographer.
Discussion
The findings of this study are discussedwithin the context of
optic disc imaging in a population-based study in Kenya. We
compared the performance of 2 imaging modalities and dif-
ferent image-gradingexpertise.Theresults indicate that smart-
phone-based adapter images, when analyzed by an indepen-
dent expert, have excellent agreement with images from a
reference desktop retinal camera read by the same expert.
Intraobserver agreement within imaging modalities was
also excellent for the reference camera and the smartphone-
based adapter images. This finding indicates a high degree of
confidence to be able tomeasure real change over timewhen
a threshold for VCDR increase of 0.2 or greater is used.
Table. Agreement (Bland-Altman andWeighted κ) of Optic Disc VCDR Scores Among Different ImagingModalities and Different Gradersa
Comparison
No.b
Reference Image Comparison Image No.
of Eyes
Mean VCDR Difference
(95% CI)
Weighted κ,
Mean (SD)Camera Grader Screen Camera Grader Screen
1 Reference
camera
Expert Large Reference
camera
Expert Large 100 −0.07 (−0.21 to 0.07) 0.90 (0.01)
2 Smartphone Expert Large Smartphone Expert Large 100 −0.01 (−0.18 to 0.16) 0.77 (0.04)
3a Reference
camera
Expert Large Smartphone Ophthalmologist Telephone 100 −0.08 (−0.11 to −0.53) 0.30 (0.07)
3b Reference
camera
Expert Large Smartphone Nonophthalmologist Telephone 100 −0.07 (−0.38 to 0.24) 0.19 (0.06)
4a Smartphone Expert Large Smartphone Ophthalmologist Telephone 100 −0.08 (−0.11 to −0.56) 0.35 (0.07)
4b Smartphone Expert Large Smartphone Nonophthalmologist Telephone 100 −0.06 (−0.33 to 0.21) 0.25 (0.06)
5 Reference
camera
Expert Large Smartphone Expert Large 2152 0.02 (−0.21 to 0.17) 0.69 (0.01)
6a Reference
camera
Expert Large Smartphone
(experienced
examiner)
Expert Large 1239 −0.02 (−0.20 to 0.17) 0.68 (0.02)
6b Reference
camera
Expert Large Peek
(lay examiner)
Expert Large 913 −0.02 (−0.21 to 0.16) 0.71 (0.02)
Abbreviation: VCDR, vertical cup-disc ratio.
a Expert indicates grading was performed by an independent trained grader or
image reader; nonophthalmologist, grading performed by a non–health care
worker; and ophthalmologist, grading performed by an ophthalmologist.
b The comparison number relates to the specific comparisons that are described
in theMethods section.
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Although the Bland-Altman limits of agreement were ac-
ceptable for all comparisons, the smartphone-based adapter,
particularly when performed by a nonclinically trained user,
was of only fair or slight agreement with the expertly graded
reference image.The lower levelsof agreementwith thesmart-
phone-based adapter may be accounted for by images being
graded on a small screenwith no user guidance given beyond
basic instructions within the app to “measure the disc” and
“measure the cup.”
Although stereoscopic disc images are the preference for
opticnervegrading,monoscopic images, asused in this study,
do not represent a disadvantage for grading glaucoma
likelihood.26 The finding that nonclinically trained person-
nel canacquire imagesof theopticdiscusinga low-cost smart-
phone adapter that are of a standard that appears comparable
to a desktop retinal camera operated by a dedicated ophthal-
mic technician or assistant suggests there is potential for use
of such devices in mobile health and tele-ophthalmology.
In this study, we only assessed optic disc features; how-
ever, potential use in retinal diseaseswarrants further investi-
gation, the findings of which would have implications for dia-
beticretinopathyscreeningprograms.Previouslydescribeduses
of smartphone-based cameras for diabetic retinopathy have
been inaclinic settingwhenoperatedbya retinal specialist and
found to provide good agreement with slitlamp biomicros-
copy examination also performed by a retinal specialist.27,28
Further assessment of smartphone-based tools bynonspecial-
ists in nonophthalmic settings is warranted.
A limitation of this study, typical of clinical research
based on highly iterative technologies, is that, in relying on
rapidly evolving platforms, the time to dissemination of
results is long compared with the evolution of the technology
itself. This limitation often results in the presentation of data
from technology that have been superseded by subsequent
prototypes or commercially available devices. In this field
study, an early iteration of the smartphone-based adapter (in-
ternally identified asmark II) was used throughout. However,
by the time of completing the analysis, a more advanced
iteration of the smartphone-based adapter (mark VI) was
available. An image acquired using mark VI is shown in
Figure 4. When compared with Figure 2, which shows an
image frommark II, a significant improvement is evident.
A further limitation is that no evaluation of optic discs
from either imaging modality was performed without
mydriasis. Previous investigations have found the limits of
agreements between nonmydriatic optic disc grading to be
outside clinically acceptable levels.29 We found it possible to
acquire good optic nerve images in undilated pupils of 2.5-
to 3.0-mm diameter.
Thesmartphone-basedadapterprototypes,subsequentcom-
mercially available devices, and alternative portable retinal
imagingsystemscouldcontributetotacklingavoidableblindness
and in screening for diseaseswith eyemanifestations, particu-
larly in low-income countries and remote communities where
mobile telephone infrastructure is ubiquitous but trained per-
sonnelare few.Existing telecommunications infrastructurecan
enable greater access to health care by permitting timely diag-
nosisusingdata sharingvia thecommunicationcapabilities in-
trinsictothetelephone.Withthedevelopmentofautomatedreti-
nal imaging systems,30wecould see real-timediagnostics by a
technician rather than by themore scarcely available eye care
personnel.
Coupling imagingwith other smartphone-baseddiagnos-
tic tests31 and geotagging enables database creation of exam-
ined individuals basedonpredeterminedparameters as dem-
onstratedby systems suchasEpiCollect.32Such systemsmake
follow-up and epidemiologic data collectionmore feasible in
resource-poor settings.
Conclusions
Smartphone penetration continues to increase with higher
computing power, purpose-built software and hardware,
greater connectivity, and lowerhandset costs. There is nowan
opportunity to reach the most underserved populations in a
manner that was not possible just a decade ago.
Figure 3. Bland-Altman Plot of 2152 Optic Nerve Images Taken From the
Reference Desktop Retinal Camera and the Smartphone-Based Adapter
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Both images were graded by an expert grader at Moorfields Eye Hospital
Reading Centre.
Figure 4. Retinal and Optic Disc Image FromPeek RetinaMark VI Taken
Through a Dilated Pupil With an Approximate Field of View of 20° to 30°
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Abstract
Background: The Portable Eye Examination Kit (Peek) is a mobile phone–based ophthalmic testing system that has been
developed to perform comprehensive eye examinations. Peek offers a solution for overcoming barriers of limited access to
traditional ophthalmic testing methods and has been pilot tested on adults in Nakuru, Kenya, and compared with traditional eye
examination tools. Shortages in ophthalmic personnel, the high cost, and the difficulty in transporting equipment have made it
challenging to offer services, particularly in rural areas.
Objective: This qualitative study evaluated the acceptability and usability of Peek in addition to perceptions regarding its
adoption and nationwide deployment.
Methods: Semistructured interviews were conducted and analyzed using a framework approach. This included analysis of
interviews from 20 patients, 8 health care providers (HCPs), and 4 key decision makers in ophthalmic health care provision in
Kenya. The participants were purposefully sampled. The coding structure involved predefined themes for assessing the following:
(1) the context, that is, environment, user, task, and technology; (2) patient acceptability, that is, patients' perceived benefits,
patient preference, and patient satisfaction; (3) usability, that is, efficiency, effectiveness, learnability, and flexibility and operability
of Peek; and (4) the benefits of Peek in strengthening eye care provision, that is, capabilities enhancer, opportunity creator, social
enabler, and knowledge generator. Emerging themes relating to the objectives were explored from the data using thematic analysis.
Results: Patients found Peek to be acceptable because of its benefits in overcoming the barriers to accessing ophthalmic services.
Most thought it to be fast, convenient, and able to reach a large population. All patients expressed being satisfied with Peek. The
HCPs perceived it to satisfy the criteria for usability and found Peek to be acceptable based on the technology acceptance model.
Peek was also found to have features required for strengthening ophthalmic delivery by aiding detection and diagnosis, provision
of decision support, improving communication between provider and patient and among providers, linking patients to services,
monitoring, and assisting in education and training. Some of the deployment-related issues included the need for government and
community involvement, communication and awareness creation, data protection, infrastructure development including capacity
creation, and training and maintenance support.
Conclusions: According to all parties interviewed, Peek is an acceptable solution, as it provides a beneficial service, supports
patients' needs, and fulfills HCPs' roles, overall contributing to strengthening eye health.
(JMIR mHealth uHealth 2016;4(1):e30)   doi:10.2196/mhealth.4746
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Introduction
Background
The estimated number of visually impaired people worldwide
is 285 million, of which 39 million are blind [1]. Up to 80% of
global visual impairment is preventable [1].The burden is
unequally distributed, with the largest proportion living in
low-income nations of Africa and Asia [2]. Loss of sight is
associated with considerable emotional, social, and economic
consequences, especially among the poor [3,4]. One of the
biggest challenges to reducing the burden of visual impairment
is the significant shortage of ophthalmic health care [5].
Ophthalmic testing equipment is often expensive, bulky, and
immobile, making it difficult to deploy an ophthalmic service
in rural areas, particularly where there are fewer ophthalmic
professionals.
Tackling avoidable vision loss requires strengthening of health
systems (HSs) in order to achieve universal access to ophthalmic
services. This has been a major focus of the global ophthalmic
public health community and a key goal of the recent World
Health Organization (WHO) global action to improve eye health
for everyone over the next 5 years, building on the principles
of VISION 2020 [6].
Mobile health (mHealth) refers to the use of mobile technology,
such as mobile phones (MPs), to provide health services. Mobile
health is a growing field and its potential in improving health
and health care delivery has been well demonstrated [7-9]. There
are significant opportunities to leverage the benefits of mHealth
in expanding health care delivery with the increasing uptake of
MPs in the developing world [10]. Furthermore, the scope of
mHealth has increased in recent years with the introduction of
smartphones, which offer enhanced functionality and user
interfaces over traditional multimedia devices.
In Africa, smartphones are becoming more affordable, driven
by greater competition among operators and manufacturers.
Smartphone subscriptions in Africa have been forecast to
increase from 79 million to 412 million between 2012 and 2018
[11]. Nevertheless, the evidence base for smartphone use in
health care is lacking, particularly contextual process and health
outcome evaluations in low- and middle-income countries
[12-16].
This study aimed to evaluate a smartphone-based ophthalmic
examination system with clip-on hardware, the Portable Eye
Examination Kit (Peek), which has been developed and
introduced as a user-friendly and affordable alternative to
perform comprehensive ophthalmic examinations. Peek offers
a potential solution to overcoming barriers of traditional
ophthalmic testing methods and thereby contributes to the
VISION 2020 goals [17].
Objectives
This qualitative study was carried out to assess patients', health
care providers' (HCPs'), and stakeholders' (decision makers in
ophthalmic service provision are referred to as “stakeholders”)
perspectives on the adoption of Peek for improving the provision
of ophthalmic services in Kenya. This included a formative
evaluation of the acceptability and usability of Peek compared
with traditional methods of ophthalmic testing. In addition, its
potential for strengthening ophthalmic services and potential
barriers and facilitators to adoption and deployment of the
technology were explored.
Methods
This study was undertaken within the follow-up phase of the
Nakuru Eye Disease Cohort Study in central Kenya, a
population-based study, which recruited 5000 individuals from
100 clusters [18].
The sampling strategy for this qualitative study involved
purposeful sampling, and the patient sample was chosen from
the 100 clusters based on varying sex, age, geographical
location, educational levels, and income. The purpose was to
maximize diversity and capture common themes relating to the
intervention across a range of participants with differing
characteristics [19]. Nakuru district was chosen because it offers
a diverse population in terms of ethnicity and economic activities
[18].
The qualitative study consisted of semistructured interviews
with all HCPs (ie, 8) recruited for testing Peek, patients (ie, 40)
examined with Peek, and key stakeholders (ie, 4) involved in
shaping ophthalmic provision in Kenya and were chosen from
the ministry of health, an ophthalmic teaching hospital, and
selected nongovernmental organizations (NGOs). All patients
underwent visual acuity (VA) testing using Peek at their homes,
whereas fundal images were taken at a temporary clinic in that
cluster. At this clinic, they also underwent repeat VA and
funduscopic examinations using traditional equipment.
Four interviewers were trained to conduct the interviews and
were provided semistructured interview guides. All interviews
were audio recorded with the consent of all participants. The
patient interviews were conducted in Kiswahili and then
transcribed and translated. Conversely, the HCP and stakeholder
interviews were conducted in English.
The Nakuru Eye Disease Cohort Study was approved by the
African Medical and Research Foundation ethics board, which
included pilot testing of Peek and conducting interviews as part
of the larger project. Full written consent was obtained from all
parties including the patients, HCPs, and stakeholders before
each interview and was available in Kiswahili and English.
The interview transcripts were analyzed using NVivo version
10 [20]. A framework analysis approach was used, creating
predefined themes for the coding structure. The coding
framework was guided by theoretical constructs from literature
on mobile usability, acceptability of technology, and previous
mHealth reviews and literature on assessing benefits of mHealth
in strengthening health care delivery [21-34].
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To assess the acceptability and usability of Peek, it was deemed
important to first understand the context within which it is to
be implemented [21-23]. The analysis of the context was
therefore carried out through a coding framework proposed by
a qualitative review of mobile usability studies, which took into
account the environment, user, task, and technology [21]. The
themes involved assessing patients' and HCPs' perceptions of
(1) ophthalmic service provision; (2) the barriers to seeking and
accessing ophthalmic services, that is, environment; (3) HCP
role and experience, that is, user; (4) understanding the purpose
of Peek, that is, task; and (5) familiarity and views regarding
mobile technology.
The coding for assessing patient acceptability of the Peek testing
process and its functionality was informed by the definition of
acceptability by Ayala and Elder (2011) [24]. They proposed
that acceptability refers to determining how well an intervention
will be received by the target population and the extent to which
the new intervention or its components meet the needs of the
target population and organizational setting. The themes
included assessing (1) patients' perceived benefits of Peek, (2)
patient satisfaction, and (3) patient preference.
The International Organization for Standardization defines
usability as the extent to which a product can be used by specific
users to achieve specific goals with efficiency, effectiveness,
and satisfaction in a specified context of use [25]. A number of
usability dimensions have been proposed by Coursaris and Kim
(2006) in their qualitative review of mobile usability studies,
which informed the coding framework for assessing usability
of Peek by HCPs [21]. The themes included (1) efficiency, (2)
effectiveness, (3) learnability, and (4) flexibility and operability.
The Technology Acceptance Model (TAM) and its extension,
TAM2, were used as a guide to assess user acceptability of the
technology [26-29]. This proposes that acceptability or
prediction of use of a technology depends on the attitude toward
it, which is a function of ease of use and perceived usefulness.
The analysis of perceived usefulness was informed by assessing
HCPs' perceptions of the benefits. Several studies to date have
looked at the benefits of mHealth, and several frameworks have
been proposed for assessing benefits in strengthening health
care provision [30]. This analysis has therefore adapted a model
based on a combination of four frameworks to appraise the
potential benefits of Peek in strengthening eye care delivery.
The four main themes of the framework were adapted from the
Information Communication Technology for Healthcare
Development Model [31]. These are capabilities enhancer, social
enabler, opportunity producer, and knowledge generator. The
subthemes were based on three other frameworks proposed for
guiding assessment of mHealth in strengthening HSs
[9,30,32,33]. The components chosen for the framework are
also in line with the categories of mHealth initiatives established
by the WHO [34].
A thematic analysis was also conducted to explore emerging
themes and subthemes related to the study objectives that were
inferred from the data [35-37]. Analysis was conducted until
saturation was reached, which was 20 patient interviews, all 8
HCP interviews, and all 4 stakeholder interviews. After this,
the coding was summarized and modified, and connections were
made between related themes and between the 3 groups of
interview participants.
Results
A summary of all the themes discussed in this section is given
in Textbox 1.
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Textbox 1. Results section summary.
Contextual factors
• Environment
• Patient demographics
• Barriers to seeking and accessing services
• Cost
• Lack of ophthalmic facilities, qualified providers, and support
• Time
• Lack of awareness
• User
• Role and experience of health care providers
• Task
• Patient's and health care provider's understanding of Portable Eye Examination Kit
• Technology
• Attitudes toward mobile phones
Patient acceptability
• Perceived benefits of Portable Eye Examination Kit
• Patient preference
• Patient satisfaction
Usability dimensions
• Efficiency
• Time
• Multitasking
• Portability and convenience
• Cost
• Effectiveness
• Learnability
• Flexibility and operability
Benefits
• Capabilities enhancer
• Detection and diagnosis
• Provider performance
• Decision support
• Social enabler
• Provider-to-patient communication
• Provider-to-provider communication
• Opportunity producer
• Linkage of patients to ophthalmic provision
• Monitoring and surveillance
• Knowledge generator
• Training and education
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Contextual Factors
Patient Demographics
The number of males and females was equal and the ages of
the patients ranged from 50 to 77 years. The educational levels
varied from no education to primary, secondary, and tertiary
education and were evenly represented in the sample of patients.
With regard to occupation, 11 patients were farmers, 2 teachers,
2 businessmen or businesswomen, an engineer, an industrial
chemist, a civil servant, and a secretary. Apart from one
businessman who reported an annual income of 4,000,000
Kenyan shillings (KES), incomes varied mainly from 1000 to
50,000 KES per month with an average of 16,000 KES.
Environment (Patients' and HCPs' Perceptions of
Current Eye Service Provision and Perceived Barriers
to Seeking and Accessing Eye Services)
Cost
Six of the HCPs and almost all patients stated seeking
ophthalmic services as unaffordable when referring to having
to pay for hospital bills and transport.
...seeking eye treatment is quite expensive. Then
again, I was not in a position to seek treatment. As
farmers, we have low standards of living and
therefore cannot afford to seek regular eye healthcare.
We only go to hospitals when eye problems persist.
[Patient #23, male]
Lack of Ophthalmic Facilities, Qualified Personnel, and
Support
The general opinion among the HCPs was that the availability
of eye services in Kenya was inconsistent, with poorer provision
in rural areas. The majority mentioned that patients had to travel
long distances to access eye care, which was made more difficult
because of poor infrastructure and roads. Another issue raised
was scarcity of qualified ophthalmic personnel. Many described
existing services as being overburdened as a result. With regard
to prevention, most HCPs reported that they were not aware of
any formal preventive measures put in place by the government
in the region studied. The majority mentioned often taking the
initiative to educate patients when seeing them.
Similarly, from patients' point of view, the government services
in rural areas were reported to be limited to dispensaries with
no specialist ophthalmic testing services, which only provide
eye medications at a cost. Most patients also mentioned being
on their own with little support posing a challenge for them to
access treatment either because of the inability to access
transport or due to having to prioritize other issues to sustain
their livelihood. All those living in remote settings stated they
were constrained from accessing more specialist services
because of long distances.
In contrast, those living in Nakuru, an urban town, felt that
ophthalmic facilities were generally accessible via government
hospitals, private hospitals, opticians, and missionary hospitals.
Most patients are very far from health facilities, we
have poor infrastructure and most clinics, health
facilities that are near people don’t have eye clinic
specialist, they just have a general doctor or clinician
and that is all. So you find that most patients don’t
get specific eye treatment. [HCP #6, female]
It is far and then again, it is not easy to find. It is hard
because even fare has to be considered and on top of
that, there is the fee for treatment which is steep.
[Patient #2, female]
Time
Time was reported as a significant barrier to accessing eye
services by 4 HCPs. Patients also had a similar opinion,
especially those living in urban settings where long queues at
government facilities were reported as a major obstacle because
of difficulty taking time off work and potential loss of income.
Transportation and also long queues, time is also a
factor because some are trying to work hard to see
how the family could get along so they say the issue
of the eye can be put aside, although he cannot see
properly he says it’s an issue he can attend to later.
[Patient #39, male]
Lack of Awareness
Six HCPs mentioned lack of knowledge of eye conditions and
lack of awareness of the importance of early detection and
treatment as a barrier to patients seeking health care in both
rural and urban settings. However, they perceived this to be
more of a problem in rural areas due to lower educational levels
and less exposure to health care in general.
Patients acknowledged that they had limited knowledge of eye
problems. Most patients gave similar explanations for causes
of eye problems and demonstrated a particularly limited
understanding of chronic conditions. The most frequently
mentioned causes, as perceived by patients, were poor hygiene,
dust, smoke from cooking, direct sunlight, and unbalanced diet.
A couple of participants mentioned “jerreri” as a cause, which
means cataracts in their local language. Few patients mentioned
other causes such as inherited diseases, work, alcohol, and
smoking.
Interestingly, most patients revealed that they did not see the
importance of regular eye checks despite being affected by
changes in their vision. Only 4 patients brought up the
importance of timely eye checkups as a means of preventing
visual deterioration.
When asked about delays in seeking treatment, the most
common reason given by patients and HCPs was that eye
problems were not perceived to be serious enough to require
urgent treatment, particularly when faced with barriers to
accessing services. Furthermore, patients and HCPs perceived
local myths and traditional practices in their communities to be
a consequence of poor knowledge, leading to patients not
seeking or accepting treatment. They highlighted the need for
awareness creation through education and involvement of village
chiefs.
...I thought that the problem was not very serious and
I waited to see whether I would get better on my own
but when that did not work, I sought medical
treatment. This is because there are no mobile eye
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doctors like you doing rounds creating awareness on
eye issues. Someone like I will wait until I am sick to
seek treatment because there is no one giving people
information to help prevent these problems. [Patient
#9, male]
They should receive help from people like chiefs who
are more knowledgeable. They should be helped in
accessing treatment. It can help in prevention.
Because most people are now useless. [Patient #2,
female]
User (Role and Experience of Health Care Providers)
There were 6 male and 2 female HCPs consisting of
ophthalmologists, ophthalmic clinical officers, and members
of the advance team. The members of the “advance team” were
responsible for tracking participants for the study enumeration,
using Peek to test vision at patients' home and ophthalmic testing
using traditional equipment in clinics. One of them had the
additional responsibility of software maintenance. An
ophthalmic nurse was also part of this team and was also
involved in counseling and preparing patients for surgery. Most
HCPs had no prior training in eye care before joining the Nakuru
Eye Disease Cohort Study. Their experience in ophthalmic
service provision was therefore mainly limited to the year during
which the study took place, with the exception of the
ophthalmologists, one of whom had 18 months and the other 4
years of experience.
Task (Understanding of Peek)
When asked to describe Peek and the examination process, the
responses from HCPs varied based on their role and experience
as ophthalmic providers. Most HCPs correctly mentioned that
Peek incorporates several examinations in one device, thus
enabling a basic eye examination comparable to traditional
techniques. All the HCPs who were primarily responsible for
providing outreach services described Peek as a tool for VA
testing, and most needed prompting before mentioning its other
uses in performing eye examinations such as anterior eye
examination and fundoscopy. Most HCPs also highlighted Peek's
capability for data analysis, information sharing, communication
with colleagues, and other basic functionalities such as
browsing, testing, and calling.
The patients interviewed demonstrated a good understanding
of the technology and its purpose for ophthalmic testing and
described it as an alternative and possible substitute for
traditional eye examination. Two patients, however, were not
aware that the MP was being used for eye examinations.
Technology (Attitudes Toward Mobile Phone
Technology)
Patients, HCPs, and stakeholders all had positive attitudes
toward MPs and smartphone technology. Mobile phones were
referred to as innovative, advanced, new, and highly
technological. They reported that the technology had made
communication easier. Several patients revealed a familiarity
in using MPs and felt that the attitude of the community toward
MPs depends on exposure, awareness, and education. The HCPs
and stakeholders had similar views and mentioned that MP use
was widespread in the area. One HCP and patient reported that
the use of MPs in Kenya was best known by the money transfer
initiative called M-Pesa that has been adopted by a large
proportion of the population. All participants were optimistic
about the potential uses of MPs, especially smartphones, and
portrayed enthusiasm for technology.
I think that the MP is a highly technological piece of
equipment. It is very advanced. [Patient #27, female]
In Kenya generally people are used to SMS, they are
used to M-Pesa and the technology which is there is
almost comparable to that. I think the kit generally
most people are able to operate. [HCP #3, male]
We all like new technology, we are all thirsty for new
innovations in eye health because of the many
challenges in service delivery. [Stakeholder #4]
Patient Acceptability
Benefits as Perceived by Patients
All patients perceived Peek to be beneficial as its portability
brings examination and treatment closer to them. They perceived
it as a way of overcoming many of the aforementioned barriers.
The patients also suggested that it could increase detection of
eye problems because it can reach a larger population. This
could be achieved by providing earlier eye examinations for
those who lack awareness or those unable to access existing eye
services. The use of Peek was also seen to have the potential to
increase awareness about eye conditions in general as it uses
mobile technology, which is considered to be acceptable for
patients. Many patients also deemed Peek to be efficient and
economical for themselves and the HS because it saves time,
costs less, and reduces the burden on health care personnel.
When patients were asked about how long it took to receive an
eye examination with Peek, 17 of the 20 patients recalled the
time to be between 2 and 20 minutes. The other 3 patients did
not mention an exact time. When they were asked about the
duration of traditional eye examinations, the responses varied
between 30 minutes and 4 hours.
Patient Satisfaction
All patients stated that they were satisfied with the service
offered. Eighteen of 20 patients did not report concerns
regarding the technology. Moreover, when asked about further
comments about Peek at the end of the interview, the majority
of patients stated that they were hoping for the service to be
more accessible to them.
Nevertheless, some patients expressed potential doubts about
their community's uptake of Peek. These will be discussed later
in this paper.
Patient Preference
When asked about whether patients preferred traditional
examinations or Peek, 10 patients expressed a preference for
Peek, 7 stated no preference, and 3 preferred the traditional
examination. The main reasons for preferring Peek were shorter
examination time, simplicity, efficiency due to multiple
examinations combined in one tool, being seen at home, and
the increased potential coverage of the population in need. Those
who did not express a preference stated that their decision would
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be dependent on the actual availability of the intervention. Two
patients who preferred traditional examinations referred to the
ease of reading larger letters. Another patient described clinic
equipment as having fewer potential side effects, although he
then conveyed his support for Peek to be incorporated into
policy service provision in rural areas where the need was
perceived to be greatest.
Patient Acceptability as Perceived by Health Care
Providers
The HCPs also perceived Peek to be acceptable to patients.
They reported that patients appreciate a service that is brought
closer. Furthermore, according to HCPs patients were curious,
interested, and willing to be examined by the new technology.
Some HCPs also mentioned that the use of Peek helped
overcome patients' fears related to being tested with traditional
techniques, as mobiles are more familiar and therefore patients
are likely to be more comfortable being tested with MPs.
The application being the first to debut in Kenya
mostly using testing people with it, it is amazing and
people are like they wish to be checked using the
phone. [HCP #4, male]
Analysis of Health Care Providers' Usability of Peek
Usability Dimensions
Bearing in mind the context of use described earlier, an analysis
of usability was carried out using the predefined usability
dimensions, that is, efficiency, effectiveness, learnability, and
flexibility and operability, as summarized in Table 1. While
assessing efficiency, the following subthemes became apparent:
speed, multitasking, convenience, and cost. Table 1 summarizes
the analysis of perceptions of the HCPs regarding usability of
Peek as per predefined usability dimensions.
Table 1. Usability dimensions.
HCP quotes
Benefits relating to
usability dimensionRationale given by HCPs
No. of
HCPsaUsability dimension
Efficiency
“...it will be more effective in that we will
be able to get to see more patients with eye
problems and in that case I will be able to
solve them early enough and our patients
will not have to go blind...”
Ability to see more
patients, early diag-
nosis, and treatment.
Simple and easy to use, with less
manual record keeping.
8Time
“...you can multi task it by doing all the ex-
amination at the same place without moving
just by the touch of the application, so it
will make it better.”
Saves human re-
sources.
Requires less equipment to navi-
gate and manpower to conduct
examinations.
6Multitasking
“...it’s portable and one can be able to ac-
cess rural areas where infrastructure is
poor so in terms of accessing those places
you will be able to get people who could not
think of getting help...”
Increase access and
coverage in remote
areas.
Easier to carry around compared
with traditional equipment.
7Portability and
convenience
“...the cost of one Portable eye kit does like
very many examination procedures com-
pared to the machines so it makes it cheap-
er, two the cost of transport is cut down
because I’ll be able to visit the client at
his/her own convenience...”
Economic gains for
patients and service
provisions.
Cheaper equipment (10,000-
40,000 KESa compared with
more than 1,000,000 KES for
traditional equipment), transport,
and negligible software costs and
replacement costs.6Cost
“The phone is automatically accurate than
the traditional type of equipment. PEEK is
more advanced than the traditional equip-
ment gives you the exact figures and images.
It is very accurate. Excellent in fact”
Ability to provide
better analysis of
findings, compared
with the substitute.
Accurate, equal, or better than
traditional equipment.
6Effectiveness
“...anybody as long as you have something
in between your ears that is a brain then
you can actually work. Because everything
is just written and where it is not written
you can actually see it everything is self-
explanatory with algorithms.”
Usable by less quali-
fied HCPs with limit-
ed smartphone
knowledge.
Clear instructions; though useful,
no expertise required.
8Learnability
“...it is still open ended it is not closed so it
is it is able to accommodate, new things and
new ideas and new situations that may vary
from one region to another from one coun-
try to another so it is adaptable.”
User-friendly, easy
to maintain, and
meets different
needs.
Quickly modifiable based on user
feedback and robust technology.
8Flexibility and
operability
a HCP: health care provider; KES: Kenyan shilling.
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HCPs' and Stakeholders' Perceptions of Benefits of
Peek in Eye Care Delivery Using a HSs Approach
Capabilities Enhancer
Detection and Diagnosis
The HCPs and stakeholders believed that Peek can increase the
chances of diagnosing eye problems and is thought to have the
potential to be used as a screening tool to increase detection of
poor vision. They perceived earlier detection to be beneficial
in reducing the burden of blinding eye disease and thereby
increasing general standards of living. Nevertheless,
stakeholders stated that the success of Peek as a screening tool
will depend on proven accuracy, sensitivity, availability, and
ensuring high-quality service delivery.
Well the more sensitize a technology you have for
detecting problems and the more easily available it
is, it means you are going to start detecting many
more patients and so that’s good for the patients so
that more people get to know more earlier that they
have a problem. [Stakeholder #1]
Provider Performance and Decision Support
The opinion among HCPs and stakeholders was that Peek could
allow for task shifting and improved human resource
management by providing support to community health
volunteers (CHVs). This was seen as a potential solution to fill
in for the shortage of ophthalmic workforce. Peek was perceived
to lead to improved outcomes of the services provided as a direct
result from its user-friendly platform, inbuilt decision-support
algorithms, and data analysis capabilities. These features of the
application were also perceived to help in managing and
organizing workload of HCPs, for example, by prioritizing
referrals. Furthermore, the application was thought to have an
impact on increasing HCP motivation and self-confidence in
detecting and consequently managing eye problems.
I can even be able to collect, gather data from the
field and it gives me some clear information on some
decisions that I am about to make. The same way the
smartphone and for example PEEK is doing; it is able
to do some basic examination that is able to separate
those who need to see a doctor urgently and those
who do not need urgently. [Stakeholder #3]
Social Enabler
Provider-to-Patient Communication or Client Education
Most stakeholders stated the value of Peek in providing instant
feedback to patients through the images, which are immediately
available on the phone. Stakeholders described its value in terms
of explaining the diagnosis to the patient, reinforcing patient
understanding, decision-making, and confidence. According to
one stakeholder, this is further enhanced by the ability to contact
relatives who are unable to make it to the clinic. Stakeholders
highlighted that seeing an image of a damaged retina and optic
nerve can help patients understand the seriousness of their
problem and thus they will be more likely to urgently seek and
comply with treatment as a result.
Provider-to-Provider Communication
Stakeholders referred to the potential role of Peek in enhancing
communication between HCPs as a beneficial feature, for
example, enabling remotely located ophthalmologists to provide
less qualified HCPs with support in decision-making. Peek was
also perceived to overcome current problems in data transfer
by generating images in a format that can easily be transferred
to other HCPs, which existing equipment does not allow. These
qualities of Peek are further reported as vital for task shifting
to be successful.
Opportunity Producer
Linkage of Patients to Ophthalmic Provision
Similar to HCP views, according to all the stakeholders
interviewed, Peek was perceived as bringing service provision
closer to patients who need it most. This was deemed possible
by being able to conveniently and efficiently provide ophthalmic
services in remote settings, thereby overcoming logistical issues
in having to set up clinics. Additionally, 2 stakeholders
commented on the ability of Peek to increase public confidence
in ophthalmic workers and in service provision, which is
currently challenged by poor uptake of eye services.
...those who are in the most remote areas who have
the highest prevalence for blindness will now be
linked to the health system and so people will be able
to find them and treat them. [HCP #7, male]
Monitoring and Surveillance
Features of Peek such as data storage and Global Positioning
System tracking are thought to be desirable by stakeholders in
strengthening monitoring and surveillance, thereby better
contributing to policy-making and resource planning.
Additionally, they perceive Peek to enhance follow-up by being
able to locate patients easily.
Knowledge Generator
Training and Education
Peek was also deemed as a training opportunity by both HCPs
and stakeholders, because discussing management of eye
problems with qualified and experienced ophthalmic
professionals is thought to increase knowledge and skills of
those with limited training. Furthermore, according to
stakeholders and HCPs, Peek offers an opportunity to educate
and sensitize the population about eye health. Consequently,
the overall opinion was that Peek contributes to increased patient
awareness and knowledge.
Analysis of Perceived Barriers, and Proposed
Facilitators for Overcoming Potential Barriers to
Adoption and Deployment
Neither the patients nor the HCPs reported any major obstacles
with the use of Peek during the examination. However, the
following themes emerged from all parties as potential
system-related challenges in implementation that need to be
considered for deployment.
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Government Involvement
Lack of integration with the national health system and potential
lack of government involvement were seen as major challenges
to deploying Peek. Early involvement of government, policy
makers, and health management teams in decision-making was
therefore considered by stakeholders and HCPs to be essential
to ensure sustainability of the program. These participants
proposed working with the government at all stages from
development to implementation. State involvement was also
regarded as essential to gain public trust in the intervention;
integrate services; and setting guidelines, standards, and
protocols for national implementation and adoption.
Funding
Lack of funding was discussed as a barrier to deployment and
sustainability of the program. Government support and
partnership with NGOs was put forward as a solution to increase
availability and affordability of Peek and integration with
existing services. The new health restructuring in Kenya, where
management has been devolved to county level, was perceived
to be most likely beneficial in sustaining the intervention as
resources are more likely to be spent where most needed.
However, the priority given to eye health nationally was seen
by the stakeholders to influence any future decisions about
funding. Moreover, as indicated by one stakeholder, a
cost-benefit analysis and evidence for effectiveness are essential
for obtaining funding.
Other options suggested for funding were donor support for
financing and other resources required for the program.
Stakeholders also suggested that the government would
financially benefit from adopting Peek, as it is perceived to be
cost-effective compared with traditional ophthalmic testing
methods.
From an economist point of view, I would say it is a
good, it is a project worth financing. [Stakeholder
#3]
Communication and Technology Awareness
Although none of the patients expressed any reservations or
fear of being examined by Peek, some mentioned that there is
a possibility that certain people may not understand the purpose
and value of the application. Another perceived barrier to
adoption of using Peek was miscommunication. For instance,
initially 1 patient reported having reservations about the use of
Peek but was comfortable with it as soon as the examination
steps were clearly explained. Furthermore, acceptance was also
deemed to be governed by the level of education. Therefore,
the importance of familiarity with MPs and the need for good
communication on the utility of Peek were highlighted by
several patients, HCPs, and stakeholders. Some examples were
given for reasons of possible misunderstanding in the
community, such as the phone being used to take patient's
pictures instead of retinal images, cultural reservations about
MPs, and fear of MPs having negative health effects.
Counselling and sharing with them and giving them
reason as to why, especially if the patient needs
examination, you just understand the patient and help
the patient to understand. [HCP #6, female]
Training and Product Support
A potential challenge mentioned by both stakeholders and HCPs
is the need for setting up training for using Peek and product
support if it were to be deployed sustainably. Consequently,
they suggested the need to plan for a strong support team.
Nevertheless, Peek was perceived as more sustainable than
traditional equipment, with less likelihood of requiring
replacement of expensive components. From patients' point of
view, equipment quality was an important factor to ensure a
high standard of care provision.
...it is more sustainable than the equipment we are
providing and that is what I see. Because if these
equipment breakdown, they have to be serviced and
they have to buy spare parts, of which right now we
have several equipment that are not working because
of spare parts. [Stakeholder #4]
Data Protection
According to HCPs and stakeholders, maintaining confidentiality
of patient information is paramount and a potential barrier to
sustainability and acceptability of the intervention. They
proposed the need to ensure that a robust and secure data
encryption system is in place. In addition, good communication
was also reported as necessary to ensure that patients understand
and are reassured about confidentiality. One stakeholder
involved in building a central ophthalmic data collection unit,
the Ophthalmic Service Unit designed to be linked to Hospital
Management Information Systems, stated that it has been
difficult to implement the system in Kenya. The suggestion for
the implementation process was that it is important to link
patient data, collected using Peek, to the HCPs' clinic as well
as the central database for safekeeping.
Another issue raised was that mobile phone devices could be
stolen when used in insecure remote areas, therefore reinforcing
the need for robust security measures in addition to a data
protection system.
Community Involvement
Stakeholders and HCPs described the benefits of training the
local population for community mobilization. They suggested
that training the local population to run the program will
overcome any potential obstacles related to acceptability and
sustainability. Patients saw the importance of community
participation as key to building trust and confidence in the
program and put the population at ease. From one stakeholder's
point of view, getting public support is also very important to
tackle cultural barriers. One patient referred to the M-Pesa
service as an example of a program that has managed to drive
community mobilization.
...early involvement and train locally available people
to actually address some of those bugs that can arise
that can cause a problem... [HCP #3, male]
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Increase in Demand for Ophthalmic Treatments
One obstacle mentioned was that the HS may not be able to
cope with managing the increase in cases detected by Peek. A
solution suggested by both HCPs and stakeholders to combat
this problem is recruiting CHVs. The value of Peek in supporting
HCPs who have limited training in eye care playing the role of
CHVs has been highlighted throughout this study. Moreover,
a stakeholder mentioned how Peek can be used to prioritize
cases, which helps with shifting demand and coping with
increasing workload. One stakeholder also proposed to introduce
Peek to those trainees in the community who will become future
HCPs.
Infrastructure
The accessibility of MPs and infrastructure supporting the use
of mobiles was reported as being key for sustainability of Peek
by HCPs and stakeholders. Infrastructure-related barriers raised
were shortage of devices and poor mobile network provision
and internet coverage, making it difficult to send across images
and patient information to the central database as well as other
HCPs for advice. They proposed partnering with and acquiring
support from key network providers to increase availability and
affordability of both the device and mobile data usage. Power
shortages in rural areas leading to inability to charge phones
were also mentioned as potential barriers to service delivery
with Peek. Provision of HCPs with a battery-powered charging
system and backing up data were given as potential solutions.
You know the challenges of network in Kenya, the
downs, you know sometimes it just disappears in some
areas and especially in the villages, in the remote
areas. [Stakeholder #2]
Discussion
This qualitative study offers a comprehensive understanding of
the potential value and barriers to the deployment of the
smartphone-based eye examination system, Peek, in developing
countries with limited coverage of ophthalmic services. Peek
as a stand-alone system is useful; however, in conjunction with
smartphone functionalities it offers a highly desirable advantage.
To date, studies evaluating mHealth have mainly assessed basic
use of MP technology with limited evidence on the value of
using smartphones for health care [7,12]. This study showed
that Peek is an acceptable examination kit for HCPs, patients,
and stakeholders and has the potential to strengthen the delivery
of eye care in resource-poor contexts. The study has also
illustrated the potential challenges and facilitators that are likely
to affect the adoption and deployment of Peek.
The analysis of the user, task, technology, and environment
gives an overall understanding of the context in which Peek is
being evaluated. The patient diversity, patient demographics,
and the HCP roles and experience utilized in this study are
considered to be the representative environment for which Peek
has been designed and in which it will likely be deployed. Most
HCPs had limited ophthalmic specialist training, serving as
CHVs with experience restricted to the year in which the Peek
study was undertaken. This has provided useful insights, because
if Peek were to be deployed, it is likely that CHVs will be
recruited because of the shortage of ophthalmic professionals
in developing countries.
Overall, HCPs demonstrated a good understanding of the utility
of Peek, that is, its task. The analysis of attitudes toward
technology revealed that HCPs, patients, and stakeholders
perceived the population as being familiar with MPs and
receptive to them being used. These views reflect the increasing
penetration of MPs and more specifically smartphones in Kenya.
This enthusiasm for MPs has been greatly influenced by a
number of initiatives: M-Pesa's money transfer initiative that
has driven MP usage in the remotest of settings and Safaricom's
initiative to make smartphones more affordable through the
introduction of cheaper android devices, which have led to
increasing smartphone subscriptions [11].
The analysis of the context also revealed significant barriers to
seeking and accessing ophthalmic services in the current HS.
Both HCPs and patients felt that there was a rural–urban
disparity with almost no established services in rural settings.
This was reported to lead to patients having to travel long
distances, having to encounter long waiting times at
overburdened government facilities, and having a lack of
awareness about timely detection and treatment.
Peek was found to be acceptable to patients, all of whom
expressed being satisfied with Peek. Moreover, the analysis
revealed that contentment with the service was often related to
the quality of service provision. Most participants supported
the use of Peek because it was perceived to be fast and
convenient and to be able to reach a larger population in need,
in addition to overcoming the aforementioned barriers. Peek is
also deemed to have generated a lot of interest among the
communities and is therefore an opportunity for increasing
awareness of eye health within the population. Although limited,
a handful of studies have shown the value of mHealth initiatives
in creating awareness, for instance, in general health, HIV/AIDS,
and women's health in low-income countries [34].
The analysis of the usability of Peek based on predefined
usability dimensions demonstrated that per HCPs' perceptions,
Peek generally fulfills the criteria for all dimensions assessed.
These included efficiency, effectiveness, learnability, and
operability and flexibility. In addition to the usability of Peek,
the analysis confirms that Peek is acceptable to HCPs. This was
demonstrated by their perceived ability to use Peek easily, fulfill
their role, and meet the challenges of ophthalmic provision.
An analysis of the views of HCPs and stakeholders using a
model adapted from relevant literature showed the value of Peek
in strengthening the HS's ability to provide eye services [30-33].
Peek was perceived to be a capabilities enhancer for HCPs
through the provision of diagnostic and decision support. This
has already been introduced as an important feature of mHealth
initiatives in supporting HSs as proposed in current literature
[9,33]. The possibility of using Peek as a screening tool is also
discussed under this theme, and its success is thought to be
dependent on being able to prove its accuracy, sensitivity,
accessibility, and ability to offer a high standard of service
delivery. It is therefore vital that these qualities are satisfied in
addition to other criteria required for enrolling a screening
service before Peek can be rolled out for this purpose [38]. A
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qualitative study of the accuracy of the tool has been carried
out alongside this qualitative study, which has proven its
accuracy, repeatability, and consistency as a vision-testing tool.
Another study is also underway to determine its suitability as
a screening tool in children at school.
Peek's value in creating opportunities that help in supporting
health care delivery was also highlighted. These included
offering eye care closer to patients and enabling monitoring and
surveillance. Additionally, Peek was deemed to be a social
enabler and improved communication between providers
themselves as well as with their patients. Another theme
highlighted was knowledge creation and development of skills
by offering training opportunities. The outlined benefits of Peek
show its potential value in supporting CHVs in providing a high
standard of care through its inbuilt functions, because these
support decision making as well as communicating with
qualified ophthalmic professionals who can offer advice
remotely. Other studies of mHealth in developing countries
have demonstrated the value of MPs in tackling the current
barriers to service provision and improving the range and quality
of services offered by CHVs [34,39,40]. Moreover, these
benefits are likely to play an important role in the near future,
with the increasing double burden of disease in Africa where
chronic ophthalmic conditions, such as glaucoma, age-related
macular degeneration, and diabetic retinopathy, are also likely
to become more prevalent. As a consequence, the need for Peek
to be offered within a well-coordinated HS that is capable of
screening for and managing these conditions as part of secondary
prevention efforts is likely to become increasingly essential.
Given the paucity of studies and established guidelines on
large-scale implementation of mHealth, the views of all parties
gathered during this qualitative analysis assisted in
understanding the challenges and facilitators in deploying Peek.
This analysis brought out several common themes that highlight
key considerations that are likely to affect adoption of Peek.
Many of the challenges reported are similar to those mentioned
in previous mHealth studies [41]; however, several unique
considerations were also revealed that are specific to Peek and
the context in which it is likely to be implemented. The themes
that emerged included the need for (1) government support and
involvement in deployment, (2) building capacity to train HCPs
and maintenance of Peek, (3) maintaining a high standard of
care and good communication about the purpose of using Peek
with all patients, (4) community mobilization, (5) increasing
capacity to manage increasing demand for eye treatments, (6)
ensuring general eye health awareness and linking with primary
health care, (7) ensuring data protection, (8) ensuring
accessibility to smartphone technology at low cost, and (9)
infrastructural support such as mobile charging systems and
improved network coverage. These considerations serve as
guidance for the future implementation of Peek.
Although previous mHealth studies have been conducted on a
small scale, a review of literature has shown that there is a clear
opportunity for successful mHealth interventions when proven
to be acceptable, accessible, easy to use, affordable, appropriate
to the local context, and integrated within the HS [8,39,42-46].
Peek therefore shows promise for success.
Limitations
Since the qualitative analysis was carried out on data that had
been collected retrospectively, there was limited opportunity
for an iterative process whereby initial data analysis can guide
further interviews. Moreover, in an attempt to answer specific
predefined objectives, data were collected from semistructured
interviews, which limited open-ended questions. Additional
open-ended questions would have allowed for a more in-depth
exploration of themes.
Conclusion
The analysis of context illustrated the perceived importance of
addressing rural-urban disparity and thereby the need to increase
access and coverage of ophthalmic provision. The key barriers
highlighted were cost, distance, time, and lack of awareness of
the importance of timely detection and treatment. From the
analysis of patient, stakeholder, and user views regarding Peek,
it can be concluded that Peek offers an acceptable solution to
overcoming barriers to access to eye care, fulfills the criteria
for usability for HCPs, and acts as a means to strengthen eye
care delivery. Peek is perceived to be valuable predominantly
in increasing coverage in rural settings, thereby contributing to
the third global goal for sustainable development [47]. As
proposed by the HCPs and stakeholders, it is also likely to have
a bearing on reducing burden on ophthalmologists who with
the help of CHVs using Peek can now work remotely through
task shifting. To successfully deploy Peek and achieve universal
coverage, it is considered imperative to build a sustainable
model by integrating and working with the government, local
communities, and NGOs. Ongoing research would be required
to evaluate the processes of deployment and to assess whether
the benefits outlined translate to improved eye health outcomes
and public health indicators.
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Increasing access to eye care . . . there’s an app
for that. Peek: smartphone technology
for eye health
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Peek, the Portable Eye Examination Kit, was developed
and validated alongside a cohort study of eye disease in
Nakuru, Kenya.1 In the cohort, the majority of participants
with visual impairment were elderly, difficult to reach and
had little or no access to eye care. Expertise and ophthal-
mic equipment required to perform a comprehensive eye
examination in areas with poor or no road access, no elec-
tricity and considerable distances from the main towns and
cities leads to an inverse relationship between eye care pro-
vision and eye care needs.2
In the past decade, mobile phone penetration has grown
to reach near ubiquity in many of the most remote parts of
Figure 1. A long queue of patients awaiting assessment in a rural village in Kenya in the Nakuru Eye Disease Cohort Study and validation of Peek
VC The Author 2016; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association 1
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Figure 2. A secondary school used as a temporary clinic in the Nakuru Eye Disease Cohort Study and validation of Peek; note the use of blackout
blinds and a generator for the ophthalmic equipment
Figure 3. A solar-powered rucksack as used by the Peek healthcare
workers visiting patients door to door, negating the need for a mains
power supply
Figure 4. Validation of the Peek Acuity app measured against the refer-
ence standard LogMAR vision chart
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the world. The growth has been greatest in low- and
middle-income countries (LMIC) with some countries hav-
ing, on average, more than one connected device per per-
son of population.3
Despite areas of Kenya and other LMIC having no ac-
cess to clean running water and sanitation services, the ma-
jority do have mobile phone connectivity. Peek harnesses
the portability and connectivity of mobile devices to enable
task-shifting and the ability to undertake a comprehensive
eye examination at, or close to, the patient’s home.
The primary measure on which ophthalmic assess-
ments are made is distance visual acuity. This is typically
done using a Snellen chart or, for research purposes, a
Figure 5. Peek Acuity being measured in a patient’s home in rural
Kenya
Figure 6. Peek Acuity being tested in the hands of a non-healthcare
worker in the Massai Mara
Figure 8. A Peek fieldworker examining a patient’s retina in their home
in rural Kenya
Figure 7. Examination of the lens for cataract using Peek in rural Kenya
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LogMAR chart which overcomes many of the limitations of
the commonly used Snellen chart. The LogMAR chart re-
quires a power source, is not designed to travel and is not
practical for use outside a clinical setting. Peek Acuity is an
accurate, repeatable and fast method to test acuity using a
smartphone.4 The test uses the touchscreen interface to re-
cord participant’s responses without the user needing to see
the screen. This makes the test both faster and more object-
ive. The inbuilt luxmeter, usually used to control screen
brightness, can give the user a warning when ambient light
levels are too bright to provide a reliable reading.
Peek Retina, a low-cost smartphone adapter, makes it
possible to examine the retina using a smartphone.5 The
user only needs to be able to acquire images, and expert
graders can review images remotely and action decisions
without having to be away from busy eye units.
With the majority of the world’s blind and visually im-
paired people living in LMIC, and 80% of these having a
condition that is reversible or preventable,6 it is vital that
we reduce the barriers to accessing basic eye care.
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Figure 9. A Peek fieldworker examining a patient’s retina in the valid-
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The Nakuru Posterior Segment Eye
Disease Study
Methods and Prevalence of Blindness and Visual
Impairment in Nakuru, Kenya
Wanjiku Mathenge, MBChB, MMed,1,2,3 Andrew Bastawrous, MRCOphth,1 Allen Foster, FRCS,1
Hannah Kuper, ScD1
Objectives: To estimate the prevalence of blindness and visual impairment (VI) in adults aged !50 years in
the Nakuru district of Kenya and to identify sociodemographic risk factors for these conditions. We also sought
to validate the Rapid Assessment of Avoidable Blindness (RAAB) methodology.
Participants: There were 5010 subjects enumerated for this study. Of these, 4414 participants underwent
examination, for a response rate of 88.1%.
Design: Cross-sectional, population-based survey.
Methods: Cluster random samplings with probability proportionate to size procedures were used to select
a representative cross-sectional sample of adults aged !50 years. Each participant was interviewed, had
distance visual acuity (VA) measured with reduced logarithm of the minimal angle of resolution tumbling-E chart,
underwent autorefraction, and thereby had measurements of presenting, uncorrected, and best-corrected VA. All
participants, regardless of vision, underwent detailed ophthalmic examinations including slit-lamp assessment
and dilated retinal photographs.
Main Outcome Measures: Visual acuity of !6/12.
Results: A representative sample of 4414 adults were enumerated (response rate, 88.1%). The prevalence
of blindness (VA ! 3/60 in better eye) was 1.6% (95% confidence interval [CI], 1.2–2.1%) and of VI, 0.4% (95%
CI, 0.3–0.7%); 8.1% (95% CI, 7.2–9.2%); and 5.1% (95% CI, 4.3–6.1%) were severely (!6/60–3/60), moderately
(!6/18–6/60), or mildly (!6/12–6/18) visually impaired, respectively. Being male, having less education, having
Kalenjin tribal origin, and being !80 years old were associated with increased blindness prevalence. Prevalence
estimates were comparable to a RAAB performed in the same area 2 years earlier.
Conclusions: This survey provides reliable estimates of blindness and VI prevalence in Nakuru. Older age
and tribal origin were identified as predictors of these conditions. This survey validates the use of RAAB as a
method of estimating blindness and VI prevalence.
Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials
discussed in this article. Ophthalmology 2012;xx:xxx © 2012 by the American Academy of Ophthalmology.
The World Health Organization (WHO) estimates 285 mil-
lion people are visually impaired worldwide, 39 million are
blind (!3/60), and 246 million have visual impairment (VI;
!6/18–3/60).1 The highest prevalences of blindness and VI
are in Africa, with 7 million blind and 27 million with VI,
although a lack of data on prevalence and causes of low
vision in Africa was highlighted in the report.2 The popu-
lation of Africa is not homogenous, and so country-specific
data are required if the goals of “VISION 2020: The Right
to Sight” global initiative to eliminate avoidable blindness
by 2020 are to be met. Avoidable blindness is defined as
blindness that could be either treated or prevented by
known, cost-effective interventions. Consequently, VISION
2020 seeks to address the main causes of avoidable blind-
ness, cataract, refractive error, trachoma, onchocerciasis,
and childhood blindness to have the greatest possible impact
on vision loss worldwide.
The majority of survey data from Africa are based on
nonstandardized methodology with a preponderance for ar-
eas with endemic diseases such as trachoma or onchocer-
ciasis. Since completion of the WHO systematic review in
2002,2 a new methodology has been proposed, the Rapid
Assessment of Avoidable Blindness (RAAB),3 which is a
rapid, standardized survey and examination methodology to
assess the prevalence of blindness and VI and avoidable
causes of vision loss. To date, in Africa, there have been
RAABs published from Kenya,4 Rwanda,5 Eritrea,6 Ma-
lawi,7 Tanzania,8 and Zanzibar.9
Large, national, population-based surveys, such as those
undertaken in The Gambia,10 Ethiopia,11 and Nigeria12 are
expensive and time consuming; accurate diagnosis of all
causes of blindness and VI require expensive and cumbersome
equipment that is infrequently used in field-based surveys.
Therefore, the RAAB provides a rapid, low-cost alternative.
1© 2012 by the American Academy of Ophthalmology ISSN 0161-6420/12/$–see front matter
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.ophtha.2012.04.019
Nakuru district (now Nakuru county) is the main district
of Kenya’s largest province, the Rift Valley province, and
has a population of 1.6 million. Nakuru district is broadly
representative of Kenya in terms of ethnic diversity and
economic activities. The Nakuru Eye Unit based at the Rift
Valley Provincial Hospital provides most of the ophthalmic
services for Nakuru district, serving approximately 10 000
patients each year. A RAAB was undertaken in Nakuru in
2005 and identified that posterior segment eye disease was
the second leading cause of blindness.4 Consequently, the
Nakuru posterior segment eye disease survey was under-
taken to explore the prevalence and predictors of these
conditions, which were not assessed in detail in the RAAB.
This study estimates the prevalence of blindness and VI
in an African population aged !50 years in the Nakuru
district of Kenya. We can also compare the results of this
survey with the previously undertaken RAAB.4 Predictors
of blindness/VI in this population were also identified. The
prevalence and causes of posterior segment eye disease
blindness and VI will be published in a later article.
Methods/Design
The study fieldwork was carried out in 2 phases from January 2007
to June 2007 and from April 2008 to November 2008.
Sample Size Calculation
The sample size required was calculated based on an expected
prevalence of a visual acuity (VA) of !6/12 in the better eye
caused by posterior segment disease of 3.0% among those aged
!50 years, a required precision of 0.5% (a 95% confidence inter-
val [CI]), a design effect of 1.5, and a response rate of 90%, so that
4996 participants were needed (Epi Info 6.04, US Centers for
Disease Control and Prevention, Atlanta, GA). We therefore aimed
to select 100 clusters, each of 50 participants.
Sampling Strategy and Recruitment
Recent census data for Kenya were not available13; therefore,
election role lists that were renewed in 2006 in preparation for the
2007 general elections were used as the sampling frame for this
survey. The population size was updated for 2007 using a popu-
lation growth rate of 2.7% per year.14 We selected 100 clusters
with a probability proportional to the size of the population. A
cluster was defined as the area served by the polling station.
Households were selected within clusters using a modified
compact segment sampling method.15 Each cluster was divided
into segments; each segment included approximately 50 people
aged!50 years. For instance, if a cluster included 200 people aged
!50 years, then it was divided into 4 segments. One of the
segments was chosen at random by drawing lots and all house-
holds in the segment were sequentially sampled, until 50 people
aged!50 years were identified. An eligible individual was defined
as someone aged!50 years living in the household for!3 months
in the previous year. Age was determined using the subject’s
testimony, national identity cards, and a calendar of historic
events. If the segment did not include 50 people aged !50 years,
then another segment was chosen at random and sampling contin-
ued. If after enumerating individual number 49 the next household
had "1 person aged !50, all were enumerated and invited for
examination.
Ophthalmic and General Examination
Suitable predetermined examination sites were selected on the
recommendation of the village leader with close proximity for
access to the cluster and electricity supply (mains or generator) for
the equipment.
The examination team was led by an ophthalmologist (W.M.)
who examined every participant in the study and included 2 nurses
delivering questionnaires; 2 fully trained ophthalmic nurses under-
took visual acuity checking and autorefraction. A trained visual
field technician performed field tests, an ophthalmic clinical officer
took fundus photographs, and another nurse took weight, height,
blood pressure, and blood tests. The team also included an office
manager and 2 data entry clerks.
Visual Acuity
The presenting another VA was defined as the number of letters
read correctly without glasses if the participant did not have
glasses or with glasses if they had them. Testing was done by an
ophthalmic nurse with an assistant. Each eye was tested separately
at 4 m using a reduced logarithm of the minimal angle of resolu-
tion tumbling “E” chart16 in a well-illuminated area. If the sub-
ject’s vision was too poor to read any letters on the chart at 4 m,
then the subject was tested at 1 m, then as follows:
● Counting fingers: Ability to count fingers at 1, 2, or 3 m
distance;
● Hand motion: Ability to distinguish whether a hand is mov-
ing in front of the patient’s face;
● Light perception: Ability to perceive any light; and
● No light perception: Inability to see any light or total
blindness.
Those who did not read 24 letters (VA !6/12) at 4 m were
scheduled for correction and to undergo a repeat VA measurement
with the correction in place, unless the vision was worse than
counting fingers, in which case no correction was undertaken
(Table 1).
Diagnosis of Causes of Blindness
Cataract. Participant’s pupils were pharmacologically dilated to a
minimum of 6.5 mm (tropicamide 1%). Anterior segment exami-
nation was performed at the slit lamp by the ophthalmologist. The
lens was graded using the WHO simplified system.17
Refractive Error. An automated Topcon autorefractor RM8800
(Topcon, Oakland, NJ) was used to provide an objective measure-
ment of all participants’ refractive error and their prescription for
glasses regardless of VA. For purposes of this study, the printout
contained readings of the sphere (–25 diopters [D] to #22 D [to
Table 1. Visual Acuity Categories Used in the Study
Visual Category
Reduced
LogMAR
Letters Seen
Snellen
Equivalent
LogMAR
Score
Equivalent
Normal !24 6/12 0.0–0.3
Mild VI 19–23 !6/12–6/18 !0.3–0.48
Moderate VI 3–18 !6/18–6/60 !0.48–1.0
Severe VI 2 !6/60–3/60 !1.0
Blindness 0.1 !3/60
LogMAR $ logarithm of the minimal angle of resolution; VI $ visual
impairment.
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the nearest 0.25 D]), cylinder (0 to!10 D [to the nearest 0.25 D]),
and axis (0°–180° [in 5°steps]). Uncorrected, presenting, and
autorefractor-corrected (using trial frames and lenses) VA were
measured on all participants.
Visual Field Testing. The Humphrey Field Analyzer II 720i
series (Carl Zeiss Ophthalmic Systems, Inc., Peabody, MA) was
used for automated visual field testing in eligible individuals as
well as in a random sample of 5 individuals per cluster identified
during enumeration.
Participants performed the Swedish Interactive Thresholding
Algorithm Standard 24-2. Every participant underwent the Swed-
ish Interactive Thresholding Algorithm Fast (quick test) to deter-
mine their threshold level. Appropriate corrective lenses for re-
fractive errors were used when needed; if the results were
unreliable (false-positives,"20%; false-negatives,"33%; fixation
losses, "33%), the participant then repeated the test once more.
Fundoscopy and Lens Grading. Pharmacologic dilation of the
participant’s pupils was performed using 1 drop of tropicamide
1%. Examination of the anterior chamber as well as the lens was
performed at the slit lamp by the ophthalmologist (W.M.) to
identify causes of reduced visual acuity or reasons for reduced
clarity of the posterior segment.
The optic nerve was examined using a 90-D lens at the slit
lamp; the clarity of the view of the optic nerve head was deter-
mined and graded as clear, hazy, or no view depending on whether
there was a complete view of the retinal details, incomplete view,
or nothing visible, respectively. Among subjects in whom an
adequate view of the disc was available, the vertical cup-to-disc
ratio was estimated and recorded. Any asymmetry !0.2 between
the 2 eyes was noted. Other characteristics of the optic nerve
including notching of the rim, vessel location perturbations, nerve
fiber layer defects, nonglaucomatous optic atrophy, and optic
nerve head hemorrhages were also recorded. If only 1 eye could be
visualized, then asymmetry was recorded as “not applicable.”
Retinal Examination. Slit-lamp biomicroscopy with a 90-D
lens involved an assessment of the macula, the retinal vasculature,
and the peripheral retina. The view of the retina was recorded as
clear, hazy, or no view, and the optic disc was assessed as outlined
above. Diabetic retinopathy was graded and recorded as absent,
nonproliferative, maculopathy (macula edema), proliferative, or
end stage (UK National Guidelines on Screening for Diabetic
Retinopathy, NHS 2010). The macula was examined for presence
of drusen, hypopigmentation, or hyperpigmentation, dry or geo-
graphic atrophy, and neovascular changes. Any other pathology of
the retina or vitreous, for example retinal detachments or vitreous
hemorrhages, were also noted and a description given.
Fundus Photography. The participants had 2 nonstereoscopic,
digital, 45° fundus photographs taken per eye by an ophthalmic
clinical officer using a TRC-NW6S Non-Mydriatic Retinal Cam-
era with 10 megapixel Nikon D80 (Topcon). The images were
digitally stored using the preinstalled IMAGEnet Telemedicine
System. One image was centered on the optic disc while the other
was centered on the macula. Images were forwarded to the Retinal
Grading Centre at Moorfields Eye Hospital Reading Centre in
London for grading and confirming the clinical diagnosis of pos-
terior segment disease. The digital photographs were graded by a
dedicated certified grader. Moorfields Eye Hospital Reading Cen-
tre is a certified Wisconsin Reading Center. All images were first
categorized for quality as excellent, good, fair borderline, or un-
gradeable. Images were graded separately for age-related macular
degeneration, diabetic retinopathy, and optic disc pathology.
Other. The presence or absence of trachoma, corneal scarring,
globe abnormalities, and any other pathology was recorded.
General Information. Detailed interviews were undertaken in
the local language covering demographic details, information on
risk factors, socioeconomic status, and full medical history. We
also measured weight, height, waist and hip circumference, blood
pressure, and random cholesterol and glucose blood levels.18
“Mother tongue” was used as a measure of tribal affiliation.
Visual Impairment and Blindness Definitions. Based on the
VA test used in this study, VI was defined by the number of letters
read (Table 1).
Data Entry
A data entry package in EpiData Entry v 2.1 was developed for this
study, which incorporated range and consistency checks. If an
error was detected, the data entry clerks asked the field team at the
end of the same day, and the error could thus be rectified or
missing information collected on the next day. Data from each
questionnaire were entered by 2 different people, on 2 separate
computers. Consistency checks were performed each evening and
inconsistencies corrected the same day. Two datasets, one for the
demographic and risk factor information and one for the ophthal-
mic examinations, were stored, each bearing the same study iden-
tification number.
Data Analysis
Prevalence of blindness and VI was estimated, and the cluster
design of the study was taken into account by using the “svy”
commands in STATA (Stata Corp, Inc., College Station, TX)
when calculating CIs around the prevalence estimates.
Socioeconomic Status. A continuous asset score was pro-
duced for each participant using principle component analysis. The
score was divided into quartiles to categorize the study participants
into 4 socioeconomic groups, with a higher score representing
higher socioeconomic status.
Obesity. Using body mass index (height [m]/weight [kg2])
was categorized as #18.5 (underweight), 18.5 to 24.99 (normal),
25 to 29.99 (overweight),!30 (obese), 30 to 34.99 (obese class 1),
35 to 39.99 (obese class 2), or !40 (obese class 3). Obesity using
waist circumference was categorized using WHO guidelines19 as
normal (male, #94 cm; female, #80 cm), overweight (male,
94–101.9 cm; female, 80–87.9 cm), or obese (male, !102 cm;
female, !88 cm).
The clusters were defined as rural or urban according to the
classification used by the District Health Statistics office.20 The
distinctions were made nationally based on population density,
administrative function, and availability of social amenities and
physical infrastructure such as hospitals, post office, schools, and
markets.
Potential risk factors for blindness were identified after assess-
ment of the literature. Logistic regression analyses were produced
to assess the univariate associations between potential risk factors
and prevalent blindness. Inclusion in the multivariable logistic
regression was by purely statistical criteria, retaining those vari-
ables that were significant correlates of blindness, always retaining
age and gender in the model.
Ethical Approval
Ethical approval was granted by the London School of Hygiene
and Tropical Medicine ethics committee and also the Kenya
Medical Research Institute. Approval was also granted by the
Provincial Medical Officer Rift Valley and the Nakuru district
Medical Officer of Health. Written approval was sought from
the administrative heads in each cluster, usually the village
chief. All participants gave written or verbal consent to partic-
ipate. Those requiring medical treatment were referred to the
appropriate center.
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Results
Study Participation and Response Rates
There were 5010 subjects enumerated for this study. Of these,
4414 participants underwent examination, for a response rate of
88.1%. The response rate was similarly high among men (89.2%)
and women (86.5%). Of the nonrespondents, 584 (98%) were
away working or visiting family outside the cluster location and 12
(2%) refused to participate; none were excluded as a result of
inability to communicate.
Comparison of Responders and Nonresponders
Details about gender were available for all of the nonresponders,
whereas age was available for 526 nonresponders (90.1%). Those
who were examined were significantly older (mean age, 63.4
years; standard deviation, 10.5 years) than those who were not
(mean, 61.9 years; standard deviation, 10.6 years; P ! 0.002).
Women were significantly overrepresented among the nonresponders
(56.8%) compared with those who were examined (52.1%; P! 0.03).
Among those enumerated, 66.5% were from rural clusters; among
those who were examined, 67.2% were rural (P! 0.7). Of those who
were not examined, none were believed to be blind.
Among those who responded, 33 had incomplete examinations
or missing data. Fifteen of these had complete demographic infor-
mation including blood tests. Therefore, 4396 participants are
included in the baseline characteristics descriptions and 4381 in
the ophthalmic analyses.
Comparison of District and Sample Populations
The sample population was slightly older than the general popu-
lation (P for chi-square " 0.001) and women were relatively
overrepresented (P for chi-square! 0.003; Table 2). However, the
district estimates for age and gender distribution were based on
census data 10 years old and so may not have been reliable.
Population Descriptions
The majority (63%) of participants were Kikuyu, the largest ethnic
group in Kenya. Kalenjin formed 23% of the sample population,
and 5 other tribes constituted 7.5% of the total. One third of
participants (33%) had no education and almost 10% had tertiary
education. Of the participants, 67.3% were from rural clusters.
Blindness and Low Vision for Nakuru and for
Kenya
Of the sample, 1.6% (95% CI, 1.2%–2.1%) were bilaterally blind,
0.4% (95% CI, 0.3%–0.7%), 8.1% (95% CI, 7.2%–9.2%), and
5.1% (95% CI, 4.3%–6.1%) were severely, moderately, or mildly
visually impaired, respectively, based on presenting VA (Table 3).
Overall prevalence of blindness was greater among men than
women.
The estimates were extrapolated to estimate the magnitude of
blindness and VI in adults aged !50 years in Nakuru (Table 4).
Based on the study findings, it is estimated that 1419 adults !50
years are blind in Nakuru district.
Visual Acuity by Age
Advancing age was associated with greater prevalence of VI. In
the age group 50 to 59 years, 95.5% had normal vision (VA! 6/12
in both eyes); however, only 42.7% in the !80 age group had
normal vision. Of adults !80 years, 9.1% were blind compared
with 0.5% in the 50 to 59, 0.9% in the 60 to 69, and 1.5% in the
70 to 79 years age groups (Fig 1).
After correcting for refractive error the prevalence of blindness
with best-corrected VA was 1.1% (95% CI, 0.8–1.5). The preva-
Table 2. Age and Gender Composition of District and Sample Populations
Age Groups
(yrs)
Male Female Total
District
(n ! 44 519)
Sample
(n ! 2113)
District
(n ! 44 195)
Sample
(n ! 2301)
District
(n ! 88 714)
Sample
(n ! 4414)
50–54 13 907 (31%) 428 (20%) 13 721 (31%) 565 (25%) 27 628 (31%) 993 (23%)
55–59 10 081 (23%) 428 (20%) 10 076 (23%) 528 (23%) 20 157 (23%) 956 (22%)
60–64 7432 (17%) 376 (18%) 7412 (17%) 380 (17%) 14 844 (17%) 756 (17%)
65–69 5482 (12%) 271 (13%) 5452 (13%) 277 (12%) 10 934 (13%) 548 (12%)
70–74 3753 (8%) 242 (12%) 3706 (11%) 206 (9%) 7459 (8%) 448 (10%)
75–79 2208 (5%) 165 (8%) 2205 (5%) 128 (6%) 4413 (5%) 293 (7%)
!80 1656 (4%) 203 (10%) 1623 (4%) 217 (9%) 3279 (4%) 420 (10%)
Table 3. Prevalence of Blindness and Visual Impairment (VI)
Presenting Visual Acuity in the
Better Eye (Snellen) (LogMAR
Letters)
Male (n ! 2099) Female (n ! 2282) Total (n ! 4381)
n Prevalence (95% CI) n Prevalence (95% CI) n Prevalence (95% CI)
Blind ("3/60) (0–1) 44 2.1% (1.5–2.9) 27 1.2% (0.8–1.8) 71 1.6% (1.2–2.1)
Severe VI ("6/60–!3/60) (2) 11 0.5% (0.3–0.9) 7 0.3% (0.2–0.6) 18 0.4% (0.3–0.7)
Moderate VI ("6/18–!6/60) (3–18) 175 8.3% (7.1–9.7) 181 7.9% (6.8–9.2) 356 8.1% (7.2–9.2)
Mild VI ("6/12–!6/18) (19–23) 105 5.0% (4.1–6.1) 119 5.2% (4.1–6.9) 224 5.1% (4.3–6.1)
Normal vision !6/12 (!24) 1764 84.0% (82.0–85.9) 1948 85.4% (83.0–87.4) 3712 84.7% (82.9–86.4)
CI ! confidence interval; LogMAR ! logarithm of the minimal angle of resolution.
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lence of mild, moderate, and severe VI with best correction was
2.3% (95% CI, 1.8–3.1), 3.5% (95% CI, 2.9–4.2), and 0.2% (95%
CI, 0.1–0.4), respectively. The prevalence of best-corrected VA
blindness was higher in men than women (1.4% vs 0.8%) but did
not attain significance.
Age and Gender. Age- and gender-adjusted logistic regression
analyses (Table 5) revealed that the prevalence of blindness in-
creased significantly with age in the!80 years age group, carrying
18.8 times (95% CI, 9.2–38.1) higher odds of blindness than those
aged 50 to 59 years. Females had 40% lower odds of blindness
than men (0.6; 95% CI, 0.4–0.9). Compared with people with no
education, the odds of blindness was lower among those with 1 to
7 years of education (odds ratio [OR], 0.3; 95% CI, 0.1– 0.5), or
!7 years of education (OR, 0.2; 95% CI, 0.1– 0.7). Odds of
blindness was similar for those residing in rural compared with
urban locations (OR, 1.0; 95% CI, 0.6 –1.8). Participants with
diabetes had more than twice the odds of blindness compared
with nondiabetics (OR, 2.3; 95% CI, 1.1– 4.7%); however, the
association with hypertension was not significant (OR, 1.2; 95%
CI, 0.8 –2.0). There was no clear relationship between blindness
and smoking or drinking. Those from the Kalenjin tribe had 2.5
times higher odds of blindness (95% CI, 1.5– 4.1) than those of
the Kikuyu tribe or others.
Using stepwise multivariate regression analysis and adjusting
for all factors significant at the P"0.05 level, male gender (P "
0.003), education level (P#0.0001), Kalenjin tribe (P " 0.003)
and age !80 years (P#0.0001) were associated with increased
odds of blindness. Diabetes (P#0.09) and hypertension (P#0.08)
had borderline associations with increased odds of blindness.
Table 4. Magnitude of Blindness in Those !50 Years in Nakuru District, Kenya
Age (yrs)
Population Size
in Nakuru, n (%)
Blindness SVI Moderate VI
Prevalence
(%)
Expected No. of
Cases (95% CI)
Prevalence
(%)
Expected No. of
Cases (95% CI)
Prevalence
(%)
Expected No. of
Cases (95% CI)
50–59 47 785 (54) 0.5 239 (143–478) 0.1 48 (10–191) 1.9 908 (669–1195)
60–69 25 778 (30) 0.9 232 (129–412) 0.4 103 (52–232) 6.1 1573 (1186–2088)
70–79 11 872 (13) 1.5 178 (95–332) 0.1 12 (5–119) 15.0 1781 (1460–4286)
80$ 3279 (4) 9.1 298 (203–433) 2.4 79 (43–141) 31.3 1026 (879–1184)
Total 88714 1.6 1419 (1065–1863) 0.4 355 (266–621) 8.1 7186 (6387–8162)
CI " confidence interval; SVI " severe visual impairment; VI " visual impairment.
0%10%
20%30%
40%50%
60%70%
80%90%
100%
50-59 60-69 70-79 80+
NormalMild VIModerate VISevere VIBlind
Figure 1. Distribution of visual impairment by age.
Table 5. Risk Factors for Blindness (n " 4314)
Blind, n (%),
n ! 71
(1.6%)
Age-adjusted
OR (95% CI)
Multivariate-
Adjusted
OR (95% CI)
Age (yrs)
50–59 10 (0.5) Baseline Baseline
60–69 12 (0.9) 1.7 (0.7–4.0) NS
70–79 11 (1.5) 2.7 (1.1–6.5) NS
!80 38 (9.1) 18.8 (9.2–38.1) 5.8 (3.4–10.1)
Gender
Male 44 (2.1) Baseline Baseline
Female 27 (1.2) 0.6 (0.4–0.9) 0.4 (0.2–0.7)
Education (yrs)
None 51 (3.5) Baseline Baseline
1–7 16 (0.8) 0.3 (0.1–0.5) 0.3 (0.1–0.5)
!7 4 (0.5) 0.2 (0.1–0.7) 0.2 (0.1–0.7)
SES
1 (poorest) 32 (2.9) Baseline —
2 14 (1.3) 0.5 (0.3–1.0) —
3 15 (1.4) 0.7 (0.4–1.3) —
4 (least poor) 9 (0.8) 0.5 (0.2–1.1) —
Habitat
Rural 53 (1.8) Baseline —
Urban 18 (1.3) 1.0 (0.6–1.8) —
Diabetes
No 61 (1.5) Baseline Baseline
Yes 10 (3.5) 2.3 (1.1–4.7) 2.1 (0.9–5.0)
Hypertension
No 27 (1.3) Baseline Baseline
Yes 44 (1.9) 1.2 (0.8–2.0) 1.6 (0.9–2.8)
Smoker
Never 45 (1.5) Baseline —
Former 24 (2.5) 1.2 (0.7–2.2) —
Current 2 (0.6) 0.4 (0.1–1.9) —
Alcohol
Never 17 (1.0) Baseline Baseline
Former 49 (2.6) 1.4 (0.7–2.6) NS
Current 5 (0.7) 0.4 (0.2–1.3) 0.2 (0.1–0.6)
Tribe
Kikuyu 34 (1.2) Baseline Baseline
Kalenjin 34 (3.2) 2.5 (1.5–4.1) 2.3 (1.3–3.9)
Others 5 (0.8) 1.1 (0.4–2.9) NS
BMI
Normal/underweight 59 (2.1) Baseline Baseline
Overweight/obese 8 (0.5) 0.4 (0.2–0.8) 0.4 (0.2–0.8)
BMI " body mass index; CI " confidence interval; NS " not significant;
OR " odds ratio; SES " socioeconomic status; —, not included in
multivariate analysis.
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Discussion
This study describes the vision status of a random sample of
Kenyan people aged !50 years living in Nakuru district
using comprehensive ophthalmic examination techniques.
The results confirm that prevalence of blindness is relatively
low as suggested by recent RAAB surveys4,21 and that it
may be declining compared with earlier surveys.22
The prevalence of bilateral blindness in this study (1.6%
[95% CI, 1.2–2.1]) is similar to that found in the RAAB
performed in the same district in 2005 (2.0% [95% CI,
1.5–2.4%]), whereas the prevalence of VI (Snellen !6/18–
6/60) is slightly higher in this survey (8.1%; 95% CI,
7.2%–9.2%) compared with that in the RAAB (5.8%, 95%
CI, 4.8%–6.8%). During the RAAB, enumeration and ex-
amination occur simultaneously, as opposed to as separate
endeavors in the survey. Furthermore, VA was assessed
using a simple tumbling E chart in the RAAB, compared
with the more detailed logarithm of the minimal angle of
resolution assessment in this survey. Finally, a simplified
examination protocol using a direct ophthalmoscope is used
in RAAB to assess causes of blindness, whereas in the
current study the examination was in more detail with more
sophisticated technology. The RAAB methodology has
been field tested in a variety of settings, showing it to be a
low-cost method of undertaking an ophthalmic survey.
However, this is the first setting in which it has been
compared with a more detailed survey protocol and found to
be appropriate for assessing the prevalence of blindness.
The prevalence of blindness and VI was similar to or
lower than that in recent African-based RAAB surveys
among people aged !50 years, which varied from a prev-
alence of 1.8% (95% CI, 1.2%–2.4%) in Rwanda5 to 9.0%
(95% CI, 8.0%–10.0%) in Eritrea.6 It was also considerably
lower than the prevalence found in the recent Nigeria sur-
vey12 of 4.2% (95% CI, 3.8%–4.6%) among people !40
years, but comparable with that of all age groups from the
neighboring country of Ethiopia,11 where the prevalence
was found to be 1.6%, but 14.8% among those !60 years.
Tribal differences were notable, with Kalenjins being 2.5
times more likely to be blind than Kikuyus and other tribes.
This may be attributed to socioeconomic status differences,
with only 9% of Kalenjins being in the upper quartile
compared with 26% of Kikuyus, although the association
persisted after adjustment for socioeconomic status. Vary-
ing levels of awareness or vulnerability to disease may also
be important. An unusually high representation of men was
seen among those found to be blind. This is possibly due to
district data not being representative because it was based
on electoral role data and extrapolated to the proportion
aged !50 years.
The strengths of this study include (1) a single senior
ophthalmologist examining each participant, (2) a large,
population-based sample, (3) high-level technological diag-
nostic equipment, and (4) the use of internationally accepted
definitions of disease.
Limitations of this study include the restriction to inclu-
sion of participants to adults "50 years of age. It has,
however, been shown that not only is most blindness and VI
found in this group, but also that restricting assessment to
this group provides a good reflection of the prevalence and
causes of VI in the general population while using a smaller
sample size, thus reducing survey time and costs.3 However,
the high cost requirement of such a study makes it difficult
to repeat, particularly in a low-income setting. Although it
seems that the data from this study closely reflect that of the
RAAB in the same area, the 2 studies were not performed
concurrently. The relatively small number of cases of blind-
ness may have constrained the power available to detect
significant associations.
Nonrespondents were found to be slightly younger than
respondents, which may lead to an overestimation of the
prevalence of blindness and VI in the study population.
The Nakuru district has approximately 1419 individuals
who are blind and a further 7541 with VI. The district is
served by the Rift Valley Provincial Hospital, which has a
48-bed dedicated eye facility staffed by 1 ophthalmologist.
There are also 2 ophthalmic clinical officers who are trained
as cataract surgeons. Further resources are required to close
the gap between currently available resources and need.
Data from this survey suggest a lower prevalence of
blindness and VI than most African populations. It is also
strongly suggestive that the RAAB methodology being used
throughout Africa and worldwide is a robust and reliable
methodology when adhered to and fulfills the authors’ rec-
ommendations on use of the RAAB methodology3 in a
population for whom there is a more complete data set.
Further work is being undertaken to assess the causes of
blindness within this population.
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ORIGINAL ARTICLE
Prevalence and Correlates of Diabetic Retinopathy in a
Population-based Survey of Older People in Nakuru,
Kenya
Wanjiku Mathenge1, Andrew Bastawrous2, Tunde Peto3, Irene Leung3,
David Yorston4, Allen Foster2, and Hannah Kuper2
1RIIO and Dr Agarwal’s Eye Hospital, Kigali, Rwanda and The Fred Hollows Foundation, Nairobi, Kenya,
2International Centre for Eye Health, Department of Clinical Research, London School of Hygiene and Tropical
Medicine, London, UK, 3NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust
and UCL Institute of Ophthalmology, London, UK, and 4Tennent Institute of Ophthalmology, Gartnavel
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ABSTRACT
Purpose: To estimate the prevalence of and factors associated with diabetic retinopathy (DR) among people aged
!50 years in Nakuru, Kenya.
Methods: Probability-proportional-to-size sampling was used to select 100 clusters of 50 people aged !50 years
during 2007–2008. Households within clusters were selected through compact segment sampling. Participants
underwent dilated slit lamp biomicroscopy (SLB) by an ophthalmologist and digital retinal photography.
Images were graded for DR at the Moorfields Eye Hospital Reading Centre, UK. Diagnosis of DR was based
on retinal images where available, otherwise on SLB. Anthropometric measures, including random glucose,
and lifestyle factors were measured.
Results: We examined 4414 adults (response rate 88.1%), of whom 287 had diabetes. A total of 277 of these were
screened for DR by SLB, and 195 also underwent retinal photography. The prevalence of any DR diagnosed by
retinal images among diabetics was 35.9% (95% confidence interval, CI, 29.7–42.6%). The most common grade
of DR was mild/moderate non-proliferative DR (NPDR; 22.1%, 95% CI 16.1–29.4%), while severe NPDR
and proliferative DR were less frequent (13.9%, 95% CI 10.0–18.8%). SLB significantly underdiagnosed
DR compared to retinal photography, particularly for milder grades. Of 87 individuals with DR, 23 had visual
impairment (visual acuity56/12). DR was associated with younger age, male sex, duration and control of
diabetes, and treatment compliance. Coverage of photocoagulation in those needing immediate laser was low
(25%).
Conclusion: DR remains a threat to sight in people with diabetes in this elderly Kenyan population. Screening
diabetics may enable those requiring treatment to be identified in time to preserve their sight.
Keywords: Diabetic retinopathy, epidemiology, kenya, ophthalmology, survey
INTRODUCTION
Diabetes is a major threat to global public health.
Approximately 347 million people worldwide have
diabetes.1 This figure is likely to rise substantially,2,3
with the greatest increases expected to be in Africa
and the Middle East as a result of population growth,
aging, and the increase in obesity and sedentary
lifestyles in these regions.4
Diabetic retinopathy (DR) is one of the microvascu-
lar complications of diabetes and is the most severe
ocular complication of diabetes. DR is the leading
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cause of blindness in adults under 75 years in high
income countries,5,6 and is responsible for at least 1%
of blindness globally.7 The predicted rise in the
proportion of adults with diabetes will inevitably
lead to an increase in the prevalence of DR.8
There is currently little evidence available on the
contribution of diabetes to blindness in African
countries. This is because detection of DR in Africa
remains a challenge, due to lack of necessary equip-
ment and skilled human resources.9 Only one popu-
lation-based survey was identified for sub-Saharan
Africa which included assessment of DR, which was
undertaken in Nigeria and showed that DR was
responsible for only 0.5% of blindness and 1.0% of low
vision.10 In a summary of hospital-based studies
published in Africa the prevalence of DR in diabetic
populations in the African continent varied between
16 and 55% depending on clinical site, and the
duration and control of diabetes in the populations
investigated.11,12 Severe forms of DR were found in
about 15% of patients.13
DR may occur early in the course of diabetes in
Africa because of inadequate control of diabetes, co-
occurring hypertension,14 and possibly because the
progression of DR is more rapid in black popula-
tions.15 As general diabetic care improves and life
expectancy for people with diabetes increases in
Africa, it is likely that more DR and more blindness
from DR will occur.
Data are urgently needed on the prevalence of DR
in order to plan treatment and preventive services.
More information is also needed on factors associated
with DR in Africa, as these may differ to those in other
settings. We have conducted a population-based
survey of ophthalmic disease among people aged
50+ years in Nakuru, Kenya, which allows these
questions to be investigated. The overall prevalence of
blindness (visual acuity, VA,53/60 in the better eye)
in the survey was 1.6% (95% confidence interval, CI,
1.2–2.1%), while 0.4% (95% CI 0.3–0.7%) had severe
visual impairment (VI); 8.1% (95% CI 7.2–9.2%) had
moderate VI, and 5.1% (95% CI 4.3–6.1%) mild VI.16
Refractive error was responsible for 51.7 % of overall
VI.17 The aim of the current study was therefore to
estimate the prevalence and risk factors of DR among
people aged 50 years and older, within this popula-
tion-based survey in the Nakuru district of Kenya.
MATERIALS AND METHODS
Nakuru district has a population of 1.2 million, one
third of which is urban. Nakuru is broadly represen-
tative of Kenya in terms of ethnic diversity and
economic activities. The study fieldwork was carried
out in two phases from January 2007 to June 2007 and
from April 2008 to November 2008. Full details of the
methods are presented elsewhere.16
Sampling Strategy and Recruitment
We selected 100 clusters of 50 people aged !50
years through probability proportional to size
sampling, using the electoral role as the sampling
frame. Households were selected within clusters
using a modified compact segment sampling
method.18 The enumeration team visited house-
holds, assisted by a village guide, and invited all
eligible participants aged !50 years to the examin-
ation clinic which would be held at a convenient
place in the cluster over the subsequent 2 days.
Eligible participants were defined as those aged !50
years resident in the cluster (i.e. living there at least
6 months per year) who had slept in the house
either the night before or were planning on sleeping
in the house that night. If an eligible person was
absent then the survey team revisited the household
at least two times.
Data Collection
At the examination clinic the following examinations
were undertaken:
Visual Acuity
Two ophthalmic nurses measured presenting VA,
which was defined as the number of letters read
correctly without glasses if the participant did not
have glasses or with glasses if they had them. Each
eye was tested separately at 4m using a reduced
logarithm of the minimum angle of resolution
(LogMAR) tumbling ‘E’ chart19 in a well-illuminated
area. If a subject’s vision was too poor to read any
letters on the chart at 4m, then the subject was tested
at 1m, then counting fingers, hand movements, light
perception or no light perception.
Ophthalmic Examination
An ophthalmic examination was performed at the
slit lamp by the study ophthalmologist (WM).
Pharmacologic dilation of the participant’s pupils
was performed using one drop of tropicamide 1%.
Slit lamp biomicroscopy (SLB) with a 90 diopter
lens involved an assessment of the macula, the
retinal vasculature, and the peripheral retina. The
view of the retina was recorded as clear, hazy or
no view. Other signs of pathology were also
recorded.16
Fundus Photography
Participants had two non-stereoscopic digital 45"
fundus photographs taken per eye by an ophthalmic
clinical officer using a TRC-NW6S non-mydriatic
retinal camera (Topcon, Oakland, NJ, USA) with 10
megapixel Nikon D80 (Nikon, Tokyo, Japan). Images
were digitally stored using the preinstalled
2 W. Mathenge et al.
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IMAGEnet Telemedicine System. One image was
centered on the optic disc while the other was
centered on the macula.
Retinal images were forwarded to the Retinal
Grading Centre at Moorfields Eye Hospital Reading
Centre, London, UK, for grading DR. All images
supplied by the Nakuru Eye Study Group, regardless
of quality, were sent for grading. No manipulation of
the images was allowed while grading other than
using grey-scale for viewing the images. All images
were first categorized for quality as excellent, good,
fair, borderline and ungradeable.
Interviews
Participants were interviewed by trained nurses.
Information was collected on demographic data,
education and asset ownership. People were
asked whether their mother tongue was ‘‘Kikuyu,’’
‘‘Kalenjin’’ or other, to assign ethnicity. Information
was also collected on health behaviors
(smoking, alcohol use) and health status (diagnosis
of diabetes or hypertension, family history and their
treatment).
Anthropometric Data Collection
A random finger-prick blood sample was taken to
measure glucose (Accutrend GC system, Roche
Diagnostics UK, Burgess Hill, UK) and cholesterol
levels (Accutrend GC system). A nurse recorded the
blood pressure of participants three times on the right
arm of the participant, at least 5 minutes apart after an
initial period of five minutes of rest using a digital
automatic monitor (HEM907, Omron, Omron health-
care UK, Milton Keynes, UK). Weight was measured
to the nearest kilogram using standard scales (Seca
761 scales, Seca, Birmingham, UK) after the partici-
pant had removed all heavy clothing and shoes.
Height was measured to the nearest centimeter while
the participant stood without shoes using a standar-
dized stadiometer (Leicester Height Measure, Seca,
Birmingham, UK). For weight and height, the average
of two readings was recorded. Waist and hip circum-
ferences were measured with a tape to the nearest
centimeter.
Grading for DR
Grading for DR was undertaken for all participants
with diabetes. The definitions used were as follows:
Non-proliferative DR (NPDR):
! SLB: Intra-retinal hemorrhages, microaneurysms
venous beading, or prominent intra-retinal micro-
vascular abnormality and no signs of proliferative
retinopathy.
Retinal images:
– Mild: microaneurysms and retinal hemor-
rhages only were seen.
– Moderate: In addition to microaneurysms,
multiple deep, round or blot hemorrhages
were noted.
– Severe: Presence of features described before
plus existence of vascular features such as
venous loops, venous beading and intra-retinal
microvascular abnormality.
Proliferative DR:
! SLB: Neovascularization and/or vitreous/pre-ret-
inal hemorrhage.
Retinal images:
– New vessels on the disc new vessels elsewhere,
pre-retinal or vitreous hemorrhage or pre-
retinal fibrosis with or without tractional ret-
inal detachment.
Macular edema:
! SLB: Retinal thickening or hard exudates in the
posterior pole within 500 mm of the fovea.
Retinal images:
– Exudates within one disc diameter, the pres-
ence of circinate exudates within the macula
and multiple hemorrhages within one disc
diameter.
Clinically significant macular edema:
! SLB: Leakages involving or near the fovea.
Retinal images:
– Not assessed
All images were graded by the senior grader (IL).
In case of difficulties, the adjudicator (TP) looked at
the images. The adjudicator also looked at 5% of
randomly selected images to ensure quality control.
As diabetic macular edema is a stereo feature, clues
seen on mono images were used. Data were entered
onto Microsoft Excel and checked for consistency by a
data monitor.
Data Entry and Analysis
A data entry package in EpiData software v2.1
(EpiData Association, Odense, Denmark) was devel-
oped for this study, which incorporated range checks.
Data were double entered and consistency checks
were performed each evening and inconsistencies
corrected the same day.
The prevalence of DR and stages of DR were
estimated, and the cluster design of the study was
taken into account when calculating CIs around the
prevalence estimates.
A continuous socioeconomic status (SES) score was
produced for each participant using principle com-
ponent analysis based on asset ownership, household
type and education. The score was divided into
quartiles to categorize the study participants into
four socioeconomic groups with a higher score rep-
resenting higher SES. Body mass index was calculated
as height in meters/weight in kilograms2.The clusters
were defined as rural or urban according to the
Diabetic Retinopathy in Nakuru, Kenya 3
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classification used by the District Health Statistics
office, Nakuru.20 Diabetes was defined as per World
Health Organization standards for population-based
studies: reported current medication (tablets or insu-
lin) or diet control for diabetes or random blood
glucose level !11.1mmol/L.21
Statistical analyses were undertaken using STATA
version 10.0 (Stata Corp Inc, College Station, TX,
USA). Logistic regression analyses were produced to
assess the univariate associations between potential
risk factors and prevalent DR among those with
diabetes. Multivariable logistic regression models
were developed through stepwise selection, with
variables at the p50.05 level retained.
Ethical Approval
Ethical approval for the study was granted by the
London School of Hygiene & Tropical Medicine ethics
committee and also Kenya Medical Research Institute.
Approval was also granted by the Provincial Medical
Officer Rift Valley and the Nakuru District Medical
Officer of Health. Written approval was sought from
the administrative heads in each cluster, usually the
village chief. All participants gave written or verbal
consent to participate. People requiring medical
treatment were referred to the appropriate center.
This research adhered to the guidelines of the
Declaration of Helsinki.
RESULTS
A total of 5010 subjects were enumerated for this
study. Of these, 4414 participants underwent examin-
ation to give a response rate of 88.1%. Of the non-
respondents 584 (98%) were away working or visiting
family outside the cluster location and 12 (2%) refused
to participate.
Of the 4414 study participants, 4387 (99.4%) had a
random blood sugar test for diabetes. A total of 244
people reported they had been previously diagnosed
with diabetes mellitus and were labeled as ‘‘known
diabetes mellitus’’ (5.6%). A further 43 had random
blood sugar levels above 11.1mmol/L and were thus
labeled ‘‘newly diagnosed diabetes mellitus’’ (1.0%).
The total number with definite diabetes mellitus was
therefore 287 (6.5%). People with diabetes were less
likely to be Kalenjin, compared to Kikuyu, were more
likely to live in urban areas, and had higher education
and SES scores than those without diabetes (Table 1).
Those with diabetes were also more likely to be
current smokers, and overweight. Among those
‘‘known diabetes mellitus,’’ 196 (80.3%) were receiv-
ing treatment. The time since diagnosis was 1–5 years
for 126 people (51.6%), 6–10 years for 64 people
(26.2%) and more than 10 years for 54 people (22.1%).
Of 4381 people who underwent ophthalmic exam-
ination (99.3%), all had slit lamp examination and
3387 had retinal photographs taken, of which 83
images were ungradable (2.5%). Among the 287 with
definite diabetes mellitus, for 10 there was no view of
the retina, and 195 had fundus photographs taken
which could be graded in at least one eye (‘‘diabetic
image group’’). For the remaining 82, DR was graded
on the basis of SLB examinations only (‘‘diabetic
SLB group’’). All subjects in the diabetic image group
also had SLB.
PREVALENCE AND SEVERITY OF DR
The overall prevalence of any DR among the 195
patients with definite diabetes and with retinal images
in the study population was 35.9% (95% CI 29.7–
42.6%; Table 2). The most common grade of DR was
TABLE 1. Participant sociodemographic variables in relation to
diabetes status, Nakaru district, Kenya.
Diabetic
n (%)
Non-diabetic
n (%)
Age-,
sex-adjusted
OR (95% CI)
Age, years
50–59 107 (37) 1825 (45) Reference
60–69 103 (36) 1196 (29) 1.5 (1.1–1.9)
70–79 46 (16) 692 (17) 1.1 (0.8–1.6)
80+ 31 (11) 387 (9) 1.4 (0.9–2.1)
Sex
Male 139 (48) 1963 (48) Reference
Female 148 (52) 2137 (52) (0.8–1.3)
Language
Kikuyu 221 (77) 2534 (62) Reference
Kalenjin 25 (9) 987 (24) 0.3 (0.2–0.4)
Other 41 (14) 579 (14) 0.9 (0.6–1.2)
Location
Urban 142 (49) 1292 (32) 2.3 (1.8–3.0)
Rural 145 (51) 2808 (68) Reference
Education
Any 222 (77) 2711 (66) 1.5 (1.3–1.7)
None 65 (23) 1389 (34) Reference
SES score
1 (poorest) 25 (9) 1067 (26) Reference
2 41 (14) 1050 (26) 1.7 (1.0–2.8)
3 84 (30) 1008 (25) 3.9 (2.5–6.1)
4 (richest) 135 (47) 956 (23) 7.1 (4.6–10.9)
Smoking status
Never 206 (72) 2861 (70) Reference
Current 5 (2) 336 (8) 5.3 (2.1–13.2)
Former 75 (26) 892 (22) 1.1 (0.8–1.5)
Alcohol consumption
Never 121 (42) 1582 (39) Reference
Ever 166 (58) 2514 (61) 1.3 (1.0–1.7)
BMI Category
Underweight 17 (6) 599 (15) 0.5 (0.3–0.9)
Normal 107 (38) 2064 (51) Reference
Overweight 94 (33) 897 (22) 2.2 (1.6–2.9)
Obese 63 (22) 504 (12) 2.8 (2.0–3.9)
BMI, body mass index; CI, confidence interval; OR, odds ratio;
SES, socioeconomic status
4 W. Mathenge et al.
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mild/moderate NPDR (22.1%, 95% CI 16.1–29.4%),
while severe NPDR or proliferative DR were less
frequent (13.9%, 95% CI 10.0–18.8%).
Among the 70 patients with DR, 65 (93%) had
macular edema including eight with clinically signifi-
cant macular edema (CSME). Macular edema was
therefore present in 33.3% (95% CI 25.8–39.4%) of
patients with diabetes, of which CSME was present
in 4.1% (95% CI 1.9–8.2). Vision-threatening DR
requiring immediate photocoagulation (i.e. those
with CSME, severe NPDR or proliferative DR) was
present in 28 of the 195 definite diabetics with retinal
images, a prevalence of 13.4% (95% CI 9.6–16.3%).
SLB significantly under-diagnosed DR compared to
retinal photography. This applied to all grades of DR.
In total, all DR was under-diagnosed by SLB by a
factor of 1.6. In comparison to gold standard grading
by retinal images, grading of DR by SLB had low
sensitivity (60%) but high specificity (100%; Table 3).
Under-diagnosis of DR by SLB was therefore largely
due to assigning a lesser grade to the severe NPDR
and reporting no DR in many with mild NPDR. The
one case with proliferative DR missed by SLB had
new vessels at the disc as the only feature seen on
images. There were no false positive cases.
A total of 87 diabetics had features of DR giving
a prevalence of 31.4% (95% CI 26.3–37.0%; Table 4).
Applying the correction factor of 1.6 for under
diagnosis by SLB to the 17 diagnosed by SLB alone
results in an adjusted estimate of 97 people with DR
among the 277 diabetics with complete data, and an
overall prevalence of DR of 35.0% (95% CI 29.5–41.0%)
among those with diabetes.
The prevalence of all levels of VI was higher among
the 87 participants with confirmed DR diagnosed (by
images or SLB) compared to participants without DR
(Table 5), and overall one in four people with DR had
visual impairment (presenting VA56/12 in the better
TABLE 2. Prevalence of diabetic retinopathy (DR) among diabetics in Nakaru district, Kenya, who underwent both
slit lamp biomicroscopy (SLB) examination and had retinal images taken.
Retinal images SLB
Prevalence ratio
Category of DR n Prevalence, % (95% CI) n Prevalence, % (95% CI) (image/SLB):
No DRa 125 64.1 (57.4–70.3) 153 78.4 (73.0–82.5)
Mild/Moderate 43 22.1 (16.1–29.4) 26 13.3 (10.1–18.8) 1.6
Severe NPDR/PDRb 27 13.9 (10.0–18.8) 16 8.2 (5.0–12.4) 1.7
Any DR 70 35.9 (29.7–42.6) 42 21.5 (17.5–27.0) 1.6
a27 with mild NPDR and 1 with PDR graded as no DR by slit lamp
b16/17 with PDR correctly diagnosed while 10 with severe NPDR graded as mild/moderate NPDR by SLB.
CI, confidence interval; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy
TABLE 3. Sensitivity and specificity of diabetic retinopathy (DR) diagnosis by slit lamp biomicroscopy (SLB),
Nakaru district, Kenya.
Gold Standard: DR diagnosis by retinal imaging
Condition positive Condition negative
Test: DR diagnosis by SLB
Test positive 42 (True positive) 0 (False positives) Positive predictive value = 100%
Test negative 28 (False negatives) 125 (True negative) Negative predictive value = 81.7%
Sensitivity = 60.0% Specificity = 100%
TABLE 4. Prevalence of diabetic retinopathy (DR) among 277 diabetics with gradable retinas from Nakaru district,
Kenya.
Mild and moderate
non-proliferative DR
Severe non-proliferative
DR and proliferative DR Any DR
DR confirmed by retinal images (A), n 43 27 70
DR confirmed by slit lamp only (B), n 11 6 17
Total DR, n 54 33 87
Correction factor [A+ (B! 1.6)]
Adjusted total, n
Adjusted prevalence, %
61 37 97
(95% CI) 22.0 (17.4–27.5) 13.4 (9.7–18.1) 35.0 (29.5–41.0)
CI, confidence interval
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eye). VI among people with DR may be attributable to
DR, cataract, refractive error or other causes. Among
the 71 people who were blind in the Nakuru study
(presenting VA53/60 in the better eye), four had DR
(5.6%), to give a prevalence of DR blindness of 0.09%
(95% CI 0.03–0.25%) in this population.
The results for the risk factor analyses were
undertaken only on participants who had DR
graded by retinal images, as case status could not be
confirmed confidently for those with only SLB exam-
ination. The prevalence of DR was lower in the older
age groups, but there was no clear association with
sex or urban/rural residence (Table 6). The prevalence
of DR was strongly associated with diabetes-related
factors, including duration of diabetes, uncontrolled
diabetes and treatment with insulin. Systemic factors
were less clearly associated with DR: DR prevalence
was higher among non-smokers and hypertensives,
but there was no association with BMI. Education,
tribe, SES, family history, waist-to-hip ratio, and
cataract surgery were not associated with prevalence
of DR (data not shown). In the multivariable analyses,
the prevalence of DR remained associated with
younger age, male sex, duration of diabetes, control
of diabetes and compliance with treatment.
Seven individuals with diabetes in the survey
population had undergone photocoagulation in the
past; six in one eye only and one in both eyes. Among
those who had received photocoagulation, three had
undergone macular grid laser in one eye, one received
both pan retinal and grid laser in both eyes and three
underwent pan retinal laser in one eye. Among the
seven who had evidence of laser treatment, five
(71.4%) still had vision-threatening DR. Among
those with vision-threatening DR, coverage of photo-
coagulation in those needing immediate laser was
25%; 24% in males and 27% in females (Table 7).
DISCUSSION
We undertook a large population-based survey of DR
among people aged 50 years and older in Nakuru,
Kenya. Prevalence of diabetes was 6.5%.22 Among
those with diabetes, the prevalence of DR was
relatively high with more than one in three diabetics
affected, though most DR was mild or moderate in
severity. SLB substantially under-diagnosed DR in
comparison to retinal photography, particularly for
the milder grades of DR, although there were no false
positives for DR by SLB. The prevalence of blindness
or VI associated with DR was very low, likely due to
the low prevalence of diabetes. Moreover, some of the
cases of VI among people with DR may be attributable
to cataract, refractive error or other causes, rather than
DR. Logistic regression analyses indicated that the
most important factors associated with DR were
younger age, male sex and factors related to diabetes
(e.g. duration and control of diabetes). The coverage
of photocoagulation was very low.
A large systematic review of the epidemiology of
DR and maculopathy in Africa identified 62 studies
from 21 countries, including 3 surveys, 2 cohort
studies, 5 case-control studies and 52 clinic-based
studies.23 Among the three population-based studies
from Nigeria, Egypt and Mauritius, the reported
prevalence of DR among diabetics ranged from 30.2–
31.6%, and the prevalence of proliferative DR from
0.9–13%. The range of estimates for the clinic-based
studies was much wider. Our findings for prevalence
of DR are therefore closely aligned with these previ-
ous studies (35.9%, 95% CI 29.7–42.6%) although we
find evidence for a higher prevalence of proliferative
DR among diabetics (8.7%, 95% CI 5.7–13.1%)
compared to those previously reported, but compar-
able to those reported in Caucasian populations.24,25
Macula edema was present in 33.3% (95% CI 25.8–
39.4%) of diabetics, of which CSME was present in
4.1% (95% CI 1.9–8.2%) of participants, similar to
findings reported previously in other non-African
populations.
The prevalence of diabetes is still relatively low in
Africa, compared to other continents, however it is
anticipated the prevalence will escalate over the
coming decades.4 Despite the relatively low preva-
lence of diabetes, the proportion of patients with DR
was similar to that reported in other settings, and
there was a clear need for treatment in this group to
prevent the onset of blindness. Given that most of the
diabetics in this sample were known to have the
condition, the most parsimonious method for iden-
tifying those with sight-threatening DR needing
treatment would be to screen those known to have
the disease, rather than undertake population-based
TABLE 5. Visual impairment (VI) and diabetic retinopathy (DR) in Nakuru district, Kenya.
People with DR (N= 87) People without DR (N= 4294)
Visual acuity n Prevalence, % (95% CI) n Prevalence, % (95% CI)
Normal, !6/12 64 73.6 (62.8–82.2) 3648 85.0 (83.8–86.0)
Mild VI,56/12–6/18 5 5.7 (2.1–13.5) 219 5.1 (4.5–5.8)
Moderate VI,56/18–6/60 13 14.9 (8.5–24.6) 343 8.0 (7.2–8.8)
Severe VI,56/60–3/60 1 1.1 (0.06–7.1) 17 0.4 (0.2–0.6)
Blind,53/60 4 4.6 (1.5–12.0) 67 1.6 (1.2–2.0)
CI, confidence interval
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screening for DR at this stage. The under-diagnosis of
DR by SLB is of concern, given the lack of availability
of retinal photography and grading in Africa.
However, it is encouraging to note that all but one
case of sight-threatening DR were identified by slit
lamp examination and that it was mainly early DR
cases that were missed. Given the low availability of
retinal photography and grading in Africa, screening
by slit lamp examination may still be a viable
screening option for detecting cases needing treat-
ment provided that the screener is adequately trained.
There were a number of limitations to this study.
Blood glucose measures were obtained from non-
fasting blood samples, rather than through use of an
oral glucose tolerance test or fasting blood glucose.
We may therefore have under-diagnosed diabetes,
and consequently underestimated the prevalence of
DR in this population. Detailed ophthalmic examin-
ations were conducted, including assessment of DR
by the gold standard method of retinal photography
with grading of images by a high quality grading
center. However, not all participants with diabetes in
the sample had DR graded by imaging (70% overall)
due to technical issues with moving the camera.
Furthermore, a few of the images were ungradable.
Since it is likely that most of the images that could not
be graded were due to cataract, and cataract is related
to diabetes, this bias may have led to an under-
estimation of the prevalence of DR in the population,
although any effect is likely to have been small.
TABLE 6. Association of risk factors and presence of diabetic retinopathy (DR; diagnosed by retinal imaging)
among diabetics in Nakaru district, Kenya.
Variable DR cases, n
Prevalence of DR,
% (95% CI)
Age– and sex–adjusted
OR (95% CI)
Multivariate–adjusted
OR (95% CI)a
Age, years
50–59 28 36.8 (26.9–48.1) Reference Reference
60–69 30 41.0 (30.3–52.8) 1.1 (0.6–2.2) Reference
70–79 7 21.9 (11.9–36.8) 0.5 (0.2–1.3) Reference
80+ 5 23.8 (10.9–44.5) 0.5 (0.2–1.6) 0.4 (0.2–1.0)
Sex
Male 44 38.6 (30.9–46.9) Reference Reference
Female 26 29.6 (20.6–40.4) 0.7 (0.4–1.3) 0.5 (0.2–1.0)
Location
Rural 29 30.9 (23.4–39.5) Reference
Urban 41 38.0 (29.1–47.8) 1.3 (0.7–2.4)
Diabetes case status
Known diabetic 61 35.9 (28.7–43.9) Reference
Newly diagnosed 9 26.5 (13.4–45.6) 0.6 (0.3–1.4)
Duration of diabetes, years
0–5 28 23.3 (16.4–32.1) Reference Reference
6–10 20 47.6 (32.4–63.3) 3.1(1.4–6.9) 4.0(1.7–9.1)
410 22 55.0 (41.2–68.1) 3.7(1.7–7.9) 4.4(1.9–10.2)
Blood glucose level, mmol/L
!11.1 29 27.4 (21.5–65.1) Reference Reference
411.1 38 44.7 (29.1–65.4) 2.0 (1.1–3.7) 2.9 (1.3–6.9)
Treatment type
Insulin 11 64.7 (40.7–83.05) Reference Reference
Oral 41 43.6 (32.7–55.2) 0.5 (0.2–1.6) Reference
Diet only 4 23.5 (9.3–48.1) 0.2 (0.04–0.8) Reference
Newly diagnosed 9 28.1 (14.4–47.7) 0.2 (0.1–0.8) Reference
None 5 18.5 (7.7–38.4) 0.1 (0.03–0.5) 0.3 (0.1–0.8)
Smoking status
Non smoker 49 36.0 (28.3–44.5) Reference Reference
Current 1 20.0 (4.2–58.7) 0.5 (0.04–5.0) 0.4 (0.2–1.0)
Former 20 32.8 (23.6–43.6) 0.6 (0.3–1.3)
Hypertension
Yes 58 37.9 (30.8–45.6) 1.9 (0.9–4.1)
No 12 24.5 (15.3–36.8) Reference
BMIb
Normal (18.5–24.9 kg/m2) 28 37.3 (28.1–47.6) Reference
Overweight (25–29.9 kg/m2) 27 37.5 (25.2–51.7) 1.3 (0.7–2.7)
Obese (430 kg/m2) 15 34.1 (24.–45.9) 1.1 (0.5–2.4)
aAdjusted for age, sex, duration of diabetes, blood glucose levels, treatment for diabetes, smoking, and visual
impairment.
bNone underweight
BMI, body mass index; CI, confidence interval; OR, odds ratio
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Macular edema traditionally has stereo definitions,
however, we only had mono images, therefore clues
from these had to be used to establish the potential
presence of macular edema. Macular edema was
graded using surrogate markers, such as exudate
within one disc diameter, circinate within the macula
and multiple hemorrhages within one disc diameter.
There was no way of determining if there was subtle
macular edema that would have required the pres-
ence of stereo images, therefore macular edema
without the presence of exudates and multiple hem-
orrhages could have been missed. For SLB, CSME
assessment did not include assessment of ‘‘one or
more disc diameters of retinal thickening, part of
which is within one disc diameter of the macular
center’’ and so may have missed some cases leading
to an underestimation of prevalence. The study
included only people aged 50 years and older, and
so the estimated prevalence of DR will not be
generalizable to the entire population. However, a
recent survey in Kenya confirmed that diabetes is
relatively rare before middle age,26 so that focusing on
the age group 50+ years would capture the vast
majority of cases with DR in the population, given the
strong association between duration of diabetes and
the development of DR. In terms of strengths, the
sample was large, and included both rural and urban
participants. There was a high response rate, and the
sample was representative across Nakuru, limiting
the impact of selection bias. Detailed lifestyle and
anthropometric data were collected.
In conclusion, DR remains a threat to the sight of
those with diabetes in this elderly Kenyan population,
despite the overall low prevalence of diabetes.
Screening for DR in those subjects known to have
diabetes may enable timely identification of those
requiring treatment, potentially resulting in preven-
tion of sight loss.
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Prevalence of Age-Related Macular Degeneration in
Nakuru, Kenya: A Cross-Sectional Population-Based Study
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Abstract
Background: Diseases of the posterior segment of the eye, including age-related macular degeneration (AMD), have recently
been recognised as the leading or second leading cause of blindness in several African countries. However, prevalence of AMD
alone has not been assessed. We hypothesized that AMD is an important cause of visual impairment among elderly people in
Nakuru, Kenya, and therefore sought to assess the prevalence and predictors of AMD in a diverse adult Kenyan population.
Methods and Findings: In a population-based cross-sectional survey in the Nakuru District of Kenya, 100 clusters of 50 people
50 y of age or older were selected by probability-proportional-to-size sampling between 26 January 2007 and 11 November 2008.
Households within clusters were selected through compact segment sampling. All participants underwent a standardised
interview and comprehensive eye examination, including dilated slit lamp examination by an ophthalmologist and digital retinal
photography. Images were graded for the presence and severity of AMD lesions following a modified version of the International
Classification and Grading System for Age-Related Maculopathy. Comparison was made between slit lamp biomicroscopy (SLB)
and photographic grading. Of 4,381 participants, fundus photographs were gradable for 3,304 persons (75.4%), and SLB was
completed for 4,312 (98%). Early and late AMD prevalence were 11.2% and 1.2%, respectively, among participants graded on
images. Prevalence of AMD by SLB was 6.7% and 0.7% for early and late AMD, respectively. SLB underdiagnosed AMD relative to
photographic grading by a factor of 1.7. After controlling for age, women had a higher prevalence of early AMD thanmen (odds
ratio 1.5; 95% CI, 1.2–1.9). Overall prevalence rose significantly with each decade of age. We estimate that, in Kenya, 283,900 to
362,800 people 50 y and older have early AMD and 25,200 to 50,500 have late AMD, based on population estimates in 2007.
Conclusions: AMD is an important cause of visual impairment and blindness in Kenya. Greater availability of low vision
services and ophthalmologist training in diagnosis and treatment of AMD would be appropriate next steps.
Please see later in the article for the Editors’ Summary.
Citation: Mathenge W, Bastawrous A, Peto T, Leung I, Foster A, et al. (2013) Prevalence of Age-Related Macular Degeneration in Nakuru, Kenya: A Cross-Sectional
Population-Based Study. PLoS Med 10(2): e1001393. doi:10.1371/journal.pmed.1001393
Academic Editor: Susan Lewallen, Kilimanjaro Centre for Community Ophthalmology, Tanzania, United Republic of
Received June 20, 2012; Accepted January 9, 2013; Published February 19, 2013
Copyright: ! 2013 Mathenge et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by funding from: British Council for the Prevention of Blindness (BCPB) and the Fred Hollows Foundation (to WM). AB is
funded by a Medical Research Council and Fight for Sight Fellowship and is in receipt of an International Glaucoma Association Award Fellowship and funding
from BCPB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: AMD, age-related macular degeneration; SES, socioeconomic status; SLB, slit lamp biomicroscopy.
* E-mail: Andrew.bastawrous@lshtm.ac.uk
Introduction
In the latest estimates of global blindness and visual impairment
undertaken by the World Health Organization, in 2010, age-
related macular degeneration (AMD) is the third most common
cause of blindness worldwide behind cataracts and glaucoma [1].
It has remained an important cause of blindness globally since the
last World Health Organization survey in 2002, in which it was
identified as the leading cause of blindness in high-income
countries [2]. As the global population ages, AMD is likely to
increase in importance. Currently, no curative treatment exists.
The recent promise of anti–vascular endothelial growth factor
treatments is unlikely to offset the growth of AMD globally, as
these treatments are only useful in exudative AMD and are not
currently widely accessible outside of high-income countries.
Nutritional interventions can reduce the progression of certain
subtypes of early AMD [3]; however, protective levels of required
vitamins and minerals are difficult to obtain in a healthy diet, and
the cost of supplementation is prohibitive for many who could
potentially benefit [4].
The majority of data on AMD available globally is from
population-based studies undertaken in white and Asian popula-
tions [5–13], and few data are from peoples of African descent.
The data that do exist for individuals of African descent are largely
from studies undertaken in populations living outside of the
African continent [14,15]. It is presumed that AMD is rare in
Africans; however, in the last 10 y, African population-based
studies have suggested that posterior segment eye diseases are
highly prevalent, and this group of disorders, which includes
AMD, diabetic retinopathy, and glaucoma, has been highlighted
as either the leading or second leading cause of blindness in
surveys undertaken in Cameroon [16], Tanzania [17], Kenya
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[18], Rwanda [19], Zanzibar [20], and Guinea [21]. These
studies, however, did not assess AMD as a specific entity and did
not use digital retinal photography. Moreover, comparative data
for whites and Africans living in the same geographical area
(Baltimore, Maryland, US) have suggested differing predispositions
towards AMD, with possible genetically protective factors for
AMD progression in individuals of African descent compared to
their white counterparts [22]. Population-based evidence for
African populations living in Africa on the prevalence of the
disease, and of the risk factors for AMD, is therefore important.
The purpose of this study was to estimate the prevalence and
risk factors for AMD in the age group 50 y and over in an African
population in Nakuru District, Kenya, using digital retinal
photography and slit lamp biomicroscopy (SLB). Nakuru District
is within the Rift Valley Province in Kenya, with a population of
nearly 10 million, approximately one-quarter of the Kenyan
population. Nakuru is diverse in its ethnic mix (all 42 tribes present
in Kenya represented within the district), range of socioeconomic
activity, and urban/rural mix.
Methods
Ethics Statement
Ethical approval was granted by the London School of Hygiene
& Tropical Medicine Ethics Committee and by the Kenya
Medical Research Institute. Approval was also granted by the Rift
Valley Provincial Medical Officer and the Nakuru District
Medical Officer of Health. Written approval was sought from
the administrative head in each cluster, usually the village chief.
All participants gave written or verbal consent to participate.
People requiring medical treatment were referred to the appro-
priate centre.
Sampling Strategy and Recruitment
The study fieldwork was carried out in two phases, from 11
January to 2 June 2007 and from 8 April to 11 November 2008.
Recent census data for Kenya were not available [23], and
therefore election roll lists that were renewed in 2006 in
preparation for the 2007 general elections were used as the
sampling frame for this survey. 100 clusters were selected with a
probability proportional to the size of the population. A cluster was
defined as the area served by a polling station.
Households were selected within clusters using a modified
compact segment sampling method [24]. Each cluster was divided
into segments so that each segment included approximately 50
people aged $50 y. One segment was selected at random, and all
eligible people were included sequentially until 50 had been
examined. Location data including GPS coordinates of houses and
mobile phone contacts were taken to allow follow-up of all those
examined.
This sample size was sufficient to estimate a prevalence of AMD
of 3.0% among those aged 50+ y, with a required precision of
0.5%, 95% confidence, a design effect to account for clustering of
1.5, and a response rate of 90% (Epi Info 6.04, US Centers for
Disease Control and Prevention).
Ophthalmic and General Examination
Suitable predetermined examination sites were selected, on the
recommendation of the village leader, with close proximity to the
cluster and to electricity supply (mains or generator).
Visual Acuity
The presenting visual acuity was defined as the number of
letters read correctly without glasses if the participant did not have
glasses or with glasses if they had them. Testing was done on each
eye separately at 4 m using a reduced LogMAR tumbling ‘‘E’’
chart [25] in a well-illuminated area, as described elsewhere [26].
Fundus Photography
The participants had two nonstereoscopic digital 45u fundus
photographs taken per eye by an ophthalmic clinical officer using
a TRC-NW6S Non-Mydriatic Retinal Camera with a ten-
megapixel Nikon D80 camera (Topcon). One image was centred
on the optic disc, while the other was centred on the macula. The
digital images were stored on hard disc, backed up on an external
drive, and one copy saved on CD was forwarded to the Retinal
Grading Centre at Moorfields Eye Hospital Reading Centre in
London for grading and confirming the clinical diagnosis of
posterior segment disease.
Image Grading
The senior grader (I. L.) graded all images. All images were first
categorised for quality as excellent, good, fair, borderline, or
ungradable. All questionable lesions and all eyes classified as
having late-stage AMD were adjudicated by the Moorfields Eye
Hospital Reading Centre clinician (T. P.). Any lesions considered
to be due to other causes such as myopia and inflammatory disease
were not graded for AMD, and these were also verified by T. P.
The adjudicator also graded 5% of randomly selected images to
ensure quality control. Data were entered into Excel and checked
for consistency by a data monitor. Those with images were
classified as ‘‘image group’’ for further analysis.
Retinal Examination
SLB was performed after pharmacological dilatation with guttae
tropicamide 1% using a 90 diopter lens. Assessment was inclusive
of the macula, the retinal vasculature, and the peripheral retina.
The view of the retina was recorded as clear, hazy, or no view.
The macula was examined for presence of drusen, hypo- or hyper-
pigmentation, dry AMD or geographic atrophy (GA), and
neovascular changes. Any other pathologies of the retina or
vitreous, e.g., retinal detachments or vitreous haemorrhages, were
also noted, and a description given. Those with slit lamp
examination were classified as ‘‘SLB group’’.
Definitions Used
A modified version of the International Classification and
Grading System for Age-Related Maculopathy and Age-Related
Macular Degeneration [27] was used for image grading. Drusen
were categorised based on size, uniformity of colour, and margins.
Based on these, patients were classified into hard or soft drusen
categories. Small drusen, less than 63 mm, were considered to be
hard. Large drusen with a uniform density, sharp margins, and a
nodular surface texture were placed in the soft distinct category,
whereas those without sharp margins were classified as indistinct.
Where end-stage disease was apparent, patients were classified as
having geographic atrophy if there were well-demarcated regions
with diameters in excess of 175 mm, within which large choridal
vessels were clearly visible, owing to the atrophy of the overlying
choriocapillaris and retinal pigment epithelium. Neovascular
AMD was graded as present when exudative features, such as
serous fluid, haemorrhage, lipid exudates, or fibrosis, were seen to
be originating primarily from the subretinal and pigmentepithelial
tissue layers.
SLB grading of AMD was as follows: (1) drusen present:
presence of discrete whitish-yellow spots at the macula area; (2)
pigmentary changes present: presence of increased pigment or
Macular Degeneration (AMD) in Kenya
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hyperpigmentation or sharply demarcated areas of depigmenta-
tion or hypopigmentation of the retinal pigment epithelium; (3) dry
AMD or geographic atrophy: atrophy of the retinal pigment
epithelium, with visible underlying choroidal vessels; (4) wet or
neovascular AMD: presence of retinal pigment epithelium
detachment, subretinal or subpigment epithelial neovasculariza-
tion, or fibrous scar tissue, haemorrhages, or exudates; (5) no
AMD: none of the features described above were present; (6)
cannot assess: the retina could not be adequately visualised for
grading. Case definitions were based on the eye with more severe
status if both eyes were gradable, and on the gradable eye if only
one eye was gradable (n=37).
Detailed interviews were undertaken in the local language
covering demographic details, information on risk factors,
socioeconomic status (SES), and full past medical history. SES
was evaluated using a continuous asset score that was produced for
each participant using a scoring system derived through principal
component analysis in an earlier study in this setting [28,29]. The
scale included assessment of 17 context-specific asset items owned
by the household, including different types of furniture, electrical
equipment, cattle, and vehicles. Information was collected on five
household characteristics, including the building material of the
floor, roof, and walls; type of toilet; and the number of rooms. The
score was divided into quartiles based on the distribution across all
the study participants, to derive a measure of relative SES.
Weight, height, waist and hip circumference, blood pressure,
and random cholesterol and glucose blood levels were also
measured. ‘‘Mother tongue’’ was used as a measure of tribal
affiliation.
Data Handling and Statistical Analysis Methods
Data entry. Data were double-entered into a specially
developed dataset (EpiData Entry, version 2.1). Consistency
checks were performed each evening, and inconsistencies correct-
ed the same day.
Data analysis. The prevalence of AMD was estimated, and
the ‘‘svy’’ command in Stata was used with a design effect of 1.5 in
order to take into account the cluster sampling survey method-
ology when calculating confidence intervals around the prevalence
estimates.
Statistical analyses were undertaken using Stata. Logistic
regression analyses were produced to assess the univariate
associations between potential risk factors (age, gender, SES,
tribal origin, hypertension, diabetes, angina, cholesterol level, body
mass index, waist:hip ratio, previous cataract surgery, smoking and
alcohol consumption, education, and urban versus rural) and
prevalent AMD. Multivariable logistic regression models were
developed through stepwise selection, with variables retained at
the p,0.05 level. These analyses were restricted to cases defined
from the image group data, since definite disease status was
available only for this group.
The data for individuals with both SLB and retinal images were
used to calculate a correction factor (if needed) to apply to the SLB
group to estimate the overall prevalence of AMD for Nakuru.
Estimated numbers of individuals within Kenya with AMD were
extrapolated from population data from the US Census Bureau
International Data Base (http://www.census.gov/population/
international/data/idb/country.php) by applying age- and sex-
specific prevalence estimates for the Kenyan population.
Results
There were 5,010 eligible individuals identified for this study.
Of these, 4,414 participants underwent examination, giving a
response rate of 88.1%, and 4,381 had full ophthalmic examina-
tion; 33 participants were not included in the ophthalmic analysis
because of missing data as a consequence of equipment failure. Of
the non-respondents, 584 (98%) were away working or visiting
family outside the cluster location, and 12 (2%) refused to
participate; none were excluded as a result of inability to
communicate. The socio-demographic characteristics of the
participant group are described in earlier publications [30]. Out
of the 4,381 individuals who had ophthalmic examinations in the
Nakuru study, 4,312 (98.4%) were successfully screened for AMD
by SLB of the retina (SLB group).
3,387 (77.3%) participants underwent retinal photography. An
image for grading for AMD in at least one eye was available for
3,304 individuals (75.4%) (image group). 3,274 individuals (74.7%)
had both methods of screening (Figure 1).
Compared to people in the SLB group, those who had images
taken were more likely to be male, younger, urban residents, not
Kikuyu, not diabetic, and not visually impaired (Tables 1 and S1).
A correction factor was necessary because there were significant
differences in the characteristics of the SLB-only group compared
to the image group, and so it was not possible to generalise the
results from the image group to the whole population.
The prevalences of drusen and pigmentary irregularities as
observed on the fundus images, by gender and age, are shown in
Table 2. Note that varying features of AMD, e.g., drusen and
pigmentation, can co-exist in a single eye and in both eyes and
therefore one individual may be listed under more than one AMD
characteristic. However, the prevalence of AMD in the population
is based on the grading of AMD in a person. Drusen were present
in a large proportion of the population. The most common type of
drusen encountered in all ages was small, hard drusen, ,63 mm,
which were present in 59.1% of the study population. Large, soft
drusen, which are considered to be indicative of early AMD, were
present in 9.4% of the population. There were significant age
trends (X2 trend test, p,0.001), with increased prevalence of all
drusen and all pigmentary changes from age 50 y to age 79 y. The
gender difference was less strong, though drusen and pigmentary
changes were more common in women than men. The overall
prevalence of retinal pigment abnormalities was 4.8% (95% CI,
3.7–6.1). Increased pigment was seen more frequently than
depigmentation in all age groups, and prevalence increased from
1.6% in the lowest age groups to 7.2% in those aged 80 y or more.
The difference in prevalence of pigment in men and women was
not significant (p=0.66).
Neovascular AMD was more common (0.9%) than geographic
atrophy (0.5%) (Table 3). There were significant age trends for both,
with geographic atrophy being prevalent in only 0.3% of those in
their 50 s and increasing to 2.0% in those age 80 y and over.
The prevalence of all stages of AMD was lower when SLB
grading was used than when grading was from retinal images
(Table 4). The total prevalence of AMD from SLB was 7.4% (early
AMD, 6.7%, and late AMD, 0.7%), while the prevalence of AMD
by retinal image grading was 12.4% (early AMD, 11.2%, and late
AMD, 1.2%). A smaller proportion of participants were classified
as ungradable by SLB (30; 1.6%) than by retinal image grading
(83; 2.6%). A correction factor of 1.7 for total AMD needs to be
applied for those who did not have retinal imaging (considered the
gold standard) to get the true prevalence estimate of AMD in the
SLB group.
Sensitivity and specificity analysis for the detection of early
AMD and late AMD by SLB grading versus retinal imaging, in
those individuals who had both SLB and image grading available,
showed that SLB grading had poor sensitivity (early, 21.3%, and
late, 36.8%) and good specificity (early, 95.2%, and late, 99.9%).
Macular Degeneration (AMD) in Kenya
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A total of 404 (366 early AMD and 38 late AMD) cases were
confirmed by images, while another 85 cases (75 early AMD and
ten late AMD) were detected in the group that received SLB only.
Combining all cases gives a total of 489 cases, or a prevalence of
11.3% for AMD (435 [10.2%] early AMD and 48 [1.1%] late
AMD) in this population. However, since SLB underdiagnosed
AMD by a factor of 1.7, if this factor is applied to the SLB
prevalences, an adjusted prevalence of 12.7% (11.4% for early
AMD and 1.3% for late AMD) is reached (Table 5).
When extrapolating these data to the entire Kenyan population
based on data from 2007, we estimated that there are 283,900 to
362,800 people over 50 y in Kenya with early AMD and 25,200 to
50,500 with late AMD.
Age/sex-adjusted analyses show that only age and gender were
significantly associated with early AMD, with those affected more
likely to be female and with prevalence increasing with each
decade of age (Table 6).
Modelling age as a continuous variable did not alter the findings
(Table S2).
Age/sex-adjusted analyses showed that only age was signifi-
cantly associated with late AMD, with increased late AMD
prevalence with every decade after 50 y (Table 7). All other
variables showed no association.
Of the 487 people with any grade of AMD (diagnosed by SLB
or retinal images), a total of 137 (28.1%) were visually impaired,
including 12 blind people (2.5%; 95% CI, 1.3–4.8), four with
severe visual impairment (0.8%; 0.3–2.2), and 82 with moderate
visual impairment (16.8%; 13.4–20.9). 350 (71.9%; 7.0–76.4) of
those with AMD had normal vision (Table 8). Among the 669
people with visual impairment in the entire Nakuru study, 137
(20.5%) had features of AMD, either exclusively or in combination
with other pathology.
28 people had visual impairment due to AMD alone (i.e., no
other visually impairing pathology found), a prevalence of 0.6%
(95% CI, 0.4–1.0) for visual impairment from AMD in the
population. 9.9% (seven of 71 people) of blindness in this survey
was attributable to AMD.
Discussion
The prevalences of early and late AMD in this African
population over 50 y of age were 11.2% and 1.2%, respectively.
Very few data exist on the prevalence and causes of AMD in
Africa, and to our knowledge, this is the only population-based
study in Africa using an internationally recognised grading system
and digital retinal photographs. Although data from Rapid
Assessment of Avoidable Blindness surveys exist, these cluster
AMD with other posterior segment eye diseases, and so no direct
comparisons can be made with the findings from this study. A
Nigerian survey used similar methodology, including a population-
based approach and fundus photographs; however, retinal
imaging was performed only in individuals with a visual acuity
Figure 1. AMD study participation chart.
doi:10.1371/journal.pmed.1001393.g001
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Table 1. Demographic characteristics of study participants (n= 4,381).
Attribute
Number (Percent) of Those with
Grading by Retinal Images, n=3,304
Number (Percent of Those with
Only SLB Diagnoses, n=1,038
Age- and Sex-Adjusted
Odds Ratio (95% CI)
Gender
Male 1,629 (49%) 450 (43%) Baseline
Female 1,675 (51%) 588 (57%) 0.8 (0.7–0.9)
Age
50–59 y 1,508 (78.0%) 426 (22.0%) Baseline
60–69 y 997 (77.3%) 292 (22.7%) 1.0 (0.8–1.2)
70–79 y 547 (75.8%) 175 (24.2%) 0.9 (0.8–1.2)
80+ y 252 (63.5%) 145 (36.5%) 0.6 (0.4–0.7)
Environment
Rural 2,143 (69%) 774 (75%) Baseline
Urban 1,161 (31%) 264 (25%) 1.5 (1.3–1.7)
SES
Poorest 783 (24%) 287 (27%) Baseline
2nd quartile 815 (25 %) 267 (26%) 1.0 (0.9–1.2)
3rd quartile 840 (26%) 243 (23%) 1.1 (0.9–1.4)
Least poor 829 (25%) 252 (24%) 1.1 (0.9–1.3)
Tribe
Kikuyu 1,997 (60%) 721 (70%) Baseline
Kalenjin 780 (24%) 211 (20%) 1.3 (1.1–1.6)
Other 527 (16%) 106 (10%) 1.7 (1.3–2.1)
Diabetes
Non-diabetic 3,091 (94%) 947 (92%) Baseline
Diabetic 192 (6%) 86 (8%) 0.7 (0.5–0.9)
Visual impairment
$6/12 2,891 (88%) 820 (79%) Baseline
,6/12 3,973 (12%) 218 (21%) 0.5 (0.4–0.6)
doi:10.1371/journal.pmed.1001393.t001
Table 2. Number and prevalence of features of early AMD (image group) and age-related maculopathy by sex and age (n= 3,304).
Attribute Small Drusen (,63 mm) Large Drusen ($63 mm) Hypopigmentation Hyperpigmentation
N Percent (95% CI) N Percent (95% CI) N Percent (95% CI) N Percent (95% CI)
Total 1,954 59.1 (56.1–62.1) 310 9.4 (8.2–10.7) 79 2.4 (1.7–3.3) 117 3.5 (2.7–4.6)
Age
50–59 y 813 53.9 (50.0–57.8) 52 3.5 (2.6–4.6) 31 2.1 (1.2–3.4) 24 1.6 (0.9–2.7)
60–69 y 603 60.4 (56.4–64.3) 92 9.2 (7.5–11.4) 26 2.6 (1.7–4.1) 41 4.1 (2.8–6.0)
70–79 y 372 68.0 (63.6–72.2) 103 18.8 (15.4–22.9) 17 3.1 (1.8–5.4) 34 6.2 (4.3–8.9)
80+ y 166 66.1 (59.0–72.6) 63 25.1 (20.1–30.9) 5 2.0 (0.7–5.3) 18 7.2 (4.2–12.1)
p-Valuea ,0.001 ,0.001 ,0.001 ,0.001
Gender
Male 889 54.6 (51.0–58.1) 123 7.6 (6.4–8.9) 36 2.2 (1.5–3.2) 45 2.8 (2.0–3.9)
Female 1,065 63.6 (60.0–67.1) 187 11.2 (9.3–13.4) 43 2.6 (1.7–3.9) 72 4.3 (3.1–5.9)
p-Valueb ,0.001 0.002 0.74 0.05
aX2 trend test for age groups.
bX2 trend for sex differences.
doi:10.1371/journal.pmed.1001393.t002
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Table 3. Number and prevalence of features of late AMD (image group) by sex and age (n= 3,304).
Attribute Neovascular AMD GA No Late AMD
N Percent (95% CI) N Percent (95% CI) N Percent (95% CI)
Total 29 0.9 (0.5–1.4) 18 0.5 (0.3–0.9) 3,266 98.9 (98.3–99.2)
Age
50–59 y 5 0.3 (0.1–0.9) 3 0.2 (0.1–0.6) 1,503 99.5(99.0–99.8)
60–69 y 10 1.0 (0.5–2.0) 4 0.4 (0.2–1.1) 987 98.8 (97.8–99.8)
70–79 y 7 1.3 (0.6–2.9) 6 1.1 (0.4–2.8) 540 98.2 (96.3–99.1)
80+ y 7 2.1 (1.1–6.8) 5 2.1 (0.8–4.6) 246 96.4 (92.5–98.3)
p-Valuea ,0.001 ,0.001 ,0.001
Gender
Male 10 0.6 (0.3–1.2) 10 0.6 (0.3–1.2) 1,614 99.1 (95.7–97.5)
Female 19 1.1 (0.7–1.9) 8 0.5 (0.2–0.9) 1,652 98.6 (95.2–97.0)
p-Valuea 0.70 0.80 0.30
aThe features of late AMD, i.e., neovascular changes and geographic atrophy, are not mutually exclusive, so individuals may appear in both columns. The data for late
AMD, and hence for ‘‘no late AMD’’, is person-specific and therefore mutually exclusive. Those with both GA and neovascular AMD are counted in the neovascular AMD
group.
Table 4. Comparison of SLB and image groups.
Variable Prevalence in Image Group Prevalence in Same People by SLB Underdiagnosis Factor for SLB
Number gradable 3,304 3,274
Early AMD 366 (11.1%) 219 (6.7%) 1.7
Late AMD 38 (1.2%) 24 (0.7%) 1.6
Total AMD 404 (12.2%) 243 (7.4%) 1.7
Data are given as number (percentage).
doi:10.1371/journal.pmed.1001393.t004
Table 5. Determination of all AMD cases and adjusted prevalence including diagnosis by SLB.
Terms Early AMD Late AMD Total AMD No AMD
Confirmed by retinal images (A) (n=3,304) 366 38 404 2,900
Confirmed only by SLB (B) (n= 4,312) 75 10 85 953
Total observed cases (n= 4,342) 441 48 489 3853
Prevalence 10.2% 1.1% 11.3% 88.7%
95% CI (9.0–11.5) (0.8–1.6) (10.0–12.7) (87.3–90.0)
Corrected prevalence (A+[B61.7 or 1.6])/3,797 11.4% 1.3% 12.7% 87.4%
doi:10.1371/journal.pmed.1001393.t005
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of #6/12 [26]. In the present study, 75.1% of individuals
identified as having AMD had an acuity of 6/12 or greater.
Only one other prospective study of AMD in Africa was found
in the peer-reviewed literature. A hospital-based study in South
Africa that looked specifically at AMD in Africans was published
in 1978 [31]. The study participants were aged 50 y and older, as
in this study, and were examined by indirect ophthalmoscopy as
well as photography. Higher levels of ‘‘senile macular degenera-
tion’’, as AMD was then termed, were reported than in this study,
affecting 17.4% of participants in the study. It is likely that the
Table 6. Risk factors for early AMD.
Category Risk Factor
Number with
Early AMD Prevalence (95% CI)
Age- and Sex-
Adjusted Odds
Ratio (95% CI)
Demographic factors Age group (years)
50–59 82 5.5% (4.2–7.1) Reference
60–69 115 11.7% (9.8–13.9) 2.3 (1.7–3.1)
70–79 110 20.5% (16.7–24.9) 4.7 (3.5–6.4)
$80 59 24.3% (19.3–30.1) 5.7 (3.9–8.3)
Gender
Female 212 9.5% (7.7–10.6) 1.5 (1.2–1.9)
Male 154 12.8% (10.6–15.5) Reference
Tribe
Kikuyu 244 12.3% (10.3–14.8) Reference
Kalenjin 80 10.4% (8.5–12.8) 0.8 (0.6–1.1)
Other 42 7.8% (5.8–11.2) 0.9 (0.7–1.3)
SES
1st quartile (poorest) 112 14.6% (12.2–17.4) Reference
2nd quartile 102 12.6% (10.0–15.8) 1.0 (0.7–1.3)
3rd quartile 84 10.1% (8.0–12.7) 0.9 (0.7–1.2)
4th quartile (richest) 65 7.9% (5.8–10.8) 0.8 (0.5–1.1)
Systemic factors Body mass index
,25 kg/m2 252 12.2% (10.6–14.0) Reference
Overweight (25–29.9 kg/m2) 78 10.5% (8.3–13.1) 1.0 (0.7–1.3)
Obese ($30.0 kg/m2) 33 7.8% (5.2–11.4) 0.7(0.5–1.0)
Diabetes
Yes 15 7.9% (4.3–14.1) 0.7 (0.4–1.1)
No 350 11.5% (9.9–13.2) Reference
Hypertension
Hypertensive 213 12.8% (10.7–15.2) 1.2 (1.0–1.5)
Non-hypertensive 152 9.7% (8.2–11.4) Reference
Angina grade
None 290 10.8% (8.7–11.9) Reference
Grade 1 55 12.4% (9.3–15.2) 1.2 (0.9–1.7)
Grade 2 20 16.4% (11.5–22.8) 1.7 (1.0–2.9)
Smoking
Current 21 7.8% (5.3–11.2) 0.8 (0.5–1.4)
Former 77 10.5% (8.5–12.9) 1.0 (0.7–1.4)
Never 267 11.9% (10.1–14.0) Reference
Alcohol
Current 68 11.6% (9.0–14.7) 1.3 (0.9–1.9)
Former 160 11.3% (9.6–13.2) 1.0 (0.8–1.3)
Never 137 11.1% (8.7–14.1) Reference
Ocular features Cataract surgery
Yes 26 15.2% (10.6–21.3) 0.9 (0.5–1.3)
No 339 11.0% (9.5–12.7) Reference
doi:10.1371/journal.pmed.1001393.t006
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hospital population sampled was not representative of the general
population, as enrolled participants had attended the hospital eye
clinic of their own volition and therefore were more likely to have
had symptomatic vision loss than the general population.
Typically, the demographic of individuals attending a hospital
clinic also differs from the general population in terms of SES and
life expectancy. No population-based studies specifically reporting
AMD in Africa have been published, to our knowledge.
The prevalence of AMD in this study was also lower than that in
a study in the Caribbean, where a 28.7% prevalence of AMD was
found [32]. In general, the prevalences in our study are similar to
or higher than those documented for Hispanic and Asian
populations (range 7.1%–13.6%) [13,33–36], but lower than
those found in white populations (range 9.3%–43.1%) [36–39].
Direct comparison between studies is not appropriate because of
the different grading systems and diagnostic techniques used.
A strength of this study was the high response rate (88.1%).
Despite the sophisticated equipment used in the examinations,
people were not transported to a fixed examination site, but
instead the examination site moved from cluster to cluster. A large,
representative population-based sample was examined by SLB and
retinal imaging. Another strength of the study is that the same
experienced ophthalmologist (W. M.) was present throughout the
study and examined all participants. However, a lack of stable
electricity supply resulted in the number of people who had retinal
images being reduced in some clusters.
A limitation of the study was our not having been able to obtain
retinal images for all study participants. This is in large part due to
the logistical constraints of performing electricity-dependent
examinations in a setting where electricity supply cannot be
guaranteed. Univariable analyses comparing those with gradable
images (n=3,304) and those without (n=83) found significant
differences. Those with no gradable images were more likely to be
older, have poor vision, and have a cataract, thus the prevalence
for this population may be slightly underestimated. The difference
between the groups is likely due to a lack of stable electricity supply
in the more rural clusters, where participants were demograph-
ically different.
When disease estimates using both methods were compared,
SLB was found to have consistently under-diagnosed AMD. An
analysis of the false negatives for late AMD revealed that lesions
were noted but were not called neovascular AMD; instead they
Table 7. Risk factors for late AMD.
Category Risk Factor
Number with Late
AMD Prevalence (95% CI)
Age- and Sex- Adjusted
Odds Ratio (95% CI)
Demographic factors Age group (years)
50–59 7 0.5% (0.2–1.0) Reference
60–69 12 1.2% (0.7–2.2) 2.8 (1.1–7.3)
70–79 10 1.8% (0.9–3.7) 5.1 (1.9–13.5)
$80 9 3.6% (1.7–7.5) 10.4 (3.8–28.2)
Gender
Female 23 1.0% (0.6–1.7) 1.8 (0.9–3.4)
Male 15 1.6% (1.0–2.4) Reference
Tribe
Kikuyu 20 1.1% (0.6–2.1) Reference
Kalenjin 11 1.5% (0.8–3.1) 1.4 (0.7–3.0)
Other 7 1.4% (0.7–3.2) 2.2 (0.9–5.5)
Environment
Rural 31 1.6% (1.0–2.6) Reference
Urban 7 0.7% (0.3–1.45) 0.6 (0.2–1.3)
Systemic factors Cholesterol
Low 31 1.1% (0.7–1.8) Reference
High 4 3.7% (1.4–9.6) 3.0 (1.0–8.9)
Smoking
Current 4 1.6% (0.6–4.1) 2.2 (0.7–6.6)
Former 6 0.9% (0.4–2.0) 1.0 (0.4–2.7)
Never 28 1.4% (0.9–2.1) Reference
Alcohol
Current 7 1.3% (0.6–3.0) 0.9 (0.3–2.4)
Former 12 0.9% (0.5–1.8) 0.5 (0.2–1.1)
Never 19 1.7% (1.1–2.7) Reference
Ocular features Cataract surgery
Yes 6 4.0% (1.9–8.1) 2.1 (0.8–5.2)
No 32 1.2% (0.7–1.8) Reference
doi:10.1371/journal.pmed.1001393.t007
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were called macular scars. This may be a reflection of general
practice in Africa, where it is often repeated in residency courses
that ‘‘wet AMD’’ does not occur in Africans, as has been asserted
in several studies [40,41]. This leads to late AMD being placed far
down in the differential diagnosis for macular scars.
There was also discrepancy in identifying pigmentary lesions of
early AMD. Retinal imaging identified many more hyperpig-
mented changes at the macula than did SLB. There are large
natural variations in retinal pigmentation, resulting in colour
differences between individuals. Such variation can tend to mask
the more subtle variation between the important lesion types [42].
Studies have shown that the macular pigment density in other
population groups is significantly lower than in African individuals
[43]. The study ophthalmologist’s perception of what constitutes
increased pigment and what is normal background pigment in an
African eye, in comparison to the reading centre’s criteria, may
have led to differences in classification.
Vision is measured based on the person’s better eye, whereas
AMD affects both eyes, and therefore a disparity between late
AMD and poor vision can be seen. For example, there were 38
participants in the present study with late AMD, but only 16 with
AMD and a visual acuity ,6/60.
Disease subgroups included limited sample sizes, particularly for
advanced AMD and blindness, which should be noted when
interpreting the results.
Data collection began in 2007 and was based on electoral roll
data from 2006. The population demographic is likely to have
changed in the time to publication, and given population growth
and increased survival, the estimated national prevalence of AMD
could underestimate current prevalence.
Of note, location information collected from participants in this
study will allow for incidence studies to be carried out in the
future, thus providing new insights into the natural progression
and incidence of AMD in this population.
Conclusion
Despite the long held belief that AMD is not a public health
concern in Africa, this study provides evidence not only that is
AMD as prevalent as in some other world regions (12.4% in this
population), but also that it is an important problem contributing
to both visual impairment and blindness in Africa. A total of 9.9%
of blindness in this survey was attributable to AMD.
New therapeutic strategies have increased the available treatment
options and improved prognostic perspectives for AMD in low-
income countries [44]. However, these emerging treatments for
AMD are largely unavailable in Kenya and most of Africa. When
they become available, cost may be a major barrier towards
accessing the treatment. Recent evidence suggests that bevacizumab
is both effective and relatively affordable [45–47], but the
infrastructure required to deliver an adequate AMD service,
including the use of expensive optical coherence tomography
machines, may be prohibitive. It is estimated that over 12 million
people in Africa have low vision [48], and AMD is certainly a major
contributor. Low vision services remain a hugely neglected area of
care on the African continent; strengthening these services might be
a cost-effective use of limited resources in the interim period. There
is a need to train African-based ophthalmologists to improve
recognition and treatment of AMD, particularly neovascular AMD,
and a need for research to support the development of treatment
programmes that are affordable and deliverable in Africa.
Table 8. Visual acuity in those with AMD.
Visual Acuity
All AMD from
Retinal Images
All AMD from
SLB Only Total AMD No AMD Total
Normal ($6/12)
Number 302 48 350 3362 3,712
Percent 75.1% 56.5% 71.9% 86.3% 84.7%
95% CI (70.1–79.5) (44.3–67.9) (67.0–76.4) (84.6–87.9) (82.9–86.4)
Mild VI (,6/12–6/18)
Number 23 16 39 185 224
Percent 5.7% 18.8% 8.0% 4.8% 5.1%
95% CI (3.9–8.3) (12.5–27.1) (6.0–10.6) (4.0–5.7) (4.3–6.1)
Moderate VI (,6/18–6/60)
Number 66 16 82 274 356
Percent 16.4% 18.8% 16.8% 7.0% 8.1%
95% CI (12.7–21.0) (11.9–28.5) (13.4–20.9) (6.2–8.0) (7.2–9.2)
Severe VI (,6/60–3/60)
Number 1 3 4 14 18
Percent 0.3% 3.5% 0.8% 0.4% 0.4%
95% CI (0.03–1.2) (1.2–9.8) (0.3–2.2) (0.2–6.4) (0.3–0.7)
Blind (,3/60)
Number 10 2 12 59 71
Percent 2.5% 2.4% 2.5% 1.5% 1.6%
95% CI (1.2–5.0) (0.6–9.2) (1.3–4.8) (1.2–2.0) (1.2–2.1)
Total Number (Percent) 402 (100%) 85 (100%) 487 (100%) 3,894 (100%) 4,381 (100%)
VI, visual impairment.
doi:10.1371/journal.pmed.1001393.t008
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Editors’ Summary
Background. Worldwide, 39 million people are blind, and
246 million people (mainly living in developing countries)
have moderate or severe visual impairment. The third
leading global cause of blindness (after cataracts and
glaucoma) is age-related macular degeneration (AMD). This
group of conditions is characterized by lesions in the macular
(central) region of the retina, the tissue at the back of the eye
that converts light into electrical messages and sends them
to the brain. AMD, which affects older people, destroys the
sharp central vision that is needed for reading or driving,
leaving only dim, blurred images or a black hole at the center
of vision. AMD can be diagnosed by examining digital
photographs of the retina or by examining the retina directly
using a special magnifying lens (slit lamp biomicroscopy).
There is no cure for AMD, although injections into the eye of
certain drugs, such as bevacizumab, that block the activity of
vascular endothelial growth factor can slow the rate of vision
loss caused by some forms of AMD.
Why Was This Study Done? Most investigations of the
prevalence (the proportion of a population with a disease) of
AMD and of risk factors for AMD have studied people with
European or Asian ancestry. Very little is known about AMD
in African populations, and the data that are available mainly
come from African populations living outside Africa. It is
important to know whether AMD is an important cause of
visual impairment and blindness in Africa, so that informed
decisions can be made about the need for AMD programs in
African countries. In this cross-sectional population-based
study, the researchers investigate the prevalence of AMD
among people aged 50 years or older living in Nakuru
District (an ethnically diverse region of Kenya) and look for
predictors of AMD in this population. In a cross-sectional
population-based study, researchers observe a representa-
tive subset of a population at a single time point.
What Did the Researchers Do and Find? The researchers
randomly selected 100 clusters of 50 people aged 50 years or
older for their study. Between January 2007 and November
2008, study participants had a comprehensive eye examina-
tion and completed a standardized interview that included
questions about their age, gender, other demographic
details, medical history, and exposure to possible risk factors
for AMD. Based on digital retinal images, the prevalences of
early and late AMD among the study population were 11.2%
and 1.2%, respectively. The prevalences of early and late
AMD judged by slit lamp biomicroscopy were 6.7% and
0.7%, respectively. After controlling for age, women had a
higher prevalence of both early and late AMD than men. The
overall prevalence of AMD rose with age: compared to the
youngest age group, the oldest age group had a three-fold
higher risk of developing late AMD. Of the people with any
grade of AMD, 25.6% had some visual impairment and 2.5%
were blind. Overall, 9.9% of the blindness seen in the study
was attributable to AMD.
What Do These Findings Mean? These findings identify
AMD as an important cause of visual impairment and
blindness in Nakuru District, Kenya. Extrapolation of these
findings to the whole of Kenya suggests that 283,900 to
362,800 Kenyans had early AMD and 25,200 to 50,500 had
late AMD in 2007. The accuracy of these findings is limited by
the inability to obtain digital retinal images from all the
participants (often because of electricity failures) and by
other aspects of the study design. Moreover, because the
methodology used in this study differed from some other
studies of AMD, the prevalence of AMD reported here cannot
be compared directly to those found in other studies.
Nevertheless, these findings have several important implica-
tions. In particular, although recent evidence suggests that
bevacizumab is likely to be both effective and affordable in
Africa, the infrastructure required to deliver an adequate
AMD service is currently prohibitively expensive in most
African countries. Thus, these findings suggest that it is
essential that research is undertaken to support the
development of AMD treatment programs that are afford-
able and deliverable in Africa, and that low vision resources
are provided for individuals with vision impairment.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001393.
N The US National Eye Institute provides detailed information
about age-related macular degeneration
N The UK National Health Service Choices website also
provides information about age-related macular
degeneration, including personal stories about the condi-
tion
N The UK Royal National Institute of Blind People has
information on age-related macular degeneration, includ-
ing a video of a person describing their experiences of the
condition
N AMD Alliance International provides written and audio
information in several languages about age-related mac-
ular degeneration, including a large selection of personal
stories; the Macular Degeneration Partnership also pro-
vides information about age-related macular degeneration,
including a simulation of the condition
N MedlinePlus has links to additional resources about age-
related macular degeneration (in English and Spanish)
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Abstract A cross-sectional study was undertaken in
Nakuru, Kenya to assess the prevalence of refractive
error and the spectacle coverage in a population aged
C50 years. Of the 5,010 subjects who were eligible,
4,414 underwent examination (response rate 88.1 %).
LogMAR visual acuity was assessed in all participants
and refractive error was measured in both eyes using a
Topcon auto refractor RM8800. Detailed interviews
were undertaken and ownership of spectacles was
assessed. Refractive error was responsible for 51.7 %
of overall visual impairment (VI), 85.3 % (n = 191)
of subjects with mild VI, 42.7 % (n = 152) of subjects
with moderate VI, 16.7 % (n = 3) of subjects with
severe VI and no cases of blindness. Myopia was more
common than hyperopia affecting 59.5 % of those
with refractive error compared to 27.4 % for hyper-
opia. High myopia (\-5.0 DS) was also more
common than extreme hyperopia ([?5.0 DS). Of
those who needed distance spectacles (spectacle
coverage), 25.5 % owned spectacles. In conclusion,
the oldest, most poor and least educated are most
likely to have no spectacles and they should be
specifically targeted when refractive services are put
in place.
Keywords Refractive error ! Spectacle coverage !
Kenya ! Visual impairment ! Blindness
Introduction
Two hundred and eight-five million people worldwide
are visually impaired with uncorrected refractive error
(URE) being the leading cause worldwide, responsible
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for 42 % of all people with visual impairment
including blindness [1]. URE is a priority of the
World Health Organisation (WHO) and the Interna-
tional Agency for the Prevention of Blindness (IAPB)
VISION2020 initiative [2]. The estimated global
potential productivity loss was calculated at US
dollars 121.4 billion in 2007 [3] and the correction
of URE with spectacles has proven to be a cost-
effective intervention in resource-poor settings [4].
The prevalence of blindness due to URE in sub-
Saharan Africa (SSA) in the C50 age group was
estimated by the WHO to be 1.64 % and the preva-
lence of VI was 5.94 % [5]. However, a recent review
of URE in recent population-based studies in SSA [6]
found the prevalence of URE blindness and URE VI in
the same age group to be considerably lower. Six of 11
population-based studies reported no blindness due to
URE. The proportion of moderate VI (presenting
visual acuity [PVA] B6/60 and[6/18) due to URE
ranged from 12.3 to 57.1 % [6].
The above review which included data from the
Rapid Assessment of Avoidable Blindness (RAAB)
study in the Nakuru district of Kenya demonstrated a
prevalence of URE blindness of 0.09 % (95 % CI
0.06–0.10 %), with URE being responsible for 4.3 %
of all persons found to be blind [7]. The RAAB
methodology does not, however, quantify the levels or
type of RE and further information is required to
establish the prevalence of varying RE status amongst
persons in Kenya, the spectacle coverage and the
unmet need. We therefore undertook a population-
based study in the same region as the previous RAAB
study to provide local prevention of blindness pro-
grams with sufficient data to tackle this unmet need.
Methods
The study fieldwork was carried out in two phases
from January 2007 to June 2007 and from April 2008
to November 2008. Detailed methodology has been
described elsewhere [8], therefore relevant methods
only are described here.
Sample size calculation
The sample size required was calculated based on an
expected prevalence of VA\ 6/12 in the better eye of
3.0 %among thoseagedC50 years, a required precision
of 0.5 % (95 % CI), a design effect of 1.5, and a
response rate of 90 %, so that 4,996 participants were
needed (Epi Info 6.04, Centers for Disease Control and
Prevention, Atlanta, GA, USA). We therefore aimed to
select 100 clusters with each containing 50 participants.
Sampling strategy and recruitment
As recent census data for Kenya were not available
[9], election role lists that were renewed in 2006 in
preparation for the 2007 general elections were used as
the sampling frame for this survey. The population
size was updated for the year 2007 using a population
growth rate of 2.7 % per year [10]. One hundred
clusters were selected with a probability proportional
to the size of the population. A cluster was defined as
the area served by the polling station.
Households were selected within clusters using a
modified compact segment sampling method [11]. An
eligible individual was defined as someone aged
C50 years living in the household for at least 3 months
in the previous year. Age was determined using the
subject’s testimony, national identity cards and a
calendar of historic events.
Ophthalmic and general examination
Suitable predetermined examination sites were selected
on the recommendation of the village leader with close
proximity for access to the cluster and electricity supply
(mains or generator) for the equipment.
Visual acuity
The presenting distance VAwas defined as the number
of letters read correctly without glasses if the partic-
ipant did not have glasses or with their own glasses if
they were present. Testing was carried out on each eye
separately at 4 meters using a reduced LogMAR
tumbling ‘E’ chart [12] in a well-lighted area. If the
subject’s vision was too poor to read any letters on the
chart at four meters, then the subject was tested at 1
meter, then as follows:
• Counting fingers (CF)—ability to count fingers at
1, 2 or 3 meter distance.
• Hand motion (HM)—ability to distinguish if a
hand is moving or not in front of the patient’s face.
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• Light perception (LP)—ability to perceive any
light.
• No light perception (NLP)—inability to see any
light or total blindness.
Those who did not read 24 letters (VA\ 6/12) at 4
meters were scheduled for correction and to undergo a
repeat VA measurement with the correction in place.
Presenting near VA, was assessed in daylight,
binocularly using a continuous chart with N8, N10,
N14 and N24 type held a constant 40 cm from the
participant’s face.
Refractive error
Presenting VA (aided or unaided) was measured on all
participants. Participants with presenting unaided
distance vision C6/12 Snellen equivalent in the better
eye were deemed not to have vision-impairing RE and
did not require RE correction. Participants with
presenting uncorrected distance vision\6/12 in the
better eye who improved to C6/12 with pinhole were
defined as having VI caused by RE requiring correc-
tion. If there was no improvement to 6/12 with pinhole
and no other pathology was present to explain the
vision loss, their VI was attributed to other than
pathology. Such participants were referred for treat-
ment for the cause attributed to the VI and were
declared not to require RE or presbyopia correction.
If a participant presented with distance spectacles
that provided vision C6/12 in the better eye they were
deemed to have a visually significant RE that was
satisfactorily corrected with their current correction.
When the presenting corrected distance vision was\6/
12 in the better eye, but improved to at least 6/12 with
pinhole, an under-corrected RE was determined to be
present and they were deemed to need further correc-
tion and replacement spectacles.
An automated Topcon auto refractor RM8800 was
used to provide an objective non-cycloplegic mea-
surement of all participants who needed RE correction
for distance. Measurement of the sphere-25 D to?22
D (to the nearest 0.25 D), cylinder 0 D to±10 D (to the
nearest 0.25 D) and axis 0! to 180! (in 5! steps) were
recorded. Each patient who did not seeC6/12 with RE
needing correction as defined above was corrected
using the auto refractor correction and VA retested to
confirm improvement to C6/12. Subjective refraction
correction was only carried out if the auto refractor
correction did not result in VAC6/12. The corrections
used for the study were not considered as the final
prescription. Instead all participants with RE were
referred for final prescriptions at the district hospital.
Near vision
Participants in this study, all of whom were aged
C50 years, were considered to have presbyopia if they
could see binocular N8 with their presenting near
spectacles, or if they were unable to read N8 with
(under-corrected) or without (uncorrected) presenting
near spectacles as long as they had normal distance
vision or their pinhole distance vision was C6/12.
Participants who had pinhole distance vision worse
than 6/12 in the better eye and did not see binocular N8
were not included in the presbyopia group.
Presbyopia correction was defined as the smallest
of five corrections (?1.0,?1.5,?2.0,?2.5,?3.0) that
allowed the participant to see N8.
General information
Detailed interviews were undertaken in the local
language covering demographic details, information
on risk factors, socio-economic status and full past
medical history. We also measured weight, height,
waist and hip circumference, blood pressure, and
random cholesterol and glucose blood levels [13].
Data entry
A data entry package in EpiData Entry v 2.1 was
developed for this study, which incorporated range
and consistency checks. Data was entered by two data
entry clerks on separate computers. Consistency
checks were performed each evening and inconsis-
tencies corrected on the same day. Two datasets, one
for the demographic and risk factor information and
one for the ophthalmic examinations, were stored each
bearing the same study identification.
Definitions used
RE was presented as spherical equivalent, taken as the
sphere power plus half the cylinder power. Statistical
analysis was performed on data from right eyes only in
keeping with methodology used in similar studies
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[14], as the correlation between the spherical equiv-
alent in the right and left eye was acceptable (Pear-
son’s coefficient 0.57) with no significant differences
between the right and left eyes on paired t test
(p = 0.19). The following definitions were used at
analyses stage:
• Refractive status refers to the refractive status on
auto refraction irrespective of Topcon auto refrac-
tor RM8800y. No cycloplegic refraction was
performed.
• RE in this study is defined as a presenting vision
\6/12 in the better eye which improves to C6/12
after correction.
• Spherical RE was presented as the spherical
equivalent, which equals the sphere power plus
half the cylinder power.
• Myopia was defined as the spherical equivalent of
-0.5Dor less. Themyopiawas categorized asmild
myopia (-0.5 D to -3.0 D), moderate myopia (-
3.1D to-5.0D) or highmyopia (less than-5.0D).
Clinically significant myopia was defined as a
spherical equivalent myopia of at least -1.0 D.
• Hyperopia was defined as the spherical equivalent
of more than ?0.5 D. Hyperopia was categorized
as low hyperopia (?0.5 D to ?3.0 D) and high
([?3.1 D). Clinically significant hypermetropia
was defined as a spherical equivalent hyperopia of
at least ?3.0 D.
• Emmetropia was defined as the spherical equiva-
lent of between ?0.5 D and -0.5 D.
• Astigmatism was defined as [0.5 D of minus
cylinder, without reference to the axis. Astigma-
tism was measured in negative cylinders with the
axis of astigmatism defined as with the rule
(0! ± 15!), against the rule (90! ± 15!), or
oblique (16–74! and 106–164!).
• Anisometropia was defined as a difference in the
spherical equivalent between the right and left eyes
of[1.0 D. Data for those with no left eye informa-
tion was not included in the analyses as well as for
those who had cataract surgery in the left eye.
• ‘Off the shelf’ implies a refractive range that can
be corrected with ready-made glasses.
Ethical approval
Ethical approval was granted by the LSHTM Ethics
Committee and also the Kenya Medical Research
Institute. Approval was also granted by the Provincial
Medical Officer Rift Valley and the Nakuru district
Medical Officer of Health. Written approval was sought
from the administrative heads in each cluster, usually the
village chief. All participants gave witnessed written or
verbal consent to participate. People requiring medical
treatments were referred to the appropriate center.
Data analysis
Prevalence of RE strata, URE blindness and VI was
estimated, and the cluster design effect (DEFF = 1.5)
of the study was taken into account when calculating
confidence intervals surrounding the prevalence
estimates.
Socio-economic status: a continuous asset score was
produced using a scoring system derived through
principal component analysis in an earlier study in this
setting [15, 16]. The score was divided into quartiles to
categorize the studyparticipants into four socioeconomic
groups with a higher score representing higher SES.
Obesity using waist circumference was categorized
using WHO guidelines [17] as normal (male \94
cm, female\80 cm), overweight (male 94–101.9 cm,
female 80–87.9 cm) and obese (male C102 cm,
female C88 cm).
The clusters were defined as rural or urban according
to the classification used by theDistrict Health Statistics
office [18].Thedistinctionsweremadenationally based
on population density, administrative function, avail-
ability of social amenities and physical infrastructure
such as hospitals, post office, schools, and markets.
Results
Study participation and response rates
Of the 5,010 subjects eligible for this study, 4,414
underwent examination (response rate 88.1 %). The
response rate was similarly high among men (89.2 %)
and women (86.5 %). Of the non-respondents, 584
(98 %) were away working or visiting family outside
the cluster location, and 12 (2 %) refused to participate.
Comparison of responders and non-responders
Details about gender were available for all of the non-
responders while age was available for 526 non-
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responders (90.1 %). Those who were examined were
significantly older (mean age 63.4 years, SD
10.5 years) than those who were not (61.9, SD
10.6 years, p = 0.002). Women were significantly
over-represented among the non-responders (56.8 %)
compared to those who were examined (52.1 %,
p = 0.03). Of those eligible, 66.5 % were from rural
clusters while 67.2 % of those who were examined
were from rural areas (p = 0.7). Of those who were
not examined none were believed to be blind.
Analysis
Among those who responded 33 had incomplete
examinations, or missing data. Therefore 4,381 par-
ticipants were included in the ophthalmic analyses.
Of the 4,381 participants with complete data, 669
had visual impairment and 71 of these were blind.
RE was responsible for 51.7 % of overall VI (i.e.,
those with VA\6/12), 85.3 % (n = 191) of subjects
with mild VI, 42.7 % (n = 152) of subjects with
moderate VI, 16.7 % (n = 3) of subjects with severe
VI and no cases of blindness.
There were 346 individuals whose main cause of VI
was RE, i.e., VA \6/12 Snellen equivalent that
improved to C6/12 on correction. Ten individuals
whose cause of VI was determined to be aphakia were
excluded from the analysis but were included in the
analyses for spectacle coverage.
Comparison of PVA and best-corrected visual
acuity showed that most (69.0 %) of the participants
who were categorized as blind based on PVA could
not be improved by correcting their refraction status
whereas the majority of those with severe VI (66.7 %)
or moderate VI (63.8 %) could be improved at least
one category (Table 1). Of those with mild VI, 86.7 %
improved on refraction to normal VA. Of the 22
participants who improved from blind to severe VI on
correction, nine had dense nuclear sclerotic cataract,
five were aphakic or had experienced surgical com-
plications while the rest had retinal pathology (two
with glaucoma, three with other retinopathies, and
three with age-related macular degeneration). Three
hundred and fifty-six people with some level of VI on
PVA, representing 8.1 % of participants, improved to
normal vision on correction (Table 2).
Types of RE
Myopia was much more common than hyperopia
affecting 59.5 % of those with RE compared to
27.4 % for hyperopia. High myopia (\-5.0 DS) was
also more common than extreme hyperopia ([?5.0
DS).
Men had significantly more myopia than women
(p = 0.05) while women had significantly more
hyperopia than men (p = 0.0001; OR 2.5; 95 % CI
1.5–4.2). Of the 45 people with emmetropic results, 13
had moderate VI and 32 had mild VI. The 13 patients
with moderate VI as well as 25 of the others had
significant astigmatism ([0.5 Dcyl). Overall the
prevalence of RE in the study was 7.4 % and the
difference in prevalence between men and women was
not significant (p = 0.31).
Suitability for ready-made (off the shelf) distance
spectacles
Eighty-one people with hypermetropia, 113 people
with myopia and 45 people with near emmetropic
(-0.5 to ?0.5 DS equivalent [excluding plano])
refraction were within the range of ‘off the shelf’
Table 1 Comparison of presenting VA and best-corrected VA
Best-corrected visual acuity
Normal Mild VI Moderate VI Severe VI Blind Total
Presenting visual acuity Normal 3,712 (100 %) 3,712 (100 %)
Mild VI 194 (86.7 %) 30 (13.4 %) 224 (100 %)
Moderate VI 157 (44.1 %) 70 (19.7 %) 129 (36.2 %) 356 (100 %)
Severe VI 3 (16.7 %) 2 (11.1 %) 7 (38.9 %) 6 (33.3 %) 18 (100 %)
Blind 2 (2.8 %) 0 17 (23.9 %) 3 (4.2 %) 49 (69.0 %) 71 (100 %)
Total No. 4,068 102 153 9 49 4,381
VI visual impairment
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spectacles using spherical equivalents (total 239
people). However 207 of them had significant astig-
matism ([0.5 Dcyl) or anisometropia ([1.0 D differ-
ence between eyes) leaving only 32 (9.3 %) suitable
for ‘off the shelf’ spectacles.
Distance vision spectacle coverage
Of the 4,381 subjects examined, 69 men and 53
women had distance spectacles. However, another
346 subjects with RE and 10 subjects with aphakia
could have had their presenting vision improved to
C6/12 if they wore spectacles. Coverage for distance
spectacles was therefore only 25.5 % and there was no
significant difference between men (27.2 %) and
women (23.7 %) in coverage (Pearson v2 (1) = 0.77
Pr = 0.38) as shown in Table 2.
Predictors of having distance spectacles
Univariate and multivariate analysis was performed
with logistical regression of key variables with RE
including age, gender, literacy, education, occupation,
and residence (urban or rural) to predict spectacle
usage (Supplementary Table 1). Univariate analyses
revealed that the older people were then the less likely
they were to wear glasses. Women were also less
likely to wear spectacles than men. Those who were
less poor, better educated, living in urban areas or
diabetics were more likely to have distance spectacles
when they needed them. After multivariate analyses,
the same factors remained significantly associated
with the unmet need for distance spectacles.
Presbyopia
Among those with best-corrected VA C 6/12, 3,993
patients were tested for presbyopia. Among them,
3,686 had presbyopia giving a prevalence of 92.3 %
(95 % CI 90.4–93.9). The prevalence in men and
women was equal at 92.3 % (p = 0.99) as was the
difference between rural and urban dwellers (91.7 vs
93.6 %, respectively p = 0.3).
Only 400 of those with presbyopia (10.9 %)
presented with reading glasses that allowed them to
see N8.
Table 2 Distribution of RE results presented as spherical equivalent for those whose principal cause of VI is RE
Range Males n (%) Females n (%) Total n (%)
[?5.01 high hypermetropia 6 (3.4 %) 2 (1.2 %) 8 (2.3 %)
?3.01 to ?5.00 DS 0 5 (3.0 %) 5 (1.5 %)
?0.51 to ?3.00 DS off the shelfa 23 (13.0 %) 58 (34.9 %) 81 (23.6 %)
Total hyperopia 29 (16.4 %) 65 (39.2 %) 94 (27.4 %)
-0.50 to ?0.50 DS off the shelfa excluding plano 25 (14.1 %) 20 (12.1 %) 45 (13.1 %)
-0.51 to -3.00 DS off the shelfa 68 (38.4 %) 45 (27.1 %) 113 (32.9 %)
-3.01 to -5.0 DS 37 (20.9 %) 18 (10.8 %) 55 (16.0 %)
\-5.01DS high myopia 18 (10.2 %) 18 (10.8 %) 36 (10.5 %)
Total myopia 123 (69.5 %) 81 (48.8 %) 204 (59.5 %)
Total with RE 177 (100 %) 166 (100 %) 343 (100 %)
Prevalence of RE in study 7.8 % (95 % CI 6.6–9.2) 7.0 % (95 % CI 5.8–8.3) 7.4 % (95 % CI 6.5–8.4)
DS dioptre sphere, RE refractive error, CI confidence interval
a ‘Off the shelf’ implies a refractive range that can be corrected with ready-made glasses
Table 3 Spectacle coverage in men and women
Male Female Total
Met need (wears distance spectacles and achieves C6/12 in the better eye) 69 (27.2 %) 53 (23.7 %) 122 (25.5 %)
Unmet need (needs distance spectacles to achieve C6/12 in the better eye) 185 (72.8 %) 171 (76.3 %) 356 (74.5 %)
Total need 254 (100 %) 224 (100 %) 478 (100 %)
Coverage (met need/total need) 27.2 % 23.7 % 25.5 %
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Discussion
Unlike studies in similar elderly populations in Europe,
Australia, Latin America and Asia [19–23], RE did not
cause any blindness in this study. The recent Nigeria
National Survey of Blindness [24] found 1.4 % of
blindnesswas caused byRE suggesting low levels even
in West Africa. However, in this survey as in Nigeria,
RE was the leading cause of mild and moderate VI. In
contrast, the Tema Survey, a population-based survey
in Ghana found a high prevalence of RE-related
blindness and VI [25]. Major genetic variations
between people of West and East African origin have
been described which may account for the differences
between the two populations. The Tema Survey also
examined a younger age group, including participants
aged C40 years. The 40–49 year age group was not
included in the Nakuru Survey; however, this age
group in the Ghanaian study included the greatest
number of participants and, as expected, age-related
causes of VI such as cataract were low in this group.
The widely used RAAB methodology had also been
previously implemented in this population [7]. RE in the
RAAB study was responsible for 4.3 % of blindness,
7.4 % of severe VI and 31.5 % of moderate VI. This
overestimated the level of blindness due toREcompared
to themore accuratemeasures ofRE and underestimated
levels of VI due to RE. Although pinhole assessment
used in the RAAB study is a useful and rapid screening
test forRE, it is unable to exclude vision loss due to other
pathologies or quantify levels or type of RE.
Correction of RE is a cost-effective implementation
and can significantly improve both quality of life and
ability to function in society.
In the age group studied, presbyopia is highly
prevalent and has an impact on the ability to carry out
near-vision-related tasks. The prevalence of presbyo-
pia in this study (92.3 %) was similar to that found in a
smaller study in the same population [26]which looked
at functional presbyopia in which 130 eligible partic-
ipants were selected for near-vision testing and inter-
view. Functional presbyopia was found in 85.4 %
(n = 111) [26].
It is also similar to a study in Zanzibar that found an
overall prevalence of presbyopia of 89.2 % [27, 28].
Among those with presbyopia in this study only
10.9 % had spectacles compared to 17.6 % in Zanzi-
bar but equal to the presbyopia coverage in the same
age group in another East African population in
Tanzania [29]. Cost was cited as the main barrier to
spectacle use in 62 % of participants with presbyopia
in the earlier smaller study in this population [26].
Among participants with functional presbyopia,
5.4 % wore reading glasses and 25.2 % had prior
contact with an eye care professional. The unmet
presbyopic need was 80.0 %, the met presbyopic need
was 5.4 % and presbyopic correction coverage was
6.3 %. Cost was cited as the main barrier to spectacle
use in 62 % of participants with presbyopia [26].
Provision of optical services in Africa has remained
largely in the hands of the private sector making
spectacles usually unaffordable for the vast majority of
thosewho need them. Severalmore complex barriers to
spectacle provision and wear exist [30]; however,
affordability and availability remains amajor obstacle.
This explains the low spectacle coverage in this study
in an elderly population where public provision of
refractive services and low-cost spectacles is non-
existent. A large number of private optometrists are
situated in Nakuru town; however, these services are
heavily reliant on auto refractors for providing final
prescriptions and the cost of spectacles is too high for
those most in need.
Based on up-to-date census data we estimate that
between 250,000 and 320,000 adults[50 years of age
in Kenya are visually impaired due to RE, of whom
currently only approximately one-quarter are wearing
adequate correction.
The oldest, most poor and least educated are most
likely to have no spectacles and they should be specif-
ically targeted when refractive services are put in place.
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